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Abstract
Protein-protein interactions govern cellular functions on the molecular level.
Post-translational modifications alter these interactions allowing highly dynamic
regulation. Protein tyrosine phosphorylation is an especially relevant post-trans-
lational modification, because it is tightly linked to intercellular regulation of
growth and development in metazoans. Diseases like cancer or autoimmune
disorders arise from misregulation of these processes generating great medical
interest in protein tyrosine phosphorylation and processes relating to it. This
study provides a comprehensive set of 292 mostly novel, high-quality phospho-
tyrosine-dependent protein-protein interactions detected in genome-scale yeast
two-hybrid screens using full-length proteins filling a gap in phosphotyrosine
signaling knowledge, which has so far been based largely on peptide binding and
affinity purification-coupled mass spectrometry experiments. The high quality
was demonstrated experimentally and computationally, in co-immunoprecip-
itation and protein complementation assays, as well as over-representation
analyses and comparison to prior knowledge. Previously reported linear peptide
motifs are reflected in the binding partners, but clearly do not account for most
of the interactions, emphasizing the relevance of full-length protein context.
The interactions were further shown to form an unusually dense, monolithic
network with a central core and reflect and expand phosphotyrosine-related
KEGG pathways. Seven of the eight core proteins are well-established signaling
hubs. The eighth core gene, SH2D2A, seems to play a more central role than
currently appreciated. Finally, selected interactions involving GRB2 were shown
to occur in different specific subcellular localizations. Together, these results
strongly suggest that the interactions presented here represent an important
step toward understanding growth and development and will benefit treatment
of pressing medical issues substantially.

Zusammenfassung
Protein-Protein-Wechselwirkungen steuern zelluläre Funktionen auf molekularer
Ebene. Posttranslationale Proteinmodifikationen beeinflussen diese Wechsel-
wirkungen und erlauben dynamische Regulierung. Tyrosinphosphorylierung ist
eine besonders relevante Modifikation, weil sie eng mit interzellulärer Regula-
tion von Wachstum und Enticklung in Vielzellern verbunden ist. Da falsche
Regulierung dieser Prozesse zu Krebs oder Autoimmunerkrankungen führen
kann, ist sie auch von großem medizinischen Interesse. In Hefe-Zwei-Hybrid-
Untersuchungen mit Volllängen-Proteinen im Genommaßstab wurde ein umfas-
sender Satz von 292 größtenteils neuen phosphotyrosinabhängigen Proteinwech-
selwirkungen erster Güte ermittelt. Damit wurde eine Wissenslücke im Bereich
der phosphotyrosinabhängigen Signalübertragung, der bisher hauptsächlich
auf Peptidbindungs- und Affinitätsaufreinigungs-gekoppelten Massenspektrono-
mieexperimenten fußte. Die Güte der Interaktionen wurde experimentell und
informatisch, in Coimmunpräzipitations- und Proteinkomplementierungs-, sowie
in Überrepräsentationsanalysen und Literaturvergleichen, gezeigt. Bekannte
lineare Bindesequenzmotive kommen zwar gehäuft vor, können die Mehrzahl
der Interaktionen aber offensichtlich nicht erklären. Die Wechselwirkungen
bilden ein dichtes, einheitliches Netzwerk und widerspiegeln phosphotyrosinab-
hängige KEGG-Signalwege. Es hat ein Herzstück aus acht Genen, von denen
sieben fest etablierte Signalverarbeitungshauptknotenpunkte darstellen. Dem
achten, SH2D2A, scheint eine deutlich wichtigere Rolle zuzukommen als bisher
wahrgenommen. Schliesslich wurde für eine Auswahl von GRB2-Interaktionen
unterschiedliche subzelluläre Verortung vorgenommen. Zusammengenommen
legen diese Ergebnisse nah, dass die hier veröffentlichten Wechselwirkungen
einen wesentlichen Schritt für das Verstehen von Wachstum und Entwicklung
markieren und zur Verbesserung der Behandlungsmöglichkeiten in wichtigen
Medizinbereichen beitragen werden.
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Chapter 1
Introduction
More than a decade after the sequencing of the human genome (Venter et al.
2001), many of its promises are still not realized (Wade 2010). The main
reason is that while the genome sequence may, in principle, contain all the
information relevant for the creation and operation of an organism, most
of the cells functions are realized by proteins (Cusick et al. 2005). This is
especially true for evolutionarily new functions (Joyce 2002). These functions
are often more relevant in a medical context, because the older functions, like
splicing or translation, are so fundamental that defects are often lethal. In fact,
human diseases usually do not arise from defects in catalytic proteins but in
regulatory proteins (Cuccato et al. 2009). Most regulatory protein functions
emerge from the interaction of several proteins (Charbonnier et al. 2008).
Therefore, understanding human cells requires the knowledge of protein-protein
interactions (Stelzl & Wanker 2006). In the recent past, several large-scale
protein-protein interaction studies have started working towards a complete
map of all human protein-protein interactions, the so-called interactome (Stelzl
et al. 2005; Rual et al. 2005).
Complex organisms require complex control mechanisms. This is reflected in
their composition. Usually, increases in compartmentalization, genome size,
number of different cell types, organism size, phenotypic diversity, and epigenetic
mechanisms like alternative splicing and post-translational modification of
proteins are correlated (Schad et al. 2011). Post-translational modifications,
in particular, play an important role, because they allow efficiently switching
protein interactions on or off (Yang 2005; Deribe et al. 2010).
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1.1 Post-translational protein modifications af-
fect protein binding
Physical interactions between proteins are fundamental for the control of cel-
lular processes. It is important to note that protein-protein interactions are
not intrinsically binary, but (simplifyingly) thinking about them in that way is
extremely fruitful. Protein-protein interactions form a network that contains all
the possibilities for information transfer, especially regulation, but is incomplete
in that it is a map only (Stelzl & Wanker 2006). In practice, protein-protein
interactions depend not only on the proteins fundamental capacity for interac-
tion, but also on protein expression, localization and state. The most efficient
way of altering the protein-protein interaction network states is by altering
protein states through covalent modification. In contrast to other possibilities,
like raising or decreasing expression or degradation rates, post-translational
protein modifications can very efficiently be coupled to energetically favorable
reactions, like hydrolysis of ATP, and therefore achieve very high turnover rates.
1.2 Phosphotyrosine is a post-translational pro-
tein modification strongly linked to multicel-
lularity
Phosphotyrosine signaling is intimately linked to the regulation of cellular
processes related to multicellularity and overcoming the challenges it entails,
as well as the diseases that arise when these processes are deregulated (Suga
et al. 2014).
1.2.1 Regulation of growth and development is related
to phosphotyrosine signaling
For individual cells to form successful multicellular organisms, they have to find
a way of agreeing on a course of action (or inaction) and abide by it (Kaiser
2001). Above all, growth and development have to be coordinated closely. In
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practice, much of this kind of communication is brought about by proteins
spanning the plasma membrane and, upon binding an extracellular peptide
ligand, effecting phosphorylation of tyrosine residues on intracellular peptide
chains, in cooperation with downstream proteins. The extracellular ligand can
be transmembrane proteins belonging to neighboring cells, but most are soluble.
These peptides are called growth factors and their receptors are called receptor
tyrosine kinases (Ullrich & Schlessinger 1990).
1.2.1.1 Growth factors activating receptor tyrosine kinases are ex-
emplary for phosphotyrosine signaling
The binding of growth factors to receptor tyrosine kinases and subsequent acti-
vation of receptor tyrosine kinase pathways is the major means of intercellular
communication in metazoans (Hubbard & Miller 2007). Focusing on the effector
side, receptor tyrosine kinase signaling starts with the binding of a growth factor
to a receptor kinase, activating it. The second step in receptor tyrosine kinase
signaling is phosphorylation of the primary substrates, often incorporated in
the receptor tyrosine kinases themselves. The primary substrates are bound
by cytoplasmic proteins through specialized protein domains, bringing them
in close proximity to the activated receptor tyrosine kinase. Commonly, these
proteins are then also phosphorylated by the receptor tyrosine kinase, or by a
non-receptor tyrosine kinase recruited to a phosphotyrosine site in a primary
substrate. Alternatively or additionally, they can serve as adapters for other
proteins. Subsequently, the pathways branch out into apparently relatively
clearly defined axes, like the PI3K-PKB-PTEN, the Ras-JNK or the JAK-STAT
axis, and canonically end in nuclear factors, like JUN, FOS or MYC (Steelman
et al. 2008). Misregulation of these pathways can lead to serious disease. For
example, a mutation simulating a growth-inducing signal can cause cancer or
an erroneous activation of immune receptor pathways can cause immunological
disease (e.g. Müllauer et al. 2001).
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1.2.2 Deregulation of phosphotyrosine signaling causes
cancer
One of the most daunting challenges for the medical sciences today is cancer.
In 2009, in the United States of America, the average lifetime risk of cancer is
higher than 40% (Howlader et al. 2012). Cancer is the result of uncontrolled cell
growth resulting from loss of regulation (Croce 2008). In cancer progression, the
cells escape the control mechanisms mediated by apoptosis and cytotoxic T cells,
acquire growth-inducing mutations and, finally, invade other tissues. Therefore,
genes that are often found mutated in cancer comprise tumor suppressor genes,
like RB1 and TP53, activating signaling components, like growth factors, kinases
or transcription factors. Because cancers result from several mutations in the
same cell and additional mutations can provide substantial growth advantages,
there is another type of gene that is systematically altered in cancers. The third
type of cancer genes is related to genetic stability. In principle, any alterations
that makes acquiring further mutations easier are retained with high probability.
(Vogelstein & Kinzler 2004) propose calling the growth activators ”oncogenes”
and the latter ”stability genes”. (Kinzler & Vogelstein 1997) use the term
”caretakers” to describe the stability genes and ”gatekeepers” for the other two
groups. The distinction of cancer genes into caretakers and gatekeepers is very
eidetic and calls attention to the association of specific mutations and cancer
types. The distinction into oncogenes, tumor suppressor genes and stability
genes is more precise, but requires additional insight. Moreover, the term
”oncogene” can be misleading, because until the early 1990s it was commonly
used to contrast the mutated, cancer-inducing forms of genes commonly found
in tumor viruses from their wild type counterparts (called proto-oncogenes).
In this classification, the most well-known genes related to phosphotyrosine
signaling are growth activators. For example, many receptor tyrosine kinases,
like KIT (Rubin et al. 2001), MET (Eder et al. 2009), RET (Santoro et al. 2004),
AXL (Linger et al. 2010) or subunits of the epidermal (Nicholson et al. 2001) or
fibroblast growth factor receptor (Turner & Grose 2010) have oncogenic potential
when overactivated. Usually, these genes carry mutations that simulate growth
factor binding. Non-receptor tyrosine kinases, especially Src family kinases
and members of related families, on the other hand, are usually activated
by mutations that neutralize intrinsic control mechanisms. SRC itself can be
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Table 1: Associations between phosphotyrosine signaling genes and
specific types of cancer indicate pathways important in particular
cell types. Phosphotyrosine signaling genes associated with a specific type of
cancer sorted alphabetically by Entrez Gene Symbol. For each gene, the Entrez
GeneID, the type of cancer it is associated with and a reference discussing the
association are listed.
GeneID Symbol Type of Cancer Reference
25 ABL1 Chronic myelogenous leukemia Mauro & Druker (2001)
558 AXL Carcinoma Li et al. (2009)
8412 BCAR3 Breast cancer Wilson et al. (2013)
29760 BLNK
Pre-B cell acute
lymphoblastic leukaemia
Jumaa et al. (2003)
695 BTK Lymphoma/leukomia Buggy & Elias (2012)
867 CBL Myeloproliferative disorders Naramura et al. (2011)
868 CBLB Myeloproliferative disorders Naramura et al. (2011)
23624 CBLC Myeloproliferative disorders Naramura et al. (2011)
1436 CSF1R Carcinoma Kacinski (1995)
1601 DAB2 Prostate/ovarian carcinoma Fazili et al. (1999)
1956 EGFR Non-small cell lung cancer Rusch et al. (1993)
2322 FLT3 Acute myeloid leukemia Warren et al. (2012)
3702 ITK Peripheral T cell lymphomas Streubel et al. (2006)
3932 LCK Lymphoma/leukemia Harr et al. (2010)
4058 LTK Leukemia Roll & Reuther (2012)
18212 NTRK2 Neuroblastoma Nakagawara et al. (1994)
10019 SH2B3 Lymphoma/leukemia Gery et al. (2009)
4068 SH2D1A B cell neoplasms Sandlund et al. (2013)
6464 SHC1 Mammary carcinoma Northey et al. (2008)
53358 SHC3 Neuroblastoma Miyake et al. (2009)
6714 SRC Metastatic carcinoma Frame (2002)
activated by mutations in its SH2 or SH3 domains or intramolecular SH2 or SH3
binding sites (Brown & Cooper 1996) and the common BCR-Abl translocation
relieves regulation by an intramolecular SH3 domain interaction (Barilá &
Superti-Furga 1998).
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Interestingly, there is often a connection between certain cancer types and
specific genes (Hanahan & Weinberg 2000). Table 1 shows a selection of
tyrosine signaling genes with strong association to a specific type of cancer.
This observation provides valuable insight into the mechanics of signaling in
nascent cancer and, by extension, into phosphotyrosine signaling. In principle,
all cancers arise from cells acquiring a set of mutations that allows an escape
from growth regulation. Accordingly, one would expect that a specific genetic
alteration has the same consequences for carcinogenesis irrespective of the cell
or tissue type it occurs in. The fact that this is not so, shows that growth
regulation differs between distinct cell types. Therefore, it seems likely that,
at the very least, the degree to which the different components of the growth
regulation interactome are relevant is cell type-specific. The same mutation can
provide initial growth advantages and constitute the first step of carcinogenesis
in one cell type while having little impact in another. As a consequence, that
mutation is found more often in the cancer subtype related to the first cell
type.
To sum up, phosphotyrosine signaling is highly relevant for cancer and the
insights gleaned from cancer research help understanding the regulation of
growth and development in normal, untransformed cells. Thus, a genome-scale
map of phosphotyrosine-dependent protein-protein interactions will be medically
important for a large part of the population.
1.2.3 Deregulation of phosphotyrosine signaling relates
to immunological disease
Another medically relevant field with a strong connection to phosphotyrosine
signaling is the regulation of the immune system. Many phosphotyrosine signal-
ing proteins are named for their involvement in immunological processes, like
B lymphocyte kinase (BLK), B cell linker (BLNK), Bruton agammaglobuline-
mia tyrosine kinase (BTK), macrophage colony stimulating factor I receptor
(CSF1R), IL-2-inducible T cell kinase (ITK), lymphocyte-specific protein ty-
rosine kinase (LCK), lymphocyte cytosolic protein 2 (LCP2), macrophage
stimulating 1 receptor (MST1R), or ζ-chain (TCR) associated protein kinase
70 kDa (ZAP70). Others have alternative names indicating immonological
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functions, like mast cell immunoreceptor signal transducer (CLNK), B cell
adapter molecule of 32 kDa (DAPP1), lymphocyte-specific adapter protein
(SH2B3), SLP-76-associated protein of 130 kDa (FYB), signaling lymphocyte
activation molecule-associated protein (SH2D1A), or T lymphocyte specific
adaptor protein (SH2D2A).
Table 2 shows a selection of phosphotyrosine signaling genes with a clearly
proven specific function in immunological cell function. Interestingly, there is a
relatively large number of genes that have been shown to carry vital roles in
several types of immune cells. This reflects the common evolutionary origin of
the hematopoietic lineage. Even more interesting, however, is which functions
concur. Mostly, the functions of a protein in different immunological cells are
related. In other words, each of the proteins carries a biological meaning. What
is striking about that, is that the semantic level is different. For example, SLA2
inhibits T cell receptor signaling in T cells (Pandey et al. 2002) and B cell
receptor signaling in B cells (Holland et al. 2001). In contrast, HSH2D inhibits
activation of T cells through the T cell receptor (Perchonock et al. 2006) but
antagonizes BCR-induced apoptosis in B cells (Herrin et al. 2005) and Nck
has been described as ”critical for maturation of the immune synapse and for
T cell activation” (Gil et al. 2002) while negatively regulating JNK activa-
tion and exerting a positive effect on apoptosis in response to BCR signaling
in B cells (Mizuno et al. 2002). Therefore, HSH2D and Nck can be thought
of as shifting immune response from T cell-mediated to B cell-mediated or
vice versa, respectively, whereas SLA2 may be considered a general immune
receptor antagonist. While these examples are very broad, others are more
clearly defined. For instance, PLCG2 KO mice ”have decreased mature B cells,
a block in pro-B cell differentiation, and B1 B cell deficiency” and display ”a
loss of [. . . ] mast cell FcεR function, and NK cell FcγRIII and 2B4 function”
(Wang et al. 2000) and DAPP1 is involved in B cell response to TI-II antigens
(Fournier et al. 2003) and is involved in Fcε RI-mediated mast cell degranulation
(Hou et al. 2010). Thus, PLCG2 can be considered important for antibody-
dependent cell-mediated cytotoxicity, an immune response that is typical for
certain parasites, and DAPP1 for non-adaptive immune response to bacterial
infections. BLK is ”required for the development of wild-type numbers of IL-17-
producing λδ T cells” (Laird et al. 2010) and regulates B cell tolerance (Hom
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et al. 2008); LYN ”plays a role in signal transduction for not only clonal ex-
pansion and terminal differentiation of peripheral B cells but also elimination
of autoreactive B cells” (Nishizumi et al. 1995) and is required for in vivo
phosphorylation of FcγRIIB in mast cells (Malbec et al. 1998). Hence, these
LYN and BLK carry biological meanings similar to those of HSH2D and Nck
in that they shift from cytotoxic to humeral immune response or the other way
around, but on a much more specific level. In addition to rather specific im-
mune-related phosphotyrosine signaling genes, there are many phosphotyrosine
signaling genes better known from other contexts that are important in immune
pathways, like PI3K (Deane & Fruman 2004), GRB2 (Gong et al. 2001) or
PLCG2 (Wang et al. 2000). Conversely, a number of well-known immune genes
is important in non-immune phosphotyrosine signaling contexts. For example,
BLK is involved in insulin sectretion (Borowiec et al. 2009), SH3B3 is a negative
regulator of PDGFR signaling (Gueller et al. 2011) and SH2D2A is required
for SRC activation in VEGFR signaling (Sun et al. 2012). This wide range of
immunological semantics covered by phosphotyrosine signaling genes brings
up a number of questions. For example, the fact that some phosphotyrosine
signaling proteins regulate different immune cells, like T cells and B cells, in
the same manner while others regulate them in opposite ways suggests that
the two proteins represent distinct semantic layers. It is tempting to speculate
that the computation between the layers is a phosphotyrosine-related function.
From an evolutionary perspective, we can ask why a system evolved in which
the biological function of a number of proteins can be best understood on an
organism level, i.e. why does protein function on the cellular level radically
differ depending on cell type for some proteins? The apparent overlap between
phosphotyrosine signaling genes with immune functions and phosphotyrosine
signaling genes with non-immune functions that the pathways regulating im-
mune cell action are embedded in a large regulatory network together with
components common to other pathways making the adjustment of cell-specific
signal integration the most frugal solution to the problems at hand. To validate
or invalidate all of these suggestions, we need to consider the respective proteins
in a network context.
In short, there is a strong connection of phosphotyrosine signaling and im-
munological control on many different levels. The general biological function
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Table 2: Roles of phosphotyrosine genes in different kinds of immune cells are mostly similar or converse.
Phosphotyrosine signaling genes with a clearly proven role in specific types of immune cells sorted alphabetically by Entrez
Gene Symbol. For each gene, the Entrez GeneID, the function it has in T cells, B cells and other immune cells is listed with a
reference discussing it, where known.
Entrez
Gene
Symbol
Entrez
GeneID
Function in
T cells B cells other immune cells
640 BLK
development of IL-17-producing
γδ T cells (Laird et al. 2010)
regulates B cell tolerance
(Hom et al. 2008)
29760 BLNK
transition from
B220+CD43+ progenitor B to
B220+CD43- precursor B cells
(Pappu et al. 1999)
695 BTK
important in B lymphocyte
development, differentiation, and
signaling (Mohamed et al. 2009)
868 CBLB
regulates peripheral tolerance and
anergy (Jeon et al. 2004)
116449 CLNK
involved in FcεRI-mediated
mast cell degranulation
(Goitsuka et al. 2000)
1436 CSF1R
regulates the survival,
proliferation, chemotaxis and
activation of macrophages
(Pixley & Stanley 2004)
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Table 2: Roles of phosphotyrosine genes in different kinds of immune cells are mostly similar or converse.
(continued)
Entrez
Gene
Symbol
Entrez
GeneID
Function in
T cells B cells other immune cells
27071 DAPP1
response to TI-II antigens
(Fournier et al. 2003)
involved in FcεRI-mediated mast cell
degranulation (Hou et al. 2010)
2322 FLT3
activates and differetiates dendritic
cells (Maraskovsky et al. 2000)
2534 FYN
NKT cell development
(Gadue et al. 1999)
84941 HSH2D
inhibits T cell activation
(Perchonock et al. 2006)
antagonizes BCR-induced apoptosis
(Herrin et al. 2005)
3635 INPP5D
negatively regulates Th2 responses
and T cell cytotoxicity
(Tarasenko et al. 2007)
attenuates a proapoptotic signal
initiated by FcγRIIB
(Ono et al. 1997)
3702 ITK
CD4+ T cell development
(Liao & Littman 1995)
3717 JAK2
DC-mediated innate immune response
and sepsis
(Zhong et al. 2010)
3932 LCK
thymocyte development
(Molina et al. 1992)
3937 LCP2
development of peripheral T cells
(Clements et al. 1998)
FcεRI-mediated activation of mast
cells (Pivniouk et al. 1999)
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Table 2: Roles of phosphotyrosine genes in different kinds of immune cells are mostly similar or converse.
(continued)
Entrez
Gene
Symbol
Entrez
GeneID
Function in
T cells B cells other immune cells
4067 LYN
expansion and differentiation of
peripheral B cells, elimination of
autoreactive B cells
(Nishizumi et al. 1995)
phosphorylation of FcγRIIB in mast
cells (Malbec et al. 1998)
4690 NCK1
maturation of the immune synapse
and T cell activation
(Gil et al. 2002)
apoptosis in response to BCR
signaling (Mizuno et al. 2002)
8440 NCK2
maturation of the immune synapse
and T cell activation
(Gil et al. 2002)
apoptosis in response to BCR
signaling (Mizuno et al. 2002)
5336 PLCG2
maturation of B cells, differentiation
of pro-B cell, B-1 B cell development
(Wang et al. 2000)
mast cell FcεR function, NK cell
FcγRIII and 2B4 function (Wang et al.
2000)
10603 SH2B2
negatively regulates B-1 B cell
development (Iseki et al. 2004)
10019 SH2B3
regulates pro-B cell proliferation
(Takaki et al. 2000)
4068 SH2D1A
CD244 function in NK cells
(Tangye et al. 2000)
9047 SH2D2A
IL2 response and antigen-induced
T cell death (Marti et al. 2005)11
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Table 2: Roles of phosphotyrosine genes in different kinds of immune cells are mostly similar or converse.
(continued)
Entrez
Gene
Symbol
Entrez
GeneID
Function in
T cells B cells other immune cells
84174 SLA2
inhibits TCR signaling
(Pandey et al. 2002)
inhibits BCR signaling
(Holland et al. 2001)
6772 STAT1
LPS-induced gene expression
in macrophages
(Ohmori & Hamilton 2001)
6778 STAT6
IL-4-mediated functions including
Th2 helper T cell differentiation
(Shimoda et al. 1996)
immunoglobulin class switching to IgE
(Shimoda et al. 1996)
6850 SYK
intraepithelial γδ T cells
(Mallick-Wood et al. 1996)
differentiation of B-lineage cells
(Cheng et al. 1995)
signaling from FcεRI in mast cells
(Siraganian et al. 2002)
7409 VAV1
selection of CD4+CD8+ T cells
(Turner et al. 1997)
7535 ZAP70
development of CD4 and CD8
single-positive T cells
(Negishi et al. 1995)
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associated with a phosphotyrosine signaling protein can be cellular or organ-
ismic. As a consequence, a number of questions regarding the processing of
signals and the relation of immunological control to other phosphotyrosine
signaling processes arise. Many of these questions are answered best from a net-
work perspective. Therefore, a genome-scale map of phosphotyrosine-dependent
protein-protein interactions can be a valuable foundation for future studies
of immune function and immune-related disease, like autoimmune disorders,
primary immune deficiency, or even allergies.
1.2.4 Tyrosine kinases, phosphatases and binders form a
”toolkit”
One of the marked characteristics of biological processes, in contrast to, for
example, chemical or physical processes, is that they are regulated (Keskin
et al. 2004). As a general rule, the more complex the processes grow, the more
the regulator and the regulans are separated. For example, in prokaryotes
genes coding for proteins of related functions are often bundled together in
operons, and transcription and translation are immediately linked, whereas, in
eukaryotes, genes are almost always individually regulated on many levels and
by many different mechanisms (Choudhuri 2004), like on the transcriptional
level by transcription factors mediating RNA polymerase binding or epigenetic
mechanisms modulating DNA accessibility, on the level of mRNA stability and
translation by RNA interference, or on the level of protein stability by protea-
somal degradation. Accordingly, there is a tendency towards higher modularity
in more complex systems (Kashtan & Alon 2005).
There are qualitative evolutionary steps that are associated with drastic in-
creases in complexity (Szathmáry & Smith 1995). One is the transition from
prokaryotes to eukaryotes. Another one is the emergence of multicellularity.
Multicellular organisms have a number of potential evolutionary advantages
over unicellular ones. Mainly, they can achieve larger sizes and develop spe-
cialized cell types (Grosberg & Strathmann 2007). To take full advantage of
this potential, however, several obstacles have to be overcome. Among these
is the coordination of cells forming an organism to produce concerted and
adequate behavior of the ensemble. In metazoans, this function is coupled, for
13
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the most part, to protein tyrosine phosphorylation. It appears that, chrono-
logically, phosphotyrosine signaling came first (Müller 2001), and it may even
be a prerequisite for the evolution of complex metazoans (Hunter & Cooper
1985). Phosphotyrosine signaling seems well-suited for this purpose, primarily
for two reasons: first, its evolutionary novelty provides a high potential for
acquiring new functions without compromising old ones; second, it comes with
a three component ”toolkit” (Pincus et al. 2008) that allows fast and efficient
regulation and transmission of signals. This toolkit consists of tyrosine kinase,
SH2 or PTB and tyrosine phosphatase domains, fulfilling ”writer”, ”reader” or
”eraser” function, respectively. The evolutionary development of this toolkit
merits special consideration, because the stabilizing evolutionary pressure is
not obvious for the incomplete system. This is especially problematic for three
component systems, because they imply two ”preadaption” steps. In the case of
phosphotyrosine signaling, it seems clear that the kinases came last. For exam-
ple, the genome of Saccharomyces cerevisiae contains a (proto-)SH2 domain and
several protein tyrosine phosphatases (Lim & Pawson 2010). Nevertheless, a
minor degree of tyrosine phosphorylation has been observed (Gnad et al. 2009).
Apparently, certain protein serine/threonine kinases are able to phosphorylate
tyrosine residues. It has been suggested that these kinases might substitute for
bona fide tyrosine kinases to some extent (Pincus et al. 2008). Indeed, there is
evidence for phosphotyrosine-dependent regulation of the MAPK-related FUS3
kinase in S. cerevisiae by the dual-specificity kinase STE7 (Errede et al. 1993).
On the other hand, the S. cerevisiae SH2 domain in the Spt6 protein has been
shown to bind phosphoserine (Dengl et al. 2009). The first step is less clear.
Although protein tyrosine phosphatase genes can be found even in prokaryotic
genomes, their regulatory function, if they have any, is not understood (Kennelly
2002; Ramponi & Stefani 1997). It is therefore conceivable that these genes were
acquired by lateral gene transfer mechanisms following the wide-spread tyrosine
phosphorylation of proteins in eukaryotes, for example to allow metabolizing
tyrosine-phosphorylated proteins or coopting the signaling potential (Kennelly
& Potts 1996). The assembly of the complete ”toolkit” was apparently quickly
followed by an evolutionary burst, possibly even an increased rate of speciation
(Pincus et al. 2008).
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1.2.5 Protein tyrosine kinases are either membrane-span-
ning receptors or cytoplasmic proteins
Metazoan bona fide tyrosine kinases come in two flavors, receptor tyrosine
kinases and non-receptor tyrosine kinases (Robinson et al. 2000).
1.2.5.1 Receptor tyrosine kinases are transmembrane proteins acti-
vated by extracellular ligand binding
Receptor tyrosine kinases (Ullrich & Schlessinger 1990) are transmembrane
proteins that typically have an extracellular domain capable of specifically
binding a small protein ligand, called growth factor, and inducing dimeriza-
tion. The dimerization activates the intracellular kinase domain which then
phosphorylates multiple tyrosine residues in the respective other monomer.
Phosphorylation of tyrosine residues in the activation loop sustain kinase activa-
tion. Other residues form a scaffold for the binding of phosphotyrosine-binding
proteins. The recruited proteins can carry enzymatic activities of their own
or they may be substrates for the receptor tyrosine kinases or other recruited
proteins or both. After being activated at the receptor kinase, the recruited
proteins relay the signal into the cytoplasm and the nucleus.
This concept is realized in many growth factor/receptor pairs. In detail, there
are often deviations from the principle. For example, the ERBB2 protein, one
of the four subunits of the epidermal growth factor receptor is incapable of
binding a ligand and relies on its dimerization partner (Klapper et al. 1999).
Hence, in this case, the ligand does not induce dimerization but merely induces
a conformational change leading to kinase activation. The insulin receptor has
a ligand-binding domain that is encoded as another peptide chain and linked
by a disulfide bridge and its scaffolding function is mostly assumed by the IRS1
and IRS2 genes. (Lee & Pilch 1994)
1.2.5.2 Receptor tyrosine kinases are classified into twenty families
based on functional and structural properties
Upon systematic inspection, the receptor tyrosine kinases can be divided into
twenty families (Robinson et al. 2000). The families differ mainly in the makeup
of the extracellular part. Many receptor tyrosine kinase families are charac-
15
1. INTRODUCTION
terized by immonoglobulin-like or fibronectin type 3 domains in this region,
other domain types are specific for a single receptor tyrosine kinase family only
(compare Figure 1).
Many growth factors can bind and activate several receptors and many receptors
can bind and be activated by more than one growth factor (compare Figure 2).
The growth factors are often most highly expressed in specific tissue or cell
types. Similarly, the receptor tyrosine kinase complement of most cell types
is highly specific. The apparent degree of growth factor/receptor promiscuity
varies, as does the amount of research done on the different groups of growth
factor/receptor pairs. For example, the EGFR family has been characterized
in great detail and the differences binding and signaling properties of indi-
vidual receptor dimers are known (Yarden & Sliwkowski 2001). Similarly, the
many different FGF binding preferences have been mapped not only to the
four FGFR genes, but even to specific exons (Zhang et al. 2006). Because of
these differences, it is conceivable that there are relevant connections missing
from our knowledge and that these connections preferentially exist between
growth factors and receptors that are not obviously related. On the other
hand, there are receptors for which no binding growth factors are known and
these have received a lot of attention and, at least in some cases, seem to be
fundamentally unable to bind any ligand. Nevertheless, these receptors can
have signaling functions, like ERBB2 (Klapper et al. 1999). The same is true
for catalytically inactive receptors. For example, the ERBB3 gene product is
catalytically inactive (Guy et al. 1994) but it can heterodimerize with other
EGFR gene products. Even the ERBB2/ERBB3 heterodimer is functional and
physiologically relevant (Citri et al. 2003). The ERBB3 monomer binds the
growth factor and changes its conformation allowing the catalytically active
ERBB2 monomer to phosphorylate it (Graus-Porta et al. 1997). An even more
peculiar example is RYK, which is also catalytically inactive (Katso et al. 1999).
It has been shown to function as a receptor for Wnt pathway ligands, like
Figure 1: Receptor tyrosine kinase families are defined by domain
composition of the extracellular region. Schematic depicting the domain
composition of receptor tyrosine kinase families. For each family of receptor
tyrosine kinase implicated in signaling, the protein domain composition is drawn
approximately to scale. Kinases are sorted alphabetically and aligned by their
16
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transmembrane region, indicated by a continuous vertical block. C-rich =
cysteine-rich domain; cad = cadherin domain; CC = disulfide bond; disc =
Discoidin domain; EGF-like = EGF-like domain; Fib3 = Fibronectin type III
domain; G-rich = glycine-rich domain; Ig = immunoglobulin domain; kringle
= kringle domain; L = L domain; L-rich = leucine-rich domain; LDLa = low
density lipoprotein class A domain; MAM = MAM domain; SAM = sterile
alpha motif domain; TyrK = tyrosine kinase domain. Adapted from (Hubbard
& Till 2000) and modified.
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Figure 2: Growth factors and receptor tyrosine kinases display di-
verse degrees of promiscuity and binding patterns seem to be gov-
erned by receptor tyrosine kinase family membership. Schematic de-
picting the binding preferences of growth factors and growth factor receptor
tyrosine kinases. Growth factor receptor tyrosine kinases are arranged alpha-
betically by family, growth factors are placed close to the binding receptors.
Convex rectangle-like polygons symbolize growth factors; concave rectangle-like
polygons symbolize growth factor receptors. Lines connecting growth factors
and receptors indicate ability to bind each other. Where known, higher affinity
binding is reflected by thicker lines. Transmembrane proteins are drawn before
a cartoon representation of a lipid bilayer; proteins integral to the extracellular
matrix are drawn before a cartoon representation of tangled helical protein
strings. Because the EPH and DDR families of receptor tyrosine kinases bind
transmembrane or extracellular matrix ligands, respectively, they are shown
separately in the lower right corner.
WNT1 and WNT3A (Lu et al. 2004). Interestingly, it also associates with and
attenuates the signaling of Ephrin receptors (Trivier & Ganesan 2002; Halford
et al. 2000).
1.2.5.2.1 A small number of proteins seems to be central to most
receptor tyrosine kinase pathways
In short, the complement of human receptor tyrosine kinases embodies a
multifarious reiteration of an efficient signaling paradigm. In addition to this
large variety in growth factor binding preference and signaling mechanisms,
18
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the receptor tyrosine kinases also appear to fulfill many different, quite spe-
cific biological roles. This is reflected in the corresponding gene knock-out
phenotypes (Table 3). Interestingly, receptor tyrosine kinases signal through
Figure 3: A small set of phosphotyrosine signaling components is
central to the ”hourglass” structure of growth factor receptor signal-
ing. Schematic depicting compound signaling pathways related to cell-cell
communication. Extracellular signals presenting in the form of neurotransmit-
ters, components of the extracellular matrix (ECM), soluble growth factors and
proteins integral to the membranes of neighboring cells, like nectins, cadherins,
antigens presented, CD48 or the main histocompatibility complex (MHC), far
outnumber their respective receptors. These receptors, comprising of neurotrans-
mitter receptors (NeuroR), integrins, receptor tyrosine kinases (RTKs), CD244,
cadherins, immune cell receptors (ImmuneR), nectins and catenins, in turn,
relay the signals through an even smaller number of cytoplasmic non-receptor
tyrosine kinases (NRTKs) and phosphotyrosine-recognizing domain-contain-
ing signaling genes (pY-signaling genes) to achieve very specific transcription
profiles appropriate to the extracellular signals.a
aNote that the number of transcription factors provided is an estimate based on the
number of genes annotated with the term GO:0003700 ”sequence-specific DNA binding
transcription factor activity” in the Gene Ontology project.
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Table 3: Receptor tyrosine kinase mouse knock-out phenotypes are
often very severe. Overview of obvious phenotypic effects of receptor tyrosine
kinase gene knock-outs in M.musculus. Genes are sorted alphabetically by
gene family and NCBI Symbols. Knock-out effects are described in terms of
easily observed differences to wild type animals and effects on life expectancy,
in particular. For each knock-out, a reference discussing its effects is provided.
Gene Obvious Phenotype Reference
Fa
m
ily
Symbol(s) Life Expectancy Effect
ALK
Alterations in
adult brain function
- Bilsland et al. (2008)
A
LK
LTK (No information available)
AXL - - Lu et al. (1999)
MERTK Retinal degradation - Duncan et al. (2003)
TYRO3 - - Lu et al. (1999)
A
X
L
AXL,
MERTK,
TYRO3
Male sterility, blindness - Lu et al. (1999)
DDR1
Reduced size
and body weight
- Vogel et al. (2001)
D
D
R
DDR2
Dwarfism,
impaired wound healing
- Labrador et al. (2001)
EGFR
Abnormalities in skin, kidney,
brain, liver, and
gastrointestinal tract
Lethal1 Threadgill et al. (1995)
ERBB2
Lack of cardiac trabuulae;
compromised motor nerve
development
Lethal
(E11)
Lee et al. (1995)
ERBB3 Severe neuropathies
Lethal
(E12.5)
Riethmacher et al. (1997)
EG
FR
ERBB4
Aborted development of the
heart muscle; abnormal
hindbrain development
Lethal
(E10.5)
Gassmann et al. (1995)
EPHA1
Abnormal tail development;
imperforate uterovaginal
development
- Duffy et al. (2008)
EPHA2 - - Chen et al. (1996)
EPHA3 Cardiac abnormalities
75%
Lethal
(P1)
Stephen et al. (2007)
EPHA4
Peroneal muscular atrophy;
absence of peroneal nerve
- Helmbacher et al. (2000)
EPHA5 - - Feldheim et al. (2004)
EPHA6 - - Savelieva et al. (2008)
EP
H
EPHA7 - - Rashid et al. (2005)
1exact time depends on genetic background
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Table 3: Receptor tyrosine kinase mouse knock-out phenotypes are
often very severe. (continued)
Gene Obvious Phenotype Reference
Fa
m
ily
Symbol(s) Life Expectancy Effect
EPHA8 - - Park et al. (1997)
EPHB1 - - Williams et al. (2003)
EPHB2 - - Orioli et al. (1996)
EPHB3 - - Orioli et al. (1996)
EPHB4
Defective cardiovascular
development
Lethal
(E10.5)
Gerety et al. (1999)
EPHB5 (Chicken only)
EPHB6 - - Shimoyama et al. (2002)
EP
H
EPHB2,
EPHB3
Secundary palate
closure failure
75%
Lethal
(P1)
Orioli et al. (1996)
FGFR1 -
Lethal
(<E10.5)
Deng et al. (1994)
FGFR2 -
Lethal
(<E8.5)
Arman et al. (1998)
FGFR3
Skeletal overgrowth;
inner ear defects
Reduced
lifespan
Colvin et al. (1996)
FGFR3,
FGFR4
Growth retardation, sickly
appearance, failure of
secondary septation
in the lungs
Severely
reduced
lifespan
Weinstein et al. (1998)
FG
FR
FGFR4 - - Weinstein et al. (1998)
INSR
Growth retardation,
pronounced hyperglycemia
Lethal
(<P7)2
Joshi et al. (1996)
INSRR - - Kitamura et al. (2001)
IN
SR
IGF1R
Respiratory failure, severe
growth retardation
Lethal
(P1)
Liu et al. (1993)
MET
Lethal
(E12.5)
Bladt et al. (1995)
M
ET
MST1R - - Waltz et al. (2001)
M
U
SK MUSK -
Lethal
(P1)
DeChiara et al. (1996)
PDGFRA Multiple neuronal, skeletal
and cardiac abnormalities
Lethal
(<E16)
Soriano (1997)
PDGFRB
Hemorrhagic,
thrombocytopenic,
severely anemic
Lethal
(P1)
Soriano (1994)
P
D
G
FR
KIT -
Lethal
(<P1)
Nocka et al. (1990)
2Note that INSR deficiency occurs naturally and is apparently not lethal in human
(Wertheimer et al. 1993).
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Table 3: Receptor tyrosine kinase mouse knock-out phenotypes are
often very severe. (continued)
Gene Obvious Phenotype Reference
Fa
m
ily
Symbol(s) Life Expectancy Effect
FLT3 - -
Mackarehtschian et al.
(1995)
P
D
G
FR
CSF1R
Toothlessness, truncated
limbs, domed skull, low body
weight, low growth rate,
deafness
- Dai et al. (2002)
P
T
K
7
PTK7 - - Lee et al. (2012)
R
ET RET
Renal agenesis or severe
dysgenesis; disrupted enteric
neurogenesis
Lethal
(P1)
Schuchardt et al. (1994)
ROR1 -
Lethal
(P1)
Nomi et al. (2001)
R
O
R
ROR2 Dwarfism, severe cyanosis
Lethal
(P1)
Takeuchi et al. (2000)
R
O
S
ROS Male sterility -
Sonnenberg-Riethmacher
et al. (1996)
R
Y
K RYK
Shortened snout and limbs,
completely cleft secondary
palate
Lethal
(P1)
Halford et al. (2000)
TIE
Severe edema, ruptured
microvasculature
Lethal
(E14)
Puri et al. (1995)
T
IE
TEK
Growth retardation,
malformation of vascular
network
Lethal
(E9.5)
Dumont et al. (1994)
NTRK1 Severe neuropathies
Lethal
(<P55)
Smeyne et al. (1994)
NTRK2 -
Lethal
(<P1)
Klein et al. (1993)
T
R
K
NTRK3 -
Lethal
(<P21)
(”most”)
Klein et al. (1994)
KDR No organized blood vessels
Lethal
(E9)
Shalaby et al. (1995)
FLT1 Abnormal vascular channels
Lethal
(E8.5)
Fong et al. (1995)
V
EG
FR
FLT4
Abnormally organized large
blood vessels
Lethal
(E9.5)
Dumont et al. (1998)
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a relatively small number of cytoplasmic proteins, like non-receptor tyrosine
kinases, GTPases, phosphoinositol and protein kinases and phosphatases and
adaptors, but ultimately effect a wide range of very specific responses (Figure 3).
This phenomenon is pictorially referred to as ”hourglass” or ”bow-tie” structure
(Oda et al. 2005). This structure has been argued to provide heightened robust-
ness (Ma & Zeng 2003; Kitano 2004), which seems peculiar given that more
than half of the receptor tyrosine kinase genes have a lethal phenotype when
knocked out in Mus musculus , but actually just underlines the importance of
phosphotyrosine signaling. More intriguing, however, is the question how the
signal specificity is retained while passing through the ”neck” in the ”hourglass”
(or the ”knot” in the ”bow-tie”) structure. Towards this end, the intracellular
phosphotyrosine signaling network has to be scrutinized.
1.2.5.3 Non-receptor tyrosine kinases are intracellular effectors of
protein phosphotyrosine signaling
The other kind of protein tyrosine kinase found in higher eukaryotes is the
group of non-receptor tyrosine kinases (Figure 4). These kinases are typically
cytoplasmatic and become activated upon being covalently modified or binding
an activated protein (Neet & Hunter 1996). Thus, they can function downstream
of the receptor tyrosine kinases in growth factor receptor pathways or they
can react to other signals, like chemokine receptor or integrin activation. In
the case of growth factor receptor signaling, the non-receptor tyrosine kinases
typically bind to sites that only become available after growth factor binding,
like a previously non-phosphorylated tyrosine residue on the receptor tyrosine
kinase itself or an associated adaptor protein. The most prominent non-recep-
tor tyrosine kinase family is the Src kinase family. Many Src kinase family
members have initially been found in tumor viruses (Gschwind et al. 2004).
The reason for this lies in the easily activatable structure and high potential
for promoting cell growth. Like most non-receptor tyrosine kinases, the Src
family kinases have a C-terminal kinase domain. The regulatory N-terminal
part consists of a ”unique” signal peptide sequence, an SH3 and an SH2 domain.
The signal peptide often contains a site for covalent modification with a fatty
acid residue, that directs the protein to the plasma membrane and activates it.
The SH3 and SH2 domains can fold back to bind intramolecular sites, rendering
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Figure 4: Non-receptor tyrosine kinase families contain protein-pro-
tein interaction domains. Schematic depicting the domain composition of
non-receptor tyrosine kinase families. For each family of non-receptor tyrosine
kinase the protein domain composition is drawn approximately to scale. Ki-
nases are sorted alphabetically and aligned by their carboxy-terminus. CRIB =
Cdc42/Rac interactive binding domain; DBD = DNA-binding domain; FABD =
F-actin-binding domain; FAT = Focal adhesion targeting domain; FCH =
Fes/CIP4 homology domain; FERM = FERM domain; PH = Pleckstrin homol-
ogy domain; SH2 = Src homology 2 domain; SH3 = Src homology 3 domain;
TyrK = Tyrosine kinase domain; TyrK-like = Tyrosine kinase-like domain
(catalytically inactive). Adapted from Blume-Jensen & Hunter (2001) and
modified to resemble the appearance in Hubbard & Till (2000).
the kinase domain catalytically inactive (Harrison 2003). To do so, the SH2
domain requires a C-terminal tyrosine residue to be phosphorylated (Y527
in SRC). Canonically, this residue is exclusively phosphorylated by the non-
receptor tyrosine kinase CSK. Consequently, these kinases can be activated in
several different ways. Besides the fatty acid modification, the intramolecular
domain interactions can be released by providing competing binding sites or by
regulating the phosphorylation status of the kinase itself. In addition to the
N-terminal inhibitory tyrosine residue, there is an activating tyrosine residue
in the activation loop within the kinase domain. Possibilities for activity-modu-
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lating mutations are equally manifold. Point mutations rendering fatty acid
modification obligatory or resembling a phosphotyrosine residue in the activa-
tion loop have an activating effect, while disruption of fatty acid modification or
a tyrosine-to-phenylalanine mutation in the activation loop have an inactivating
effect. Moreover, and more relevant for tumor viruses, both, N- and C-terminal
truncation of the kinase gene, can release intramolecular inhibition and activate
Src family kinases to a degree that brings about transforming potential. Under
healthy physiological conditions, however, activation usually requires binding
to a protein that has limited motility or undergoes transition to its activated
form only at very specific subcellular localizations. As a result, non-receptor
tyrosine kinase domain specificity is often low, because activation is linked to
binding and localization. Another consequence of this property is that non-
receptor tyrosine kinases are often active when transferred to an unnatural
environment, since the inhibiting factors, like CSK, are absent.
In short, non-receptor tyrosine kinases are important players in the context
of phosphotyrosine signaling, are highly relevant for cancer development, are
often also phosphotyrosine binders and are usually ”naturally active”, making
them very suitable for application out of the native cellular environment.
1.2.6 Phosphotyrosine-mediated protein-protein interac-
tions are mediated by specialized protein domains
Protein tyrosine phosphorylation is a post-translational modification that pro-
vides a mechanism for highly efficient dynamic regulation of protein-protein
interactions, both in terms of low latency and slim energy costs. Due to the
small size of the phospho group, the recognizing domains have to be optimized
for differentiating very similar structures. At the same time, phosphotyrosine-
recognizing proteins have to be specific for their binding partners to allow the
construction of complex regulatory networks. This specificity can be conferred
by the immediate surroundings of the phosphorylation site or by additional,
allosteric sites, or both. Early peptide binding experiments assume that binding
specificity stems from linear phosphotyrosine peptide motifs and the structure
of the phosphotyrosine-recognizing domain, alone. Apparently, these peptide
motif/binding domain specificities explain most of the biologically relevant phos-
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photyrosine-dependent protein-protein interactions. Nevertheless, it is possible
that the peptide binding experiments gave direction to the field of phosphotyro-
sine-dependent signaling and, therefore, possible binding events not fitting the
prevalent paradigm may just have been discarded without being examined. This
notion is supported by recent findings indicating that many phosphorylated
tyrosine residues in proteins do not fit the peptide motif knoledge (Olsen et al.
2006) and that multi-site tyrosine phosphorylation of proteins and multi-site
phosphotyrosine-recognition by the same interaction partner is the rule rather
than the exception (Schulze et al. 2005; Hanke & Mann 2009). Similarly, several
proteins contain more than one phosphotyrosine-recognizing domain and the
normal function of these arrangements seems binding to several sites on the
same interaction partner (O’Brien et al. 2000).
Phosphotyrosine recognition is mediated mainly by two types of domains: Src
Homology 2 (SH2) domains and PhosphoTyrosine Binding (PTB) domains.
Additionally, a small fraction of Pleckstrin Homology (PH) domains has been
shown to be able to recognize phosphotyrosine moieties. Finally, there are even
occasional reports of phosphotyrosine recognition by other domains.
1.2.7 SH2 domains are the primary mediators of phos-
photyrosine-dependent protein interactions
The protein domain most closely linked to phosphotyrosine recognition is the
Src Homology 2 (SH2) domain. This domain was named for the non-receptor
tyrosine kinase SRC and has first received attention, because it was conserved
among cytoplasmic, but not membrane-spanning, tyrosine kinases and was
able to influence kinase activity in a chimeric viral FES-related kinase gene
(Sadowski et al. 1986). The SH2 domain is a conserved region that is found in
121 instances in 111 human genes (Liu et al. 2011a), nearly all of which are
known to recognize phosphotyrosine residues in proteins.
1.2.7.1 SH2 domain structure is highly conserved and contains an
arginine residue critical for phosphotyrosine binding
The canonical SH2 domain fold consists of two α-helices and seven β-strands
arranged in the sequence β-α-β-β-β-β-β-α-β (Figure 5). The parts are labeled
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Figure 5: Src homology 2 (SH2) domains share a common fold with
a central, highly conserved motif responsible for phosphotyrosine
recognition. Schematic depicting the fold of a prototypic Src homology 2
(SH2) domain as 2-dimensional (a) and 3-dimensional structure model (b). Sec-
ondary structural elements are labeled in the 2-dimensional structure model (a)
and color-coded identically in the two models. In the 3-dimensional structure
model (b), the conserved FLVRES-motif and the recognized phosphotyrosine
residue (pY) are shown as sticks, the rest of the binding peptide (light blue)
and backbone of the SH2 domain are shown as cartoons. The 3-dimensional
structure model (b) is based on the Protein Data Bank (PDB) entry 1SHA, a
crystal structure model of the v-Src SH2 domain (Waksman et al. 1992).
by a secondary structure denominator and a consecutive capital Roman letter.
Loops and turns are addressed by two Roman letters, corresponding to the
connected secondary structure elements. The most conserved part of the SH2
fold is made up by the two α-helices flanking a central anti-paralell β-sheet made
up by three β-strands, βB, βC and βD. The interaction interface is formed by βD,
the N-terminal part of αA and less conserved features specific to the individual
SH2 domain gene. βE and βF form an extension of the anti-paralell β-sheet,
annealing to the C-terminal part of βD. βD can be split into two parts, referred
to as βD and βD′. The phosphotyrosine residue binding cleft is located between
27
1. INTRODUCTION
αA and the β-sheet; the C-terminal extension of the tyrosine-phosphorylated
peptide or protein proceeds perpendicular to the β-sheet towards αB. In this
region, there are often gene-specific features contributing to binding specificity,
like additional loops or α-helices. The N- and C-termini of the SH2 domain lie
at the side opposite to the binding surface and are canonically connected by βA
and βG. Thus, βA and βG are usually very short and often hard to recognize
as β-strands, often appearing highly bent with one end approaching a parallel
β-sheet with βB.
Accordingly, the binding surface is usually on the most exposed side of the
SH2 domain. The recognition of the phosphotyrosine residue itself is ensured by
several contacts. The FLVRES-motif, the most highly conserved peptide motif in
the SH2 domain, is central to βB. The first three residues position βB in relation
to the other features. The arginine residue makes two hydrogen bonds to two
terminal oxygen atoms in the phospho group with its primary amino groups. It
is often stabilized by a hydrogen bond between a serine or threonine residue in
βC and the secondary amine connecting the guanidinium group. According to
recent knowledge, this residue is indispensable for phosphotyrosine recognition
by SH2 domains (Mayer et al. 1992). The glutamate residue in the FLVRES-
motif is not directly involved in phosphotyrosine recognition and actually points
away from the binding surface. Nevertheless, it is highly conserved and is often
involved in several hydrogen bonds with αA and αB or additional structural
elements, like loops. The FLVRES serine residue makes a hydrogen bond to the
oxygen atom connecting the phospho group to the phenyl group. The residue
immediately C-terminal to the FLVRES-motif makes a hydrogen bond to the
phospho group with its backbone amine. The next residue is often a serine or
threonine that makes another hydrogen bond to the last oxygen atom in the
phospho group. The phenyl ring of the phosphotyrosine residue is recognized
by two basic amino acid residues forming amino-aromatic interactions. There
is a conserved arginine residue at the N-terminal end of αA, that typically also
makes a hydrogen bond to the phospho group. The second one is either a lysine
or an arginine residue in βD. This residue is often preceded by an aromatic
residue, that contributes to the binding surface. Before that, there is a highly
conserved histidine residue that contacts and positions the arginine residues in
αA and the FLVRES arginine residue.
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Overall, the SH2 domain is well-conserved structurally and in terms of actual
amino acid sequence. This is especially true for the residues involved in phospho-
tyrosine recognition and the residues forming the fold-determining secondary
structures.
1.2.7.2 SH2 proteins often contain other domains defining their
functions
The complement of SH2 domain-containing proteins is commonly divided into
groups according to biological function, as biological function and domain
composition are strongly related (Liu et al. 2006). Some SH2 proteins have
catalytic domains. For example, many non-receptor tyrosine kinases are SH2 pro-
teins (Neet & Hunter 1996). Similarly, there are protein tyrosine phosphatases
with SH2 domains (Neel et al. 2003). Interestingly, there are apparently no
protein serine or threonine kinases or phosphatases containing SH2 domains.
Nevertheless, a number of SH2 proteins carry domains related to phosphoinosi-
tol signaling (Carpenter & Cantley 1996), connecting phosphotyrosine signal-
ing to phosphoserine/-threonine signaling. Specifically, PLCG1 and PLCG2
cleave the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into dia-
cyl glycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates the
serine/threonine kinase protein kinase C (PKC). IP3 causes a release of intra-
cellular Ca2+ and activates Ca2+/calmodulin-dependent protein kinases and
PKC. The regulatory subunits of PI3K are also SH2 proteins, the catalytic sub-
units phosphorylate PIP2 producing phosphatidylinositol 3,4,5-trisphosphate
(PIP3). PIP3 activates PDK1 and AKT kinases, providing another link to phos-
phoserine/-threonine signaling. Finally, two of the phosphatases that inactive
PIP3, INPP5D and INPPL1, are also SH2 proteins. Thus, while there is no
SH2 protein with a domain related to phosphoserine/-threonine signaling, there
are many indirect links between the two. Other catalytic domains found in SH2
domains are more generic with regard to biological process. STAT proteins have
DNA binding domains identifying them as transcription factors, the Cbl family
proteins have RING and UBA domains, because they are E3 ubiquitin ligases.
SUPT6H has a chromatin remodelling domain and many SH2 proteins have
domains related to G-protein function. CHN1 and CHN2 have RhoGAP do-
mains, VAV1, VAV2 and VAV3 have RhoGEF domains; RASA1 has a RasGAP
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domain, SH2D3A, SH2D3C and BCAR3 have RasGEF domains, and RIN1,
RIN2 and RIN3 have Ras association domains. In addition to SH2 proteins
with domains related to other functions, some SH2 proteins have functions that
are not associated to a specific protein domain, like the tensin proteins, all of
which have cytoskeletal regulatory functions, or have binding domains only,
making their cellular function less obvious. By virtue of their many binding
domains and binding sites, proteins in the latter group are often able to bind
many interaction partners. Their function is therefore usually thought of as
bringing several other proteins together. For this reason, they are often referred
to as adaptor or scaffold proteins. Other protein interaction domains that are
often found in SH2 proteins are PTB, PH and SH3 domains, as well as SOCS
boxes.
To sum up, SH2 domains are often paired with other domains and fulfill many
different molecular functions related to several biological processes. Additionally,
some SH2 proteins seem to function as adaptor proteins, connecting tyrosine-
phosphorylated proteins to other proteins. Many SH2 proteins are also tyrosine-
phosphorylated and have been shown to interact with other SH2 proteins. As
a result, much of the phosphotyrosine function knowledge is related. On the
other hand, due to the knowledge-driven nature of low throughput experiments
investigating specific biological function, phosphotyrosine-dependent interaction
not fitting the prevalent paradigms may have been simply overlooked. There-
fore, the expected network resulting from an unbiased, genome-scale screen for
phosphotyrosine-dependent protein-protein interactions is a, for the most part,
connected network, that may or may not show a modular or hierarchical struc-
ture, but no systematic study involving full-length proteins has been produced
so far.
1.2.8 Many PTB domains bind phosphotyrosine residues
The second major phosphotyrosine-recognizing domain is the phosphotyrosine
binding (PTB) domain. The first description of a PTB domain was of the SHC1
PTB domain (Blaikie et al. 1994). In an effort to find new binders of tyrosine-
phosphorylated EGFR (Blaikie et al. 1994) randomly primed cDNA from mouse
fibroblasts was tested for binding to several human EGFR constructs. They
isolated a clone that was highly similar to the human SHC1 gene, but did
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not contain the SH2 domain, and corroborated this result by showing that
the homologous region in the human gene also binds EGFR in a tyrosine
phosphorylation-dependent fashion. Another such non-SH2 phosphotyrosine-
recognizing domain was found in IRS1 (Wolf et al. 1995) and, in spite of low
primary sequence similarity, adopts a similar fold (Zhou et al. 1996). This
domain represents another type of PTB domain. Subsequently, PTB domains
were classified as either ”Shc-like” or ”IRS-like”. Despite the suggestive name, the
PTB domain is actually less strongly implicated in phosphotyrosine recognition
than SH2 domains. In fact, (Uhlik et al. 2005) divide the PTB domains into
three groups and classify the largest group, comprising 75% of all PTB domains,
as phosphorylation-independent protein tyrosine binding. The PTB domain
groups heterogeneity is reflected in the fact that the members of the newly
proposed group of (non-phosphotyrosine-binding) ”Dab-like” PTB domains is
more similar to the (phosphotyrosine-binding) ”Shc-like” PTB domains than
the (also phosphotyrosine-binding) ”IRS-like” PTB domains are to each other.
1.2.8.1 PTB domains are structurally similar to PH domains
PTB domains represent a subgroup of domains with a pleckstrin homology (PH)
superfold, and are sometimes referred to as PH domains themselves (Blomberg
et al. 1999). As such, they are characterized by two antiparalell β-sheets forming
a perpendicular sandwich structure and an amphipatic C-terminal α-helix
contacting both β-sheets at the edge of the sandwich structure (Figure 6).
Peptides are bound at an interface between the C-terminal helix and one of
the β-sheets. Both β-sheets consist of four strands with one strand being part
of both sheets, displaying a strong bend in the middle. Labeling the parts by a
secondary structure denominater and a consecutive capital Roman letter the
first sheet is formed by the N-terminal part of βA, βB, βC and βD. The second
one is formed by βE, βF, βG and the C-terminal part of βA. αA connects βA
and βB. αB is the conserved C-terminal helix and contacts the β-sheets along
βE and the N-terminal half of βA in an ”antiparalell” manner. The binding
surface is formed by αB and βE. The bound peptide aligns to the second
β-sheet, forming an antiparalell extension. This is referred to as antiparallel
β-sheet augmentation (Harrison 1996). Deviations from this basic scheme are
relatively seldom and slight. For example, the PTB domains of SHC1, DAB1
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Figure 6: Phosphotyrosine binding (PTB) domains share a fold with
Pleckstrin homology (PH) domains. Schematic depicting the fold of a
prototypic Phosphotyrosine binding (PTB) domain as 3-dimensional (a) and
2-dimensional structure models. Secondary structural elements are labeled in
the 2-dimensional structure model (b) and color-coded identically in the two
models. In the 3-dimensional structure model (a), the amino-terminal α-helix
is only partly shown. The recognized phosphotyrosine residue (pY) is shown as
sticks, the rest of the binding peptide (light blue) and backbone of the PTB
domain are shown as cartoons. The 3-dimensional structure model (a) is based
on the Protein Data Bank (PDB) entry 2ELA, a crystal structure model of
the APPL1 PTB domain (Li et al. 2007), the recognized peptide was modeled
based on the Protein Data Bank (PDB) entry 1SHC, a crystal structure model
of the SHC1 PTB domain (Zhou et al. 1995).
and NUMB have an extra α-helix N-terminal to the first β-strand (Farooq et al.
2003; Yun et al. 2003; Zwahlen et al. 2000); in the IRS1 PTB domain βA does
not partake in the second β-sheet (Zhou et al. 1996); in the SHC1 PTB domain,
βA is split into two β-strands and αA is followed by a short additional β-strand
that extends the second anti-paralell β-sheet next to the second part of βA
(Farooq et al. 2003). However, since there is no highly conserved amino acid
sequence and because the connector regions are highly variable, PTB domains
are not easily recognized from primary sequence, despite their conserved fold.
32
1.2. Tyrosine phosphorylation is strongly linked to multicellularity
In contrast to SH2 domains, PTB domains fail to show a highly conserved
phosphotyrosine binding site.
1.2.8.2 PTB domain proteins are almost exclusively adaptor pro-
teins
Structurally, the largest group of PTB domain proteins has an N-terminal
PTB domain and is devoid of other defined protein domains (Yaffe 2002).
The second largest group pairs the PTB domain with a PH domain, that is
located N-terminal to the PTB domain. Other protein interaction domains are
also often found in combination with PTB domain, but, with the exception
of the phosphatase domain-containing tensin proteins, there are virtually no
conserved catalytic domains described in PTB domain proteins. Fittingly, the
PTB domain proteins are less well characterized in a functional context than
SH2 proteins, although this might also result from the comparatively lower
attention they received due to their late description and the smaller number of
oncogenes. While the group of PH and PTB domain-containing proteins are
almost exclusively thought of as adaptor proteins involved in growth factor
receptor signaling, the PTB domain proteins as a whole seem to have functions
ranging from cytoskeletal and focal adhesion regulation to G-protein association
and activation. Interestingly, the PTB domain proteins with similar domain
configuration often have diverse PTB domains, indicating cases of convergent
evolution. For example, the group of proteins containing a PTB domain only
comprises NUMB and DAB1 with their ”Shc-like” or ”Dab-like” PTB domain
as well as FRS2 with its ”IRS1-like” PTB domain; similarly, the group of PH
and PTB domain-containing adaptors contains the eponymous IRS1 and also
APPL1 and APPL2, the PTB domains of which resemble those of SHC1 and
DAB1 more than that of IRS1.
1.2.9 Phosphotyrosine binding by other protein domains
is rare
Aside from SH2 domains and PTB domains, several other protein domains
have been shown to bind to phosphorylated tyrosine residues on other proteins
(Kaneko et al. 2012b). Nevertheless, these reports seem singular and incidental.
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The PH domain is closely related to the PTB domain. The most common func-
tion of PH domains is phosphoinositol binding and other common PH domain
functions are often related, like phospholipid binding. Tyrosine-phosphorylated
peptides are also very similar to phosphoinositol or phospholipids. Therefore,
the PH domain suggests itself for non-SH2, non-PTB domain phosphotyrosine
binding. Indeed, there are examples of this, although the number is low. For
example, the PH domain of IQSEC1 binds EGFR-derived peptide in phospho-
tyrosine-dependent manner (Morishige et al. 2008) and even the name-giving
PLEK PH domain specifically binds a tyrosine-phosphorylated protein (Liu &
Makowske 1999). In addition to this, a number of other domains or domain ar-
rangements have also been shown to recognize phosphorylated tyrosine residues
in a protein or peptide context. For example, the C2 domains of PRKCD and
PRKCQ bind a CDCP1-derived phosphotyrosine-containing peptide. Interest-
ingly, PRKCQ, but not PRKCD, becomes activated upon binding (Stahelin
et al. 2012). Canonically, C2 domains bind Ca2+ and, usually dependent on
Ca2+ binding, phospholipids (Rizo & Südhof 1998). A PKM isoform binds
phosphotyrosine peptides causing the release of FBP1 (Christofk et al. 2008).
CBLL1 uses a novel HYB domain to bind phosphotyrosine peptides (Fujita
et al. 2002) and PEBP1 binds RAF1 in a phosphotyrosine-dependent manner
(Simister et al. 2011). In Caenorhabditis elegans , tyrosine-phosphorylated mbk-2
has been shown to be sequestered by deficient PTP domains of egg4 and egg5
(Cheng et al. 2009).
1.2.10 Protein tyrosine phosphatases are the oldest phos-
photyrosine signaling components
Protein tyrosine phosphatases complete the phosphtyrosine signaling ”toolkit”
(Pincus et al. 2008) by providing the final component. While there is no
inherently necessary association of semantic categories and biochemical function,
the tyrosine kinases are canonically considered ”writers” and the phosphatases
”erasers”. This may be mere historical accident, resulting from the much earlier
description and characterization of kinases (Hunter 2009). On the other hand,
the biological utilization of phosphotyrosine signaling seems to largely match this
interpretation. Specifically, tyrosine kinases are usually activated in response
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to specific signals, often embodied as or associated with specific signaling
molecules, like growth factor proteins. Further, protein-protein interactions
are usually induced (as opposed to inhibited) by tyrosine phosphorylation
and often have an activating effect on downstream processes. Finally, protein
tyrosine phosphatases are often inactivated following signaling events like ligand
binding, either forming inhibitory intra- or intermolecular interactions or by
becoming covalently but reversibly oxidized on the catalytic cysteine residue as a
consequence of hydrogen peroxide release (Ostman & Böhmer 2001). Hydrogen
peroxide has been recognized relatively early as an inducer of intracellular
tyrosine phosphorylation (Kadota et al. 1987), but the exact and complete
mechanism of action is still unclear. It seems clear, however, that, dependent
on the cell type, a CYBB- or a NOX1-containing NADPH oxidase complex
is one of the main producers of physiological hydrogen peroxide and that
hydrogen peroxide production is a response to growth factor / receptor binding
and involves PI3K action (Rhee et al. 2003). Such a mechanism of tyrosine
phosphatase regulation provides ties to other processes involving hydrogen
peroxide, like cytotoxic immune response or mitochondrially controlled apoptosis
(Bae et al. 2011), but seems inherently unspecific. Additionally, protein tyrosine
phosphatases are the evolutionarily oldest part of the phosphotyrosine signaling
”toolkit”, suggesting that they are the least specific components. Thus, protein
tyrosine phosphatases have often been considered unspecific and less relevant for
medical purposes than protein tyrosine kinases, even in spite of circumstantial
evidence to the contrary, like the high number of active tyrosine phosphatases
(107 in human (Alonso et al. 2004)), which rivals the number of tyrosine kinases
(90 in human (Robinson et al. 2000)). However, the universality expressed in
this view is currently being revised (Ramponi & Stefani 1997).
1.2.10.1 There are several groups of protein tyrosine phosphatases
Systematically, protein tyrosine phosphatases are rather diverse and usually di-
vided into three groups: classical protein tyrosine phosphatases, dual specificity
phosphatases and low molecular weight phosphatases (Zhang 1998; Andersen
et al. 2001; Neel & Tonks 1997; Tonks 2006). Others (Alonso et al. 2004) group
tyrosine phosphatases based on amino acid sequence of the catalytic domain and
come up with four classes: class I Cys-based protein tyrosine phosphatases, in-
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cluding classical protein tyrosine phosphatases and dual specificity phosphatases,
class II Cys-based protein tyrosine phosphatases, including low molecular weight
phosphatases, class III Cys-based protein tyrosine phosphatases and Asp-based
protein tyrosine phosphatases.
1.2.10.1.1 Classical protein tyrosine phosphatases are either intra-
membrane receptors or cytoplasmic
Analogous to protein tyrosine kinases, classical protein tyrosine phosphatases
come in two forms, transmembrane receptor phosphatases and non-transmem-
brane receptor phosphatases (Zhang 1998; Andersen et al. 2001; Neel & Tonks
1997; Tonks 2006). Akin to receptor tyrosine kinases, transmembrane receptor
phosphatases dimerize upon ligand binding. However, in contrast to receptor
tyrosine kinases, dimerization is usually accompanied by trans-binding of an
”inhibitory wedge”, reducing catalytic activity (Majeti et al. 2000). The ligands
of transmembrane phosphatases are often extracellular matrix proteins or they
form homophilic interactions, i.e. they bind the extracellular domains of identi-
cal transmembrane phosphatases expressed by neighboring cells (Ostman &
Böhmer 2001). Non-transmembrane phosphatases are thought to be inactivated
via receptor tyrosine kinase action, either by becoming phosphorylated and
forming inhibitory intra- or intermolecular interactions, like PTPN11 (Hof et al.
1998), or as a consequence of hydrogen peroxide release.
1.2.10.1.2 Dual-specificity phosphatases are mostly specialized on
MAP kinase signaling
Dual-specificity phosphatases are strongly associated with MAP kinase signal-
ing (Keyse 2000). As indicated by the designation, dual-specificity phosphatases
are capable of removing phospho groups from tyrosine, serine and threonine
residues in proteins. This behavior seems sensible in the context of MAP kinase
signaling, since MAP kinases auto-phosphorylate on tyrosine residues in the
activation loop (Huang & Tan 2012). However, dual-specificity phosphatases
are increasingly recognized as functioning outside of this context (Huang &
Tan 2012). In human, there are twenty-five dual-specificity phosphatase genes,
two of which (DUSP24 and DUSP27) are rendered catalytically inactive by a
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cysteine-serine substitution in the active site (Huang & Tan 2012). The group
is sub-classified as typical or atypical, based on the presence or absence of
a CDC25 domain, respectively. This domain is generally responsible for the
specific binding of MAP kinases. Interestingly, there are several dual-specificity
phosphatases without this domain that have been shown to be involved in
MAP kinase signaling and several dual-specificity phosphatases carrying this
domain that seem to have no function in MAP kinase signaling (Huang & Tan
2012). The typical dual-specificity phosphatases are further divided into three
groups based on their predominant subcellular localization. The non-MAP
kinase signaling-related functions associated with dual-specificity phosphatases
are mostly related to JAK/STAT signaling. Specifically, many dual-specificity
phosphatases interact with and dephosphorylate STAT proteins or regulate
them indirectly (Huang & Tan 2012). For many dual-specificity phosphatases,
knock-out mice show phenotypes related to immune function, the most obvious
field of intersection between MAP kinase signaling and JAK/STAT signaling.
1.2.10.1.3 Low molecular weight phosphatases appear to be the old-
est group of protein tyrosine phosphatases
Low molecular weight phosphatases are the group most different from the
other protein tyrosine phosphatases, possibly indicating a different evolutionary
origin or an earlier divergence. In comparison to the other tyrosine phosphatases,
they are rather small, with a typical molecular weight of about 20 kDa, are
probably the most unspecific group of tyrosine phosphatases and are also
prevalent in prokaryotes (Ramponi & Stefani 1997). Thus, low molecular weight
phosphatases may function as unspecific antagonists of protein tyrosine kinases,
counteracting ligand-independent activation of receptor tyrosine kinase signaling
pathways.
1.2.10.2 The protein tyrosine phosphatases complement kinase ac-
tion providing a fully adjustable signaling mechanism
In essence, efficient phosphotyrosine signaling is possible only in the interplay
of tyrosine kinases, tyrosine phosphatases and phosphotyrosine-recognizing
proteins. Apparently, phosphatases emerged earliest and, thus, are overall less
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specific than kinases and phosphotyrosine-recognizing proteins. The tyrosine
phosphatases seem to be a polyphyletic group and the evolutionarily younger
members are apparently more prone to carrying out functions specific to a
limited set of phosphorylation sites, while the older ones counter kinase action
in a more unspecific fashion. At the very least, this mechanism guarantees that
kinase activation can have constant effects over time. However, it may even
be superior to more complex and more frugal (in terms of ATP consumption)
systems that directly regulate phoshorylation levels when subcellular gradients
of phosphorylated proteins are advantageous, provided the kinase or the phos-
phatase activity is properly localized. In any case, insights into phosphatase
action, especially in connection with kinases, will surely prove useful for un-
derstanding how proteins interacting in a phosphotyrosine-dependent manner
turn external stimuli into appropriate cellular responses.
1.3 Protein-protein interactions form networks
1.3.1 Protein interactions are more directly related to
cellular function than gene sequences
The vast majority of cellular processes is regulated and carried out by proteins.
Therefore, understanding what proteins do and under which conditions is vital
for understanding cells on the molecular level (Cusick et al. 2005). The Human
Genome Project (Venter et al. 2001) is a valuable basis for research in this
direction in that it provides an inventory of possibly expressed proteins that
is in principle complete. This information has to be complemented by protein
expression data and protein-protein interaction information. Protein expression
data is being collected in many cell types and under many different conditions
in microarray and RNASeq experiments, both of which are high troughput
compatible. Protein-protein interaction data are more difficult to obtain, for a
number of reasons (Braun et al. 2009). First of all, protein-protein interactions
are fundamentally transient and cannot be directly observed in cells that have
not been tampered with in some manner. In other words, proteins have to be
modified or overexpressed, or cells have to be manipulated to allow for interaction
detection, e.g. by antibody binding. Additionally, native protein expression
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levels differ by many orders of magnitude and protein interactions detected in a
natural environment may be of a secondary nature, i.e. both proteins may bind
to a third one, but not directly to each other. A way around these problems is
assessing protein-protein interactions in more artificial settings, like in vitro
or yeast two-hybrid assays. As a consequence, each protein-protein method
detects only a relatively small subset of interactions and the results of several
methods have to be combined to obtain a complete picture. At the same time,
the number of possible interactions that have to be assayed is a second order
function of the number of proteins of interest. Therefore, most high throughput
protein-protein interaction screens operate on a gene level (ignoring isoform
specificity) and post-translational modifications. Especially the latter are of
extreme importance for the regulation of growth and development, however,
because they are capable of signaling on a much faster time-scale and with
higher efficiency.
1.3.2 Protein interaction networks are a source for bio-
logical hypotheses
Protein-protein interaction networks are a rich source for novel hypotheses
regarding the biological relevance of individual proteins, the relation of biological
pathways and the fundamental organization of cellular regulatory mechanisms
(Barabási & Oltvai 2004). These hypotheses can be based on the network
structure alone, for example, proteins with a higher number of interactions are
more like to be important, as are proteins and interaction that are more central
to the network (Batada et al. 2006). Even more extensive hypotheses can be
reached, when the interaction network is coupled with additional information.
For example, interacting proteins whose expression is highly correlated are
probably members of the same complex or a protein interacting with many
other proteins often found mutated in connection with a specific disease likely
play a role in the development of said disease (Chuang et al. 2007; Barabási
et al. 2011).
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1.3.3 Low throughput follow-up experiments raise confi-
dence in protein-protein interaction screens
Large scale protein-protein interaction screening experiments are often con-
cluded by low throughput experiments focusing on a very small subset of
interactions underlining the biological relevance of the data set (Goehler et al.
2004; Lim et al. 2006; Wong et al. 2007). At the same time, such follow-up
experiments often support the quality of the data set in terms of false positive
rate estimates. Unfortunately, these two purposes suggest different strategies.
Investigation of biological context usually requires restriction to a very small
subset of interactions, whereas demonstrating data set quality demands a large
subset, if it is supposed to be nearly as meaningful as statistical bioinformatics
analyses, like comparison to other datasets or interaction co-enrichment analysis.
Therefore, the quality, range of suitable further applications and degree of ac-
ceptance received from the scientific community of a protein-protein interaction
study profit greatly from an expedient selection of low throughput follow-up
assays.
1.3.4 Biological pathways are reflected in protein-protein
interactions
Protein-protein interaction networks are strongly related to biological pathway
maps (Scott et al. 2006). Nevertheless, there are substantial differences. First
and foremost, protein-protein interaction maps focus on biophysical information
and lead to biological function as an emerging property of a complex system
in a bottom-up fashion. Biological pathway maps, on the other hand, focus
on a specific biological function or subsystem and aim to explain the internal
workings of the system in question in terms of interacting components in a
top-down approach. As a consequence, protein-protein interaction networks
may contain interactions whose function is unknown, or, in the extreme case,
that have no biological function, and biological pathway maps may contain
links that have no direct biophysical correlate. Nevertheless, in an ideal world
(with perfect interaction networks and pathway maps), the pathway map should
be traceable in terms of physical interactions, because transfer of information
between proteins without physical interaction is extremely unlikely.
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Thus, it almost seems like a necessary consequence that the view of biologi-
cal regulation is shifting more and more from individual, isolated pathways
to strongly interconnected pathways and, finally, regulatory networks. This
development is especially prominent when it comes to pathways involved in
the regulation of growth and development, because there is a striking overlap
in the components involved, leading to the question: how can growth factor
receptor pathways achieve specific outcomes employing similar sets of proteins
(Chao 1992)?
Unbiased, genome-wide screening results are especially valuable due to the
high potential for finding functional connections otherwise concealed (Stelzl
& Wanker 2006). Protein-protein interaction networks therefore grant addi-
tional clarity above all, where biological semantics deviate from one-to-one
relationships between genes or proteins and functions. Some examples of such
situations are (a) where direct experimental analysis is impossible because the
gene in question has other functions that interfere with the assay, for example,
because mutants are not viable, (b) where conventional approaches report
inconclusive results due to cooperative effects, for example as a result of partial
compensation by another gene with overlapping function, or (c) where emergent
properties are concerned, i.e. when the complex system develops properties
that are different from the combined properties of its parts.
1.3.5 Protein-protein interaction networks improve clas-
sification of cancers
A very direct link from fundamental research to medical application is the use
of protein interaction networks for the diagnosis, comprehension and treatment
of disease (Barabási et al. 2011). A prime example of a complex disease that is
difficult to understand because of its plasticity, is cancer (Hong & Hait 2010).
In fact, it has been argued, that cancer should be regarded as a multitude
of diseases, and the number of different types of cancer is usually estimated
as more than one hundred (Hanahan & Weinberg 2000). Generally, cancers
derived from the same type of tissue are often similar. Therefore, a classification
scheme based on tissue type is widely used. On the other hand, cancers derived
from the same tissue are also often very different, resulting in a more specific
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classification scheme, for example, lung cancer is divided into small cell and
non-small cell lung cancer and breast cancer is commonly classified based on
the expression levels of ESR1/2, PGR and ERBB2 or the mutational state of
BRCA1/2. Other times, it is even argued that every cancer is different (Greaves
& Maley 2012). Therefore, analysis of cancer development is a prime candidate
for the application of network-based methods.
A prime example for the application of protein interaction network-based meth-
ods for cancer research is the work of Chuang et al. (2007), who overlayed a
protein-protein interaction network with information about expression changes
in breast cancer and extracted discriminative subnetworks. They further demon-
strated that these subnetworks are more accurate and more robust classifiers of
metastasis than those based on single genes. Pujana et al. (2007) combined PPI
and expression data to identify novel breast cancer genes and prove the validity
of their method by way of example on the HMMR gene. Taylor et al. (2009)
analysed coexpression differences between hubs and their interaction partners in
breast cancer to find diagnostic network modules. Nibbe et al. (2009) combined
PPI and expression data to identify subnetworks discriminative for colon cancer.
Li et al. (2012) used nearest neighbor-, GO- and shortest path-based methods
to derive novel colon cancer genes from known colon cancer genes and protein-
protein interaction information. Interesting about all of these examples is the
restriction to relatively well-known and homogenous forms of cancer, like breast
and colon cancer, and the motivation for the selection of the additional data.
Almost all of the authors explicitly state that they aim to attach a dynamic
element to the protein-protein interaction maps. This indicates a demand for
protein interaction maps that have intrinsic dynamic elements, especially for
the analysis of more complex types of cancer.
1.3.6 Assays of dynamic interactions are focused on small
subsets of protein-protein combinations
Protein-protein interactions are generally detected in artificial settings, either in
vitro, in artificial cellular environments, or as tagged and overexpressed versions
(Braun et al. 2009). Additionally, protein-protein detection methods have high
false negative rates. As a consequence, protein-protein interaction maps gener-
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ally contain all detected interactions without context information (Rinner et al.
2007). In principle, protein-protein interactions that can be detected by affin-
ity purification/mass spectrometry-based methods are amenable to dynamic
analysis, because they allow comparing results from different cells, states etc.
In practice, there are several studies exemplifying the possibilities, but have a
very limited scope in terms of interacting proteins, especially bait genes. For
example, Blagoev et al. (2003) used SILAC to compare proteins precipitated
from HeLa cells with the GRB2 SH2 domain before and after EGF stimulation;
Brand et al. (2004) used an ICAT-LC/MS approach to compare co-immunopre-
cipitation partners of Mafk in murine erythroleukemia cells before and after
DMSO-induced differentiation; Blagoev et al. (2004) used SILAC to compare
proteins precipitated from HeLa cells with a phosphotyrosine-specific antibody
(4G10) before and after 1 min and 10 min of EGF stimulation; Wu et al. (2006)
compared EGFR binders in A 431 cells before and after 0.5 min, 2 min, 10 min
and 240 min of EGF stimulation; Wang & Huang (2008) used (mixing after
purification)-SILAC to differentiate stable and dynamic RPN11 binders, Mous-
son et al. (2008) compared MAP (mixing after purification)-SILAC and PAM-
SILAC results to differentiate stable and dynamic TBP binders in HeLa cells
and Kito et al. (2008) used a similar method for eIF2Bβ(GCD7 locus) binders
in S. cerevisiae. A very noteworthy example is the study presented by Bisson
et al. (2011). Here, affinity precipitation(AP)-coupled selected reaction moni-
toring (SRM) was used to identify dynamic binders of GRB2 in HEK293T cells.
Binders were classified as SH2- and SH3-dependent with the help of domain
mutations. Additionally, EGF, FGF, HGF, IGF, INS and PDGFB stimulation
were compared, and for EGF stimulation, samples from five different time points
were assessed. Nevertheless, not one of these studies employs more than one
bait gene. Thus, a comprehensive study addressing the dynamics of interactions
among full-length proteins experimentally, is currently missing.
1.4 Protein-protein interactions detected by dif-
ferent methods are complementary
The detection of biologically relevant protein-protein interactions is difficult due
to the high number and diversity of proteins and their interactions. In contrast
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Figure 7: Complementary methods for detecting protein-protein in-
teractions use different molecular mechanisms. Schematic depicting the
most common methods for detecting protein-protein interaction. In affinity
purification-coupled mass spectrometry-based methods (a) complexes of pro-
teins containing a usually tagged protein of interested are purified and member
proteins are identified in mass spectrometric analyses. In peptide array binding
assays (b) spots of peptides are immobilized on a membrane and probed with
the protein of interest; after washing, bound proteins are visualized either di-
rectly or indirectly. In high throughput co-immunoprecipitation (c) two tagged
proteins of interested are expressed in mammalian culture and immobilized in
a microplate using the tag fused to one of the proteins; binding is determined
by measuring the activity of the luciferase tag fused to the other protein. In
protein complementation assays (d) a suitable reporter protein is split and
fused to two proteins of interest; if the two proteins interact, the reporter is
reconstituted when the two fusion proteins are expressed in mammalian cell
culture. In yeast two-hybrid experiments (e) two proteins of interest are fused
to the DNA-binding and the RNA-polymerase activation doamin, respectively,
and expressed in a yeast cell containing one or more reporter gene constructs;
interaction of the two proteins activates the reporter genes, usually conferring
the ability to grow on selection medium.
to other macromolecules carrying biological functions, like RNA and DNA,
proteins are made up from a high number of building blocks with versatile
biochemical properties. As a consequence, protein-protein interaction surfaces
and interaction parameters, like kon and koff rates or dissociation constants,
are highly diverse, making protein-protein interactions almost impossible to
predict from protein structure alone and each protein-protein detection method
44
1.4. PPIs detected by different methods are complementary
suitable for a limited subset of interactions only. Thus, protein-protein knowledge
relies heavily on ”Professoral intuition”-driven low throughput experiments and
repeated unbiased high throughput experiments with different methods, the
results of which are combined in a complementary fashion. Accordingly, there
are many methods for the detection of interactions between proteins (Figure 7).
1.4.1 Affinity purification-coupled mass spectrometry is
the main method for detecting stable protein com-
plex associations
A powerful method for the detection of protein-protein interactions, especially
in the context of protein complexes is affinity purification coupled with mass
spectrometry (Aebersold & Mann 2003; Bauer & Kuster 2003). Typically, a
bait protein construct containing an affinity purification tag is overexpressed in
the cells of interest and this tag is utilized in purifying the bait protein and its
binders. The binders are then prepared for mass spectrometric analysis and
identified (Figure 7a).
Commonly used purification tags are TAP, FLAG, Protein A, HA or Myc
tag, but other purification methods, like His-Nickel-NTA or glutathione-GST
purification, or antibodies against endogenous proteins can also be used. well-
established tag systems are preferred for high throughput experiments, because
they provide experimental procedures amenable to parallelization and equalize
expression level and purification efficiency (Lichty et al. 2005).
Almost all mass spectrometric analysis methods rely on peptide cleavage by
trypsin, followed by a database comparison (Fenyö 2000). Specifically, sequences
obtained by exact mass determination of b- and y-ions, specific combinations
of precursor and product ions (SRM, Lange et al. 2008) or characteristic co-
occurrence of tryptic peptides (MASCOT, Perkins et al. 1999) are used to select
proteins from a database prepared for the respective analysis.
Due to the enormous advances in mass spectrometry technology in the last
decades, mass spectrometry-based method are very effective tools for detecting
protein-protein interactions. Nevertheless, these methods are far from perfect
or universally applicable (Aebersold & Goodlett 2001). First of all, because
complexes are analyzed, the detected interactions are not binary, i.e. it is unclear
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whether the interactions are direct or mediated by other members of the complex.
Secondly, due to the huge differences in protein expression rates, interactors in
low abundance can easily be masked by highly abundant interactors or even
non-specific binders. Additionally, many weak or transient binders are lost in
the washing steps and proteins that do not produce suitable peptides when
treated with trypsin cannot be detected at all.
1.4.2 Peptide array binding is an efficient method for de-
tecting protein-peptide interactions
Another method that can be used to discover protein-protein interaction is
peptide array binding (Volkmer et al. 2012). For this type of experiment, many
different peptides are spotted on a surface, typically a glass slide, incubated
with a purified tagged protein, and subsequently with a fluorescently labeled
antibody (Figure 7b). Even though this method requires purified proteins, it is
very powerful, because a very high number of peptides can be assayed at the
same time. The biggest drawback of this method is the use of peptides instead of
full-length proteins. Many protein-protein interactions rely on complex surfaces,
not just linear peptide motifs (Chakrabarti & Janin 2002).
1.4.3 Luciferase makes co-immunoprecipitation amena-
ble to high throughput approaches
The LUMIER method is a high throughput adaptation of an established
method for the detection of protein-protein interactions, co-immunoprecipitation
(Barrios-Rodiles et al. 2005). Classical co-immunoprecipitation experiments
employ two antibodies. The first one is used to precipitate the first protein of
interest from a cell lysate. The second one demonstrates the binding of the
second protein of interests on a Western blot. In LUMIER type experiments,
the first protein is bound to the surface of a 96-well microplate and the second
protein is fused to a luciferase gene. Luciferases are enzymes that can activate
specific substrates to produce bioluminescence (Figure 7c). This way, the co-
immunoprecipitation can be performed in 96-well format and read out in a lumi-
nescence reader, making LUMIER-type methods suitable for high throughput
protein-protein interaction screens.
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1.4.4 Protein complementation assays visualize protein
interactions in intact mammalian cells
Protein complementation assays utilize proteins that can be easily observed and
can be split into two parts that regain their function when brought together
(Kerppola 2006). The two parts are fused to two proteins of interest and the
resulting hybrid proteins are expressed in cell culture. If the two proteins
interact, the reporter protein is reconstituted and becomes active, for example,
a split-GPF becomes fluorescent or a split-luciferase produces luminescence
(Figure 7d). A big advantage of this method is that the interaction can be
observed in intact cells and in a specific subcellular localization. On the other
hand, the method requires a relatively large manual effort to ward against false-
positives resulting from signals produced by misfolded proteins finding each
other in the endoplasmic reticulum.
1.4.5 The yeast two-hybrid systems is the prime method
for detecting binary protein-protein interactions in
screening assays
The yeast two-hybrid system (Fields & Song 1989) is a very well-established
method for the detection of protein-protein interactions. The proteins that are
assayed for interaction are fused to transcription factor domains, the so-called
bait proteins to a DNA-binding domain and the so-called prey proteins to a
transcriptional activation domain. These hybrid proteins are overexpressed in a
yeast cell containing one or several appropriate reporter gene constructs. If the
two proteins interact, the reporter gene activation provides an easily observable
signal (Figure 7e).
Typical reporter genes are genes encoding enzymes involved in the synthesis
of fundamental cellular anabolites, like amino acids or nucleotides, employed
in respective auxotroph mutant yeast strains. In this case, the yeast can grow
on medium lacking these anabolites only if the two hybrid proteins interact.
Another commonly used reporter gene is β-galactosidase. Observing this signal
requires an additional reporter gene assay in which the yeast cells are opened
and treated with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (XGAL) to
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produce a blue stain where the proteins interact. The vast majority of yeast
two-hybrid systems employs GAL4 or LexA DNA-binding and transcriptional
activation domains.
Historically, the majority of yeast two-hybrid experiments relied on complex
prey libraries. These libraries were often cDNA libraries generated by reverse
transcription using oligo(dT) primers. As a consequence, the results of the
early yeast two-hybrid experiments are biased towards interactions mediated by
C-terminal proteins domains and, more importantly, towards highly expressed
genes. Therefore, more thorough investigations employ prey matrices instead, i.e.
arrays of defined prey cultures. This setup requires a higher initial effort, but has
many advantages. The most import ones are equal testing probabilities for all
prey strains and defined testing parameters allowing repeating and comparing
of individual assays.
Yeast two-hybrid provides binary interactions at an extremely low false-positive
rate (Braun et al. 2009; Venkatesan et al. 2009), making it the method of choice
for screening applications without distinctive prior estimation. Thus, we applied
the yeast two-hybrid system as the primary screening method in this study.
1.4.5.1 The yeast two-hybrid system is inherently well-suited for
high throughput applications
In addition to its inherent ability to produce high quality interactions in terms
of low false positive rate, the yeast two-hybrid system has several other virtues
making it extremely suitable for screening assays. The most important ones are
the ones making it amenable to high throughput studies (Parrish et al. 2006).
Specifically, the robustness of experimental procedures especially related to
the screening itself allows working in microplate format and using robots to
combine and process bait and prey strains, thereby combating the combinatorial
explosion effect.
1.4.5.2 Analysis of phosphotyrosine-dependent protein interactions
requires introduction of a tyrosine kinase gene
The analysis of protein phosphotyrosine-related effects in S. cerevisiae is in-
trinsically artificial, since there is no phosphotyrosine signaling in yeast. As
a consequence, there is virtually no background in terms of protein tyrosine
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kinase and protein tyrosine phosphatase activity (Gnad et al. 2009). Therefore,
every important component related to tyrosine phosphorylation, like the kinase,
has to be provided by the experimental setup. This implies that native regu-
latory mechanisms common to organisms that make use of phosphotyrosine
signaling are absent in the yeast environment. In turn, this makes the experi-
ments cleaner and the attribution of modifying and recognizing proteins easier
in several respects. In mammalian cells, in contrast, protein tyrosine kinase
activity can never be abolished completely, because that would cause the cells
early demise. Furthermore, even if it were possible, experimental validation
of the absence of kinase activity would be practically impossible. In addition,
kinases often activate other kinases, which makes actually determining which
kinase phosphorylates a specific site or enables a specific interaction extremely
difficult.
Modified yeast two-hybrid systems have been used to detect phosphotyrosine-
dependent protein-protein interactions several times before (Keegan & Cooper
1996; Dombrosky-Ferlan & Corey 1997; Osborne et al. 1995; Rocchi et al.
1998; Marti et al. 1998; Delahaye et al. 2000; Warner et al. 2000; Yamada
et al. 2001; Cao et al. 2002; Sayós et al. 2004; Ingley et al. 2006; Sylvester
et al. 2010), but, to our knowledge, there has never been a comprehensive
screen for phosphotyrosine-dependent interactions based on the yeast two-
hybrid technology.
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1.5 Aim of the study
Proteins are the most important functional units on the molecular level of biolog-
ical systems. As a consequence, understanding protein-protein interactions is key
to understanding how cells work. Phosphotyrosine-dependent protein-protein
interactions are especially interesting, because they are extremely important
in regulating growth and development and can be highly dynamic. The close
connection to regulation of growth and development makes phosphotyrosine
signaling extremely relevant for many fields of interest in current biomedical
research, like cancer or immunological disease.
This study attempts to fill a gap in protein-protein interaction knowledge by
presenting an unbiased genome-scale set of phosphotyrosine-dependent protein-
protein interactions found in yeast two-hybrid experiments. In doing so, we seek
to gain insight into the architecture of the central cellular regulatory network
in terms of general, structural make-up as well as identifying specific proteins
fulfilling important network functions.
The current knowledge of phosphotyrosine-dependent protein-protein interac-
tions stems mainly from low throughput experiments based on serendipitous
observations or high throughput studies relying on peptide microarray or com-
plex purification/mass spectrometry techniques.
We address this issue by screening a comprehensive set of genes with protein
domains strongly implicated in protein phosphotyrosine recognition against a
genome-scale prey matrix using an extended version of a well-established yeast
two-hybrid system and methodology. We mean to assess the quality of our
results in independent coimmunoprecipitation experiments from mammalian
cell culture. Complementary to this experimental validation we are going to
use computational analyses to test the data set for consistency and estimate
its novelty and completeness.
Following the successful validation of our data, we will demonstrate its power
as basis for hypothesis generation by exploring a small number of hypotheses
prompted by our screen that are particularly interesting in that they improve
upon current paradigms of phosphotyrosine signaling.
To sum up, we aim to assemble a comprehensive set of phosphotyrosine-depen-
dent protein-protein interactions that is largely complementary to the current
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knowledge, because we employ a yeast two-hybrid approach. Further, we mean to
demonstrate the data sets high quality using a number of established validation
tools.
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Chapter 2
Material and Methods
2.1 Buffers and reagents
2.1.1 Vendors
All materials used for this study were acquired from well-established vendors
through the purchase department of the Max-Planck-Institute for Molecular
Genetics. The vendors are detailed here. In the remainder of this work, vendors
are referred to by the short names.
Vendor
(Short Name)
Details
Abcam Abcam plc
330 Cambridge Science Park
Cambridge CB4 0FL, UK
http://www.abcam.com
Agilent Agilent Technologies Sales & Services GmbH & Co.KG
Life Sciences & Chemical Analysis
Hewlett-Packard-Str. 8
D-76337 Waldbronn
http://www.agilent.com/chem
Applichem AppliChem GmbH
Ottoweg 4
D-64291 Darmstadt
http://www.applichem.com
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Vendor
(Short Name)
Details
BD Biosciences Becton, Dickinson and Company
1 Becton Drive
Franklin Lakes, New Jersey 07417-1880
http://www.bd.com
BioTez BioTeZ Berlin Buch GmbH
Robert-Rössle-Strasse 10
Haus D 79 3.OG
D-13125 Berlin
http://www.biotez.de
Bio-Rad Bio-Rad Laboratories Headquarters
1000 Alfred Nobel Drive
Hercules, CA 94547
http://www.bio-rad.com
Eppendorf Eppendorf Vertrieb Deutschland GmbH
Peter-Henlein-Str. 2
50389 Wesseling-Berzdorf
http://www.eppendorf.com
Fermentas Fermentas UAB
Fermentas
LT-02241 Vilnius
V. Graiciuno 8
http://www.fermentas.com
now fully owned subsidiary of:
Thermo Fisher Scientific Inc.
81 Wyman Street Waltham, MA USA 02451
http://www.thermofisher.com
GE Healthcare GE Healthcare Europe GmbH
Munzinger Str. 5
D-79111 Freiburg
http://www.gelifesciences.com
Greiner Bio-One Greiner Bio-One North America, Inc.,
4238 Capital Drive
Monroe, NC 28110 USA
http://us.gbo.com
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Vendor
(Short Name)
Details
Invitrogen brand of:
Life Technologies GmbH
Frankfurter Straße 129B
D-64293 Darmstadt
www.lifetechnologies.com
now fully owned subsidiary of:
Thermo Fisher Scientific Inc.
81 Wyman Street Waltham, MA USA 02451
http://www.thermofisher.com
Jackson
ImmunoResearch
Jackson ImmunoResearch Europe Ltd.
Unit 7, Acorn Business Centre, Oaks Drive
Newmarket, Suffolk, CB8 7SY, UK
http://jireurope.com/
Merck Merck KGaA
Frankfurter Straße 250
D-64293 Darmstadt
http://www.merck.de
Millipore Millipore Corporation
290 Concord Road, Billerica
Massachusetts, USA
http://www.millipore.com
now fully owned subsidiary of:
Merck KGaA
Frankfurter Straße 250
D-64293 Darmstadt
http://www.merck.de
MWG MWG-Biotech AG
Anzinger Str. 7a
D-85560 Ebersberg
http://www.mwg-biotech.com/
NEB New England Biolabs
240 County Road
Ipswich, MA 01938-2723 USA
https://www.neb.com/
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Vendor
(Short Name)
Details
Perkin Elmer PerkinElmer LAS (Germany) GmbH
Ferdinand-Porsche-Ring 17
D-63110 Rodgau
http://www.perkinelmer.de/
Promega Promega Corporation
2800 Woods Hollow Road
Madison, WI 53711 USA
http://www.promega.com
Roche Roche Diagnostics GmbH
Sandhofer Straße 116
D-68305 Mannheim
http://www.roche.de
Roth CARL ROTH GMBH + CO. KG
Schoemperlenstr. 1-5
D-76185 Karlsruhe
http://www.carlroth.de
Santa Cruz Santa Cruz Biotechnology, Inc.
10410 Finnell Street
Dallas, Texas 75220 USA
http://www.scbt.com
Serva SERVA Electrophoresis GmbH
Carl-Benz-Str. 7
D-69115 Heidelberg
http://www.serva.de
Sigma Sigma-Aldrich Chemie GmbH
Riedstraße 2
D-89555 Steinheim
http://www.sigmaaldrich.com
Thermo Fisher Thermo Fisher Scientific Inc.
81 Wyman Street Waltham, MA USA 02451
http://www.thermofisher.com
TPP TPP Techno Plastic Products AG
Zollstrasse 7
CH-8219 Trasadingen
http://www.tpp.ch
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2.1.2 Consumables
Deionized water (H2O) was produced in house using a Barnstead Nanopure
Diamond Life Science (Thermo Fisher) water system or a multi-stage distillation
system assembled by the technical department, and had a specific resistance
of at least 18 MΩ/cm. Additionally, for all microbiological applications, it was
autoclaved.
The gene-specific oligodeoxyribonucleotides used for generating new Entry
clones were purchased from MWG. All other oligodeoxyribonucleotides used
in this study were obtained from BioTez. All oligodeoxyribonucleotides were
order at 10 nmol scale and RP-HPLC purified.
Simple, standardized chemicals, i.e. those commonly referred to by IUPAC
nomenclature, were ordered in per analysis quality from either Applichem,
Merck, Promega, Roth, Serva or Sigma, according to the current best offer, and
were considered, for all practical purposes, pure and identical.
The other consumables used in this study are listed here:
Plastic labware: ArticleID
(according
Name (according to vendor) Vendor to vendor)
384 Well Microplate, PS, F-Bottom Greiner Bio-One 781186
96 Well Microplate, PS, F-Bottom Greiner Bio-One 655101
Deepwell Plates 96 / 2000 μl Eppendorf 0030.501.3XX
Lid for Microplates, PS Greiner Bio-One 656190
Nunc Low Profile BioAssay Dish Thermo Fisher 240845
OmniTray Single Well w/Lid Sterile PS Thermo Fisher 242811
Tissue Culture Test Plate 24-Well F TPP 92024
96 Well Flat Top PCR Platte Biozym 710875
For cloning: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Gateway BP Clonase II Enzyme mix Invitrogen 11789100
Gateway LR Clonase II Enzyme mix Invitrogen 11791100
Deoxynucleotide (dNTP) Solution Set NEB N0446S
Phusion Hot Start High-Fidelity DNA Polymerase NEB F-540L
QuikChange Site-Directed Mutagenesis Kit Agilent 200518
57
2. MATERIAL AND METHODS
For microbiology and related assays: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Adenine hemisulfate salt Sigma A9126
Agar BD Biosciences 214010
Betaine Sigma B2629
L-Histidine Sigma H8125
L-Leucine Sigma L8912
L-Tryptophan Sigma T0254
Peptone BD Biosciences 211677
Tryptone BD Biosciences 211705
Uracil Sigma U0750
Yeast Extract BD Biosciences 212750
Yeast Nitrogen Base without Amino Acids BD Biosciences 291920
Polyethylene Glycol 6000 Applichem A1387
Salmon Sperm DNA Sigma D1626
Hybond-N+ Chargen Nylon Membrane GE Healthcare RPN2250B
X-Gal Fermentas R0402
For Western Blotting and related experiments: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Anti-Phosphotyrosine Antibody clone 4G10 Millipore 05-321X
Bovine Serum Albumin, Fraction V (BSA) Sigma A7906
Coomassie Brilliant Blue R 250 Serva 17525
Glass beads Sigma G4649
MagicMark Western Protein Invitrogen LC5600
Standard (20-120 kDa)
Nitrocellulose Bio-Rad 162-0115
Rotiphorese Gel 40 (37,5:1) Roth T802.1
UltraPure TEMED Invitrogen 15524010
Western Lightning Plus-ECL Perkin Elmer NEL104001EA
For mammalian cell culture: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Dulbecco’s Modified Eagle Medium Invitrogen 31966047
Dulbecco’s phosphate-buffered saline (PBS) Invitrogen 14190094
Lipofectamine 2000 Transfection Reagent Invitrogen 11688019
Opti-MEM Invitrogen 31985062
Triton-X 100 Serva 39795
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For Co-Immunoprecipitation assays: ArticleID
(according
Name (according to vendor) Vendor to vendor)
AffiniPure Rabbit Anti-Sheep IgG (H+L) Jackson
ImmunoResearch
313-005-003
Bright-Glo Promega E2620
cOmplete, Mini, EDTA-free Roche 11836170001
Phosphatase Inhibitor Cocktail 1 Sigma P2850
Phosphatase Inhibitor Cocktail 2 Sigma P5726
Doxycycline hyclate Sigma D9891
For protein complementation assays: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Poly-D-lysine hydrobromide Sigma P1149
DAPI Roth 6335
Depex Serva 18243
NEO-Clear Merck 1098435000
Rhodamine Phalloidin Invitrogen R415
For immunofluorescent analysis: ArticleID
(according
Name (according to vendor) Vendor to vendor)
Anti-TSPAN2 antibody Abcam ab77105
Bovine Serum Albumin, Fraction V Sigma A7906
DyLight 488-conjugated AffiniPure
Donkey Anti-Rabbit IgG (H+L)
Jackson
ImmunoResearch
711-485-152
DyLight 488-conjugated AffiniPure
Rabbit Anti-Mouse IgG (H+L)
Jackson
ImmunoResearch
315-485-003
GRB2 Antibody (C-23) Santa Cruz SC-255
Purified Mouse Anti-Human
Retinoblastoma Protein Antibody BD Biosciences
554136
2.1.3 Solutions and media for yeast growth experiments
Glucose and supplements for auxotrophic selection were prepared and autoclaved
separately:
• 20 x Glucose stock solution: 1 mol glucose was dissolved in 500 ml H2O
and autoclaved.
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• 100 x histidine stock solution: 0.8 g L-histidine were dissolved in 400 ml
H2O and autoclaved.
• 100 x adenine stock solution: 0.8 g adenine hemisulfate salt were dissolved
in 400 ml H2O and autoclaved.
• 100 x uracil stock solution: 0.8 g uracil were dissolved in 400 ml H2O and
autoclaved.
• 100 x leucine stock solution: 4 g L-leucine were dissolved in 400 ml H2O
and autoclaved.
• 100 x tryptophan stock solution: 0.8 g L-tryptophan were dissolved in
400 ml H2O and autoclaved.
• Copper(II) sulphate was prepared as 200 mM stock solution and sterilized
by filtration.
Liquid medium was prepared as stock solution without glucose or supplements
for auxotrophic selection:
• 1.25 x YPD stock solution: 5 g yeast extract and 10 g peptone were
dissolved in 400 ml H2O and autoclaved.
• 1.25 x NB stock solution: 3.35 g Yeast Nitrogen Base without Amino
Acids (BD Biosciences) were dissolved in 400 ml H2O and autoclaved.
• 1.25 x NBG stock solution: 3.35 g Yeast Nitrogen Base without Amino
Acids (BD Biosciences) and 29.44 g betain were dissolved in 250 ml
62.5% glycerol and autoclaved.
Before use, 25 ml 20 x glucose stock solution and 5 ml 100 x stock solution
of each desired supplement were added to the desired medium stock solution,
then they were filled up to 500 ml with H2O and mixed. NBG medium was
used for freezing and storing at -80°C. Yeast cultures were frozen up to two
times in this medium.
Solid medium was prepared either from stock solutions, similar to liquid
medium, or directly, in a ProfiClav PC20B (biomedis Vertriebsgesellschaft mbH,
D-35394 Giessen). For stock solutions agar and Yeast Nitrogen Base without
Amino Acids (BD Biosciences) were autoclaved separately:
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• 1.25 x YPD agar stock: 5 g yeast extract, 10 g peptone and 10 g agar
were dissolved in 400 ml H2O and autoclaved.
• 2.5 x NB stock solution: 6.7 g Yeast Nitrogen Base without Amino Acids
(BD Biosciences) were dissolved in 400 ml H2O and autoclaved.
• 2.5 x Agar: In a 500 ml bottle, 10 g agar were dissolved in 200 ml H2O
and autoclaved.
Before use, 25 ml 20 x glucose stock solution and 5 ml 100 x stock solution of
each desired supplement were added to each stock solution, then they were filled
up to 500 ml with H2O. For medium with 20 μM Cu2+ 50 μl 200 mM CuSO4
stock solution were added. Afterwards, the agar was solubilized by heating
to 90°C in a microwave oven and mixed by swirling carefully. The agar solution
was allowed to cool down to 60°C before casting. For preparation of YPD
solid medium with the ProfiClav PC20B, for 1 l of medium, 10 g yeast extract,
20 g peptone, 20 g agar and 950 ml H2O were added, autoclaved and cooled
to 60°C. Once 60°C were reached, 50 ml 20 x glucose stock solution were
added, allowed to be mixed thoroughly and cast. For preparation of NB solid
medium with the ProfiClav PC20B, for 1 l of medium, 13.4 g Yeast Nitrogen
Base without Amino Acids (BD Biosciences) 40 g agar and H2O were added,
autoclaved and cooled to 60°C. The amount of water was chosen to amount
to 1 l after addition of glucose and supplements. Once a temperature of 60°C
was reached, 50 ml 20 x glucose stock solution and 10 ml 100 x stock solution
of each desired supplement were added, as well as 100 μl 200 mM CuSO4 for
Cu2+ medium, allowed to be mixed thoroughly and cast. NB and NBG media
were referred to according to the supplements added and left out. Each of the
five supplements was represented by a single letter:
H histidine
A adenine
U uracil
L leucine
T tryptophane
Supplements that were left out were listed first, preceded by a minus sign,
followed by a slash, then the supplements added. The order of supplements was
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H, A, U, L, T on both sides of the slash. Addition of 20 μM Cu2+ was indicated
as ”(Cu2+)”.
2.2 Plasmids
The plasmids used in this study are listed here with short descriptions and
relevant characteristics:
Name Reference /Source Function Markers
pDONR221 Invitrogen Gateway Entry Kanamycin(Escherichia coli)
pDONR223 (Rual et al. 2004) Gateway Entry Spectinomycin(E. coli)
pBTM116-D9 (Worseck et al. 2012) yeast two-hybridbait expression
Tetracycline (E. coli)
Tryptophan
(S. cerevisiae)
pACT-4-DM
pGAD426-D3 (Worseck et al. 2012)
yeast two-hybrid
prey expression
Ampicillin (E. coli)
Leucine
(S. cerevisiae)
pASZ-C-DMtet (Stotz & Linder 1990) yeast two-hybridkinase expression
Tetracycline (E. coli)
Adenine
(S. cerevisiae)
pASZ-CN-DM (Stotz & Linder 1990)
yeast two-hybrid
kinase expression
with NLS
Ampicillin (E. coli)
Adenine
(S. cerevisiae)
pPAReni-DM (Palidwor et al. 2009)
Protein A-fusion
expression in
mammalian cell
culture
Tetracycline
(E. coli)
pFireV5-DM (Palidwor et al. 2009)
luciferase-fusion
expression in
mammalian cell
culture
Ampicillin (E. coli)
pVEN-F1N-DM
pVEN-F1C-DM
pVEN-F2N-DM
pVEN-F2C-DM
created in our
laboratory, based on
YFP PCA fusion
expression vectors in
(Remy et al. 2004)
protein fragment
complementation
assay construct
expression
Ampicillin (E. coli)
As Gateway plasmids, all of these contain a chloramphenicol resistance gene
and a ccdB gene, as long as they contain the ”death cassette”. The ccdB gene
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will kill any E. coli cells with wildtype gyrase unless the ”death cassette” has
been replaced by an ORF.
The yeast two-hybrid prey matrix also contained classical, i.e. non-Gateway,
plasmids. For a description of the prey matrix see (Suter et al. 2013).
2.3 Cells
2.3.1 Yeast strains
In this study, three well-established haploid S. cerevisiae strains were used as
basis for mating and subsequent yeast two-hybrid experiments. All three are
incapable of switching mating types and auxotrophic for adenine, tryptophan
and leucine, which is exploited for selecting strains transformed with pASZ,
pBTM, or pGAD/pACT plasmids, respectively. The resulting diploid strains
contain a lexA-based reporter gene system for growth on medium without
histidine and uracil and expression of β-galactosidase. Genotypes are provided
in (Goehler et al. 2004). An overview of the strains and the types of plasmids
they were transformed with for the assays presented in this study is provided
here:
Strain
Mating
Type transformed with (for)
L40c MATa pBTM & pASZ (screening)pASZ (kinase plate assay)
L40ccU2 MATa pBTM & pASZ (screening)pASZ (kinase plate assay)
L40ccα MATα pGAD/pACT (screening)pBTM & pGAD/pACT (kinase plate assay)
2.3.2 Mammalian cell lines
Mammalian cell culture experiments presented here were based exclusively on
derivatives of HEK293 cells. These cells were initially created by transforming
primary human embryonic kidney cells with adenovirus DNA (Graham et al.
1977). Specifically, ”T-Rex” cells were obtained from Invitrogen. Where induction
of a kinase was desired, a version with a stably integrated doxycycline-inducible
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ABL2 ORF was employed. This version was created in our laboratory using
the ”Flip-In” system provided by Invitrogen.
2.4 Gateway cloning
High throughput molecular biological experiments often require testing the
same ORFs in several different plasmids. For example, in this study, all bait
ORFs were also used as prey. In addition, examining interactions in mammalian
cell culture required sub-cloning the respective ORFs into plasmids allowing the
expression of Protein A, luciferase or split-YFP fusion proteins in mammalian
cells. To facilitate the sub-cloning and make it amenable to high throughput
approaches, we employed the Gateway system (Invitrogen). This system relies
on the lambda phages enzymes for genomic integration and excision and the
respective attachment sites. Except for a small number of prey plasmids, all
plasmids used in this study were Gateway plasmids. Each ORF was either
obtained as a Gateway Entry clone or such a clones was produced by PCR
and Gateway BP cloning. The plasmids used for functional experiments were
subsequently generated by Gateway LR cloning. When an ORF was desired in
two Gateway Destination plasmids with different E. coli resistance markers, up
to two Gateway LR reactions were combined.
2.4.1 Generation of Gateway Entry clones
For ORFs not available as Gateway Entry clones, PCR primers specific to the
ORF were generated and used to amplify the ORF sequence while introducing
invariable flanking sequences:
1 μl 2 ng/μl template DNA (plasmid, see below)
2.5 μl 10 μM forward and reverse primer mix (each)
1 μl 10 mM dNTP mix (each)
10 μl 5 x Phusion buffer
1.5 μl DMSO
0.5 μl 2 U/μl Phusion polymerase
33.5 μl H2O
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The PCRs were processed in a thermocycler according to this protocol:
Initial denaturation:
98°C 30 seconds
Elongation (25 cycles):
98°C 8 seconds
55°C 23 seconds
72°C 2 minutes
Final elongation:
72°C 8 minutes
Cool down:
4°C until removed from machine
In a second PCR step, these flanking regions were extended to form functional
attB sites:
1 μl template DNA (PCR products, diluted 1:100 with H2O)
2.5 μl 10 μM attB1for & attB2rev (each)
1 μl 10 mM dNTP mix (each)
10 μl 5 x Phusion buffer
1.5 μl DMSO
0.5 μl 2 U/μl Phusion polymerase
33.5 μl H2O
The PCRs were processed in a thermocycler using the same protocol as for the
first PCR.
The PCR products were purified by PEG/CaCl2 precipitation, as recommended
by the manufacturer:
1. For each ORF, 25 μl PCR were added to 75 μl TE (10 mM Tris-HCl pH 8,
1 mM EDTA) in a fresh tube and mixed by vortexing.
2. 50 μl 30% PEG 8000 / 30 mM MgCl2 Solution (Invitrogen) were added
to each tube and mixed by vortexing.
3. The PCR products were centrifuged for 15 min at 25°C and 15,000 xg.
4. The supernatant was removed with a pipette and discarded.
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5. The pellets were dissolved in 10 μl TE, each.
The purified PCR products were used as substrate in a Gateway BP reaction:
3 μl MgCl2/PEG purified PCR product
1 μl 75 ng/μl pDONR221
1 μl 5 x Gateway BP Clonase II Enzyme Mix (Invitrogen)
Each reaction was incubated at 25°C for 18 h and directly used for E. coli
transformation. Each Gateway Entry clone generated this way was verified by
Sanger sequencing.
Non-Gateway-compatible plasmids were ordered from Imagenes (now Invitro-
gen) and Gateway Entry clones were generated for these genes, using these
templates and primers:
GeneID Gene IMAGE clone Plasmid GenBankID
321 APBA2 IRALp962P1059Q pOTB7 BC082986
forward primer AAAAAGCAGGCTTAATGGCCCACCGGAAGC
reverse primer AGAAAGCTGGGTCCTACTAGATGTACAGCGGGG
9479 MAPK8IP1 IRATp970G0988D pBluescriptR BC068470
forward primer AAAAAGCAGGCTTAATGGCGGAGCGAGAAAG
reverse primer AGAAAGCTGGGTCCTACTACTCCAGGTAGATATC
5355 PLCG1 IRAKp961M0798Q pCMV-SPORT6 BQ876810
forward primer AAAAAGCAGGCTTAATGGCGGGCGCCGC
reverse primer AGAAAGCTGGGTCCTACTAGAGGCGGTTGTCTC
79890 RIN31 IRAKp961I19168Q pBluescriptR BC070062
forward primer AAAAAGCAGGCTTAATGATCCGACACGCCG
reverse primer AGAAAGCTGGGTCCTATCACAGGAAGTTGGGCTC
55620 STAP2 IRAKp961M034Q pCMV-SPORT6 BC000795
forward primer AAAAAGCAGGCTTAATGGCCTCTGCCCTGAG
reverse primer AGAAAGCTGGGTCCTATCAGTGCTCCAGTGCC
7410 VAV2 DKFZp686B22207Q pSPORT1_Sfi BX640754
forward primer AAAAAGCAGGCTTAGACGGGGTCCTTCTGTG
reverse primer AGAAAGCTGGGTCCTATCACTGGATGCCCTCC
1Note that for RIN3 two different Gateway Entry clones were obtained this way, both of
which were successfully mapped to the RIN3 gene.
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2.4.2 Generation of assay-specific plasmids by Gateway
LR recombination
To employ in different assays, ORFs available as Gateway Entry clones could
be moved to appropriate Gateway Destination vectors in simple and high
throughput amenable Gateway LR recombination reactions:
1 μl 200 ng/μl Gateway Entry clone DNA
3 μl 25 ng/μl Gateway Destination plasmid(s) (total concentration)
1 μl 5 x Gateway LR Clonase II Enzyme Mix (Invitrogen)
Each reaction was incubated at 25°C for 18 h and directly used for E. coli trans-
formation. Where two Gateway Destination vectors were used, E. coli strains
were grown to completion in LB liquid medium and tested for transformation
with multiple plasmids by placing a drop (>1 μl) of this culture on an agar
plate containing the other respective antibiotic. Strains growing in this test
were discarded.
All of the Gateway LR recombination reactions with the Destination plasmids
pPAReni-DM or pFireV5-DM were performed by Nouhad Benlasfer.
2.5 Yeast Two-Hybrid
2.5.1 Yeast transformation
The first step in most yeast two-hybrid experiments is the creation of yeast
strains containing the yeast two-hybrid plasmids with the ORFs of interest.
A high throughput-adapted version of the lithium acetate method (Gietz &
Woods 2002) was used this study:
1. A 3 ml tube of YPD liquid medium was inoculated with the yeast strain
that was supposed to be transformed from a freshly grown agar plate and
incubated at 30°C until the next day. In case of strains already containing
a kinase plasmid (pASZ-C or pASZ-CN), -A/HULT medium was used
instead of YPD.
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2. On the next day, 2 ml of the over-night culture were transferred to
a 1 l Erlenmeyer flask without baffles containing 30 ml YPD liquid
medium preheated to 30°C and incubated at 30°C shaking vigorously. In
case of strains already containing a kinase plasmid (pASZ-C or pASZ-CN),
-A/HULT medium was used instead of YPD.
3. After 3 h 30 min, the yeast culture was transferred to a 50 ml tube and
centrifuged for 5 min at 2000 rpm in an Eppendorf A-4-81 centrifuge
rotor.
4. The supernatant was discarded and the pellet was resuspended in 10 ml TE
(10 mM Tris-HCl pH 8, 1 mM EDTA).
5. The cells were centrifuged again for 5 min at 2000 rpm an Eppendorf
A-4-81 centrifuge rotor.
6. The supernatant was discarded and the pellet was resuspended in 1.1 ml
100 mM LiCH3COO, 0.5 x TE, 1 M Sorbitol and incubated for 15 min
at 25°C.
7. In an individual well of a PCR plate for each transformation reaction,
500 ng plasmid DNA were mixed with 15 μg Salmon Sperm DNA (Sigma)
in 4 μl 0−1 x TE. In case of transformation with two plasmids at once
(for the kinase plate assay), the amount of plasmid DNA was increased
to 1 μg, 500 ng per plasmid.
8. 11 μl yeast cell suspension were added to each well and mixed by vortexing
carefully.
9. 58 μl 100 mM LiCH3COO, 1 x TE, 40% PEG 6000 were added to each
well and mixed by vortexing carefully.
10. The PCR plate was incubated at 30°C for 30 min.
11. 8 μl DMSO were added to each well and mixed by vortexing carefully.
12. The PCR plate was incubated at 42°C for 7 min.
13. For the desired number of copies, a drop (∼5 μl) of yeast solution from
each well was placed on an agar plate selective for the plasmid or plasmids
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that were transformed with, using a pipette or pin tool, allowed to dry
and incubated at 30°C for 3 days.
14. Before use for functional assays, the generated yeast strains were trans-
ferred to NBG medium and replicated on agar plates.
2.5.2 Generation of Yeast Two-Hybrid Bait strains
Yeast two-hybrid bait strains were generated by transforming haploid MATa
strains with pASZ plasmids first, and, in a second step, transforming these
strains with pBTM plasmids. Transformations of pASZ plasmid-containing
strains with pBTM plasmids selected for the second round of screened were
performed by Petra Birth.
1. The haploid MATa yeast strains L40c and L40ccU2 were transformed
with the nine non-receptor tyrosine kinase ORFs selected for screening,
each in both, pASZ-C and pASZ-CN plasmid backbones, as well as empty
pASZ-C and pASZ-CN plasmids.
2. The resulting yeast strains were transformed with the pBTM-D9 plasmids
of the ORFs that were selected as bait for screening. For the second round,
only the strains carrying the three kinase ORFs selected for screening in
the second round and the empty pASZ-C and pASZ-CN plasmids were
transformed.
3. The bait strains were re-arrayed to produce 96-well plates in which
pBTM116-D9 inserts were identical in each well in the same row and
pASZ version (pASZ-C or pASZ-CN) and inserts were identical in each
well in the same column. Further, all strains containing identical inserts in
the pBTM116-D9 plasmid were arranged in the same row and all strains
containing identical pASZ version (pASZ-C or pASZ-CN) and inserts were
arranged in the same column in all plates, with the exception of the empty
pASZ-C and pASZ-CN plasmids, which were present in three columns,
each. The eight pBTM116-D9 inserts in each plate were supposed to form
the pools for screening and retesting (assuming the absence of growth
in the autoactivation test). Thus, for the second round of screening all
ORFs for a GeneID were placed in the same 96-well plates.
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2.5.3 Autoactivation test
Before any yeast two-hybrid screen, each individual bait strain was tested for
autoactivation. Each bait strain was mated with a prey strain containing an
empty pACT4 plasmid, i.e. a plasmid from which only the GAL4 activation
domain is expressed. Any bait strains growing on selective agar lacking histidine
and uracil were disqualified from further yeast two-hybrid experiments, i.e.
they were not used for screening and disregarded in the evaluation of retest
experiments. The autoactivation tests of bait strains prepared for the second
round of screening were performed by Petra Birth.
This is the protocol that was followed for the autoactivation test:
1. The bait strains were stamped on -AT/HUL NB agar plates in 96-well
format and incubated for 3 days at 30°C.
2. Two days after stamping the bait strains, a -L/HAUT NB liquid culture
of prey strain containing an empty pACT4 plasmid was inoculated and
incubated at 30°C until the next day shaking vigorously in an Erlenmeyer
flask without baffles with a nominal volume of at least five times the
culture volume. The volume of the culture was 120 ml plus 12 ml per
96-well plate of bait strains.
3. The liquid culture was distributed to 96-well flat-bottom plates (120 μl
per well).
4. The bait strains were transferred from the -AT/HUL NB agar plates to
the microplates, mixed and stamped on YPD agar using a pin tool.
5. The YPD agar plates were incubated at 30°C until the next day.
6. Yeast spots were transferred from YPD agar plates to 96-well flat-bottom
plates containing 120 μl -ALT/HU NB medium in each well, mixed and
stamped on -ALT/HU NB agar plates using a pin tool.
7. The -ALT/HU NB agar plates were incubated at 30°C for 2 days and
controlled for complete growth.
8. The yeast spots were transferred from the -ALT/HU NB agar plates to
96-well flat-bottom plates containing 120 μl -ALT/HU NB medium in
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each well, mixed and stamped on -HAULT(Cu2+) NB agar plates using a
pin tool.
9. The -HAULT(Cu2+) NB agar plates were incubated at 30°C for 5 days
and evaluated. Each bait strain corresponding to a spot growing on
-HAULT(Cu2+) NB agar was disqualified from further yeast two-hybrid
experiments, i.e. not used for screening and disregarded evaluating retest
experiments.
2.5.4 Yeast Two-Hybrid Screening
For genome-scale screening, bait strains were tested in pools comprising all
combinations of up to eight ORFs representing phosphotyrosine-recognizing
domain-containing genes in pBTM116-D9 and up to nine non-receptor tyrosine
kinase ORFs in pASZ-C or pASZ-CN (one pBTM116-D9 and one pASZ plasmid
per strain; see Appendix XXX for exact combinations screened). Each bait
pool was mated individually with each prey strain available in our laboratorys
prey matrix at the time (note that a substantial number of prey strains became
available between the first and the second round of screening; see Appendix
XXX for exact combinations screened) up to four times using independently
transformed bait strains. Combinations of bait pools and prey strains growing
were considered primary hits potentially representing protein-protein interac-
tions. Most of the screening using L40c-derived bait strains in the first round
and all of the screening in the second round were performed by Petra Birth.
In detail, yeast two-hybrid screening experiments followed this protocol:
1. For each bait pool, the bait strains were stamped on -AT/HUL NB agar
plates and incubated for 3 days at 30°C.
2. On the following day, for each bait pool, one copy of the prey matrix was
stamped on -L/HAUT NB agar plates and incubated for 3 days at 30°C.
3. The fully grown bait strains were transferred from the -AT/HUL NB
agar plates to 96-well flat-bottom plates containing 120 μl -AT/HUL NB
liquid medium per well using a pin tool and mixed by vortexing carefully.
4. Eight 96-well deepwell plates containing 1.2 ml -AT/HUL NB liquid
medium per well were inoculated for each bait pool by adding 5 μl medium
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from one well of the 96-well flat-bottom plates containing the bait strains.
The first microplate for each bait pool, five deepwell plates were inocu-
lated. The other three deepwell plates were inoculated with the left half
(columns 1-6) of the second microplate for the bait pool, twice. For this
purpose, the left half of the deepwell plate was inoculated with the left
half of the 96-well flat-bottom plate, the deepwell plate was turned by 180°
and inoculated again. Positions corresponding to autoactive bait strains
were not inoculated in this step by removing the respective tips before
transferring the 5 μl yeast suspension to the deepwell plates. (The right
half of the second 96-well plates, containing the pASZ plasmid without
kinase ORFs, were not included in the primary screen.)
5. The deepwell plates were incubated at 30°C shaking vigorously until the
next day.
6. For each bait pool, all eight deepwell plates were vortexed until any yeast
accumulated at the bottom of the wells was completely suspended, brought
together in a 5 l beaker and mixed by swirling.
7. The mixture of bait strains was distributed to 384-well flat-bottom plates,
adding 43 μl to each well. The number of microplates filled corresponded
to the number of 384-well plates comprising the prey matrix, plus one
(for control purposes).
8. The prey strains were transferred from the -L/HAUT NB agar plates to
the 384-well plates containing the bait strains, mixed and stamped on
YPD agar plates using a pin tool.
9. The YPD agar plates were incubated at 30°C until the day after the next.
10. The yeast spots were transferred from the YPD agar plates to 384-well
flat-bottom plates containing 43 μl -ALT/HU NB medium in each well,
mixed and stamped on -HAULT(Cu2+) NB agar plates using a pin tool.
11. The -HAULT(Cu2+) agar plates were incubated at 30°C for 5 days and
evaluated. For each spot, the corresponding prey strain and bait pool
were noted as a primary hit.
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2.5.5 Retesting of primary Yeast Two-Hybrid hits
Potentially interacting protein pairs producing yeast growth in the screening
experiments were only considered interacting if they could be reproduced in
an independent retest experiment. In addition to making the interaction data
more reliable and stringent, the retest experiment provides specific information
regarding which bait strains produced the signal identifying the interaction
partners and allowing a distinction between phosphotyrosine-dependent and
independent interactions. It also reveals autoactive prey strains. To achieve a
high positive retest rate, only combinations of bait pools and non-autoactive prey
strains with at least two primary hits were included in the retest experiments.
Autoactive prey strains were identified using growth statistics collected in the
laboratory of Erich Wanker at the MDC Berlin, as well as ours. All of the
retesting of primary hits following screening with L4oc-derived bait strains in
the first round and most of the retesting following the second round of screening
were performed by Petra Birth.
In detail, yeast two-hybrid screening experiments followed this protocol:
1. Each combination of bait pool and prey strain with at least two primary
hits was included in the retest set.
2. Each combination involving an autoactive prey strain was removed from
the retest set. For this purpose, a prey strain was considered autoactive
if it grew in more than 9 of 24 primary screens related to prior studies
performed in our laboratory and either fulfilled the retesting criteria in
more than 17 of 19 compound screens performed in the laboratory of
Erich Wanker at the MDC Berlin or there was no information about it
available from this source.
3. For each bait pool, the 96-well plates were combined into 384-well plates
by transferring two independent transformations of the first 96-well plate
into the first and fourth quadrant and two transformations of the second
96-wells plate into the second and third quadrant.
4. For each combination of bait pool and prey strain in the retest set, one
copy of the corresponding 384-well bait plate was stamped on -AT/HUL
NB agar and incubated at 30°C for 3 days.
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5. After two days, 30 ml -L/HAUT NB liquid medium per combination
in the retest list were inoculated with the respective prey strain and
incubated at 30°C shaking vigorously until the next day.
6. On the next day, the -L/HAUT NB liquid prey cultures were distributed
to 384-well flat-bottom plates, adding 43 μl to each well, one microplate
per 30 ml liquid medium.
7. For each combination in the retest list, the bait strains from one copy of
the respective 384-well bait plate were transferred from the -AT/HUL NB
agar plates to the 384-well flat-bottom plates containing the respective
prey strain, mixed and stamped on -ALT/HU NB agar plates using a pin
tool.
8. The -ALT/HU NB agar plates were incubated at 30°C for 3 days and
controlled for complete growth.
9. Yeast spots were transferred from -ALT/HU NB agar plates to 384-well
flat-bottom plates containing 43 μl -ALT/HU NB medium in each well,
mixed and stamped on -HAULT(Cu2+) NB agar plates using a pin tool.
10. The -HAULT(Cu2+) NB agar plates were incubated at 30°C for 5 days and
evaluated. Each spot growing on -HAULT(Cu2+) NB agar represented one
combination of interacting proteins and kinase. Each combination of bait
and prey plasmids corresponded to two rows, identical kinase plasmids to
two diagonally adjacent positions with the two rows. As a consequence,
the following pattern were used to derive protein-protein interactions on
an Entrez GeneID level (ignoring autoactive bait strains):
Pattern Interpretation
Growth on the whole plate autoactive prey strain(no interaction)
Fully grown pair of rows independent interaction
Pair of rows grown in several
kinase-containing positions only
phosphotyrosine-dependent
interaction
single spots late autoactivity(no interaction)
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2.5.6 Assessment of Tyrosine Phosphorylation parame-
ters
To assess the influence of copper sulfate to the interaction-selective -HAULT
agar plate, diploid yeast two-hybrid strains can be transferred to -HAULT agar
with and without added copper sulfate.
1. A yeast two-hybrid experiment was performed as described for the retest
experiments up to the last stamping step.
2. Instead of the last stamping step, the yeast spots were transferred from
the -ALT/HU NB agar plates to 96-well flat-bottom plates containing
120 μl -ALT/HU NB medium in each well, mixed by vortexing carefully
and spotted on -ALT/HU, -HAULT and -HAULT(Cu2+) NB agar by
pipetting 5 μl yeast suspension onto the surface of each. For β-galactosidase
activity read-out, the yeast suspension was spotted on -HAULT and
-HAULT(Cu2+) NB agar with a piece of Nylon membrane (GE Healthcare
Hybond-N+), additionally.
3. The agar plates were incubated for 3 days and evaluated, either directly
or by β-galactosidase activity determination. (Note that the yeast spots
can be used for Western blotting.)
2.5.7 Kinase interaction specificity analysis
2.5.7.1 Generation of catalytically inactive kinase ORFs
Protein-protein interactions allowing growth in yeast two-hybrid experiments
in the presence of an active tyrosine kinase, but not in its absence, could be
explained by other mechanisms than phosphotyrosine binding. For example,
the kinase might bind to the bait and prey proteins simulating the effects
of direct binding, a concept often referred to as ”bridging”. To be able to
refute these hypotheses, catalytically inactive kinase versions were generated by
introducing a mutation to a highly conserved lysine residue in the ATP-binding
cassette, which, when changed to a methionine residue, renders the kinase
inactive. The mutations were introduced by PCR using the QuikChange Site-
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Directed Mutagenesis Kit (Agilent) for all kinases that were used for screening
or retesting:
ORF RefSeq RNA ORF RefSeq
Primer Sequence Start End Start End
ABL2 NM_005158.4 1 3504 46 3549
forward cagccttacagttgctgtgATGacattgaaggaagatacc 930 969
reverse ggtatcttccttcaatgtCATcacagcaactgtaaggctg 969 930
BMX (ORF #1) NM_001721.6 1 2026 112 2137
forward gtatgatgttgctgttATGatgatcaaggagggctcc 1428 1464
reverse gtctctcgacaagaCATcaccgccaccagg 1464 1428
FES NM_002005.3 1 2469 97 2565
forward cctggtggcggtgATGtcttgtcgagagac 1851 1880
reverse ggtatcttccttcaatgtCATcacagcaactgtaaggctg 1880 1851
FRK NM_002031.2 1 1518 448 1965
forward ccactccagtagcagtgATGacattaaaaccaggttcaatg 1214 1254
reverse cattgaacctggttttaatgtCATcactgctactggagtgg 1254 1214
FYN (ORF #1) NM_002037.5 1 1613 608 2220
forward gaaacacaaaagtagccataATGactcttaaaccaggcac 1482 1521
reverse gtgcctggtttaagagtCATtatggctacttttgtgtttc 1521 1482
JAK2 NM_004972.3 1 3397 495 3891
forward gggaggtggtcgctgtaATGaagcttcagcatagtac 3121 3157
reverse gtactatgctgaagcttCATtacagcgaccacctccc 3157 3121
PTK2 (ORF #1) NM_005607.4 59 2043 1474 3458
forward cagctttggcggttgcaattATGacatgtaaaaactgtacttcg 1639 1682
reverse cgaagtacagtttttacatgtCATaattgcaaccgccaaagctg 1682 1639
SYK (ORF #1) NM_003177.6 1 1908 256 2163
forward gtgaaaaccgtggctgtgATGatactgaaaaacgaggcc 1441 1479
reverse ggcctcgtttttcagtatCATcacagccacggttttcac 1479 1441
TNK1 NM_003985.4 1 1986 233 2218
forward ccagtggctgtcATGtccctccgggtag 662 689
reverse ctacccggagggaCATgacagccactgg 689 662
In this protocol, complimentary PCR primers carrying the mutated version
of the site that is supposed to be changed and matching the nucleotide residues
surrounding the site are used for a PCR replicating the complete template
plasmid. Afterward, the template is removed by incubating with DpnI, a re-
striction endonuclease specifically recognizing dam methylated DNA. Since the
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mutation is introduced in the Gateway Entry vectors, the common problem
of additional mutations resulting from the comparatively low fidelity of DNA
replication by PCR (compared to within intact E. coli cells) is minimized.
Each reaction was set up like this:
19.5 μl H2O
2.5 μl 10 x QuikChange reaction buffer
0.5 μl 50 x QuikChange dNTP mix
1 μl 5 ng/μl template DNA
0.5 μl 10 μM forward primer
0.5 μl 10 μM reverse primer
0.5 μl 50 x PfuTurbo Polymerase
and was processed in a thermocycler according to this protocol:
Initial denaturation:
95°C 30 seconds
Elongation (25 cycles):
95°C 30 seconds
55°C 60 seconds
68°C 5 / 6 minutes
(
BMX, FRK, FYN, PTK2, SYK,
TNK1 / ABL2, JAK2, FES
)
Final cooling:
4°C until removed from machine
Upon completion, 0.5 μl DpnI (Agilent) were added to each PCR sample,
carefully mixed in several slow aspirate-dispense cycles with a pipette. Subse-
quently, the samples were incubated at 37°C for 1 hour and stored at -20°C
for bacterial transformation. All generated mutations were verified by Sanger
sequencing. All catalytically deficient kinase mutant were generated by Sylvia
Wowro instructed by Arndt Großmann as part of her undergrad education.
2.5.7.2 Kinase Plate Assay
For a comprehensive analysis of kinase interaction specificity in the yeast two-
hybrid system, haploid yeast strains containing pASZ-C and pASZ-CN plasmids
with ORFs for 31 non-receptor tyrosine kinase genes, including wildtype and
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catalytically inactive versions of the ORFs used for screening, were arranged in
96-well format with five empty pASZ-C and five empty pASZ-CN plasmids and
mated with yeast strains containing yeast two-hybrid bait and prey plasmids
known to allow yeast growth in a kinase-dependent manner. Each interaction
was tested twice with independently transformed kinase plates, one based on
L40c, the other on L40ccU2, by placing 5 μl drops of diploid yeast suspension
on -HAULT(Cu2+) agar.
The kinase plate assay was performed according to this protocol:
1. The haploid MATα yeast strain L40ccα was transformed with combina-
tions of yeast two-hybrid bait and prey plasmids, i.e. a pBTM116-D9 and
either a pGAD or a pACT plasmid, known to allow yeast growth in a
kinase-dependent manner.
2. The haploid MATa yeast strains L40c and L40ccU2 were transformed
with 43 non-receptor tyrosine kinase ORFs selected for screening, each in
pASZ-C and pASZ-CN, as well as empty pASZ-C and pASZ-CN plasmids,
five times each. The non-receptor tyrosine kinase ORFs were selected
to cover 31 non-receptor tyrosine kinase genes and include catalytically
inactive versions of the nine ORFs used for screening. (Note that for
JAK1, the only non-receptor tyrosine kinase gene not covered by the ORF
selection, several plasmids have been obtained and sequenced; none of
these could be confirmed; we believe that all of them derive from the
same incorrectly annotated MGC clone.)
3. The resulting kinase strains were arrayed in 96-well format in two plates
identical in all aspects except parent strain. Similarly, within each plate,
the left and the right half, i.e. columns 1-6 and 7-12, respectively, were
identical in all aspects except plasmid backbone, i.e. pASZ-C or pASZ-CN.
In addition, the ORFs were arranged to avoid placing two highly active
kinases next to each other, as far as information was available. Where such
information was unavailable, the ORFs carrying mutations in the ATP-
binding cassette and the empty plasmids were assumed to be inactive
and for the remaining kinases members of the same family were assumed
to display correlated levels of activity.
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4. The kinase yeast strains were stamped on -A/HULT NB agar plates and
incubated at 30°C for 3 days. Each 96-well plate was stamped once for
each MATα yeast strain to be tested.
5. After two days, 60 ml -LT/HAU NB liquid medium each were inoculated
with the MATα yeast strains in an Erlenmeyer flasks without baffles and
incubated at 30°C until the next day shaking vigorously.
6. The liquid cultures were distributed to two 96-well flat-bottom plates,
each (120 μl per well).
7. The kinase strains were transferred from the -A/HULT NB agar plates
to the microplates, mixed and stamped on YPD agar using a pin tool.
8. The YPD agar plates were incubated at 30°C until the next day.
9. The yeast spots were transferred from the YPD agar plates to 96-well
flat-bottom plates containing 120 μl -ALT/HU NB medium in each well,
mixed and stamped on -ALT/HU NB agar plates using a pin tool.
10. The -ALT/HU NB agar plates were incubated at 30°C for 2 days.
11. The -ALT/HU NB agar plates were controlled for complete growth.
12. The yeast spots were transferred from the -ALT/HU NB agar plates to
96-well flat-bottom plates containing 120 μl -ALT/HU NB medium in
each well.
13. The microplates were mixed by vortexing carefully and spotted on selective
-HAULT(Cu2+) NB agar plates by pipetting 5 μl liquid medium onto the
surface of an agar plate for each well.
14. The -HAULT(Cu2+) NB agar plates were incubated at 30°C for 5 days
and evaluated.
2.5.8 β-Galactosidase Assay
The yeast two-hybrid system employed in this study involves three reporter genes
and offers two kinds of protein interaction read-out. The histidine and uracil
reporters can be queried simply by testing for growth on selective medium. The
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third reporter gene, β-galactosidase, expresses an enzyme capable of hydrolyzing
β-galactosides into monosaccharides. It also accepts the analog 5-bromo-4-chloro-
3-indolyl-β-D-galactopyranoside (X-Gal) as a substrate producing galactose
and 5-bromo-4-chloro-3-hydroxyindole. Under oxidative conditions, the latter
forms 5,5′-dibromo-4,4′-dichloro-indigo, which is blue, making the reaction
immediately observable.
In detail, the following protocol was used for the β-galactosidase assay:
1. Nylon membranes (GE Healthcare Hybond-N+) were placed on interac-
tion-selective agar plates (-HAULT(Cu2+)).
2. After spotting on interaction-selective agar plates as described for the
retest experiments, diploid yeast two-hybrid cultures were spotted on the
nylon membranes and incubated at 30°C for several days until colonies
were fully grown, but not any longer.
3. Membranes were carefully removed from the agar plates and transferred
to liquid nitrogen.
4. Thoroughly frozen membranes were removed from the nitrogen and
allowed to reach at least 15°C.
5. Completely thawed membranes were again frozen by transferring to -80°C
and stored until the next day or up to a week.
6. Membranes were allowed to thaw at 25°C.
7. For each piece of membrane, two sheets of 3MM chromatography paper
(Whatman), slightly larger than the piece of membrane were stacked in
an empty agar dish and soaked with β-galactosidase activity detection
solution (750 μMX-Gal, 10 mMDTT, 60 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mM MgSO4). X-Gal and DTT were added immediately
before every experiment (from 20 g/l dimethylformamide and 1 M aqueous
stock solutions, respectively).
8. Membranes were places onto the X-Gal-soaked papers and incubated
at 37°C for several hours until blue staining was developed. Since the
color-producing reaction is oxidative, the time at which the staining
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develops varies with DTT freshness. Therefore, the exact incubation time
was determined by monitoring the reaction.
9. When the staining was developed, the reaction was stopped by removing
the membranes from the agar dishes and allowing to dry by evaporation.
2.6 Western Blot analysis of tyrosine-phospho-
rylated proteins
To visualize kinase activity in the yeast environment, native yeast proteins tyro-
sine-phosphorylated by the overexpressed human tyrosine kinase were separated
by SDS-PAGE (12%), immobilized on a nitrocellulose membrane and recognized
by the well-characterized pan-protein phosphotyrosine 4G10 antibody.
In detail, the following protocol was employed for the Western blot:
Preparation of yeast protein extracts:
1. A yeast two-hybrid experiment was performed as described for the retest
experiments up to the last stamping step.
2. Instead of the last stamping step, the yeast spots were transferred from
the -ALT/HU NB agar plates to 96-well flat-bottom plates containing
120 μl -ALT/HU NB medium in each well, mixed by vortexing carefully
and spotted on -ALT/HU, -HAULT and -HAULT(Cu2+) NB agar by
pipetting 5 μl yeast suspension onto the surface of each.
3. The agar plates were incubated for 3 days.
4. For each yeast spot, a 1.5 ml tube containing 50 μl SDS loading buffer
(2% SDS, 90 mM Tris/HCl pH 6.8, 10% glycerol, 0.2% 2-mercaptoethanol)
and a spatula tip full of glass beads was prepared.
5. The yeast spots were carefully transferred to the 1.5 ml tubes using an
inoculation loop.
6. Each tube was heated up to 95°C, vortexed three times for one second on
the highest setting, incubated for 2 min at 95°C, vortexed three times for
one second on the highest setting, incubated for another 3 min at 95°C,
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vortexed three times for one second on the highest setting, and allowed
to coll down to 25°C.
Preparation of polyacrylamide gels for electrophoresis:
7. Two mini-gel scaffolds (Bio-rad Mini-PROTEAN 1 mm) were assembled
for casting.
8. In a beaker, 10 ml separating gel solution were prepared by adding
4.4 ml H2O
100 μl 10% SDS solution
2.5 ml 1.5 M Tris/HCl pH 8.8
3 ml 40% acrylamide/bisacrylamide solution (37.5:1)
9. The solution was mixed by swiveling carefully.
10. The polymerization reaction was started by adding 50 μl 10% APS solution
and 5 μl TEMED.
11. The solution was mixed by swiveling carefully and immediately slowly
poured into the mini-gel scaffolds, leaving room for the combs plus 5 mm
for the stacking gel.
12. Each gel was overlaid with 300 μl 1-butanol equalized with separat-
ing gel buffer. (1-butanol was equalized by adding an equal amount
of 375 mM Tris/HCl pH 8.8, 0.1% SDS, mixing by shaking and allowing
the phases to separate.)
13. The gels were allowed to polymerize by leaving them undisturbed for
1 hour.
14. The 1-butanol was removed by decanting.
15. In a beaker, 5 ml stacking gel solution were prepared by adding
3.7 ml H2O
50 μl 10% SDS solution
625 μl 1 M Tris/HCl pH 6.8
3 ml 40% acrylamide/bisacrylamide solution (37.5:1)
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16. The solution was mixed by swiveling carefully.
17. The polymerization reaction was started by adding 25 μl 10% APS solution
and 2.5 μl TEMED.
18. The solution was mixed by swiveling carefully and immediately slowly
poured into the mini-gel scaffolds, enough to fill the space between the
glass plates completely after addition of the combs.
19. One ten-well comb was inserted carefully into each scaffold and polymer-
ization was allowed for by leaving the gels undisturbed for 1 hour.
Separation of protein according to size by discontinuous SDS PAGE:
20. Both gels were set up in a Mini-PROTEAN Tetra Cell (Bio-rad) by placing
them in the same gel holder cassette, adding running buffer (25 mM Tris,
1.44% glycine, 0.1% SDS), carefully removing the combs and rinsing the
wells (by quickly pipetting running buffer from the reservoir into the
wells).
21. Equal amounts of each sample were added to both gels in identical order.
For yeast protein extract samples, 10 μl were used for each lane; for protein
size standard (Invitrogen MagicMark), 5μl were used for each lane.
22. Proteins were electrophoretically separated by applying a constant current
of 70 mA (35 mA per gel) until the buffer fronts reached the bottom of
the gels.
23. Electrophoresis was stopped, the gels were retrieved, the stacking gels
were removed and discarded and the separating gels were used for Western
blotting and Coomassie staining.
Unspecific protein staining with Coomassie:
24. The first gel was transferred to a tray with Coomassie staining solution
(50% methanol, 10% acetic acid, 0.25% Coomassie Brilliant Blue G-250)
and incubated for 1 hour at 25°C slowly shaking in an undulating fashion.
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25. The staining solution was removed by decanting, rinsing with destaining
solution (30% methanol, 10% acetic acid), then by incubating in destaining
solution until destained at 25°C slowly shaking in an undulating fashion.
The destaining solution was refreshed whenever thoroughly blue.
Detection of protein tyrosine phosphorylation by Western blotting:
26. The second gel was transferred to blot buffer (48 mM Tris, 39 mM glycine,
1.3 mM SDS, 20% methanol) and incubated for 2 min.
27. One piece of nitrocellulose membrane, slightly larger than the gel, and
two pieces of 3 mm chromatography paper (Whatman), both of equal
size and slightly larger than the piece of membrane, were soaked in blot
buffer.
28. The two pieces of chromatography paper, the membrane and the gel were
stacked in a Trans-Blot SD Semi-Dry Transfer Cell (Bio-rad) in the order
chromatography paper, membrane, chromatography paper, from bottom
to top. The creation of air bubbles was carefully avoided, as was any
unnecessary touching of the membrane.
29. The proteins were transferred to the membrane by applying a constant
voltage of 20 V for 25 min.
30. The membrane was transferred to 2% BSA in TBS (25 mM Tris, 150 mM
NaCl, 0.555% HCl) and incubated until the next day at 4°C slowly shaking
in an undulating fashion.
31. The BSA solution was removed by decanting and replaced by 10 ml TBS
containing 5 μl 4G10 antibody solution (1 g/l, Millipore).
32. The membrane was incubated with the antibody solution for 90 min
at 4°C slowly shaking in an undulating fashion.
33. The membrane was washed three times with 15 ml TBS-T (1% Tween 20
in TBS) for 5 min each.
34. The membrane was washed three times with 15 ml TBS for 5 min each.
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35. The membrane was incubated in 10 ml TBS containing 4 μl HRP-conju-
gated sheep anti-mouse antibody solution (0.55 g/l, GE Healthcare) for
60 min at 4°C slowly shaking in an undulating fashion.
36. The membrane was washed three times with 15 ml TBS-T (1% Tween 20
in TBS) for 5 min each.
37. The membrane was washed three times with 15 ml TBS for 5 min each.
38. For documentation, HRP activity was triggered using Western Lightning
reagent (PerkinElmer) according to the manufacturers instructions.
2.7 Protein co-immunoprecipitation from mam-
malian cell culture
A subset of the protein-protein interactions found in yeast two-hybrid ex-
periments was assayed by high throughput co-immunoprecipitation. Towards
this end, the respective constructs were subcloned into the pPAReni-DM or
pFireV5-DM plasmids by Gateway LR cloning, allowing expression of Protein A-
tagged or firefly luciferase-tagged proteins in mammalian cell culture. For each
combination of constructs analysed, three wells of a 96-well microplate with
ABL2-overexpressing T-Rex (HEK293) cells were transfected with pPAReni
and pFireV5 plasmids containing the respective ORFs, induced with doxycyclin
or control medium on the next day and finally evaluated after another day. To
do this, the cells were washed, lysed and the Protein A-tagged protein was pre-
cipitated in an IgG-coated microplate. The amount of co-immunoprecipitated
luciferase-tagged protein was determined by measuring the luciferase activity
using the BrightGlo kit (Promega). Input activity was determined by measuring
luciferase activity in the lysate before precipitation. Background signal was
measured using cells not transfected with luciferase constructs. Input activity
was used to control assay quality. Average backround signal was subtracted
from each measurement. Corrected measurements were averaged and compared
to the respective control, i.e. non-binding protein pairs involving the same firefly
luciferase-tagged construct, or, for mutation analyses, the respective wildtype
construct, based on a simple multiplicative model. Differences of a factor of
85
2. MATERIAL AND METHODS
at least two and with a Z-score of at least two were considered significant and
substantial. The experimental part of the co-immunoprecipitation assay was
performed by Nouhad Benlasfer. Detailed protocol:
1. Inoculation was begun by plating 2.5 x 104 ABL2 T-Rex cells in six wells
in 75 μl DMEM of a 96-well cell culture plate for each combination of
Protein A-tagged and firefly luciferase-tagged constructs, and incubating
at 37°C in a 5% CO2 atmosphere until the next day.
2. For each combination of constructs, a transfection master mix theoretically
sufficient for seven wells was prepared from two pre-mixes:
DNA mix Lipofectamine mix
3 μl pPAReni DNA (100 ng/μl) 1.4 μl Lipofectamine 2000
3 μl pFireV5 DNA (100 ng/μl) 129.6 μl Opti-MEM
125 μl Opti-MEM
3. Both mixes were incubated separately for 5 min at 25°C, pooled and
mixed by flicking carefully.
4. The combined master mix was incubated for 25 min at 25°C.
5. 37.4 μl master mix were added to each of the six wells.
6. The cells were incubated at 37°C in a 5% CO2 atmosphere until the next
day.
7. 37.5 μl DMEM were added to each well, containing 0 or 150 ng doxycyclin
hyclate, bringing the concentration to 0 or 1 μg/ml, for samples without
or with ABL2 induction, respectively.
8. The cells were incubated at 37°C in a 5% CO2 atmosphere until the next
day.
9. The supernatant was removed and the cells were washed with 100 μl PBS
per well.
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10. Lysis buffer was prepared by adding
500 μl 1 M HEPES / NaOH pH 7.4
1.5 ml 1 M NaCl
300 μl 33 mM EDTA / NaOH pH 8.0
2 ml 50% glycerol
500 μl 20% Triton-X 100
100 μl 100% PTP-Inhibitor mix I
100 μl 100% PTP-Inhibitor mix II
1 cOmplete Mini protease inhibitor cocktail tablet (Roche)
5 ml H2O
11. Cells were lysed by adding 100 μl lysis buffer to each well and slowly
shaking in a nutating fashion on ice for 30 min.
12. From each well, 5 μl of supernatant were taken off, diluted eight-fold by
adding 35 μl PBS and stored on ice (input samples).
13. Another 70 μl of supernatant were transferred to an IgG-coated microplate
and incubated shaking in a nutating fashion at 4°C for 90 min.
14. The supernatant was discarded and the bound complexes were washed
three times with 100 μl PBS per well, each. Finally, 40 μl PBS were added
to each well (output samples).
15. 40 μl Bright-Glo Luciferase Assay Reagent (Promega) were added to each
sample (input & output) and incubated at 25°C for 5 min shaking in an
orbital fashion.
16. Total sample luminescence was measured in a Beckman Coulter DTX 880
integrated over 1 second.
17. Background luminescence was measured in at least six empty wells.
18. The relative multiplicative average for empty wells was calculated by
taking the arithmetic mean of the natural logarithm of all empty well
measurement.
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19. The relative multiplicative standard deviation for empty wells was cal-
culated by adding the squares of the differences between the natural
logarithm of each individual empty well measurement and the relative
multiplicative average for empty wells, taking the square root of the sum
and dividing by the number of measurements minus one.
20. For each condition, i.e. each combination of Protein A-tagged and firefly
luciferase-tagged constructs with or without induction, a relative multi-
plicative average was calculated by taking the arithmetic mean of the
natural logarithm of the individual measurements. These values were
corrected by taking the logarithm of the antilogarithm of the relative
multiplicative average minus the antilorithm of the relative multiplicative
average for empty wells, essentially the same as subtracting the empty
well measurements before applying the multiplicative model.
21. For each condition, the relative multiplicative standard deviation was
calculated by adding the squares of the differences between the natural
logarithm of each individual measurement and the relative multiplicative
average, taking the square root of the sum and dividing by the number of
measurements minus one, i.e. two. These values were corrected by adding
the relative multiplicative standard deviation for empty wells.
22. Finally, fold-binding values are obtained taking the antilogarithm of the
difference between the condition of interest and the respective comparison,
i.e. non-binding protein pairs involving the same firefly luciferase-tagged
construct, or, for mutation analyses, the respective wildtype construct.
23. The corresponding Z-scores are calculated by dividing the difference
between the condition of interest and the respective comparison by the
sum of the relative multiplicative standard deviations.
24. Differences of a factor of at least two and with a Z-score of at least two
were considered significant and substantial.
2.7.1 Tyrosine to Phenylalanine Mutations
To test phosphotyrosine-dependent protein-protein interactions in mammalian
cell culture, mutant versions of selected ORFS were generated by replacing
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tyrosine with phenylalanine residues. These constructs are referenced as ”ORF
Y(XX)XF”, where ORF indicates the template ORF and (XX)X indicates
the position of the modified tyrosine residue, and were generated by Nouhad
Benlasfer in a conservative fashion, i.e. changing TAT and TAC codons to TTT
and TTC, respectively.
2.7.2 SH2 Domain Mutations
To test phosphotyrosine-dependent protein-protein interactions in mammalian
cell culture, SH2 domain constructs incapable of binding protein tyrosine
phosphorylation sites were generated by replacing the most conserved amino
acid residue, an arginine canonically making direct contact to the phospho
group, with a lysine or a leucine residue. These constructs are referenced as
”ORF R(XX)XK” or ”ORF R(XX)XL”, respectively, where ORF indicates
the template ORF and (XX)X indicates the position of the modified arginine
residue. The following constructs were generated by Nouhad Benlasfer to make
phosphotyrosine dependency accessible in mammalian cell culture:
ORF
wildtype
codon(s)
mutant
codon(s)
BCAR3 (R177L) CGT CTT
GRB2 (ORF #2 R86K) CGA AAG
PIK3R1 (R88KR379K) CGA CGG AAG, AAG
PIK3R3 (ORF #1 R90LR383L) CGA, CGT CTA, CTT
PIK3R3 (ORF #2 R90LR383L) CGA, CGT CTA, CTT
SH2D2A (R120K) CGG AAG
SOCS4 (R311K) CGA AAG
SOCS4 (R311L) CGA CTA
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2.8 Analysis of sub-cellular Localization by Im-
munofluorescence
A subset of protein-protein interactions were visualized in protein fragment
complementation assays, determining their subcellular localization. We provided
a context for the protein fragment complementation assay results by immuno-
staining the endogenous proteins, where a specific antibody was available, and
overexpressed Protein A-tagged constructs. Confocal images or the mounted
samples were produced in a Zeiss LSM700 laser scanning microscope and
processed using the accompanying AxioVision software, Version 4.8.2.0 (Carl
Zeiss Microimaging GmbH). For each image shown, the transfection, staining
and mounting steps were performed by Nouhad Benlasfer.
2.8.1 Coating of glass cover slips with poly-D-lysine
First, glass cover slips were coated with poly-D-lysine to provide a suitable
surface for attachment of mammalian HEK293 cells:
1. For each combination of YFP fragment-tagged constructs, a sterile round
glass cover slip was placed in one well of a 24-well cell culture plate.
2. To each of these wells, 500 μl poly-D-lysine solution (0.1 g/l in H2O) were
added and incubated at 25°C for 30 min while shaking in an undulating
fashion.
3. The supernatant was discarded, the cover slips were washed three times
with 500 μl H2O and completely dried by leaving them under the cell
culture hood for 1 hour.
2.8.2 Protein fragment complementation assay
For visualization and determination of subcellular localization of protein-pro-
tein interactions in intact mammalian cells, split-YFP fusion constructs were
generated by Gateway cloning, co-expressed in HEK293 cells and analyzed by
confocal laser microscopy.
Each interaction assessed was assayed in all possible sensible configurations, i.e.,
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for ORFs without stop codons at the 3′-end, each interacting protein was fused
to both, the N-terminus and the C-terminus, of both, the N-terminal and the
C-terminal part of YFP, and assayed in combination with each complimentary
construct of the respective interaction partner. ORFs containing a 3′-stop codon
were tested in the C-terminal position only. Each fusion construct was further
assayed with at least one complimentary construct of a non-interacting protein
as a negative control.
Each YFP fragment complementation experiment was considered positive if
YFP fluorescence could be observed outside the endoplasmic reticulum. YFP
fluorescence in the endoplasmic reticulum only was assumed to result from
unspecific adherence of misfolded proteins. To ensure specificity of the signals,
only experiments involving only constructs with negative results in other pair-
ings were considered. Positive experiments were documented as digital images.
Detailed protocol:
1. Inoculation was begun by plating one well of 5 x 104 T-Rex cells in
500 μl DMEM in 24-well cell culture plates containing a poly-D-lysine-
coated glass cover slide in each well for each combination of YFP fragment-
tagged constructs, and incubating at 37°C in a 5% CO2 atmosphere until
the next day.
2. For each combination of constructs, a transfection mix was prepared from
two pre-mixes:
DNA mix Lipofectamine mix
3 μl pVEN-F1C/F1N DNA (100 ng/μl) 1.4 μl Lipofectamine 2000
3 μl pVEN-F2C/F2N DNA (100 ng/μl) 129.6 μl Opti-MEM
125 μl Opti-MEM
3. Both mixes were incubated separately for 5 min at 25°C, pooled and
mixed by carefully aspirating and dispensing three times with a pipette.
4. The combined transfection mix was incubated for 25 min at 25°C.
5. 250 μl transfection mix were added to the well.
6. The cells were incubated at 37°C in a 5% CO2 atmosphere until the next
day.
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7. Cells were fixed by replacing the medium with 500 μl 2% PFA in PBS to
each well and incubating at 25°C for 20 min.
8. The PFA solution was discarded. Residual PFA and DMEM were removed
by washing twice with 500 μl PBS per well.
9. 500 μl 70% ethanol were added to each well. Samples were stored at -20°C
over night or for several days.
10. To stain the cytoskeleton the supernatant was replaced by 200 μl PBS
containing 1 U Rhodamine Phalloidin (Invitrogen) and incubating for
20 min at 25°C.
11. The supernatant was removed, the cells were washed twice with 500 μl PBS
per well and 100 μl PBS were added to each well.
12. The nuclei were stained by adding 50 μl DAPI (1.6 mg/l in PBS) to each
well and incubating for 1 min at 25°C.
13. The cells were washed twice with 500 μl PBS per well.
14. 500 μl 70% ethanol were added to each well and incubated for 1 min
at 25°C.
15. The supernatant was replaced with 500 μl 96% ethanol and incubated for
1 min at 25°C.
16. The supernatant was replaced with 500 μl NEO-CLEAR (Merck) and
incubated for 1 min at 25°C.
17. For each well, a drop of Depex (Serva) was placed on a glass microscope
slide, the cover slide was removed from the 24-well plate and carefully
placed on the drop of Depex, face down.
18. Finally, the microscope slides were turned around once more and allowed
to try over night.
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2.8.3 Detection of endogenous proteins
The endogenous proteins were stained following this protocol:
1. Inoculation was begun by plating one well of 5 x 104 T-Rex cells in
500 μl DMEM in 24-well cell culture plates containing a poly-D-lysine-
coated glass cover slide in each well for each protein of interest, and
incubating at 37°C in a 5% CO2 atmosphere for two days.
2. The medium was removed. Cells were fixed by adding 500 μl 2% PFA in
PBS to each well and incubating at 25°C for 20 min.
3. The PFA solution was discarded. Residual PFA and DMEM were removed
by washing twice with 500 μl PBS per well.
4. The cells were permeabilized by adding 500 μl 0.2% Triton-X 100 in PBS
and incubating at 25°C for 10 min.
5. The supernatant was removed and the cells were washed twice with
500 μl PBS per well.
6. Unspecific protein binding sites were saturated by adding 150 μl 1% BSA
in PBS to each well and incubating at 25°C for 30 min shaking in an
undulating fashion.
7. The supernatant was removed and the cells were washed twice with
500 μl PBS per well.
8. The cells were incubated with 200 μl primary antibody solution at 25°C
until the next day, shaking in an undulating fashion. The primary antibody
solution was prepared by diluting the respective primary antibody in PBS
with 0.003% Triton-X 100, diluted 1:100, 1:200 or 1:400 for the GRB2-,
RB1- or TSPAN2-specific antibody, respectively.
9. The supernatant was removed and the cells were washed twice with
500 μl PBS per well.
10. The cells were incubated with 200 μl secondary antibody solution at 25°C
for 1 h, shaking in an undulating fashion. The secondary antibody so-
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lution was prepared by diluting the secondary antibody in PBS with
0.003% Triton-X 100, 1:500.
11. The supernatant was discarded and the cells were washed twice with
500 μl 0.003% Triton-X 100 in PBS per well.
12. 100 μl 0.003% Triton-X 100 in PBS were added to each well.
13. The cytoskeleton was stained by adding 200 μl PBS containing 1 U Rho-
damine Phalloidin (Invitrogen) to the supernatant and incubating for
20 min at 25°C.
14. The supernatant was removed, the cells were washed twice with 500 μl PBS
per well and 100 μl PBS were added to each well.
15. The nuclei were stained by adding 50 μl DAPI (1.6 mg/l in PBS) to each
well and incubating for 1 min at 25°C.
16. The cells were washed twice with 500 μl PBS per well.
17. 500 μl 70% ethanol were added to each well and incubated for 1 min
at 25°C.
18. The supernatant was replaced with 500 μl 96% ethanol and incubated for
1 min at 25°C.
19. The supernatant was replaced with 500 μl NEO-CLEAR (Merck) and
incubated for 1 min at 25°C.
20. For each well, a drop of Depex (Serva) was placed on a glass microscope
slide, the cover slide was removed from the 24-well plate and carefully
placed on the drop of Depex, face down.
21. Finally, the microscope slides were turned around once more and allowed
to try over night.
2.8.4 Detection of over-expressed Protein A-tagged pro-
teins
To obtain subcellular localization data of proteins for genes without com-
mercially available antibodies and to gauge the influence of overexpression,
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ORFs used for protein complentation were overexpressed as Protein A-tagged
constructs:
1. Inoculation was begun by plating one well of 5 x 104 T-Rex cells in
500 μl DMEM in 24-well cell culture plates containing a poly-D-lysine-
coated glass cover slide in each well for each protein of interest, and
incubating at 37°C in a 5% CO2 atmosphere until the next day.
2. For each combination of constructs, a transfection mix was prepared from
two pre-mixes:
DNA mix Lipofectamine mix
6 μl pPAReni DNA (100 ng/μl) 1.4 μl Lipofectamine 2000
125 μl Opti-MEM 129.6 μl Opti-MEM
3. Both mixes were incubated separately for 5 min at 25°C, pooled and
mixed by carefully aspirating and dispensing three times with a pipette.
4. The combined transfection mix was incubated for 25 min at 25°C.
5. 250 μl transfection mix were added to the well.
6. The cells were incubated at 37°C in a 5% CO2 atmosphere until the next
day.
7. Cells were fixed by replacing the medium with 500 μl 2% PFA in PBS to
each well and incubating at 25°C for 20 min.
8. The PFA solution was discarded. Residual PFA and DMEM were removed
by washing twice with 500 μl PBS per well.
9. The cells were permeabilized by adding 500 μl 0.2% Triton-X 100 in PBS
and incubating at 25°C for 10 min.
10. The supernatant was removed and the cells were washed twice with
500 μl PBS per well.
11. Unspecific protein binding sites were saturated by adding 150 μl 1% BSA
in PBS to each well and incubating at 25°C for 30 min shaking in an
undulating fashion.
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12. The supernatant was removed and the cells were washed twice with
500 μl PBS per well.
13. The cells were incubated with 200 μ l antibody solution at 25°C for 1 h,
shaking in an undulating fashion. The antibody solution was prepared
by diluting the DyLight 488-conjugated AffiniPure Rabbit Anti-Mouse
IgG (H+L) and the DyLight 488-conjugated AffiniPure Donkey Anti-
Rabbit IgG (H+L) in PBS with 0.003% Triton-X 100, 1:500 each.
14. The supernatant was discarded and the cells were washed twice with
500 μl 0.003% Triton-X 100 in PBS per well.
15. 100 μl 0.003% Triton-X 100 in PBS were added to each well.
16. The cytoskeleton was stained by adding 200 μl PBS containing 1 U Rho-
damine Phalloidin (Invitrogen) to the supernatant and incubating for
20 min at 25°C.
17. The supernatant was removed, the cells were washed twice with 500 μl PBS
per well and 100 μl PBS were added to each well.
18. The nuclei were stained by adding 50 μl DAPI (1.6 mg/l in PBS) to each
well and incubating for 1 min at 25°C.
19. The cells were washed twice with 500 μl PBS per well.
20. 500 μl 70% ethanol were added to each well and incubated for 1 min
at 25°C.
21. The supernatant was replaced with 500 μl 96% ethanol and incubated for
1 min at 25°C.
22. The supernatant was replaced with 500 μl NEO-CLEAR (Merck) and
incubated for 1 min at 25°C.
23. For each well, a drop of Depex (Serva) was placed on a glass microscope
slide, the cover slide was removed from the 24-well plate and carefully
placed on the drop of Depex, face down.
24. Finally, the microscope slides were turned around once more and allowed
to try over night.
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2.9 Selection of phosphotyrosine-binding genes
and ORFs
To provide a comprehensive resource for phosphotyrosine-dependent interactome
analysis, we defined a set of phosphotyrosine-recognizing domains, used the
InterPro database to identify all proteins comprising these domains, mapped
the proteins to Entrez Genes and selected at least one ORF for screening, as far
as available. For the second round, we used all available ORFs for the previously
unsuccessful genes.
In detail, we took these steps:
Compilation of target Entrez GeneIDs:
1. The InterPro database (Release 19) was queried for all UniProt identifiers
associated with the InterPro identifiers
InterProID Short Name Description
IPR000980 SH2 SH2 motif
IPR002404 Insln_rcpt_S1 Insulin receptor substrate-1, PTB
IPR006020 PTB_PID Phosphotyrosine interaction region
2. The amino acid sequences of the UniProt identifiers were retrieved from
the UniProt database (Release 14).
3. All RefSeq RNA sequences were retrieved from the RefSeq database
(Release 31).
4. For each mRNA, the coding sequence was determined according to the
annotations in the RefSeq database and the respective amino acid sequence
was generated using the BioPerl Bio::Seq objects translate() function
and the Bio::Tools::CodonTable #1 (”Stardard”).
5. A BLAST database was prepared from the translated RefSeq RNA coding
sequences.
6. The UniProt sequences comprising the phosphotyrosine-recognizing do-
main-containing proteins were aligned to the RefSeq RNA sequences
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using the NCBI standalone BLAST package (Version 2.0) and the respec-
tive BioPerl package. The parameters e and F were set to 10 and ”F”,
respectively, to ensure inclusion of every query in the results.
7. The BLAST results were evaluated manually to assign each UniProt
sequence the matching RefSeq RNA sequences.
8. The Entrez GeneIDs corresponding to the RefSeq RNA identifiers matched
by the phosphotyrosine-recognizing domain-containing proteins were ob-
tained using the annotations in the RefSeq database.
Selection of ORFs for screening:
9. The insert sequence of each Gateway Entry clone available in our labora-
tory was to assigned to an Entrez GeneIDs by matching it to the best
fitting RefSeq mRNA using the NCBI standalone BLAST package, as
before, except that the blastn program was used instead of blastp.
10. The Gateway Entry clones assigned to Entrez GeneIDs carrying phospho-
tyrosine-recognizing domains were selected as potential bait candidates
for screening.
11. For each Gateway Entry clone in the phosphotyrosine-recognizing subset,
the best matching UniProt identifiers were selected from the set defined
by the InterPro identifiers IPR000980, IPR002404 and IPR006020 and
aligned using the NCBI standalone BLAST package, as before, except
that the blastx program was used.
12. For each UniProt identifier in the set defined by the InterPro identifiers
IPR000980, IPR002404 and IPR006020 and each of the respective identi-
fiers, minimal domain footprints were defined by the highest number of an
amino acid residue annotated as a domain start and the lowest number
of an amino acid residue annotated as a domain end, for all overlapping
annotations for each identifier in the InterPro database.
13. Gateway Entry clones that failed to comprise at least one minimal domain
footprint were disqualified from screening for phosphotyrosine-dependent
protein-protein interactions.
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14. For round one, for each GeneID with at least one Entry clone in the
set of potential bait candidates, the Entry clone that best represented
the respective gene was manually selected for screening. Where the best
candidate was not obvious, two heuristics were applied. Where available,
the Entry clone originating from the hORFeome collection was chosen.
Where this was not enough, Entry clones with a 3′-stop codon were
preferred.
15. For round two, for each GeneID with at least one Entry clone in the set of
potential bait candidates that has not been included in the first round, all
clones were selected for screening. In addition, we obtained Entry clones
for genes in the target list, for which we did not possess Entry clones
already. For target genes without Entry clones in our selection for which
no Entry clones were available from external sources, we obtained non-
Gateway-compatible clones. In these cases, the annotations provided by
the suppliers were used.
2.10 Statistical Network Analysis
Basic statistical network parameters were computed in Cytoscape (Version 3.1.1)
using the NetworkAnalyser tool provided therein:
1. Every protein-protein interaction found in this study was normalized by
placing the lower GeneID on the left.
2. The set of unique normalized interactions was supplied with information
about protein tyrosine phosphorylation-dependency and imported to
Cytoscape (Version 3.1.1).
3. Each node in the network was annotated with boolean attributes whether
the respective gene was a successful bait genes, whether the gene was
found as prey at least once, and whether the gene was included in the
cancer gene census list (Futreal et al. 2004).
4. All loops and all nodes not connected to the largest component were
removed.
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5. The network was analyzed as an undirected network using the Network-
Analyser tool.
6. The parameters average clustering coefficient, diameter, radius, central-
ization, average shortest path length, average number of neighbors and
number of nodes were a direct result of the analysis.
7. The degree distribution was exported and used to calculate the line of
best fit assuming a log-log linear distribution weighed by experimental
data input (see below).
8. The parameters average clustering coefficient, diameter, radius, central-
ization, average shortest path length, average number of neighbors and
number of nodes were determined accordingly for the set of bait, the set
of non-bait genes, the set of cancer genes, the set of cancer genes that are
also successful bait genes and the set of cancer genes that are also prey
genes by selecting the respective nodes and using the option ”Analyze
Subset of Nodes”.
9. The nodes representing the genes PIK3R3, CRK, CBL, SH2D2A, STAT3,
SOCS4, GRB2 and APPL1 were removed and the analysis was repeated
to obtain the parameters without core nodes.
10. The process was repeated for the phosphotyrosine-dependent protein-
protein interactions only.
11. The data sets provided by Stelzl et al. (2005); Rual et al. (2005); Lim
et al. (2006); Wong et al. (2007) were analyzed similarly, except that
none of the aspects phosphotyrosine dependency, bait, prey or cancer
gene status were regarded.
12. The exponent γ of the line of best fit describing the scale-free model was
calculated as
γ =
N∑
i=1
ln(ni) ln(ki)niki
N∑
i=1
niki−
N∑
i=1
ln(ni)niki
N∑
i=1
ln(ki)niki
N∑
i=1
(ln(ni))2niki−
(
N∑
i=1
ln(ni)niki
)2
with N , the number of points in the degree distribution; i ∈ {1, . . . N};
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ki, the degree of the i-th point in the degree distribution; and ni, the
number of nodes for the i-th point in the degree distribution.
13. The intercept was calculated as
α =
N∑
i=1
ln(ni)ln(ki)niki−γ
N∑
i=1
ln(ki)niki
N∑
i=1
niki
.
14. The equation describes the line of best fit assuming a scale-free model and
weighing each data point by the amount of protein-protein interactions
involved.
2.11 Alignment of kinase sequence and struc-
ture
To visualize the high degree of conservation and position of the residue mutated
in generating the catalytically inactive kinase versions, the kinase domains
have been aligned on primary sequence and three-dimensional protein structure
model levels:
Sequence alignment:
1. The amino acid sequence of the nine kinases were obtained from the
UniProt database (Release 14.0) using the previously determined identi-
fiers (P42685, P06241, P51813, P42684, P07332, P43405, Q05397, Q13470,
O60674).
2. The kinase domain sequences were obtained by trimming these to the
region annotated as the kinase domain in the UniProt database.
3. The sequence alignment was produced with the ClustalW software (Ver-
sion 2.0.10), hosted by the European Bioinformatics Institute at http:
//www.ebi.ac.uk/Tools/msa/clustalw2/. The alignment options were
protein, slow, gonnet, gap open penalty = 10, gap extension
penalty = 0.1 for the pairwise alignment and gonnet, gap open
penalty = 10, gap extension penalty = 0.2, minimum gap distance
= 5, clustering method = neighbor joining without iteration
for the multiple alignment.
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Structural alignment:
4. The crystal structure models for the kinases were obtained from the RCSB
Protein Data Bank, where available, using the identifiers 2DQ7, 2XA4,
3BKB, 3FQS, 3GVU.
5. The structure models were opened in PyMOL (Version 1.4.1) and aligned
using the align function provided therein on the respective FLVRES
motifs and standard parameters (cutoff=2.0, cycles=5, gap=-10.0,
extend=-0.5, max_gap=50, object=None, matrix=’BLOSUM62’,
mobile_state=0, target_state=0, quiet=1, reset=0, max_skip=0,
transform=1).
2.12 Clustering of kinase specificity patterns
To avoid introducing any kind of bias stemming from human pattern recognition
compulsion, we used a computational method to group interactions by kinase
specificity according to the kinase plate assay results:
1. Kinase plate assay results were converted to a bipartite graph of interac-
tions and kinases. Edges were placed connecting any pair of interaction
and kinase that produced growth in the kinase plate assay.
2. Kinases with less than two spots were removed from the analysis.
3. The bipartite graph was used compute a similarity matrix. For each pair
of interactions, the similarity was computed as
sij =
|Ni∩Nj |2
|Ni|·|Nj |
with sij, the similarity between interactions i and j; and Nn the number
of neighbors of the n-th interaction.
4. The obtained similarity matrix was used as input for clustering with affinity
propagation clustering algorithm, implemented in R as the APCluster
package. The input preference was set to the median for all interactions
(q=0).
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2.13 Semantic similarity of interaction partners
1. The network of phosphotyrosine-dependent interactions, the complete
network, as well as the reference networks provided by (Stelzl et al. 2005)
and (Rual et al. 2005) were converted to Entrez GeneID and cleared of
loops (i.e. self-interactions).
2. A randomized version of the network was generated by adding both
GeneIDs to the pool of GeneIDs, for each interaction in the original
network. Two GeneIDs were drawn at random. If they were different and
the combination was not present in the randomized network, they were
removed from the pool and the interaction was added to the network.
Otherwise, a random interaction was removed from the nascent random-
ized network (unless empty) and the two GeneIDs added to the pool.
This process was repeated until the pool of GeneIDs was empty. At this
point, the randomized network was finished.
3. For each network, 1000 randomized versions were generated this way.
4. For each of the three ontologies (Biological Pathway, Cellular Component,
Molecular Function), the 4004 networks (4 input + 4 x 1000 randomized
versions) were reduced by the interactions not annotated in the respective
ontology.
5. For each interaction in any of the 12012 networks (4004 x 3 ontologies),
the semantic similarity of the two GeneIDs according to the respective
ontology was calculated using the Bioconductor R package GOSemSim
(Version 1.22.0) and the geneSim function provided therein. The respective
ontology was chosen as ontology. Otherwise, the parameters measure =
”Resnik”, drop = ”IEA”, organism = ”human”, combine = ”BMA”
were used.
6. For each network, the average semantic similarity was calculated by adding
all the individual semantic similarity values belonging to the network and
dividing by the number of interactions. Interactions for which the semantic
similarity could not be computed (”NA”) were valued as 0, interactions
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with an infinite calculated semantic similarity value (”Inf”) were valued
as 1.
7. For each of the four network categories, the density of the distribution
of the average semantic similarity values was plotted. The average se-
mantic similarity value calculated for the respective input network was
indicated by a vertical arrow. The density was calculated using the
stats::density() function provided in R using the parameters n=2048,
bw=”SJ”.
2.14 Over-representation of GO terms, biologi-
cal pathways, NESTs and cancer genes
The genes found as prey were tested for statistical over-representation. In other
words, the probability of selecting at least the obtained number of genes with
a certain annotation from a defined set of genes assuming equal chances of
selection for each gene in the set was calculated. A low probability suggests that
the selection of genes was biased. To make the obtained probability values more
meaningful and more comparable, the values were corrected by multiplying
with number of annotations tested. For comparison, the genes used as bait were
tested the same way. For GO terms, biological pathways annotated in pathway
databases and NESTs, the webserver provided by the ConsensusPathDB was
used. The over-representation analysis for cancer genes was calculated using R:
1. The ORFs used as bait were converted to Entrez GeneID as described
above. The obtained prey ORFs and the ORFs included in the prey matrix
and non-autoactive were converted the same way, if they were derived
from Gateway Entry clones. For ORFs derives from cDNA, obtained
by classical ligation cloning, partial sequences were available only. The
partial sequences were assigned to RefSeq RNA sequences as described
above and only the best matching identifier was used for conversion to
Entrez GeneID. For each of these categories a unique set of GeneIDs was
assembled.
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2. For GO term over-representation analysis, the set of prey GeneIDs was
uploaded to the ConsensusPathDB (version 21) over-representation anal-
ysis tool, the set of matrix GeneIDs was provided as background. The
option ”gene ontology level 4 categories” was chosen, the box for
”biological process” was checked and 0.01 was set as p-value cutoff.
This was repeated for ”molecular function” instead of ”biological
process”, and for ”cellular component”.
3. For pathway over-representation analysis, ”pathways as defined by
pathway databases” was selected instead of ”gene ontology level 4
categories”, and the databases PID, Reactome, NetPath, Wikipathways,
KEGG, INOH and Biocarta were selected. Minimum overlap with input
list and p-value cutoff were set to 2 and 0.01, respectively.
4. For network neighborhood-based entity sets (NESTs), ”1-next neighbors”
was checked with minimum set size, minimum connectivity, minimum
overlap with input list and p-value cutoff were set to 2, 0, 2 and 0.001,
respectively.
5. The over-representation analysis for cancer genes was performed in R
using the stats::phyper() function. The function parameters p, m, n,
k, lower.tail, log.p were set to the number of cancer genes in the
prey set, the number of cancer genes in the prey matrix, the number of
non-cancer genes in the prey matrix, the total number of genes in the prey
set, FALSE and FALSE, respectively. For interaction-based analyses, the
numbers of genes were replaced by the respective numbers of interactions
that were found or could have been found. This analyses were carried
out twice, once for the complete protein interaction set and once for the
phosphotyrosine-dependent interactions, only.
2.15 Linear peptide motifs
Although the focus of this study lies on protein-protein interactions, and no
binding surfaces were determined, we estimated how well previously reported
linear interaction motif preferences are reflected in our data. For each phos-
photyrosine-dependent interaction partner of a phosphotyrosine-recognizing
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domain-containing protein with a previously reported motif, we determined the
best-fitting tyrosine-centered peptide motif and whether it has been reported to
be phosphorylated. For comparison, we did the same for independent interaction
partners. We further determined additional parameters for the two data set to
refute alternative hypotheses, like the average total number of tyrosine residues
and the average total number of reported tyrosine phosphorylation sites, for
both sets.
In detail, data were processed according to this protocol:
1. For all protein tyrosine phosphorylation sites reported in the RefSeq
(Release 14), UniProt (Release 2010_12) and PhosphoSite (downloaded
on October 10, 2010) for human (Homo sapiens) or mouse (M.musculus),
15-amino acid motifs centered on the reported position were extracted
from the respective sequences.
2. Motifs not containing a tyrosine residue in the central position were
considered incorrectly annotated and removed.
3. Phosphotyrosine motifs reported in mouse were converted to human, by
aligning the identifiers to the respective human identifiers using BLAST,
i.e. mouse RefSeq to human RefSeq and mouse UniProt to human UniProt.
Phosphotyrosine sites inside aligned regions were converted to human by
identifying the best-fitting 15-amino acid residue window for the mouse
motif in the human sequence. Human sequence motifs not containing a
central tyrosine residue were discarded, as were motifs lying in regions
which could not be aligned to a corresponding human sequence.
4. For each ORF that interacted with a phosphotyrosine-recognizing domain-
containing protein, the phosphotyrosine motifs reported for the respective
identifiers were aligned to the ORFs amino acid sequence. Motifs not
contained in the ORF sequence or for which the corresponding ORF
sequence was lacking the central tyrosine residue were discarded, the
others were considered reported phosphotyrosine sites.
5. For each ORF that interacted with a phosphotyrosine-recognizing domain-
containing protein, for each tyrosine residue in the amino acid sequence a
15-amino acid motif was extracted centered on the tyrosine residue.
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6. The literature SH2 domain binding motifs aggregated in Table S3 of
(Liu et al. 2006) were compared to the corresponding tyrosine-centered
motifs by counting the number of matching positions. For each interaction
partner, the highest numbers of matching residues was assumed to identify
the most likely binding site. The significance of the difference of the
distributions for the phosphotyrosine-dependent and the independent
interaction partners was assessed by a Wilcoxon rank sum test with
continuity correction using the stats::wilcox.test() function provided
in R and the two distribution vectors as input.
7. For each interaction partner, all best-matching motifs were compared
to the reported phosphotyrosine sites and the percentage of reported
phosphotyrosine sites was determined by dividing the number of best-
matching sites reported as phosphorylated by the total number of best-
matching sites, for each category.
8. The average number of tyrosine residues per interaction partner was
determined by adding the number of tyrosine residues in all interaction
partners, then dividing by the total number interaction partners.
9. The average number of phosphorylated tyrosine residues per interaction
partner was determined by adding the number of tyrosine residues reported
to be phosphorylated in all interaction partners, then dividing by the
total number interaction partners.
10. The average percentage of tyrosine residues reported to be phosphorylated
per interaction partner was determined by dividing the number of tyrosine
residues reported to be phosphorylated by the total number of tyrosine
residues for all interaction partners.
11. The quotients of phosphorylated tyrosine residues and the total number
of tyrosine residues in the complete sets was determined by dividing the
average number of tyrosine residues per interaction partner by the average
number of tyrosine residues per interaction partner.
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2.16 Comparison to Protein Interaction Litera-
ture
In terms of assessing ones results in the context of data produced by a wide
variety of methods and researchers, comparison to literature knowledge is often
considered a ”gold standard” for high throughput studies. This kind of com-
parison is especially useful for estimating false-negative rate and novelty. The
novelty estimate is critically dependent on a comprehensive literature data set.
In addition, the false-negative estimate requires a defined interaction space.
Therefore, we queried the protein-protein interaction meta-database Consen-
susPathDB (Kamburov et al. 2009) for each interaction found in our study, as
well as each combination of bait genes. We also combined the information to
create an estimate of the total phosphotyrosine-dependent interactome size.
2.16.1 Assembly of a curated Literature-based interac-
tion set
First, we generated a manually curated literature interaction data set:
1. Every GeneID of a successful bait gene was combined with each other
GeneID of a successful bait gene, generating the complete list of possible
interactions in the bait-bait space.
2. The union of the complete list of possible interactions in the bait-bait
space and every interaction found in this study was formed, generating
the target list for literature database search.
3. The protein-protein interaction meta-database ConsensusPathDB (ver-
sion 19) was queried for each interaction on the target list. The PubMed
identifiers (PMIDs) for each interaction in the results were exported.
4. For each interaction with at least one reported PMID in the Consen-
susPathDB, we used the PMID to obtain the publications supposedly
reporting the interaction, checking each publication until the interaction
was either verified or the list of PMIDs for the interaction was depleted.
In this case, the interaction was considered annotated incorrectly and
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removed from the set of literature interactions. Interactions that could be
verified were used for further analysis. For each publication verifying an
interaction we also noted whether there were any hints indicating phospho-
tyrosine dependence or independence. This annotation was very liberal,
for example, interaction induced by a known tyrosine kinase stimulant
were considered phosphotyrosine dependent.
2.16.2 Estimation of Novelty
Once a comprehensive literature is available, estimating the novelty is fairly
straight-forward:
1. The number protein-protein interactions in the overlap of the literature
data set and our results was divided by the total number of interactions
found in this study to obtain the fraction of known interactions.
2. The fraction of novel interactions is the complement of the fraction of
known interactions. Therefore, we obtained the fraction of novel interac-
tions by subtracting the fraction of known interaction from one.
3. The calculation was repeated for the interactions among bait genes and
its complement, i.e. the interactions among one bait gene and one non-
bait gene.
2.16.3 Estimation of false-negative rate
For the estimation of false negatives, information about possible results is
required. Therefore, the analysis was limited to the bait-bait interaction space:
1. Assuming the number false-positive interactions in the literature set
is negligible, the number protein-protein interactions in the overlap of
the literature data set and our results was divided by the number of
interactions among bait genes in the literature set to obtain the fraction
of recovered interactions.
2. The fraction of recovered interactions is the complement of the false-
negative rate. Therefore, we obtained the false-negative rate by subtracting
the fraction of recovered interactions from one.
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3. The false-negative rate for the complete data set is approximated as the
square root of the false-negative rate for interactions among bait genes,
since the latter have been assayed twice.
2.16.4 Estimation of phosphotyrosine interactome size
To estimate the size of the complete phosphotyrosine-dependent interactome,
we assumed that the false-negative rate obtained before is reliable and that
our approach is comprehensive, i.e. that the number of phosphotyrosine-depen-
dent interaction among genes without phosphotyrosine-recognizing domains is
negligible:
1. We calculated the fraction of recovered interactions for the complete
interaction space by subtracting the false-negative rate obtained for the
complete interaction space.
2. The approximate number of phosphotyrosine-dependent interactions in
the complete interaction space was obtained by dividing the number of
interactions found by the fraction of recovered interactions.
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Results
3.1 Comprehensive, genome-scale screening pro-
duced a dense network of phosphotyrosine-
dependent protein-protein interactions
3.1.1 A modified yeast two-hybrid allows finding phos-
phorylation-dependent interactions
In conventional yeast two-hybrid analysis (Fields & Song 1989), two plasmids
carrying complementary transcription factor hybrids of proteins to be tested
for interaction are brought together in a yeast cell carrying reporter gene con-
structs. The reporters are auxotrophic markers allowing growth on selective
medium or enzymes whose activity can be measured in simple enzymatic tests.
Such yeast two-hybrid systems are incapable of finding interactions that need
post-translational protein modification uncommon to yeast. Therefore, a third
plasmid encoding a non-receptor tyrosine kinase gene under the control of a
Cu2+-inducible CUP1 promoter was employed for the analysis of phosphotyro-
sine-dependent interactions. For screening, the kinase plasmid was introduced
together with the bait plasmid into MATa yeast strains and mated against an
array of MATα prey strains. Diploid strains are able to make histidine only
if the two hybrid proteins interact. An enzyme that allows easy colorimetric
assaying, β-galactosidase, can be used as additional reporter gene. In a proof-
of-principle experiment, the phosphotyrosine-dependently interacting proteins
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Figure 8: The interaction between IRS1 and PIK3R3 is phosphoty-
rosine-dependent. (left) Yeast two-hybrid results for the interaction between
IRS1 as bait and PIK3R3 as prey in the presence (FYN) or absence (Vector) of
a FYN non-receptor tyrosine. The kinase is expressed with (+NLS) and without
(-NLS) nuclear localization sequence under the control of a copper-inducible
CUP1 promoter. The first column shows a mating control on -ALT/HU medium,
the second and third column show growth results on selective -HAULT medium
without and with 20 μM copper, respectively . The fourth and fifth column
show the result of a β-galactosidase assay corresponding to the second and third
column, respectively. The mating control shows growth for all conditions, while
the other tests are positive for the kinase-containing yeast only, irrespective of
added copper.
(right) Phosphotyrosine-specific immuno blot and coomassie-stained PAA gel
of yeast extract. Yeast colonies containing the plasmids for the phosphotyro-
sine-dependently interacting proteins IRS1 as bait and PIK3R3 as prey and a
FYN kinase plasmid without nuclear localization sequence have been grown on
selective -HAULT agar without or with 20 μM copper. The yeast proteins were
extracted, seperated on a 12% PAA gel, blotted and detected with a phosphoty-
rosine-specific 4G10 antibody (Anti-pY). For comparison, yeast containing bait
and prey plasmids for FRS3, which dimerizes phosphorylation-independently,
with and without kinase, was prepared the same way. A second PAA gel that
has been run in parallel to the one used for the immuno blot was stained with
Coomassie for total protein content and is shown on the bottom (Coomassie),
as a loading control.
PIK3R3 and IRS1 (Felder et al. 1993; Pons et al. 1995; Mothe et al. 1997)
bestowed the ability to grow on -HAULT medium (Figure 8, top) and produce
blue staining in a β-galactosidase assay in the presence of a FYN kinase con-
struct, but not without. When induced, the kinase phosphorylates not only
the bait and prey proteins. It also phoshorylates yeast proteins, which can
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be seen on Western blots with a phosphotyrosine-specific antibody (Figure 8,
bottom). Without induction, the phosphorylation signal on the Western blot is
indistinguishable from the control without kinase plasmid, demonstrating the
high sensitivity of the growth assay. These results show that introducing an
active non-receptor tyrosine kinase into the yeast two-hybrid system makes the
detection of phosphotyrosine-dependent protein-protein interactions possible
and allows distinguishing kinase dependent PPIs from independent ones in
a simple growth assay. Its modular nature, i.e. the fact that it just uses an
additional plasmid, makes it very flexible and compatible with a genome-scale
prey matrix prepared by Stelzl et al. (2005) and maintained in the Wanker
laboratory.
3.1.2 Seventy of 126 genes containing phosphotyrosine-
recognizing domains produced interactions in an
unbiased, targeted yeast two-hybrid screen
We planned to perform a comprehensive and unbiased screen for phosphoty-
rosine-dependent interactions using full length proteins. Information about
specific amino acid residues, or even proteins, that have been shown to be phos-
phorylated is far from complete. So, in principle, all human proteins containing
at least one tyrosine residue qualify as potentially phosphorylated proteins.
The number of phosphotyrosine-recognizing domain-containing proteins, on the
other hand, is much better defined. It is also much smaller. It is even smaller
than the number of proteins currently known to be tyrosine-phosphorylated.
Thus, phosphotyrosine-recognizing domain-containing proteins were screened
as bait against a genome-scale prey matrix, under the assumption that prey
proteins will be phosphorylated by the coexpressed kinases. This screen will
provide a comprehensive approach to a phosphotyrosine-dependent protein-
protein interaction network. It is much more feasible and less prone to errors
of omission than using e.g. known tyrosine-phosphorylated proteins as bait and
screening for phosphotyrosine-recognizing proteins.
There are two major kinds of phosphotyrosine-recognizing domains, SRC ho-
mology 2 (SH2) and phosphotyrosine-binding (PTB) domains (Pawson & Scott
1997; Yaffe 2002; Kuriyan & Cowburn 1997). SH2 domains are very clearly
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defined and distinguished in terms of structure and function (Liu et al. 2006;
Jones et al. 2006; Pawson et al. 2001; Liu et al. 2011a). For PTB domains,
there are several subgroups, some of which clearly recognize phosphotyrosine
motifs, while others have been shown to bind phospholipids, but do not usually
interact with proteins (Rebecchi & Scarlata 1998; Uhlik et al. 2005; DiNitto &
Lambright 2006). Structurally, PTB domains have a Pleckstrin homology-like
fold and are therefore sometimes classified as a subgroub of the PH domains
(Rebecchi & Scarlata 1998; Blomberg et al. 1999). For the purposes of this
study, the phosphotyrosine-recognizing domains were defined using the InterPro
database (Hunter et al. 2012), focusing on SH2 domains and PTB subgroups
which have been widely implicated in phosphotyrosine recognition. UniProt
entries containing at least one of the InterPro identifiers IPR000980 (SH2),
IPR002404 (PTB_IRS1) or IPR006020 (PTB_PID) were mapped to Entrez
GeneIDs using RefSeq sequences (SEE APPENDIX). The three InterPro iden-
tifiers were annotated to 418 UniprotIDs, corresponding to 149 Entrez GeneIDs
(TABLE X). We planned to obtain at least one full length clone for each
GeneID, or, failing that, a clone containing the complete respective domain. All
corresponding clones from the Gateway entry clone collection existing in the
laboratory, consisting of the hORFeome 1.1 (Rual et al. 2004), 3.1 (Lamesch
et al. 2007) and 5.1, supplemented with specific Ultimate ORF clones (Invitro-
gen) and other clones generated in the context of the NGFN project NeuroNet
(BMBF) were used. Additional clones for phosphotyrosine-recognizing genes
not found in this collection were obtained from the FLJ entry clone collection
(Ota et al. 2004) and the german cDNA consortium (Bechtel et al. 2007).
For the genes MAPK8IP1, RIN3, VAV2, PLCG1, APBA2 and STAP2 cDNA
clones were purchased and Gateway entry clones were generated by PCR and
subsequent Gateway BP shuttling reaction. Altogether, clones for 126 genes
(83%) were collected. For 25 genes (17%), no correct clones were obtained (grey
entries in Table 4). The inserts of the entry clones were subcloned by Gateway
LR reaction into the yeast two-hybrid bait vector pBTM116-D9, prepared for
yeast two-hybrid screening (SEE BELOW) and tested for autoactivation. For
autoactive GeneIDs, all other clones were tested. For five genes (4% of all
tested ones), all available clones were autoactive (yellow rows in Table 4). Non-
autoactive strains were screened against the proteome-scale prey matrix. Of
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Table 4: The screen covers the target gene set very well.Overview of the
target genes, sorted by the Entrez Symbol. For each gene, the Entrez GeneID,
the most representative UniProtID, the number of SH2 domains and PTB
domains (as defined by the InterPro identifiers IPR000980 (SH2), IPR002404
(IRS1) and IPR006020 (PID)) and the number of clones, is shown. The total
number of clones, the number of clones that were screened and the number
of successful clones (i.e. clones that produced interactions) are provided. The
entries in this column are color-coded according to success state. Genes with
at least one successful clone are colored dark green, genes that were screened
as bait but failed to produce interactions are colored light green, genes for
which all available clones were autoactive (i.e. produced interaction signal in
the absence of a prey insert) are colored yellow and genes for which no clones
were available are grey.
Domains ORFs
Symbol GeneID UniProtID SH
2
IR
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Is
ABL1 25 ABL1_HUMAN 1 0 0 0
ABL2 27 ABL2_HUMAN 1 1 1 1
ANKS1A 23294 ANKS1_HUMAN 1 1 1 1
ANKS1B 56899 ANS1B_HUMAN 1 2 2 0
APBA1 320 APBA1_HUMAN 1 0 0 0
APBA2 321 APBA2_HUMAN 1 1 1 0
APBA3 9546 APBA3_HUMAN 1 0 0 0
APBB1 322 APBB1_HUMAN 2 2 1 0
APBB2 323 APBB2_HUMAN 2 2 2 0
APBB3 10307 APBB3_HUMAN 2 2 2 1
APPL1 26060 DP13A_HUMAN 1 2 2 2
APPL2 55198 DP13B_HUMAN 1 1 1 1
BCAR3 8412 BCAR3_HUMAN 1 1 1 0
BLK 640 BLK_HUMAN 1 1 1 0
BLNK 29760 BLNK_HUMAN 1 2 1 0
BMX 660 BMX_HUMAN 1 0 0 0
BTK 695 BTK_HUMAN 1 1 1 1
CBL 867 A3KMP8_HUMAN 1 1 1 1
CBLB 868 CBLB_HUMAN 1 2 1 1
CBLC 23624 CBLC_HUMAN 1 2 2 0
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Table 4: The screen covers the target gene set very well. (continued)
Domains ORFs
Symbol GeneID UniProtID SH
2
IR
S1
P
ID
to
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w
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P
Is
CCM2 83605 CCM2_HUMAN 1 2 2 1
CHN1 1123 CHIN_HUMAN 1 2 2 0
CHN2 1124 CHIO_HUMAN 1 1 1 1
CISH 1154 CISH_HUMAN 1 1 1 0
CRK 1398 CRK_HUMAN 1 4 3 3
CRKL 1399 CRKL_HUMAN 1 2 1 1
CSK 1445 CSK_HUMAN 1 1 1 1
DAB1 1600 DAB1_HUMAN 1 0 0 0
DAB2 1601 DAB2_HUMAN 1 3 1 0
DAPP1 27071 DAPP1_HUMAN 1 2 2 2
DOK1 1796 DOK1_HUMAN 1 2 1 1
DOK2 9046 DOK2_HUMAN 1 2 1 1
DOK3 79930 DOK3_HUMAN 1 0 0 0
DOK4 55715 DOK4_HUMAN 1 1 1 1
DOK5 55816 DOK5_HUMAN 1 1 1 1
DOK6 220164 DOK6_HUMAN 1 1 1 0
DOK7 285489 DOK7_HUMAN 1 2 1 1
EPS8 2059 EPS8_HUMAN 1 1 1 1
EPS8L2 64787 ES8L2_HUMAN 1 1 1 0
FER 2241 FER_HUMAN 1 1 1 1
FES 2242 FES_HUMAN 1 2 2 0
FGR 2268 FGR_HUMAN 1 1 0 0
FRK 2444 FRK_HUMAN 1 2 2 0
FRS2 10818 FRS2_HUMAN 1 1 1 1
FRS3 10817 FRS3_HUMAN 1 2 2 1
FYN 2534 FYN_HUMAN 1 2 2 1
GRAP 10750 GRAP_HUMAN 1 2 1 0
GRAP2 9402 GRAP2_HUMAN 1 3 1 1
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Table 4: The screen covers the target gene set very well. (continued)
Domains ORFs
Symbol GeneID UniProtID SH
2
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GRB2 2885 GRB2_HUMAN 1 3 2 2
GRB7 2886 GRB7_HUMAN 1 2 2 1
GRB10 2887 GRB10_HUMAN 1 1 1 1
GRB14 2888 GRB14_HUMAN 1 1 1 1
GULP1 51454 GULP1_HUMAN 1 0 0 0
HCK 3055 HCK_HUMAN 1 3 3 1
HSH2D 84941 HSH2D_HUMAN 1 1 1 1
INPP5D 3635 SHIP1_HUMAN 1 2 2 0
INPPL1 3636 SHIP2_HUMAN 1 0 0 0
IRS1 3667 IRS1_HUMAN 1 1 1 1
IRS2 8660 IRS2_HUMAN 1 0 0 0
ITGB1BP1 9270 ITBP1_HUMAN 1 2 2 2
ITK 3702 ITK_HUMAN 1 1 1 0
JAK1 3716 JAK1_HUMAN 1 0 0 0
JAK2 3717 JAK2_HUMAN 1 1 0 0
JAK3 3718 JAK3_HUMAN 1 1 1 1
LCK 3932 LCK_HUMAN 1 0 0 0
LCP2 3937 LCP2_HUMAN 1 2 2 0
LDLRAP1 26119 ARH_HUMAN 1 1 1 0
LYN 4067 LYN_HUMAN 1 3 3 1
MAPK8IP1 9479 JIP1_HUMAN 1 1 1 0
MAPK8IP2 23542 JIP2_HUMAN 1 2 2 1
MATK 4145 MATK_HUMAN 1 1 1 0
MIST 116449 CLNK_HUMAN 1 1 1 1
NCK1 4690 NCK1_HUMAN 1 2 2 2
NCK2 8440 NCK2_HUMAN 1 2 0 0
NOS1AP 9722 CAPON_HUMAN 1 1 1 1
NUMB 8650 NUMB_HUMAN 1 1 1 1
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Table 4: The screen covers the target gene set very well. (continued)
Domains ORFs
Symbol GeneID UniProtID SH
2
IR
S1
P
ID
to
ta
l
sc
re
en
ed
w
/P
P
Is
NUMBL 9253 NUMBL_HUMAN 1 0 0 0
PID1 55022 PCLI1_HUMAN 1 1 1 0
PIK3R1 5295 P85A_HUMAN 2 2 1 0
PIK3R2 5296 Q96CK7_HUMAN 2 1 1 1
PIK3R3 8503 P55G_HUMAN 2 2 2 1
PLCG1 5335 PLCG1_HUMAN 2 1 1 0
PLCG2 5336 PLCG2_HUMAN 2 1 1 1
PTK6 5753 PTK6_HUMAN 1 1 1 0
PTPN11 5781 PTN11_HUMAN 2 1 1 1
PTPN6 5777 PTN6_HUMAN 2 3 3 1
RABGAP1 23637 RBGP1_HUMAN 1 2 2 0
RABGAP1L 9910 RBG1L_HUMAN 1 3 3 1
RASA1 5921 RASA1_HUMAN 2 2 2 1
RGS12 6002 RGS12_HUMAN 1 0 0 0
RIN1 9610 RIN1_HUMAN 1 1 1 1
RIN2 54453 RIN2_HUMAN 1 1 1 0
RIN3 79890 RIN3_HUMAN 1 3 3 3
SH2B1 25970 SH2B1_HUMAN 1 1 1 1
SH2B2 10603 SH2B2_HUMAN 1 0 0 0
SH2B3 10019 SH2B3_HUMAN 1 0 0 0
SH2D1A 4068 SH21A_HUMAN 1 2 2 1
SH2D1B 117157 SH21B_HUMAN 1 3 3 2
SH2D2A 9047 SH22A_HUMAN 1 1 1 1
SH2D3A 10045 SH23A_HUMAN 1 1 1 1
SH2D3C 10044 SH2D3_HUMAN 1 1 1 0
SH2D4A 63898 SH24A_HUMAN 1 1 1 1
SH2D4B 387694 SH24B_HUMAN 1 0 0 0
SH2D5 400745 SH2D5_HUMAN 1 1 1 0
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Table 4: The screen covers the target gene set very well. (continued)
Domains ORFs
Symbol GeneID UniProtID SH
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SH2D6 284948 SH2D6_HUMAN 1 0 0 0
SH3BP2 6452 3BP2_HUMAN 1 1 1 1
SHB 6461 SHB_HUMAN 1 0 0 0
SHC1 6464 SHC1_HUMAN 1 1 0 0 0
SHC2 25759 SHC2_HUMAN 1 1 0 0 0
SHC3 53358 SHC3_HUMAN 1 1 1 1 0
SHC4 399694 SHC4_HUMAN 1 1 1 1 0
SHD 56961 SHD_HUMAN 1 2 1 1
SHE 126669 SHE_HUMAN 1 1 1 1
SHF 90525 SHF_HUMAN 1 0 0 0
SLA 6503 SLAP1_HUMAN 1 2 1 0
SLA2 84174 SLAP2_HUMAN 1 1 0 0
SOCS1 8651 SOCS1_HUMAN 1 1 1 1
SOCS2 8835 SOCS2_HUMAN 1 1 1 0
SOCS3 9021 SOCS3_HUMAN 1 2 1 1
SOCS4 122809 SOCS4_HUMAN 1 1 1 1
SOCS5 9655 SOCS5_HUMAN 1 2 2 0
SOCS6 9306 SOCS6_HUMAN 2 1 1 1
SOCS7 30837 SOCS7_HUMAN 1 0 0 0
SRC 6714 SRC_HUMAN 1 2 2 2
SRMS 6725 SRMS_HUMAN 1 1 1 0
STAP1 26228 STAP1_HUMAN 1 1 1 0
STAP2 55620 STAP2_HUMAN 1 1 1 0
STAT1 6772 STAT1_HUMAN 1 1 1 1
STAT2 6773 STAT2_HUMAN 1 0 0 0
STAT3 6774 STAT3_HUMAN 1 4 2 2
STAT4 6775 STAT4_HUMAN 1 0 0 0
STAT5A 6776 STA5A_HUMAN 1 2 1 1
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Table 4: The screen covers the target gene set very well. (continued)
Domains ORFs
Symbol GeneID UniProtID SH
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STAT5B 6777 STA5B_HUMAN 1 2 0 0
STAT6 6778 STAT6_HUMAN 1 1 1 0
SUPT6H 6830 SPT6H_HUMAN 1 0 0 0
SYK 6850 KSYK_HUMAN 2 2 1 1
TBC1D4 9882 TBCD4_HUMAN 2 1 1 0
TEC 7006 TEC_HUMAN 1 1 1 0
TENC1 23371 TENC1_HUMAN 1 1 1 1 1
TNS1 7145 TENS1_HUMAN 1 1 0 0 0
TNS3 64759 TENS3_HUMAN 1 1 1 1 0
TNS4 84951 TENS4_HUMAN 1 1 1 1
TXK 7294 TXK_HUMAN 1 1 1 0
TYK2 7297 TYK2_HUMAN 1 1 1 0
VAV1 7409 VAV_HUMAN 1 1 1 0
VAV2 7410 VAV2_HUMAN 1 1 1 0
VAV3 10451 VAV3_HUMAN 1 1 1 0
YES1 7525 YES_HUMAN 1 1 1 1
ZAP70 7535 ZAP70_HUMAN 2 2 2 0
total 188 159 82
the 126 genes screened, 70 (56%) were functional, i.e. produced at least one
interaction (dark green in Table 4). Fifty-one genes (40%) were screened but
failed to produce any interaction as bait (light green in Table 4). On the clone
level, 188 phosphotyrosine-recognizing gene-coding sequences were cloned and
tested for autoactivity, 159 (85%) clones were screened and 82 (44%) clones
were functional. This is in agreement with previous large scale yeast two-hybrid
screens, that show a similar fraction of clones that did not result interactions
(Stelzl et al. 2005; Rual et al. 2005; Goehler et al. 2004). The relative numbers
are smaller for the clones, because more clones were tried for genes that were
autoactive or non-functional.
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In conclusion, a comprehensive set of phosphotyrosine-recognizing domain-
containing genes was screened against a proteome-scale prey matrix. In these
experiments, about half of all phosphotyrosine-recognizing domain-containing
genes interacted with at least one prey protein.
3.1.3 Genome-scale yeast two-hybrid screening of a com-
prehensive phosphotyrosine gene set produced 292
phosphotyrosine-dependent interactions
A comprehensive set of phosphotyrosine-recognizing proteins was selected as
bait for genome-scale screening for phosphotyrosine-dependent protein-protein
interactions. Towards this end, the relevant tyrosine residues in the potentially
interacting prey proteins had to be phosphorylated in the yeast cellular envi-
ronment. There are no endogenous bone fide tyrosine kinases in S. cerevisiae
(Manning et al. 2002a; Gnad et al. 2009), so they were supplied exogenously. In
our experiments, they were supplied on an additional ade2 selectable plasmid
under the control of a copper-inducible CUP1 promoter (Butt et al. 1984). We
used one member of each non-receptor tyrosine kinase family, except for the CSK
family which is known to exclusively add repressive phopsphotyrosine marks to
non-receptor tyrosine kinases (Levinson et al. 2008). The use of representative
kinases of different families increases the chances of phosphorylating each rel-
evant tyrosine residue in the assay. The yeast two-hybrid MATa strains were
successively transformed with the kinase and the bait vectors. The resulting
yeast strains were arrayed in twenty sets of two microplates each. Each plate
contained up to eight different bait genes arranged in rows and up to nine
kinases arranged in columns. Each such set of two microplates constitutes one
complete set of kinases and controls for eight bait proteins and was screened as
one pool.
The proteome-wide screen was performed in three main steps: test for au-
toactivation, primary screen and retest. As an example, Figure 9 shows the
autoactivation test of pool 11, the primary screen of pool 11 with matrix plate 26
and the corresponding retest. Before the genome-scale screen against the prey
matrix, all strains were tested for autoactivation (Figure 9A) to avoid collecting
false positives and masking of true positive interactions when using a pooled
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Figure 9: The matrix screen produces high-quality phosphotyrosine-
dependent and independent protein interactions. Exemplary illustration
of the matrix screening process of autoactivation test, primary screen and retest
using bait pool 11 and matrix plate 26. For the autoactivation test, the array of
bait strains with kinases were mated with an empty prey vector strain, diploids
were recovered on -ALT/HU agar and transferred to -HAULT(Cu2+) agar (A).
Any positions growing in the autoactivation test, like the ones seen for NCK1
and GRB2, were removed from the assay. The others were grown separately,
mixed and used as bait for a genome-scale matrix screen. This was repeated
for four independent replicates. Prey strains growing in at least two of the
four repeats (B) that were not known autoactivators (i.e. prey strains growing
with almost any bait) were retested using fresh yeast (C). In the retest, the
bait strains were arrayed in 384-well format, and tested against single prey
strains. The retest plate for CBL (C, left) shows a phosphotyrosine-dependent
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approach. To test for autoactivation, the bait strains were mated with a MATα
strain containing a prey vector without insert. This procedure provides a diploid
yeast environment with an expressed RNA polymerase-recruiting domain. To
ensure diploid recovery, after mating, the yeast was first spotted on -ALT/HU
agar and controlled for full growth. The -ALT/HU spots were then transferred
to -HAULT(Cu2+) agar to test for autoactivation. Any bait strains growing on
-HAULT(Cu2+) agar in the autoactivation test, were removed from the pool for
screening (like the spots seen for NCK1 and GRB2 in Figure 9A). Strains that
did not grow on -ALT/HU agar were also removed from the respective pools or
the autoactivation test was repeated. In the primary screen, strains contained in
separate positions of the microplates were grown separately in deepwell plates,
pooled, mixed and mated against a matrix of individual prey strains. After
mating, the diploids were transferred directly to selective agar (-HAULT(Cu2+))
and growing colonies were recorded as primary hits (Figure 9B). Each pool was
screened this way four times using independent replicas.
In the evaluation of primary hits, known autoactivating prey strains were dis-
regarded. All remaining combinations of bait pools and prey strains that led
to yeast growth in at least two out of the four replicate screens were retested
independently using fresh yeast. Figure 9B shows four potentially interacting
prey genes for pool 11 on matrix plate 26, i.e. four positions growing in at
least two replicas. PIAS1 is a known autoactive prey and was excluded from
retesting, CBL, TERF2 and KRIT1 were retested. For retesting, the 96-well
bait pool microplates were merged into 384-well microplates with two copies
of identical combinations of bait constructs and kinases at diagonal, i.e. non-
neighboring positions. The prey strains corresponding to the primary hits were
mated against the microplate corresponding to the bait pool (Figure 9C). This
step not only provided greater stringency by confirming the interaction in a sec-
ond, independent experiment, but also deconvoluted interacting bait constructs
interaction with PIK3R3 that allows growth only in the presence of an ABL2
or FYN kinase and an independent interaction with GRB2. KRIT1 (C, right)
interacted with ITGB1BP1.a
aNote that all bait clones were controlled after the screen and the NCK1 clone was removed
from the data set because it produced questionable results.
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and kinases, effectively discriminating phosphotyrosine-dependent interactions
from independent ones. It serves as an additional control for prey autoactivity,
because only one or two bait constructs in any pool are expected to interact
with any given prey. The left side of Figure 9C shows the retest for CBL, the
right side for KRIT1. CBL interacted with two of the bait genes in the pool.
It interacted with GRB2 in a phosphorylation-independent manner allowing
growth on -HAULT(Cu2+) medium irrespective of the presence or identity of
the kinase. The interaction between PIK3R3 and CBL, on the other hand, is
phosphorylation-dependent. The two proteins interacted in the presence of
a FYN or ABL2 kinase only. This resulted in a very characteristic growth
pattern of diagonally adjacent spots on -HAULT(Cu2+) agar. The other retest
result shows an independent interaction between ITGB1BP1 and KRIT1. The
weak growth/few spots seen on the KRIT1 retest plate for RABGAP1L, GRB2
and PIK3R3 and on the CBL retest plate for STAT5A were either autoactives
known from the autoactivation test, late autoactives or the interactions were
too weak or produced too few spots to be considered.
The yeast two-hybrid screen was performed in two rounds. In the first round
Table 5: The Two-Step Screening Protocol improved the output sub-
stantially. Overview of parameters of the yeast two-hybrid screens. The number
of bait, kinase and prey genes screened, as well as the size of the covered in-
teraction space is shown for the whole screen (total) and for the two rounds
individually (Round 1 & Round 2). Additionally, the size of the retest experiment
and the output in term of total, phosphotyrosine-dependent (pY-dependent) and
phosphotyrosine-independent (pY-independent) protein-protein interactions is
presented.
Number of Round 1 Round 2 Total
bait genes 80 41 121
kinase genes 9 3 9
prey genes 13,807 17,007 17,007
possible interactions 1,104,560 697,287 1,801,847
double, triple & quadruple hits retested 899 324 1,223
interactions 359 270 628
–pY-dependent 172 121 292
–pY-independent 187 149 336
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of screening eighty bait genes were screened in combination with nine kinases
(Table 5). In the meantime, bait clones for 41 genes missing in our collections
or without interactions (because the first clones was autoactive or unsuccessful)
were obtained. These clones were screened in the second round (Table 5). At
this point, the number of clones in the prey matrix had been extended from
13,807 to 17,007 in the laboratories of Erich Wanker at the Max Delbrück
Center for Molecular Medicine in Berlin. The number of different kinases em-
ployed was reduced from nine to three, because the other six returned very
few interactions with the first set of bait constructs tested and the workload
reduction was substantial. The second round of screening expanded the probed
interaction space by about 63%, adding another 697,287 possible interactions to
the 1,104,560 possible interactions probed in the first round (Table 5). Conse-
quently, the number of interactions increased by 120 tyrosine phosphorylation-
dependent and 149 independent interactions. In total, 121 bait genes were
screened with up to nine kinases and up to 17,007 prey strains, covering an
interaction space of almost two million possible interactions in four replicate
screens. In these screens, 1,223 combinations of bait pools and prey strains
came up at least twice and were retested. After retesting, these amounted to
292 phosphotyrosine-dependent and 336 independent interactions.
3.1.4 The phosphotyrosine-dependent interactions form
a network of unusually high density
In a genome-scale screen, a comprehensive set of genes involved in phospho-
tyrosine signaling has been screened for phosphorylation-dependent protein-
protein interactions. As a result of this screen, 292 phosphorylation-dependent
and 336 independent protein-protein interactions involving 82 bait clones have
been established in the retest. The set of bait genes screened covers the whole
phylogeny of SH2 domains (Figure 10). The interacting SH2 domain-containing
proteins are distributed across the phylogenetic tree reflecting the sequence
similarity and evolution of human SH2 domains (Liu et al. 2006). The SH2
domain-containing proteins with the highest number of interaction partners
are PIK3R3, CRK, STAT3, TENC1, CLNK, SH2D2A and GRB2. Generally
we observed that, if a functional clone exists for a gene, it produces tyrosine
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phosphorylation-dependent interactions, as well as independent ones. TENC1 is
the only gene with a high number of interactions, but without phosphorylation-
dependent ones. Except for the clades of VAV1, VAV2 and VAV3 and SHC1,
SHC2, SHC3 and SHC4, most of which have been screened, but did not produce
interactions, there is no apparent group of sequence-related genes without work-
Figure 10: The phosphotyrosine-dependent protein-protein interac-
tions are distributed among the SH2 domain phylogenetic tree. Phy-
logenetic tree reflecting the evolution of SH2 domains. For each SH2 domain,
the number and type of interactions is indicated by the size and color of the
pie charts. The phylogenetic tree is based on the SH2 domain peptide structure
alignment presented in Liu et al. (2006), which has been manually corrected
based on tertiary structure information. The number of interactions is pro-
portional to the area of the pie. Phosphotyrosine-dependent interactions are
signified by the purple area, independent interactions by the yellow area. SH2
genes without interactions are coded by circles of size one according to class.
Screened as bait but without interactions is green. Genes with autoactive clones
(i.e. clones inducing growth regardless of the prey) only are blue, genes without
clones are grey. PTB domain-containing without SH2 domains are shown in
separate boxes. Only genes with interactions are shown.
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Figure 11: The network of phosphotyrosine-dependent protein-pro-
tein interactions is highly connected. ”Hairball” representation of the
phosphotyrosine-dependent protein-protein interaction network. Proteins are
represented by nodes, links represent protein-protein interactions. Phospho-
tyrosine-independent interactions linking the nodes are shown in blue, phos-
photyrosine-dependent interactions are purple. Strong links signify protein
interactions validated in mammalian cell culture. The node shape is rectangular
with rounded corners for bait genes and round for genes that were screened as
prey only.
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ing clones. For the PTB domain-containing genes, we observed a trend for genes
with the IRS1 subtype to show a higher fraction of phosphorylation-dependent
interactions compared to the PID. It has to be noted however that the former
are strongly dominated by DOK proteins, which, while not extremely similar
in primary sequence, all contain a PH domain in addition to the PTB domain.
The latter have more total interactions per gene.
Figure 11 shows a graphical representation of the phosphorylation-dependent
protein-protein interaction network. Nodes represent proteins, links represent
protein-protein interactions. The phosphotyrosine-dependent interactions are
represented by purple links, and independent interactions linking the nodes
have been added in blue. Proteins that were screened as bait are represented
by rectangular nodes with rounded corners, proteins that interacted as prey
only are round. The network appears to be very dense and highly connected. It
has several highly connected nodes and many nodes with few interactions only
making it seem scale-free. It contains many well-characterized interactions, like
the one between PIK3R3 and IRS1 (Felder et al. 1993; Pons et al. 1995; Mothe
et al. 1997) or the one between CBL and CRK (Fukazawa et al. 1996), as well
as interactions with virtually uncharacterized proteins like C10orf81, which
interacted with both, PIK3R3 and GRB2. To substantiate the impressions
about the network structure we performed systematic tests.
Figure 12 shows the networks degree distribution. The network satisfies the
small world criterion and is scale-free. That is, it contains many nodes of low
degree and few nodes, called hubs, of high degree, making the average shortest
path length very small (Cohen & Havlin 2003). It has a log-log linear degree
distribution, and, hence, no scale (Albert & Barabási 2002). The unusually high
density of the network can also be seen in the degree distribution. Scale-free
degree distributions can be described by an exponential function. The exponent
is expected to lie between -2 and -3, but it is -1.41 for the data in this study
(Figure 12) (Yook et al. 2004; Cohen & Havlin 2003). This means that the
ratio of high-degree nodes to low-degree nodes is higher than in other protein-
protein interaction networks.
The network of phosphorylation-dependent interactions alone has a giant com-
ponent comprising all but eleven interactions, namely the interactions of APPL2,
GRB10, SHD, ITGB1BP1 and SH2B1. Four of these five proteins are linked
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Figure 12: The network of phosphotyrosine-dependent protein-pro-
tein interactions is scale-free. Degree distribution of the phosphotyro-
sine-dependent protein-protein interaction network. The number of nodes for
each degree is plotted against the node degree. Both axes have a logarithmic
scale. The distribution fits a scale-free distribution described by the formula
f(x) = e5.07x−1.41.
to the giant component by a single phosphorylation-independent interaction.
Only ITGB1BP1 has a distance of two independent interactions to the giant
component. The network has a core formed around the eight genes PIK3R3,
CRK, CBL, SH2D2A, STAT3, SOCS4, GRB2 and APPL1 (Table 6). Removal
of these core nodes led to drastic losses of clustering coefficient and centrality,
accompanied by a substantial increase in average shortest path length, radius
and diameter. Taken alone, the network of phosphorylation-dependent interac-
tions broke apart, decreasing the size of the largest component from 201 to 59
nodes. Simultaneously, the average path length, diameter and radius increased.
There are 51 phosphorylation-dependent and 30 independent bait-bait interac-
tions. This number is much greater than expected by chance. Given the search
space and the total number of interactions found and assuming an average num-
ber of interactors per gene (independent of whether the prey is also a member
of the bait set), one would expect little more than eight bait-bait interactions
in the complete set and less than three in the set of phosphotyrosine-dependent
interactions alone. The odds of seeing the much greater numbers we actually
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Table 6: Characteristics of the phosphotyrosine-dependent protein
interaction network Network parameters of the phosphorylation-dependent
protein-protein interaction network with (”complete network”) and without (”pY-
dependent network”) independent interactions. ”Bait/Nonbait only”: Considering
only nodes that are either bait genes or not. ”Without core”: Statistics for the
same network without PIK3R3, CRK, CBL, SH2D2A, STAT3, SOCS4, GRB2
and APPL1.
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pY-dependent network 201 2.726 0.027 0.219 9 5 3.823
bait only 50 6.500 0.048 n.a. n.a. n.a. n.a.
nonbait only 151 1.477 0.020 n.a. n.a. n.a. n.a.
without core 59 2.237 0.000 0.174 11 7 4.980
complete network 405 3.081 0.026 0.189 9 5 3.751
bait only 69 10.203 0.074 n.a. n.a. n.a. n.a.
nonbait only 336 1.619 0.016 n.a. n.a. n.a. n.a.
without core 270 2.526 0.010 0.170 11 6 4.717
observe by chance are 4.41× 10−58 and 6.31× 10−38 for the complete network
and the network of phosphorylation-dependent interactions only, respectively.
These observations together with the observation that the network is kept
together via a small core set of PPIs and the relatively low power coefficient
of the degree distribution suggest that phosphotyrosine signaling involves a
relatively restricted subset of proteins of the human proteome.
In conclusion, the network shows characteristics expected for a protein-protein
interaction network, but is more coherent than seen for other large protein-pro-
tein interaction networks (Yook et al. 2004; Cohen & Havlin 2003). It contains a
high number of bait-bait interactions, suggesting a strong functional connection
(Bader & Hogue 2003; Bu et al. 2003; Spirin & Mirny 2003). These observations
are more pronounced for the network of phosphorylation-dependent interactions
alone than for the complete network.
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3.2 Kinase specificity of the phosphotyrosine-de-
pendent protein-protein interactions in the
yeast two-hybrid system is non-trivial
Kinase specificity in the yeast system can be investigated in great detail in a
”kinase plate assay”. For this assay, pairs of interacting bait and prey constructs
are prepared in haploid MATα yeast and mated against an array of MATa
yeast carrying different kinase plasmids in microplate format. Each bait-prey
interaction was tested in parallel with 31 non-receptor tyrosine kinases in the
kinase plate assay. A crucial point is that the yeast is pipetted on Omnitray agar
plates. The relatively large amount of 5 μl yeast suspension per spot is more
than an order of magnitude greater than the amount spotted by stamping. This
provides high confidence not only in positive results, but also in negative results.
Differential growth signals with different kinases are specific to the interactions.
Because of the added confidence in negative results, the kinase plate assay
serves another purpose, as well. In addition to non-receptor tyrosine kinases
and a number of empty vector controls, the kinase plate contained kinase-
deficient mutant versions of all kinases used for screening. It demonstrates that
the interactions that show a differential signal in the retest with the kinase-
deficient mutant when compared to the active kinase are indeed phosphorylation-
dependent, not just kinase-dependent.
Like all human protein kinases, non-receptor tyrosine kinases have a conserved
kinase domain, that is made up by an amino-terminal lobe rich in anti-parallel
β-strands responsible for ATP binding and a C-terminal lobe rich in α-helical
structures, that contains the activation loop (Figure 13a and b) (Hubbard &
Till 2000). The two lobes are connected by a less conserved linker region. The
structurally or functionally important residues in the lobe regions are generally
highly conserved. Interestingly, the activation loop is not well conserved sequence-
wise and very flexible structure-wise (Figure 13a and b, purple). Therefore, a
conserved lysine residue in the N-terminal lobe that is necessary for ATP binding
(Figure 13a and b, red) was replaced by methionine to abrogate kinase activity
(Kamps et al. 1984). The kinase plate contains 31 of 32 described human non-
receptor tyrosine kinases (Figure 13c) (Robinson et al. 2000). For JAK1 several
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Figure 13: ATP binding-deficient kinases qualify kinase-dependent
interactions as phosphotyrosine-dependent. (a) Amino acid sequence
alignment of the kinase domains of all kinases used for yeast two-hybrid screening.
UniProt entries P42684 (ABL2), P51813 (BMX), P07332 (FES), P42685 (FRK),
P06241 (FYN), O60674 (JAK2), Q05397 (PTK2), P43405 (SYK) and Q13470
(TNK1) were used to define kinase domain boundaries. The red arrow points out
a conserved lysine residue in the ATP binding cassette that has been shown to
disrupt ATP binding when mutated to methionine. (b) Protein structure model
alignment of the kinase domains of all kinases used in the screen for which crystal
structure models in the PDB. Polypeptide backbone structures are shown as
cartoon colored according to kinase, the lysine responsible for ATP binding,
that has been mutated to generate the kinase-deficient versions is shown as red
spacefill. Light blue: FYN (PDB accession 2DQ7, UniProt accession P06241,
residues 271-524), light orange: JAK2 (2XA4, O60674, residues 849-1124),
light pink: FES (3BKB, P07332, residues 561-822), dark teal: SYK (3FQS,
P43405, residues 371-631), lime: ABL2 (3GVU, P42684, residues 288-539).
Protein structure models have been aligned using the PyMol align function. (c)
Arrangement of kinases in the kinase plate assay. For active kinases, the degree
of redness indicates the activity (i.e. the number of interactions growing with the
kinase), kinase-deficient mutants are colored blue and empty vector controls are
grey. (e-g) kinase plate assay results on -HAULT(Cu2+) agar the interactions
IRS1-BCAR3 (d), GRB7-OLIG1 (e), DOK4-PTK2 (f) and HSH2D-PIK3R3 (g).
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clones were obtained and analyzed, but turned out to be falsely annotated,
suggesting an annotation error of the MGC clone (Temple et al. 2006). For
PTK2, SYK and ZAP70 two clones representing different isoforms were used.
Empty kinase vectors serve as controls for late autoactivity and to sort out
conceivable interactions that can be bridged by non-receptor tyrosine kinases
irrespective of protein phosphorylation activity. The kinases were arranged on
the microplate to avoid clusters of spots expected to grow or expected not to
grow for phosphorylation-dependent interactions (Figure 13c). Interactions were
assayed with kinases in the kinase vectors pASZ-CN-DM and pASZ-C-DMtet,
i.e. with and without nuclear localization signal sequence, in two replicates each.
Some kinases work equally well in both kinase vectors, while others display a
clear difference.
The kinases showed different levels of activity (highly active kinases are shown
in red in Figure 13c). The most active kinases (i.e. the kinases that enable the
highest number of interactions) were the Src family kinases FYN, HCK, YES1,
BLK and FGR and the non-Src family kinases ABL2 and FER. This could be
a consequence of the different modes of regulation. Where most other kinases
are inactive by default and biochemically activated following an appropriate
signaling event, Src family kinases, Abl kinases and FER are active by default
and inactivated by CSK (Okada et al. 1991), PRDX1 (Wen & Van Etten 1997)
and PLEC (Lunter & Wiche 2002), respectively. It is therefore conceivable
that these kinases are the most active ones, because the inhibitory proteins
are simply not present in yeast. Interacting pairs of bait and prey constructs
function with different numbers of kinases. For example, some interactions, like
the one between IRS1 and BCAR3 (Figure 13d) function with twelve kinases,
while others, like the one between GRB7 and OLIG1 (Figure 13e) is enabled
by only two kinases in our assay. The most frugal explanation for these two
facts is that the kinases differ in catalytic activity leading to higher or lower
phosphorylation levels and interactions display different levels of sensitivity
needing higher or lower phosphorylation levels to enable yeast growth. This
would result in patterns that are subsets of each other. This not what we observe.
Clearly, the kinase plate assay patterns point towards interaction specificity
that can be seen for example in the difference between the kinase patterns
of GRB7-OLIG1 (Figure 13e) and DOK4-PTK2 (Figure 13f). GRB7-OLIG1
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Figure 14: Phosphotyrosine-dependent interactions have different
profiles in the kinase plate assay. Clusters of kinase plate assay results.
For each interaction, pictures of the yeast colonies are shown, as well as a
schematic representation of the spots considered for clustering. Clusters are
labeled by the most distinguishing characteristics. Exemplars are colored for
each cluster. Three interactions that did not cluster are shown in the lower
right corner. In the top left corner, there is a schematic showing the arrange-
ment of kinases in the kinase plate assay. For active kinases, the degree of
redness indicates the activity (i.e. the number of interactions growing with the
kinase), kinase-deficient mutants are colored blue and empty vector controls
are grey. Note that for the interactions SH2D2A-LRRFIP1, PIK3R3-C10orf81
and SH2D1B-HSPA1A (marked by an astrisk(*)), there are colonies that were
not considered for clustering.
grows with ABL2 and FER only. DOK4-PTK2 grows with six kinases, but not
with ABL2 or FER. To provide another example, HSH2D-PIK3R3 (Figure 13g)
grows with BLK, FYN, YES1 and FGR, that also allow DOK4-PTK2 growth, as
well as with FER. It does not grow with HCK or SRC, that allow DOK4-PTK2
growth, or with ABL2.
In total, 37 interactions have been successfully assayed with two different kinase
vectors in two independent replicates each. The resulting patterns (Figure 14)
were evaluated in terms of growth with the fourteen kinases that gave rise to
most of the signals and clustered using affinity propagation clustering (Frey &
Dueck 2007). Affinity propagation clustering is a method for the identification
134
3.2. Non-trivial kinase specificity in the yeast two-hybrid system
of groups of similar elements in many data sets. These groups are called clusters.
In an iterative process, so-called examplars are found. The examplars are the
most representative members of each cluster. For each pair of interactions, the
squared number of common kinases, divided by the product of the number
of interactions of both interactions, was used as a proxy for similarity. The
resulting clusters are shown in Figure 14, the exemplars are marked by colored
boxes. There are three small, specific clusters of three interactions each, three
larger and more general clusters and three interactions that did not cluster. The
first small cluster (Figure 14, green) seems to be defined by growth with SRC,
but not with TNK1 or ABL2. The interactions in the next cluster (Figure 14,
blue) are very clearly set apart from the others, because they grow with FER
and ABL2 only. The third cluster (Figure 14, orange), in contrast, is made up
by three interactions with at least twelve kinases, the most distinguishing ones
being FRK and PTK2. Notably, SYK and FES are not seen. The three larger
clusters are less specific. The first one (Figure 14, red) can best be described
by the absence of specific kinase signals. Its exemplars grow with FYN, FER,
FGR and ABL2, and all members of the cluster grow with at least three of
the four and not more than one other kinase. The last two clusters encompass
the majority of the clustered interactions. The most notable difference between
the two is the absence of SRC and TNK1 from the larger one (Figure 14,
purple). All interactions in the smaller one (Figure 14, yellow) have at least
one of them. Interestingly, almost all interactions growing with FRK are in the
”IRS1-NUMB/IRS1-PIK3R3” (orange) or in the ”GRB2-VCP/GRB2-C10orf81”
(yellow) cluster. Some of the interacting proteins demonstrate fidelity towards
the clusters, but fail to fully explain the clusters. The three small clusters
reflect to a high degree interactions with one particular protein. The first one
(Figure 14, green) has both PTK2 interactions. The second one (Figure 14, blue)
consists of three of the four OLIG1 interactions, the third one (Figure 14, orange)
of all three IRS1 interactions. Apart from that, the two YES1 interactions
can be found in the purple cluster and the two C10orf81 interactions are in
the yellow cluster. The two proteins occurring most in the data set, GRB2
and PIK3R3, do not appear to be very cluster-specific, even though almost
all PIK3R3 interactions grow with ABL2, BLK, FER, FYN, HCK, YES1 and
FGR. In conclusion, the analyzed interactions showed principally similar but
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appreciably different kinase patterns. The fact that they are similar indicates
different levels of kinase activity. The fact that they are appreciably different as
well indicates specificity of protein interactions towards kinases. The specificity
is only partly explained by just one of the interacting proteins.
3.3 Bait and prey genes share process and func-
tion annotations
Next, we wanted to test our data in a biologically meaningful context. To do
this, we tested how well our data agree with previous annotations in terms of
biological role, localization and enzymatic activity. Towards this end, we used
the Gene Ontology (GO) term annotations. Gene Ontology is a project that
aims to characterize every gene using a clearly defined vocabulary (Ashburner
et al. 2000). It uses a directed acyclic graph of terms linked by relationships,
like ”is-a”. The ontology has three parts rooted in the most general terms,
”Cellular Component”, ”Molecular Function” and ”Biological Process”. Cellular
Component collects terms related to subcellular localization, like nucleus or
even specific complexes. Molecular Function describes low-level activities of
genes and gene products, like enzymatic activities or specific binding abilities.
Biological Process terms deal with more abstract roles the genes play on a
systemic level, like eye development or apoptosis.
In principle, each gene is associated each appropriate GO term. Statistically,
pairs of genes that interact in any way, especially genes whose products interact
physically, are expected to have more similar GO terms than randomly paired
genes. While this analysis has been conducted successfully in protein interaction
research (Lehner & Fraser 2004), it produces statistically meaningful results
only with very large numbers of interactions. There are several reasons for this.
The first one is that some genes are more intensively researched than others
influencing the degree of specificity of the annotated GO terms. Another one is
that some GO terms are very common, potentially masking significant signals
from less common GO terms. To address these issues instead of simply counting
GO term matches, semantic similarities were calculated following the method
of Resnik (Resnik 1995) implemented in the GOSemSim package for R (Yu
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et al. 2010). To avoid creating bias in the selection of random interactions, the
network of phosphorylation-dependent interactions and the complete network
have been randomized in a way that preserves each proteins degree (Giot et al.
2003). If the average semantic similarity of interacting pairs of genes in the real
networks is substantially different from the distribution of the average semantic
similarity of interacting pairs of genes in the randomized networks, then we
conclude that the network comprises mostly true interactions. The opposite is
not true, neither can the method be applied to single interactions.
Figure 15 shows the average semantic similarity distribution for the randomized
network with and without phosphorylation-independent interactions in blue and
purple, respectively. The average semantic similarity of the original networks is
indicated by arrows of the same color. For comparison, two large human yeast
two-hybrid data sets, published by Rual et al. (2005) and Stelzl et al. (2005),
were analyzed the same way and plotted in yellow and dark green, respectively.
For all three ontologies, the average semantic similarities of both networks, with
Figure 15: There is no significant enrichment in semantic similarity
of Gene Ontology terms among interactions in the phosphotyrosine-
dependent protein-protein interaction network. Interaction semantic
similarity plots for the three Gene Ontologies ”Cellular Compartment”, ”Biolog-
ical Process” and ”Molecular Function”. One thousand randomized instances of
the network of phosphotyrosine-dependent protein-protein interactions (purple)
have been generated and the semantic similarity among interactions determined.
The frequency is plotted against the average semantic similarity. The average
semantic similarity of the original network is indicated by an arrow. For com-
parison, the values for the network of independent interactions and two high
throughput yeast two-hybrid data sets presented by Stelzl et al. (2005) and
Rual et al. (2005) are shown in blue, green and yellow, respectively.
137
3. RESULTS
and without independent interactions, clearly lies within the distribution of the
randomized networks, while both reference networks show a clear difference
between real and randomized networks, as has been reported before (Venkatesan
et al. 2009). Interestingly, for two of the three ontologies, Biological Process
and Molecular Function, the average semantic similarities for the randomized
networks are much higher than the values for the reference sets. This might
indicate that the prey set is too homogeneous to result a strong decrease in
average semantic similarity through randomization in comparison to the real
network. This would in turn mean that certain GO terms are over-represented
in the set of interacting proteins as a whole.
Therefore we next analyzed the set of identified prey proteins for functional
over-representation. Since the bait set is biased, because the bait genes have
been selected according to a specific molecular function, that is known to be
important in specific biological processes, like regulation of growth and de-
velopment, only the prey set was analyzed for GO term over-representation.
Because the different levels of the Gene Ontology contain largely overlapping
information, we used only the level 4 terms. We counted the number of genes
for each GO term in the prey set and in the background set. We used the
genes in the prey matrix as the background set and calculated the specific over-
representation using the hypergeometric test. The over-representation is more
significant the more prey genes share a specific annotation and the smaller the
total number of genes share this annotation. For example, there are 35 prey
gene annotated as ”kinase binding”, and only 12 genes annotated as ”protein
phosphorylated amino acid binding”. Nevertheless, the latter is more significant,
because there are only 30 genes in the prey matrix with this annotation and 328
genes annotated as ”kinase binding” (Figure 16). The p-values were corrected
for multiple hypothesis testing by multiplying each p-value with the number of
tests (Benjamini & Hochberg 1995). The same method was used to calculate
over-representation p-values for the bait set to confirm and measure the bias in
the bait selection. The terms that are also significantly over-represented for the
bait set are indicated by circles next to the bars. Larger circles indicate higher
levels of significance.
Significant over-representation of GO terms is indeed observed for all three
ontologies. For Biological Process (Figure 17), the most significantly over-repre-
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Figure 16: The interacting proteins are tied functionally to phospho-
tyrosine signaling. Over-representation of Gene Ontology Molecular Function
terms in the set of prey proteins. The most over-represented Gene Ontology
”Molecular Function” terms are shown with the number of genes with the an-
notation in the prey set, the number of genes with the annotation in the prey
matrix, and the enrichment p-value calculated based on these values using
the hypergeometric test. The length of the bars indicates the number of prey
genes in the interaction network, the color indicates the over-representation
p-value. Purple circles next to the bars indicate terms with significant over-
representation in the bait gene set. Larger circles indicate higher levels of
significance.
sented GO term has a p-value of 4× 10−15, for Molecular Function (Figure 16),
it is 5.6× 10−10, and for Cellular Component (Figure 18) it is 2.2× 10−5. The
number of over-represented GO terms common to the prey set and the bait set
(marked by circles) is high for the Biological Process and Molecular Function
ontologies and substantially lower for Cellular Compartment, as was suggested
by the semantic similarity analysis of interacting pairs (Figure 15). In fact, the
GO terms most highly over-represented and shared by the highest numbers
of prey genes are ”nucleus” and ”nuclear lumen”. This explains the fact, that
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Figure 17: The interacting proteins are tied to phosphotyrosine-re-
lated processes. Over-representation of Gene Ontology Biological Process
terms in the set of prey proteins. The most over-represented Gene Ontology
”Biological Process” terms are shown with the number of genes with the anno-
tation in the prey set, the number of genes with the annotation in the prey
matrix, and the enrichment p-value calculated based on these values using
the hypergeometric test. The length of the bars indicates the number of prey
genes in the interaction network, the color indicates the over-representation
p-value. Purple circles next to the bars indicate terms with significant over-
representation in the bait gene set. Larger circles indicate higher levels of
significance.
the average semantic similarity values for Cellular Compartment are lower
than the values for the reference networks. For Molecular Function, the most
highly over-represented GO terms are ”SH3/SH2 adaptor activity”, ”protein
phosphorylated amino acid binding” and ”kinase binding”. The term shared
by most prey genes is ”metal ion binding”, but it is not the most significant
one, because the number of metal ion-binding proteins in the background set is
very high. It stemmed mainly from DNA binding proteins and kinases, which
is another over-represented function. The over-representation of ”SH3 domain
binding” proteins is easily explained by the many proteins that contain both
SH2 and SH3 domains. For Biological Process, the most over-represented and
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Figure 18: Most interacting proteins are cytoplasmic or nuclear. Over-
representation of Gene Ontology Cellular Compartment terms in the set of prey
proteins. The most over-represented Gene Ontology ”Cellular Compartment”
terms are shown with the number of genes with the annotation in the prey set,
the number of genes with the annotation in the prey matrix, and the enrichment
p-value calculated based on these values using the hypergeometric test. The
length of the bars indicates the number of prey genes in the interaction network,
the color indicates the over-representation p-value. Purple circles next to the
bars indicate terms with significant over-representation in the bait gene set.
Larger circles indicate higher levels of significance.
most common term is ”intracellular signal transduction”, which is also the most
highly over-represented one for the bait set. Actually, most terms are common
to the bait and the prey set except for negative regulation of processes related to
growth and development. This might be due to mechanisms of down-regulation
by binding or over-representation of transcription factors in the prey set. This
agrees with the over-representation in nuclear and DNA-binding genes.
In conclusion, in terms of subcellular localization, the nuclear genes are most
strongly over-represented in the prey set, while in the bait set, membrane-asso-
ciated proteins are most strongly over-represented. In terms of biological and
functional context, the prey set annotations agree very well with the biological
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functions of the bait genes.
3.4 Bait and prey genes tend to belong to the
same biological pathways
The Gene Ontology term over-representation analysis shows that genes im-
portant for the same biological functions are over-represented in the bait and
Figure 19: The interacting proteins are involved in phosphotyrosine
signaling pathways. Over-representation of pathway annotations in the set
of prey proteins. For the pathway annotation databases PID (Schaefer et al.
2009), Reactome (Matthews et al. 2009), NetPath (Kandasamy et al. 2010),
Wikipathways (Kelder et al. 2012), KEGG (Kanehisa et al. 2012), INOH
(Yamamoto et al. 2011) and Biocarta (www.biocarta.com) the most over-
represented pathways are shown with the number of genes with the annotation
in the prey set, the number of genes with the annotation in the prey matrix,
and the over-representation p-value calculated based on these values using
the hypergeometric test. The length of the bars indicates the number of prey
genes in the interaction network, the color indicates the over-representation
p-value. Purple circles next to the bars indicate pathways with significant
over-representation in the bait gene set. Larger cirlces indicate higher levels of
significance.
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prey sets. This suggests that genes belonging to the same cellular pathways
might also be over-represented. To determine pathway over-representation the
ConsensusPathDB pathway meta-database (Kamburov et al. 2009) was queried
for all genes overlapping between pathways in BioCarta (www.biocarta.com),
INOH (Yamamoto et al. 2011), KEGG (Kanehisa et al. 2012), NetPath (Kan-
dasamy et al. 2010), PID (Schaefer et al. 2009), Reactome (Matthews et al.
2009) or Wikipathways (Kelder et al. 2012) and the sets of bait, prey and
background GeneIDs already used for the GO term over-representation analysis.
Over-representation was calculated using the hypergeometric test, also as for
the Gene Ontology term over-representation analysis.
Figure 19 shows the over-represented pathways among the prey genes. There is
a large overlap between the over-represented pathways in bait genes and prey
genes. The over-represented pathways are cytokine signaling, e.g. interleukin
signaling, and growth factor receptor signaling pathways, like BCR, Kit Recep-
tor, ErbB, VEGFR, Tie2, insulin and FGF signaling, as is expected for genes
related to phosphotyrosine signaling (Lemmon & Schlessinger 2010). Interest-
ingly, there are several insulin-related pathways significantly over-represented in
the prey genes, but not the bait genes. Note that pathways with similar names
defined by different sources are often quite different (Kamburov 2012). This is
exemplified by Kit receptor signaling defined by NetPath and Wikipathways.
Both are over-represented in the prey set, although the NetPath p-value is
two orders of magnitude lower, but for the bait set the NetPath Kit receptor
pathway is the most over-represented one, while the Wikipathways Kit pathway
fails to reach significance. This is why it is important to query several pathway
databases and judge the composite result (Kamburov et al. 2011). In conclusion,
pathways related to phosphotyrosine signaling are over-represented in the prey
set, as well as the bait set, demonstrating the relevance of the biological context
of the presented data set.
3.5 Bait and prey genes are over-represented in
the same interaction neighborhoods
Similar to the analyses of the genes interacting with phosphotyrosine-recog-
nizing genes for over-representation of specific functions and pathways, we
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Figure 20: The interacting proteins are known to interact with phos-
photyrosine signaling proteins, especially protein tyrosine kinases.
Over-representation of network-based entity sets (NESTs) in the set of prey
proteins. For all NESTs in the ConsensusPathDB database the most NESTs are
shown with the number of genes with the annotation in the prey set, the number
of genes with the annotation in the prey matrix, and the over-representation
p-value calculated based on these values using the hypergeometric test. The
length of the bars indicates the number of prey genes in the interaction network,
the color indicates the over-representation p-value. NESTs centered around
receptor tyrosine kinases (RTK) or non-receptor tyrosine kinases (NRTK) are
indicated.
examined the network neighborhood of the proteins. We searched for over-
represented genes that interact with specific other genes. This links the newly
discovered interactions directly to existing protein-protein interaction knowl-
edge (Kamburov et al. 2009) and thus provides valuable information about
protein function. In the easiest case, the result should reflect the network hubs,
but it can also show areas of high coherence not immediately apparent from
a network determined with a specific experimental method. We observed the
latter. The analysis showed many receptor tyrosine kinases, which are not easily
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amiable to analysis by yeast two-hybrid analysis, because they are membrane
proteins (Figure 20). The prey set was tested for over-representation of genes
from radius one neighborhoods of all genes in the ConsensusPathDB protein
interactions meta-database. The hypergeometric test with multiple testing
correction was used to calculate the over-representation p-values. The most
strongly over-represented neighborhood is the KIT receptor tyrosine kinase
neighborhood, which is consistent with the result from the pathway analysis.
Of the 31 over-represented neighborhoods, nine are receptor tyrosine kinases,
another five are non-receptor tyrosine kinases, and well-known phosphotyrosine
signaling genes. These findings provide strong support for the hypothesis that
prey proteins interacting with phosphotyrosine-recognizing bait proteins are
phosphorylated, based on the assumption that phosphorylation encompasses
interaction with a kinase.
3.6 Cancer genes are strongly over-represented
in the phosphotyrosine-dependent protein-
protein interaction network
To test the applicability of the detected interactions in a biological or medi-
cal context, we assayed for over-representation of genes implicated in related
human diseases. In the case of phosphotyrosine signaling, the most relevant
disease association is cancer (Blume-Jensen & Hunter 2001). To assess the
over-representation of cancer genes we refer to a cancer genes definition from a
group of cancer specialists from the Wellcome Trust Sanger Institute (Futreal
et al. 2004). The cancer gene list contains 487 genes found to carry mutations
in cancer patients.
The analysis is presented in Table 7: The prey matrix has 13,931 non-autoactive
prey strains. Among these are 303 cancer genes. There are 22 cancer genes
among the 366 prey genes that have been found to interact with phosphotyro-
sine-recognizing domain-containing proteins. The chance of choosing 22 or more
cancer genes from the prey matrix in 366 random draws without replacement are
2.4× 10−5 (hypergeometric test). Considering the phosphorylation-dependent
network alone, there are only 187 prey and 13 cancer genes, raising the odds
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Table 7: Cancer genes are strongly over-represented among the pro-
tein-protein interactions. The cancer genes defined by Futreal et al. (2004)
were tested for over-representation in the protein-protein interactions using the
hypergeometric test. The analysis was performed on the basis of cancer genes
found as prey and on the basis of interactions involving cancer genes as prey.
For the first part, the number of total prey genes screened (prey matrix size),
cancer genes screened (cancer prey genes total), total number of prey genes
interacting with at least one bait (prey genes found) and the number of cancer
prey genes interacting with at least one bait (cancer prey genes found) were
determined for all interactions found in this study (complete network) and all
phosphotyrosine-dependent interactions found in this study (phosphotyrosine-
dependent only). Based on these values, the hypergeometric test was used to
calculate the probability of seeing this kind of over-representation by chance
alone (p-value). For the second part, the number of bait genes interacting with
at least one prey gene (bait genes) was multiplied with the number of prey
genes to calculate the total number of interactions (interactions possible) and
the number of interactions involving cancer prey genes (cancer interactions pos-
sible) that could have been found. These values, and the actual number of total
interactions (interactions found) and interactions involving cancer prey genes
(cancer PPIs found) found in this study were used to calculate the probability
of seeing this kind of enrichment by chance alone (p-value).
complete network phosphotyrosine-
dependent only
prey matrix size 13931 13931
cancer prey genes total 303 303
prey genes found 366 187
cancer prey genes found 22 13
p-value 2.38× 10−5 2.83× 10−4
bait genes 70 59
interactions possible 975170 821929
cancer interactions possible 21210 17877
interactions found 628 292
cancer PPIs found 64 35
p-value 1.96× 10−23 1.13× 10−15
of a purely random occurrence to 2.8 × 10−4. This probability is even lower
when interactions are considered, not just whether a prey gene is present in
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the set. In this case, the pool of possible interactions is the number bait genes
multiplied by the number of prey genes in the matrix (13,931), the number of
possible cancer gene interactions is given by the number of bait genes times
the number of cancer genes in the matrix (303). In the complete set, there are
628 protein-protein interaction found with 70 bait genes. Sixty-four of these
have cancer genes as prey. This corresponds to a probability of 2× 10−23. The
292 phosphorylation-dependent interactions, found with 59 bait genes, contain
35 interaction with cancer genes as prey. The probability of this happening
randomly is 1.1× 10−15. The interaction-based analyses produce lower p-values
not only because statistics on bigger numbers usually produce lower p-values,
but also because the average number of bait geness that the cancer prey genes
interact with is 3.27, which is significantly higher than the network average
of 2.34 (Wilcoxon rank sum test with continuity correction, p = 0.002774).
In conclusion, there is a clear over-representation of genes implicated in cancer
in the proteins interacting with phosphotyrosine-recognizing domain-containing
proteins. The over-representation is more pronounced for the phosphorylation-
dependent network than for the complete network. This suggests that the
protein-protein interaction data set is biologically meaningful and may contain
many relevant relationships that can be exploited for medical applications.
3.7 SH2 gene interactions can partially be ac-
counted for by peptide binding motifs
We screened a comprehensive set of phosphotyrosine-recognizing domain-con-
taining proteins for phosphotyrosine-dependent protein-protein interactions
using full length human proteins. For many protein domains, especially SH2
domains, linear consensus peptide binding motifs based on peptide binding
assays have been reported previously (Liu et al. 2006). Typically, in such an
assay peptides of ten to fifteen amino acids, or mixtures of peptides with ran-
domized amino acid positions, are assayed for the binding of purified domain
constructs in vitro (Songyang et al. 1994, 1993; Lupher et al. 1997; Bunnell
et al. 2000; Beebe et al. 2000; Huang et al. 2008). Since the proteins in this
study, both the domain-containing and the recognized ones, were employed as
full-length constructs, it is interesting to ask how well the results from the yeast
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two-hybrid screen agree with the results of the peptide-based assays.
There are at least two possible approaches to this question. The first one is
to search the amino acid sequences of the proteins in the prey matrix for the
respective motifs and to assess the number of interactions with these genes
as prey. This approach carries with it several problems. First, because of the
high false negative rate in protein-protein interaction assays, distinguishing
non-binding motifs from missed interactions is very hard, if not impossible.
Second, tyrosine residues might be buried inside the protein, so the domain-
containing protein cannot recognize them. Third, even if the motif is accessible,
the respective tyrosine residue might not be phosphorylated in the assay system.
The second one is to consider only interactors of each domain-containing protein
and look for the presence of a known or novel motif. This approach is less
influenced by false negative data and is thus more appropriate for yeast two-
hybrid data (Weisberg 2010). The second and third problem still apply but are
less problematic in this case. We simply assumed that all tyrosine residues are
exposed and phosphorylated. If the putative phosphorylated protein does not
contain a motive, then we can conclude that there must be a mechanisms of
binding that is not governed by peptide motifs. The motifs collected by Liu
et al. (2006) were used as literature consensus motifs. The complete set of
phosphotyrosine-dependent interactions was analyzed rather than interactors
of selected domain-containing proteins because of the large size of the data set,
the natural heterogeneity in terms of numbers and size of interaction partners
per domain-containing gene, and in terms of numbers of potential recognition
sites per putative motif-containing protein as well as biases based on general
sequence homology rather than motif-driven convergence.
By comparing the set of phosphorylation-dependent interactions to the complete
Figure 21: Phosphotyrosine-dependent interactors contain more
known SH2 binding motifs than independent ones and are phospho-
rylated more often.
(Top) Number of positions matching known SH2 binding consensus motifs. For
each protein interacting with an SH2 protein that has a consensus motif (defined
by Liu et al. (2006)) the highest number of matching amino acid residues has
been determined. The number of interaction partners is shown by best matching
tyrosine motif for the phosphotyrosine-dependent and independent network.
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(Bottom left) Histogram of the data presented in the top table. The distributions
are significantly different with an error probability of p = 3.769 × 10−7 (as
determined by a Wilcoxon rank sum test with continuity correction).
(Bottom right) Percentages of best matching sites known to be phosphorylated.
For each best matching site, the RefSeq, UniProt and PhosphoSite databases
have been searched for reports of phosphorylation in human or mouse.
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set, statistical differences were found and quantified. Figure 21 (top) summa-
rizes all literature motifs that have been found in the interaction set. For each
domain-containing gene and each interactor, all tyrosine motifs, i.e. all tyrosine
residues with surrounding residues, were compared to the consensus motif(s).
The amino acids that were common to the consensus motif were counted and the
highest count was defined as representing the most probable binding site. The
purple and blue columns in Figure 21 (top) represent the counts of matching
residues for phosphorylation-dependent and independent interactions, respec-
tively. Because there is no obvious extrinsic reference and because of the high
density of the phosphorylation-dependent interaction set, the set of independent
interactions was used as a negative reference. Figure 21 (bottom left) shows the
distribution of consensus matching-amino acid residues for all pairs of domain-
containing proteins and interaction partners in the phosphorylation-dependent
and independent set in purple and blue, respectively. The distribution corre-
sponding to the phosphorylation-dependent interaction set is clearly shifted
to the right. Since the values are not distributed normally, the Wilcoxon rank
sum test was used to evaluate the significance of this difference. According to
this test, the probability that both distributions are samples drawn from the
same underlying distribution is p = 3.769× 10−7. This analysis suggests that
the p-dependent interaction partners contain more linear recognition motifs
that may serve as recognition sites for their SH2 domain-containing partners.
We also asked whether we can find known phosphorylated tyrosine residues in
the putative recognition sites. The expectation is that tyrosine residues that
are recognized by SH2 domains are phosphorylated in some type of human cell
under certain conditions. This means, that known phosphorylation sites should
be highly over-represented in the set of recognized tyrosine residues. Since the
specific interaction sites are not known, the motifs matching the SH2 domain
consensus binding motifs were used as proxies (Figure 21, bottom right). The
known phosphorylation sites collected in the PhosphoSite, RefSeq and Swis-
sProt databases were extracted for all prey proteins and their mouse homologs,
assuming that tyrosine phosphorylation is conserved well between mouse and
human. For each interaction, all tyrosine residues in the putative phosphory-
lated protein were categorized according to the number of surrounding residues
matching the respective consensus motif. For phosphotyrosine-dependent inter-
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actions, the percentage of known phosphorylation sites among tyrosine motifs
matching the consensus motif in at least two positions is substantially elevated.
The background level for non-matching motifs is around 18%-23%. For motifs
matching in two or more than two positions the percentages are 33% and
40%, respectively. It must be noted that a similar trend can be observed for
phosphorylation-independent interactions. The background level of 15%-17% is
substantially lower than for phosphorylation-dependent interactions. For motifs
matching in two positions, it is elevated to 24%. For three matching positions,
the number of cases is very low and none of the two cases are reported to be
phosphorylated.
We wondered whether the effect we observed is simply due to a difference in
amino acid composition of the proteins. Therefore, we next considered the
numbers of total and phosphorylated tyrosine residues in the two data sets.
The average number of phosphorylated tyrosine residues reported is 2.17 per
protein for the putative phosphorylated proteins in the phosphotyrosine-de-
pendent interaction set and 1.25 for the proteins interacting with domain-
containing proteins in the independent set, while the average total number
of tyrosine residues is similar for both sets (phosphorylation-dependent: 12.5;
independent: 10.3). The average percentage of tyrosine residues reported to
be phosphorylated per protein is 14.4% and 10.4% for the phosphorylation-
dependent and the independent set, respectively. Interestingly, these numbers
differ from the quotients of phosphorylated tyrosine residues and the total
number of tyrosine residues in the complete sets, which are 17.4% and 12.2%
for the phosphorylation-dependent and the complete set, respectively. This
suggests that the ratio of phosphorylated tyrosine residues is higher on average
for proteins containing fewer tyrosine residues and that tyrosine phosphorylation
is more protein-specific than site-specific, i.e. if a tyrosine phosphorylation site
is observed for a protein, it is more likely that another tyrosine site in the same
protein is observed to be phosphorylated. Thus, while proteins in the dependent
and independent prey set differ in regard to tyrosine phosphorylation, there is
no reason to believe that this difference may have caused the observed effects.
The fact that the background levels of tyrosine phosphorylation are elevated in
the interaction-centered analysis indicates that the proteins that are known to
be phosphorylated have more interactions on average.
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In conclusion, new SH2 domain binding peptide motifs could not be found,
however, the SH2 domain consensus binding motifs reported in the literature
are enriched in the phosphotyrosine-dependent interaction set and coincide
with residues known to be phosphorylated in vivo. On the other hand, linear
peptide motifs are not prominent in our data and are not sufficient to explain
all of the phosphotyrosine-dependent interactions.
3.8 Systematic validation of phosphotyrosine-de-
pendent protein interactions in mammalian
cell culture suggests very high quality
The quality of protein-protein interaction data sets can be tested experimentally
by assaying individual interactions with an independent protein interaction
detection method, ideally one as different from the original method as possible
(Braun et al. 2009). For yeast two-hybrid data, co-immunoprecipitation is an
appropriate method, because it works in human cells, as opposed to yeast cells
and is a complex-based method instead of a reporter activity-based, transient
one (Phizicky et al. 2003). To validate the protein interaction set detected in this
study, a set of 169 interactions was assayed in a high throughput luminescence
based co-immunoprecipitation assay, 147 produced usable results, i.e. both
proteins were successfully expressed at levels that allow detection by western
blotting. The use of this type of assay for the validation of yeast two-hybrid
results is well-established (Horn et al. 2006; Stelzl & Wanker 2006). In this
co-immunoprecipitation assay, one of the two proteins was Protein A-tagged,
while the other one was fused to a firefly luciferase gene (Figure 21a). Both
were transiently expressed in mammalian HEK293 cells. The cells were lysed
and the Protein A-tagged proteins were allowed to bind to immunoglobulin G-
coated microplates. After washing, the amount of the second protein bound is
measured in a luminescence assay and compared to a non-binding control. Pairs
for which the signal exceeded the background by a factor of at least two and by
at least two standard deviations from triplicate values, were considered positive.
A total of 76 interactions were successfully validated this way (Figure 21b). The
strength of the resulting signals ranges from two-fold (which is the cut-off), like
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Figure 21: Seventy-eight protein-protein interactions were success-
fully validated in mammalian cell culture. (A) Principle of the Lumines-
cence assay. The putatively interacting protein pair were genetically fused to
a Protein A tag or a Firefly Luciferase gene and expressed in HEK293 from
transiently expressed plasmids. The cells were lysed and the Protein A-tagged
fusion proteins in the lysate were bound to immobilized IgG proteins. After
washing, luciferase activity was determined. If the luciferase fusion protein was
bound to the Protein A-tagged protein, luciferase activity could be detected.
(B) Network view of all interactions validated. Proteins are represented by nodes,
links represent protein-protein interactions. Phosphotyrosine-independent in-
teractions linking the nodes are shown in blue, phosphotyrosine-dependent
interactions are purple. The emphasized links are shown in (C).
(C) Luminescence assay results for the interactions highlighted in (B). The
fold binding over non-binding control is plotted. Error bars show standard
deviations. Interactions were scored as positive if the binding signal was at
least two-fold over non-binding control and differed by at least two standard
deviations.
for PIK3R3-CBL, to more than thirty-fold binding for the PIK3R3-IRS1 protein
pair (Figure 21c). Since protein interaction detection systems are orthogonal,
which means that they each detect their own subset of all true interactions
(Braun et al. 2009; Venkatesan et al. 2009), evaluation of data sets means
comparing validation rates to validation rates obtained with a positive reference
set rather than discarding interactions that fail to come back in the validation
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assay as false. Interestingly, the validation rate of about 52% (Table 8), which is
similar for phosphotyrosine-dependent and independent interactions, compares
well to validation rates reported for this type of assay (Braun et al. 2009).
In conclusion, a substantial subset of the detected interactions has been assayed
in mammalian co-immunoprecipitation experiments with validation rates that
indicate high data quality.
Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. One hundred and sixty-nine interactions were
selected for co-immunoprecipitation from mammalian cell culture. Of these,
147 produced detectable levels of both interacting proteins. Interactions were
considered validated if the luciferase signal exceeded non-binding control by
a factor of at least two and by at least two standard deviations, assuming a
multiplicative error model. The position of each ORF (”Protein A” or ”Luciferase”
for pPAReni-DM or pFireV5-DM, respectively), whether the interaction was
phosphotyrosine-dependent in the yeast two-hybrid assay (”pY-dependent”),
whether it could be validated (”validated”), the binding signal strength (”Fold
Binding”) and its statistical reliability in terms of standard deviations (”Z-
Score”) are provided for each evaluable pair of ORFs.
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
IRS1 – PIK3R3 yes yes 186.12×÷1.89 8.23
PPP1R12B – PIK3R3 no yes 157.64×÷1.34 17.48
IRS1 – PIK3R1 yes yes 91.85×÷1.43 12.68
TSPAN2 – GRB2 yes yes 39.66×÷1.98 5.4
PARD6A – PIK3R3 yes yes 27.33×÷1.41 9.58
ZNF767 – PIK3R3 yes yes 20.27×÷1.12 26.55
PLEKHB1 – SH2D2A yes yes 17.12×÷1.12 26.02
PGRMC1 – ITGB1BP1 yes yes 15.3×÷1.46 7.22
GRB2 – VCP yes yes 14.15×÷1.44 7.26
MAPRE3 – APPL2 yes yes 13.49×÷1.08 35.69
CRYBA2 – PIK3R3 yes yes 13.25×÷1.17 16.7
SH2D2A – FAM46A yes yes 12.37×÷1.12 22.66
FRS3 – SOCS4 no yes 12.13×÷1.39 7.54
PELI3 – PIK3R3 yes yes 11.85×÷1.1 26.69
MAPK8IP2 – UBD yes yes 11.09×÷1.33 8.48
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Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. (continued)
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
FAM46B – SH2D2A yes yes 10.94×÷1.09 27.55
PARD6A – GRB2 yes yes 10.38×÷2.05 3.25
MAPK8IP2 – HSPA1A no yes 10.22×÷1.12 20.27
PTK2 – HCK no yes 9.83×÷1.2 12.68
FRS3 – PIK3R3 yes yes 8.57×÷1.25 9.55
PTK2 – PIK3R3 no yes 8.27×÷1.21 11.09
SH2D2A – PIK3R3 yes yes 7.95×÷2.06 2.87
PIK3R3 – SOCS4 yes yes 7.87×÷1.26 9.04
PIK3R3 – OTUD7B yes yes 7.59×÷1.64 4.12
RABGAP1L – EVI1 yes yes 7.19×÷1.15 14.02
GRB2 – CBL no yes 6.94×÷1.1 20.14
FRS3 – HCK no yes 6.87×÷1.2 10.54
C10orf81 – PIK3R3 yes yes 6.56×÷1.1 19.75
FRS3 – FRS3 no yes 6.02×÷1.14 13.73
RAD54B – SH2D2A yes yes 5.88×÷1.15 12.34
OLIG1 – PIK3R3 no yes 5.19×÷1.23 7.81
GRB7 – PTK2 yes yes 4.78×÷1.69 2.97
PTK2 – SH2D2A yes yes 4.61×÷1.12 13.38
GRB2 – DBN1 yes yes 4.36×÷1.34 4.98
SYK – FAM46A yes yes 4.27×÷1.33 5.05
CCM2 – VSTM2L yes yes 4.24×÷1.63 2.96
DOK4 – DOK3 yes yes 4.22×÷1.56 3.22
GRB2 – TMEM128 yes yes 4.18×÷1.22 7.08
SPSB2 – PIK3R3 yes yes 4.11×÷1.18 8.55
ARL6IP4 – GRB2 no yes 4.08×÷1.74 2.53
PIK3R3 – ARL6IP4 yes yes 4.05×÷1.23 6.82
MAPK8IP2 – RABGAP1L no yes 3.87×÷1.27 5.57
LASP1 – SH2D2A no yes 3.87×÷1.17 8.52
HSPA1A – SH2D1B yes yes 3.53×÷1.24 5.84
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Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. (continued)
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
PIK3R1 – SH2D2A yes yes 3.37×÷1.11 11.29
TWIST2 – CCM2 yes yes 3.37×÷1.21 6.48
ASB9 – CRK no yes 3.36×÷1.67 2.36
C22orf28 – APPL1 yes yes 3.35×÷1.25 5.48
RAD54B – PLCG2 no yes 3.35×÷1.59 2.59
WDR20 – DAPP1 yes yes 3.34×÷1.31 4.53
PTPN6 – PTK2 yes yes 3.31×÷1.75 2.14
GRB2 – RB1 yes yes 3.29×÷1.27 5.02
PIK3R3 – WBSCR27 yes yes 3.15×÷1.17 7.25
OLIG1 – SH2D1B no yes 3.1×÷1.32 4.08
OLIG1 – HCK no yes 3.1×÷1.27 4.73
OLIG1 – YES1 yes yes 3×÷1.19 6.44
BCAR3 – IRS1 yes yes 2.95×÷1.4 3.2
GRB2 – PPARA yes yes 2.87×÷1.12 9.49
GRB2 – C10orf81 yes yes 2.83×÷1.16 6.95
LMX1A – GRB2 yes yes 2.82×÷1.48 2.63
MAPK8IP2 – ANGPT1 yes yes 2.66×÷1.2 5.32
RBP7 – PIK3R3 yes yes 2.66×÷1.15 7.2
APBB3 – DAPP1 no yes 2.65×÷1.32 3.55
GRB2 – SOCS4 yes yes 2.59×÷1.19 5.55
PIK3R3 – WDFY3 no yes 2.49×÷1.19 5.15
PINK1 – SOCS4 yes yes 2.46×÷1.11 8.71
CBL – PIK3R3 yes yes 2.41×÷1.52 2.11
PIK3R3 – HCK yes yes 2.38×÷1.38 2.68
OLIG1 – GRB7 yes yes 2.32×÷1.31 3.1
WDR40B – SH2D2A yes yes 2.29×÷1.15 5.76
CCM2 – DOK4 yes yes 2.27×÷1.4 2.44
RBP7 – SOCS4 yes yes 2.24×÷1.22 4.07
RCAN3 – GRB10 yes yes 2.21×÷1.1 8.69
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Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. (continued)
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
SH2D2A – ASB3 yes yes 2.09×÷1.16 4.83
C9orf43 – RABGAP1L yes yes 2.03×÷1.14 5.39
PSMD3 – PLCG2 no yes 2.02×÷1.19 4.09
SH2D2A – TSC1 yes no 3.31×÷1.92 1.84
ASB9 – PLCG2 no no 2.17×÷1.86 1.25
PTK2 – SRC no no 1.96×÷1.35 2.24
GRB2 – WBSCR27 no no 1.94×÷1.22 3.37
CRK – SH2D2A yes no 1.94×÷1.19 3.84
PIK3R3 – PPARA yes no 1.87×÷1.38 1.94
RABGAP1L – WDFY3 yes no 1.79×÷1.39 1.79
APBB3 – PDPK1 yes no 1.76×÷1.76 1.01
OLIG1 – STAT5A yes no 1.64×÷2.45 0.55
OLIG1 – GRB2 no no 1.58×÷1.69 0.87
RALBP1 – PLCG2 no no 1.58×÷1.19 2.58
BECN1 – YES1 yes no 1.57×÷1.36 1.47
FYN – CBLB no no 1.56×÷1.3 1.72
PIK3R3 – VCP yes no 1.53×÷1.55 0.97
MAPK8IP2 – SH2D1B no no 1.51×÷1.26 1.76
OLIG1 – PTPN6 yes no 1.5×÷1.52 0.98
PLAGL2 – DAPP1 no no 1.49×÷1.47 1.03
LRRFIP1 – SH2D2A yes no 1.45×÷1.12 3.4
STAT4 – CRK yes no 1.39×÷1.75 0.59
CRK – CBLB yes no 1.39×÷1.43 0.92
TWIST2 – PLCG2 no no 1.38×÷1.21 1.65
ELK1 – PLCG2 yes no 1.37×÷1.45 0.85
SH2D2A – LNX1 yes no 1.34×÷1.26 1.27
PIK3R3 – PACRGL no no 1.31×÷1.22 1.34
MAPK8IP2 – TMEM128 yes no 1.29×÷1.12 2.21
RABGAP1L – DBN1 yes no 1.27×÷1.24 1.09
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Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. (continued)
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
CSK – PDPK1 yes no 1.24×÷1.26 0.95
PIK3R1 – CRK yes no 1.17×÷1.47 0.42
C22orf28 – CRK yes no 1.16×÷1.67 0.29
VASP – FRS3 yes no 1.15×÷1.43 0.4
PIK3R3 – C1orf135 no no 1.13×÷1.09 1.43
EPS8 – RCAN3 no no 1.13×÷1.42 0.34
PTK2 – SH2D1B no no 1.11×÷1.34 0.36
JAK3 – LNX1 yes no 1.08×÷1.38 0.24
HSH2D – PIK3R3 yes no 1.07×÷1.73 0.13
PIK3R3 – SRC yes no 1.07×÷1.44 0.19
TWIST2 – CRK no no 1.05×÷1.73 0.09
MAPK8IP2 – LOC492311 yes no 1×÷1.13 0.03
GRB2 – MYOZ1 yes no 1×÷1.14 0.01
LIX1 – APPL2 yes no 1×÷1.31 −0.02
STAT4 – SH2D1B yes no 0.99×÷1.32 −0.04
RABGAP1L – RB1 yes no 0.97×÷1.42 −0.08
OLIG1 – NUMB yes no 0.96×÷1.23 −0.18
LGALS9C – APPL2 yes no 0.95×÷1.24 −0.24
DOK5 – SCOC yes no 0.93×÷2.33 −0.08
RABGAP1L – TSPAN2 yes no 0.92×÷1.14 −0.62
PTK2 – DOK4 yes no 0.9×÷1.35 −0.34
FRS3 – NUMB yes no 0.88×÷1.13 −1.05
CBL – PIK3R2 yes no 0.84×÷1.45 −0.47
ZHX3 – SH2D2A yes no 0.83×÷1.27 −0.76
IRS1 – NUMB yes no 0.83×÷1.12 −1.62
OLIG1 – DOK4 no no 0.8×÷1.3 −0.82
C8orf33 – MAPK8IP2 yes no 0.79×÷1.94 −0.35
FRS3 – MATK yes no 0.79×÷1.25 −1.06
ELK1 – CRK yes no 0.78×÷1.75 −0.45
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Table 8: Validation rate in co-immunoprecipitation assays confirm
the interactions high quality. (continued)
Protein A – Luciferase validated Z-Score
pY-dependent Fold Binding
ARFGAP1 – RABGAP1L yes no 0.77×÷1.15 −1.92
GRB2 – WDFY3 yes no 0.74×÷1.45 −0.8
KLRAQ1 – SH2D2A yes no 0.73×÷1.14 −2.52
GRB2 – PACRGL yes no 0.72×÷1.15 −2.43
CBL – STAT5A yes no 0.69×÷2.11 −0.5
APPL1 – SH2D2A yes no 0.65×÷1.23 −2.11
PIK3R3 – EVI1 yes no 0.62×÷1.15 −3.53
MPP5 – SOCS4 yes no 0.6×÷1.42 −1.47
STAT2 – DOK4 yes no 0.58×÷1.24 −2.51
C22orf39 – MAPK8IP2 yes no 0.56×÷1.89 −0.92
CRK – LASP1 yes no 0.51×÷1.35 −2.25
PIK3R3 – ZNF281 yes no 0.49×÷1.26 −3.08
APPL1 – PIK3R2 no no 0.41×÷1.15 −6.45
CRK – PIK3R2 yes no 0.38×÷1.21 −5.08
LDHAL6B – SOCS4 yes no 0.22×÷1.57 −3.4
CRK – SEMA4D yes no 0.13×÷3.47 −1.63
3.9 Binding-impaired SH2 domains corroborate
phosphotyrosine-dependency in co-immuno-
precipitation experiments
We performed a genome-scale yeast two-hybrid screen for phosphotyrosine-
dependent protein-protein interactions. Further, we showed that the interact-
ing proteins are functionally related and have a high validation rate in co-
immunoprecipitation experiments from human cells. While the functional over-
representation analyses showed a clear connection to tyrosine phosphorylation,
the co-immunoprecipitation experiments did not. Therefore, we propose three
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Figure 22: SH2 domain mutations prove phosphotyrosine-depen-
dency in mammalian cell culture.
(Left) Schematic of three approaches to distinguish phosphotyrosine-dependent
protein-protein interactions from independent ones. From top to bottom: Mod-
ulating tyrosine phosphorylation state by varying kinase expression; disruption
of binding by replacing the target tyrosine residue by one that cannot be
phoshporylated; mutation of the SH2 domain rendering it unable to bind to
phosphotyrosine.
(Right) Corresponding experimental results.
(Top) All 75 interactions scoring positive in the luminescence assay were tested
with and without induction of an ABL2 kinase. Plotted is the relative binding
signal compared to the non-induced result. Three showed a significant and
substantial increase when induced. (Middle) Single tyrosine-to-phenylalanine
mutations have been generated for all tyrosine residues in two proteins inter-
acting with GRB2 and tested for binding in the Luminescence assay. Plotted is
the relative binding signal compared to the wild type result. Several mutations
caused a decrease in binding signal but none of them led to a significant
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different ways of demonstrating that protein-protein interactions are phospho-
rylation-dependent (Figure 22). The first one is comparing the binding signals
of two interacting proteins with or without kinases or with different kinases
or different kinase expression levels (Figure 22, top). In the yeast two-hybrid
retest experiments, this principle was exploited comparing yeast growth between
experiments using kinase vectors with and without active kinases.
In the co-immunoprecipitation assays, a large fraction of interactions from a
comprehensive set of phosphotyrosine-dependent protein-protein interactions
was validated successfully. All of these were tested in HEK293 cells carrying
a stably integrated ABL2 kinase gene under the control of a tetracycline-de-
pendent promoter with and without tetracycline induction. Only three of them
showed a clear difference upon the induction (Figure 22, top right). The most
likely explanation for this finding is the high endogenous kinase activity in fast-
growing cells such as HEK293. Clearly, one of the other two principles needed
to be applied.
A phosphotyrosine-dependent interaction can be disrupted by mutating either
the tyrosine residue or the phosphotyrosine-recognizing domain. For a successful
tyrosine residue mutation strategy, the interaction has to follow a simple mode
of binding involving only a single tyrosine residue. Further, it requires knowledge
about which residue is recognized by the domain-containing protein. If this infor-
mation is unavailable, all tyrosine residues need to be examined in the protein-
protein interaction perturbation tests. In this case it provides this knowledge,
but requires a much greater effort. We created phenylalanine mutant clones for
all tyrosine residues in C10orf81 and TSPAN2, four in C10ORF81 and seven
in TSPAN2, and tested the binding to GRB2 in the co-immunoprecipitation
assay in comparison to the wild type proteins. While there is a tendency for a
reduction in binding, all effect sizes were smaller than two-fold and statistically
not significant (Figure 22, center right).
Mutating the phosphotyrosine-recognizing domain, on the other hand, proofed
decrease.
(Bottom) Phosphotyrosine binding-disrupting SH2 domain mutations have been
generated for GRB2 and PIK3R3 and tested in the Luminescence assay. Plotted
is the relative binding signal compared to the wild type result.
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more efficient. In SH2 domains, there is a conserved arginine residue that is
known to reduce the ABL1 SH2 domains phosphotyrosine binding affinity by
more than 100-fold when mutated to lysine (Mayer et al. 1992). (Marengere &
Pawson 1992) used a similar mutation to distinguish binding of the N-terminal
and C-terminal RASA1 SH2 domain binding to the EGF receptor. In this
study, employing SH2 domain mutants required a relatively lower cloning effort,
because there are only one or two SH2 domains per protein and many tyrosine
residues in most putative tyrosine-phosphorylated proteins (i.e. their interaction
partners). Additionally, it allowed testing of all interactions that have been
detected with the respective protein and SH2 proteins have more phoshotyro-
sine-dependent interaction partners than the putative tyrosine-phosphorylated
proteins. This point is especially important, because some interactions are
enabled by several tyrosine residues, if they are phosphorylated. For example,
Kouhara et al. (1997) showed that there are four binding sites, each sufficient
for interaction between GRB2 and FRS2. A disadvantage of this approach is
that it can be applied to SH2 domains much better than to PTB domains.
In PTB domains, no generally conserved residue that is strictly required for
phosphotyrosine binding is known. Another problem, that applies to both muta-
tional approaches, is that there are many interactions among domain-containing
proteins. In these cases it is unclear which of the two proteins is phosphorylated
and which one is recognizing the phosphorylated tyrosine residue. Nevertheless,
it is easier to test all domains that might be involved than all tyrosine residues.
For these reasons thirty phosphotyrosine-dependent protein-protein interactions
that tested positive in co-immmnoprecipitation validation assays were tested
with mutated SH2 domains (Figure 22, bottom). Twenty of them showed a sig-
nificant decrease of binding by at least 50% compared to wild type binding. The
phosphotyrosine-recognizing domain-containing genes chosen to demonstrate
phosphorylation-dependency in mammalian cell culture were PIK3R3, GRB2,
PIK3R1 and SOCS4. PIK3R3 and GRB2 were selected because they have a
larger number of phosphotyrosine-dependent interaction partners, PIK3R1 for
its high sequence similarity to PIK3R3 and SOCS4 because it also interacts
with PIK3R3 and GRB2.
Thus, for a large fraction of phosphotyrosine-dependent interactions, we con-
firmed the requirement of the phosphotyrosine-recognizing domain for binding.
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3.10 The phosphotyrosine-dependent protein in-
teractions found in this study are mostly
novel
A comprehensive phosphotyrosine-dependent protein-protein interaction data
set has been collected in a genome-scale yeast two-hybrid screen and shown
to be of high quality in mammalian cell culture. However, the luminescence-
based co-immunoprecipitation experiments can only assess the quality of the
detected interactions, but it does not allow drawing conclusions about the data
completeness. In more technical terms, the validation assays help evaluate the
precision but not the sensitivity of the screen (Wilson 1927).
We wanted to estimate the number of true interactions missed to calculate the
false negative rate in our assay. Because the complete set of true interactions
is unknown, a literature-curated interaction set is commonly used as a proxy
(Simonis et al. 2009; Braun et al. 2009, for example). For the purposes of this
analysis all possible interactions between successful bait genes were used as a
defined interaction space. The protein interaction meta-database Consensus-
PathDB (Release 19) (Kamburov et al. 2009) was used to find all interactions in
the bait-bait interaction space annotated in the databases BIND, Biogrid, DIP,
HPRD, InnateDB, IntAct, MINT, MIPS, NetPath and Spike. Two hundred and
thirty-nine annotated interactions were obtained and controlled by manually
surveying the references until at least one was found that contains evidence
for a physical interaction between the two genes in question. This included e.g.
GST pull-down, yeast two-hybrid or co-immunoprecipitation. The literature-
curated interaction set contains 147 interactions that could be validated this
way. This data set was compared to the set of interactions detected in this
study (Figure 22). In this study, 81 protein-protein interaction were found
in the interaction space, 51 phoshotyrosine-dependent and 30 independent
ones. Of these, 15 overlapped with the literature-curated interaction set (red in
Figure 22). This suggests a false negative rate of almost 90%, which is common
for protein-protein interaction sets based on a single detection method (Braun
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Figure 22: Most of the interactions found in this study are novel.
(Left) Overview of the overlap of the interactions found in this study and
interactions found in the literature. The ConsensusPathDB protein-protein
interaction meta-database was queried for all possible interactions among
successful bait proteins, as well as all other interactions found in this study. The
retrieved articles were controlled and until an interaction was validated or until
all article for that interaction were exhausted. Were applicable, information
about phosphotyrosine-dependency was collected. Column denote literature
results, rows results of this study. The fields are the respective overlaps. The
colored fields contain data used on the right.
(Right) Graphical representation of the bait-bait interaction space, the space
covered by literature interactions (green), the space covered by this study
(blue), the overlap between the two (red) and the space of expected unknown
interactions (grey), based on the assumption that the results found in the
literature and the results of this study are independent and unbiased.
et al. 2009; Venkatesan et al. 2009).
The comparison to the literature allows the assessment of two other interesting
parameters. The first one is the novelty of the interaction set (i.e. the degree to
which the detected interactions expand the protein interaction knowledge), the
other one is the number of interactions in the interaction space that have not
been found yet (Figure 22, right). The novelty is approximated by the ratio of
interactions in the screen not covered by the literature. Eighty-one interactions
have been found in the bait-bait space. Fifteen of those overlap with the litera-
ture-curated data set. This means that only about 18.5% of the interactions
are known, assuming there are no biases in the literature-curated set. The total
number of true interactions in the bait-bait space can be estimated from the size
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of the two interaction sets and the overlap. If we assume the interactions found
in this study and the interactions in the literature-curated set to be two samples
independently drawn from a common pool of true protein-protein interactions
in the interaction space and the probability of finding an interaction to be
uniform, the total number of interactions in the interaction space is given by
the formula . This estimates the number of unknown interactions to be about
five hundred and eighty-one (grey box in Figure 22).
To get a better estimate of the novelty, the same databases used to generate
the literature-curated interaction set were queried for the rest of the detected
interactions and controlled in the same way. Interestingly, there are only 35
interactions in the literature for the complete set of 628 interactions, which is
only 5.6% making it considerably lower than the 18.5% in the bait-bait interac-
tion set. This indicates a relatively strong research bias towards interactions
among phosphotyrosine-recognizing domain-containing proteins.
For the yeast two-hybrid-derived data set, each interaction is detected as either
phosphotyrosine-dependent or independent. For the literature-curated set, this
information is not always available. For the purposes of this comparison, phos-
phorylation dependency was inferred for 20 of the 35 interactions, wherever
reasonable. For example, if an SH3 domain alone is sufficient for a successful
GST-pulldown experiment, it is reasonable to assume that the interaction is
independent (Chan et al. 2003). Similarly, if an interaction can be disrupted
replacing a tyrosine by a phenylalanine residue, it is probably phosphorylation-
dependent (Elly et al. 1999). Interestingly, for some interactions, information
pointing in both directions is available (Bandyopadhyay et al. 2010; Blagoev
et al. 2003; Howlett et al. 1999; Elly et al. 1999; Kotani et al. 1998; Scholz et al.
2000). This can result from conflicting reports, but it can also be reported in
the same publication. For example, Sattler et al. (1997) found that both, the
CRKL-SH2 and the CRKL-SH3 domain, are able to bind CBL. In principle,
the results regarding phosphotyrosine-dependency from the literature agree
with the result from our screen. The interactions BMX-STAT3, SRC-PTK2 and
NUMB-LNX2 have been described as dependent but were found as independent
in this study. The first two are interactions involving kinases, and it is conceiv-
able that the kinase activity of the bait or prey can make a phosphorylation-
dependent interaction appear independent in the yeast two-hybrid system. The
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latter is possibly classified incorrectly, or it is an example of a PTB domain
binding in a phosphotyrosine-independent manner, as it has been suggested
in (Rice et al. 2001). The interactions ABL2-CRK, CRK-CBLC, CRK-SOCS1
and PIK3R1-SOCS1 have been described as independent but were found as
dependent in this study. Interestingly, three of these involve CRK. It is possible,
that these are more examples of a simultaneous SH2 and SH3 binding. It is
also possible to imagine a mechanism of intramolecular rearrangement allowing
an SH3 domain-mediated interaction only upon phosphorylation. Of note, the
interaction between CRKL and SOCS3 has been reported to be mediated by
the CRKL SH2 domain (Sitko et al. 2004).
In conclusion, the comparison to the literature shows that, while the data set is
of high quality and mostly new, the number of missed interactions is probably
very high, as is common in protein-protein interaction detection experiments
(Braun et al. 2009).
3.11 Subcellular protein interaction localization
in intact cells reveals high flexibility of the
GRB2 adaptor protein
To further raise the level of confidence in the phosphotyrosine-dependent protein-
protein interaction set, especially in biological context, interactions between
differentially located proteins were selected and visualized in intact mammalian
cells using a split-YFP assay. To ward against faulty literature data, the local-
ization information was controlled in immunofluorescence experiments using
Protein A-tagged proteins and, where available, using antibodies against the en-
dogenous proteins. Figure 23 shows very different localization of GRB2 protein
interactions. GRB2 alone can be seen mainly in the cytoplasm (Figure 23 A
and D). With RB1, which is nuclear (Figure 23 B and E), GRB2 interacts in
the nucleus (Figure 23 H). With C10orf81, which can be found in the cytoplasm
and in the nucleus (Figure 23 F), the GRB2 interaction can be seen in the
cytoplasm (Figure 23I). The interaction with the membrane protein TSPAN2
(Figure 23 C and G) is found in membranous outgrowths induced by TSPAN2
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Figure 23: The adapter protein GRB2 shows high locational flexi-
bility in its interactions. (A-C) Endogenous localization of GRB2, RB1
and TSPAN2, as determined by immunoflurescence using specific antibod-
ies (green), (D-G) subcellular localization of Protein A-tagged GRB2, RB1,
C10orf81 and TSPAN2, as determined by immunoflurescence using generic
antibodies (green), (H-J) protein complementation assay results for the inter-
actions GRB2-RB1 (H), GRB2-C10orf81 (I) and GRB2-TSPAN2 (J) (green),
(all) phalloidin (red), nucleus/DAPI (blue).
(Figure 23 J). In agreement with its role as signaling hub, GRB2 is a prime
example of a protein that can interact in different localizations, maybe triggered
by the activity of different kinases. It should be noted that the protein com-
plementation assay visualizes only the interactions. In other words, the overall
distribution of the two proteins may remain unchanged. This would mean that
the same protein can be present in several distinct complexes, possibly fulfilling
different biological functions, simultaneously.
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Chapter 4
Discussion
4.1 Yeast two-hybrid screening for phosphoty-
rosine-dependent protein interactions is the
best way of improving our understanding of
multicellular regulation of growth and devel-
opment and related disease
4.1.1 Fast and efficient signaling is important for multi-
cellularity
From an evolutionary perspective, signaling is an extremely important prereq-
uisite for the development of complex systems. Biological entities form complex
systems by building hypercycles (Eigen & Schuster 1977) that act as single
evolutionary units. When multicellular lifeforms emerge, the single cells give
up their independence and selection acts one organisms instead of single cells
(Hoenigsberg et al. 2008; Smith & Szathmary 1997). Where cells start showing
selfish behavior, the organism develops cancer and perishes. Once the transition
from unicellular to multicellular organisms starts, the multicellular entities that
display the most coordinated responses to the challenges they encounter have
a selective advantage over those that do not. For an efficient coordination of
cellular behavior on an organism/tissue scale, signaling mechanisms need to
function in a highly effective, fast and independent manner.
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4.1.2 Dedicated proteins with phosphotyrosine reader-,
writer-, or eraser-function facilitate rapid and spe-
cific signaling
The use of dedicated signaling molecules achieves a high degree of indepen-
dence from the regulated systems and has a high potential for effectiveness.
Augmenting the established mechanisms of protein regulation by synthesis and
degradation with mechanisms that employ ”stand-by” systems that need only
be switched on or off enables more rapid responses. Second-messenger and post-
translational protein modification systems are possible solutions meeting these
criteria. Both of these solutions require three kinds of proteins to constitute
marked improvements upon other signaling mechanisms: one type of protein
to effect the activation of the system, one type of protein to reverse the effect
of the first and one type of protein that can sense the state of the system
and act accordingly. Post-translational modifications are distinguished from
second-messenger systems by the fact that post-translational modifications are
clearly attributed to a specific signaling context by virtue of the protein they
are attached to. In the case of phosphotyrosine signaling, the close connection
between kinase function and phosphotyrosine binding is reflected in the tight
evolutionary link in the diversification of SH2 domains and protein tyrosine
kinases (Liu et al. 2011a). It is assumed that the SH2 domain and the protein
tyrosine phosphatases emerged first, and, after the appearance of protein tyro-
sine kinases, formed a complete ”toolkit”, consisting of ”writer”, ”reader” and
”eraser” of protein tyrosine phosphorylation (Lim & Pawson 2010; Pincus et al.
2008).
4.1.3 Evolution of metazoan complexity parallels phos-
photyrosine signaling
In practice, the writer and eraser functions are often found in association
with the reader function, either in the same amino acid chain or by virtue of
adapter proteins. For example, in the case of phosphotyrosine signaling, most
non-receptor tyrosine kinases have at least one SH2 or PTB domain or are
closely associated with one or more adapter proteins (Hubbard & Till 2000;
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Blume-Jensen & Hunter 2001; Manning et al. 2002b).
Conversely, phosphotyrosine signaling is one of the hallmarks of metazoan
evolution (Müller 2001; Hunter 2009; Darnell 1997). This can also be seen in a
correlation of the number of different tyrosine kinases and the ”complexity” of
an organism (Hunter & Cooper 1985). A similar connection has been shown
for the number of SH2 domain protein families and the number of different cell
types of an organism (Vogel & Chothia 2006).
The importance of phosphotyrosine signaling for multicellular organisms is
further exemplified by the rapid evolutionary burst following the emergence of
multicellularity. In yeast, there is only a single known SH2 domain-containing
protein (Maclennan & Shaw 1993), whereas in higher eukaryotes the SH2
domain family is one of the largest protein domain families (Venter et al. 2001).
Interestingly, the genome with the highest number of SH2 domains belongs
to a unicellular organism, Monosiga brevicollis (Manning et al. 2008). This
organism is thought to be closely related to the last unicellular ancestor of
multicellular organisms (King et al. 2008). Nevertheless, M. brevicollis has only
20 SH2 protein families (Liu et al. 2011a).
In human and other mammals there are 38 SH2 domain protein families, thirty-
four of which were already present before the split of echinoderms and chordates
(Liu et al. 2011a). Pincus et al. (2008) analyzed 41 eukaryotic genomes and found
significant co-evolution of SH2 domain proteins, protein tyrosine phosphatases
and protein tyrosine kinases.
As a result of the emergence of wide-spread protein tyrosine phosphorylation,
evolutionary pressure against deleterious phosphporylation events led to a
reduction in the relative number of tyrosine residues with increasing complexity
in metazoans (Tan et al. 2009b). This observation, in turn, lends credibility
to the conjecture that phosphorylation events retained through evolution are
mostly functional. The results of SH2 domain profiling experiments performed
by Machida et al. (2003) who find that in their experiments ”nearly all of the
bands detected in the anti-pTyr blot are represented in the superimposed SH2
profile” further support this line of reasoning.
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4.1.4 Phosphotyropsine signaling is intimately connected
to cancer and other diseases
Because of the intimate connection between phosphotyrosine signaling and
regulation of growth and development, there is a number of highly relevant
diseases for which alteration of phosphotyrosine signaling is a central aspect.
First and foremost, virtually all kinds of cancer are associated with mutations
in phosphotyrosine signaling genes, especially kinases (Blume-Jensen & Hunter
2001; Gschwind et al. 2004; Futreal et al. 2004). The most relevant cancer
pathways contain many genes that are also found in phosphotyrosine signaling
pathways (Vogelstein & Kinzler 2004). Nevertheless, phosphotyrosine signaling
has also been shown to play a pivotal role in a number of other diseases,
like agammaglobulinemia and Noonan’s syndrome (Yaffe 2002), dyslipidemia,
hypertension, cardiovascular disease, stroke, blindness, kidney disease, female
infertility, and neurodegeneration (White 2003), as well as hypercholesteremia,
familial stroke, coronary artery disease, Alzheimer’s disease, and diabetes (Uhlik
et al. 2005).
4.1.5 Several, orthogonal methods have been used to in-
vestigate phosphotyrosine signaling
4.1.5.1 Peptide binding arrays efficiently assay preference for linear
peptide motifs
SH2 domains often display a preference for certain amino acid residues in a
fixed position toward the recognized phosphorylated tyrosine residue. These
preferences are most noticeable for residues that are close to the phosphorylated
tyrosine residue in the primary structure. Therefore, many SH2 domain binding
preferences have been characterized in terms of short linear amino acid motifs
using in-vitro peptide binding arrays using peptide arrays. There are two
different approaches for peptide array binding experiments. The first one uses
randomized oligopeptides (commonly 11-15-mers) that have a single fixed
position in each spot. By probing each combination of amino acid residue and
position and comparing relative binding signals, binding preference sequence
motifs were determined for many SH2 domains with relative ease (e.g. Beebe
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et al. 2000; Huang et al. 2008). However, these motifs assume an absence of
cooperative effects, either positive or negative. They also fail when SH2 domains
show multiple specificity, like the SH2 domain of PTPN11 (Wavreille et al.
2007). Empirically, the resulting motifs fit some protein-protein interactions
very well, but fail at explaining others. Further, there are tyrosine motifs that
match the consensus, but are not observed in the context of a full-length protein.
Therefore, a second, more sophisticated, approach has been developed. Instead
of randomized peptides, all (or the most relevant) naturally occurring tyrosine
motifs can be used (e.g. Liu et al. 2012). This approach has the advantage
that an observed binding event can be more easily used to derive a biological
hypothesis, but it still measures peptide binding only. Another approach, that
can be considered an intermediate, is a two-step peptide array system that
determines permissive residues first, and then, in the second step, non-permissive
residues, i.e. residues that abrogate binding (Liu et al. 2010).
4.1.5.2 Affinity purification-coupled mass spectrometry-based ex-
periments inherently detect phosphorylation-dependent and
-independent protein interactions
Another type of experiment that has proven fruitful not only in the field of
phosphotyrosine binding analysis is affinity purification coupled to mass spec-
trometry. In experiments of this kind, affinity-tagged proteins are expressed
in mammalian cells and enriched by binding to a chemical ligand or an an-
tibody. Proteins bound to the tagged proteins are then identified by mass
spectrometry, potentially allowing the detection of all proteins complexed with
the protein of interest in the biological sample. In contrast to peptide array
binding experiments, this method has several advantages. First and foremost,
the binding event is observed in the context of complete proteins. Factors that
are completely ignored in peptide-based experiments, like accessibility and pro-
tein conformation, have a normal influence in affinity purification experiments
and even complex binding surfaces are intact. Furthermore, binding occurs, at
least initially, in intact mammalian cells and post-translational modifications
can be assumed to resemble biologically relevant situations. On the other hand,
purified complexes have to be washed thoroughly before protein identification.
Therefore, mass spectrometry-based methods are thought to have a bias toward
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strong and stable interactions. Additionally, affinity purification-mass spectrom-
etry interactions are not binary. Membership of the same complex does not
necessarily imply physical interaction. Failure to account for these inherent
differences leads to faulty analyses (Venkatesan et al. 2009).
While direct observation of phosphorylated peptide species is possible using
mass spectrometric methods, special care must be taken in order to detect
these signals. Therefore, most studies rely on secondary rationales, like compar-
ing stimulated and unstimulated cells and reasoning that stimulation implies
phosphorylation. Another disadvantage of mass spectrometry-based methods
for the detection of phosphorylation-dependent protein interactions is that the
observed effect can always be indirect and that there is always a background
of kinase activity, that cannot be suppressed, because it is necessary for the
survival of the mammalian cells.
In principle, dynamics of phosphorylation and protein binding are amenable for
analysis by mass spectrometry-based methods. In practice, only a ”countable
number of studies have been reported on linking dynamics of protein interac-
tion networks of protein complexes to cellular processes or signaling pathways
using AP-QMS strategies” (Kaake et al. 2010). Most of the studies examining
dynamics of phosphorylation or phosphorylation-dependent protein binding,
rely on some kind of stimulating molecule related to the biological question
under investigation. Proteins from stimulated cells are compared to proteins
from unstimulated cells and differences are interpreted as consequences of the
treatment (Pflieger et al. 2008; Rinner et al. 2007; von Kriegsheim et al. 2009;
Olsen et al. 2006). Combination of growth factor stimulation and mutated bait
proteins provide additional insight. For example, (Bisson et al. 2011) compare
GRB2 complex composition for six different growth factor treatments using
SH2 or SH3 binding-incompetent as well as wildtype constructs in AP/MS
experiments. This approach allowed the characterization of 89 GRB2 complex
binding partners in terms of SH2 or SH3 domain dependency. For 65 proteins
binding depended on either domain. Signal strength for these interactions were
compared after treatment with EGF, FGF, HGF, IGF, PDGF or insulin. Last
but not least, the duration of EGF treatment was even varied from 1 through
100 minutes.
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4.1.5.3 The yeast two-hybrid system relies on external tyrosine ki-
nases for phosphorylation-dependent protein interaction de-
tection
The yeast two-hybrid system is a well-tried method for the detection of protein-
protein interactions. The two proteins of interest are fused to a transcription
factors DNA binding or transcriptional activation domain, respectively. Inter-
action of the two proteins results in the expression of reporter genes fused
to the corresponding transcription factor binding site. Accordingly, the yeast
two-hybrid system produces binary interaction and is able to detect transient,
”between-complex” interactions (Phizicky et al. 2003). It is very popular for
proteome-wide screening because yeast two-hybrid are usually of high quality
and it is amenable to automation. For example, Yu et al. (2008) reexamined
about 100 interactions from the high throughput yeast data sets provided by
Uetz et al. (2000) and Ito et al. (2001), the high throughput mass spectrom-
etry data sets provided by Gavin et al. (2002) and Krogan et al. (2006), as
well as literature-curated low throughput data, by yeast two-hybrid and YFP
complementation and found that high throughput yeast two-hybrid data are
of very high quality, when analyzed in the proper, binary context. Venkatesan
et al. (2009) determined a precision of 79% for the yeast two-hybrid system in
a proteome-wide context.
Because there is virtually no tyrosine kinase activity in S. cerevisiae (Gnad
et al. 2009), phosphotyrosine-dependent interaction can only be detected where
external kinase genes are introduced.
4.1.5.4 High throughput mass spectrometry continues to reveal vast
numbers of protein phosphorylation sites
A question that is closely related to phosphotyrosine-dependent protein-pro-
tein interactions is which tyrosine residues are phosphorylated under which
conditions. In some regards, this question can be regarded as basal to phospho-
rylation-dependent protein interaction research. Historically, the description
of protein tyrosine phosphorylation laid the foundation for the discovery of
phosphotyrosine-dependent protein-protein interactions (Sadowski et al. 1986).
In a functional framing, the protein tyrosine phosphorylation is a prerequisite
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for phosphotyrosine-dependent binding.
Protein tyrosine phosphorylation began receiving scientific attention after the
description of SRC protein tyrosine kinase activity (Hunter & Sefton 1980) and
the realization that this activity plays an important role in cellular transforma-
tion (Sefton et al. 1980). Yet, the amount of protein tyrosine phosphorylation
is much lower than the amount of protein serine or protein threonine phospho-
rylation. Hunter & Sefton (1980) determined the relative amounts of protein
serine, threonine and tyrosine phosphorylation as roughly 90%, 10%, and 0.05%,
respectively. Olsen et al. (2006) measured relative amounts of 86.4%, 11.8%,
and 1.8%, respectively. The striking difference in the proportion of tyrosine
phosphorylation originates in the different methods. While the former used
isotopic labeling to determine the relative number of actual phospho groups
bound, the latter used mass spectrometry to identify unique sites. In other
words, proteins carrying tyrosine phosphorylations are apparently less abun-
dant than those carrying serine or threonine phosphorylations, on average. A
comparison of the numbers of annotated phosphorylation sites comes out even
more on the side of tyrosine phosphorylation due to research bias and owing to
the high quality of pan-phosphotyrosine-specific antibodies. The first tyrosine
phosphorylation sites were found by focusing on the targets of the first de-
scribed protein tyrosine kinases, like the kinases themselves (Smart et al. 1981;
Downward et al. 1984) or other, non-kinase proteins, such as ANXA2 (Radke
et al. 1980). More recently, large-scale mass spectrometry-based studies have
probed the phosphoproteome in an unbiased fashion and revealed large numbers
of mostly novel phosphorylation sites (Beausoleil et al. 2004; Rush et al. 2005;
Olsen et al. 2006). In 2009, Tan et al. (2009a) found 11,731 phosphoserine/-
threonine and 9,283 phosphotyrosine sites in the publicly available resources.
They determined that more than 65% of the conserved phosphosites were found
in the 5 years prior. More recently, (Woodsmith et al. 2013) reported the
number of phosphoserine/-threonine and phosphotyrosine sites as 56,251 and
13,241, respectively. In other words, in contrast to phosphotyrosine-recognizing
domains, the number of reported phosphotyrosine sites is growing rapidly and
does not show any indications of reaching saturation.
Therefore, a genome-scale screen focusing on phosphotyrosine-recognizing do-
main-containing proteins promised much more comprehensive results than one
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based on known tyrosine-phosphorylated proteins.
4.1.5.5 Full-length protein context has been largely neglected in
phosphotyrosine-dependent protein interaction investigation
The ever-growing number of protein tyrosine phosphorylation sites calls at-
tention to the limited knowledge about phosphotyrosine binding. In light of
the notion that the number of non-functional protein tyrosine phosphorylation
events is expected to be small, it suggests that there are factors different from
primary amino acid sequence contributing to phosphotyrosine binding specificity.
An exact quantification of the impact the peptide motif sequence immediately
surrounding the phosphorylated tyrosine residue has on binding is difficult. For
phospholipase C γ, Bae et al. (2009) used isothermal titration calorimetry to
show that binding to FGFR1 is much stronger than to the respective peptide
alone and Min et al. (2009) demonstrated, that point mutations outside the
peptide binding pocket diminish binding of ITK. For kinases, Linding et al.
(2007) estimated the context to contribute at least 60% to substrate specificity.
It seems likely that context contributes equally to protein-protein interactions.
Therefore, the current knowledge of phosphotyrosine-dependent protein-protein
interaction will profit greatly from an interaction map derived from experiments
using full-length bait, prey and kinase proteins.
4.1.6 Genome-scale yeast two-hybrid screening of SH2
and PTB domain genes fills a gap in phosphoty-
rosine-dependent protein-protein interaction litera-
ture
4.1.6.1 Signaling proteins employ domains as molecular building
blocks
The increase in complexity seen in eukaryotes goes hand in hand with higher
modularity. In protein structure, relatively self-contained modules called do-
mains evolved. Protein domains can usually fold independently (Bagowski et al.
2010) and tend to lie with single exons, especially in complexer organisms (Liu &
Grigoriev 2004). Consequently, in protein evolution, structure is retained more
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than amino acid sequence (Chothia & Lesk 1986). Most proteins comprise more
than one domain and fulfill functions that are directly related to their domain
composition (Han et al. 2007). Alternatively, adapter proteins are employed
(Pawson & Scott 1997). Novel combinations of existing domains allowed for
more complex organisms (Koonin et al. 2000). Indeed, this principle was even
exploited very successfully in protein engineering. Desai et al. (1993) demon-
strated that PTPRC-deficient Jurkat cells can be rescued by an EGFR-PTPRC
chimera. Even more, EGF inhibits PTPRC function by inducing dimerization.
Howard et al. (2003) created chimeric adaptors by fusing the GRB2 SH2 domain
or SHC1 PTB domain to the death effector domain of FADD. These chimeric
adaptors were able to induce caspase activation and cell death in response to
mitogenic or transforming RTK signals. It has been observed early, that ”[t]he
main biological role of protein modules seems to be for specific protein-protein
interactions.” (Campbell & Baron 1991). While others (Yu & Lemmon 2003)
report the percentage of human genes with protein interaction domains to be
only 2.5%, the percentage of signaling genes is very similar and the two sets
have a high overlap. Therefore, it can be safely assumed that most signaling
protein interactions are domain-mediated. In fact, even in prokaryotes domain
information can be used to improve protein interaction prediction significantly.
This was demonstrated by Wojcik & Schächter (2001), who compared protein-
protein interaction prediction for Heliobacter pylori based on E. coli interac-
tions with and without domain information and benchmarked the results using
the experimentally generated interaction map provided by Rain et al. (2001).
Therefore, we followed a domain-driven approach in our analysis of tyrosine
phosphorylation-dependent protein-protein interactions.
4.1.6.2 SH2 domains are highly relevant for phosphotyrosine signal-
ing
Using prior knowledge as an indication, a relatively small number of SH2
domain-containing proteins was expected to account for the majority of the
phosphotyrosine-dependent interaction data, but these estimates can be highly
influenced by research bias. For example, GRB2 was first described in the context
of phosphotyrosine signaling (Lowenstein et al. 1992) and has been scrutinized
for phosphotyrosine binding since then while TP53 has been recognized as
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an important cancer gene in 1979, but has not been researched in terms of
phosphotyrosine signaling until the 1990s (Harris 1996). Furthermore, almost
all SH2 domains are expected to bind to phosphotyrosine residues in proteins
(Liu et al. 2006). Admittedly, there are reports of SH2 domains fulfilling other
functions. For example, the SH2 domains of PI3K are able to bind PIP3,
which competes for bindings with INSR (Rameh et al. 1995), the TENC1
SH2 domain binds DLC1 in a phosphorylation-independent manner (Dai et al.
2011), and the SH2 of JAK1 was suggested to function mainly as a peptide
linker, because introducing a mutation known to disrupt phosphotyrosine
recognition did not affect its subcellular localization or signaling capacity
(Radtke et al. 2005). Nevertheless, these reports seem singular and do not
necessarily preclude tyrosine recognition. Therefore, all human SH2 domains
should be assayed in a comprehensive screen for phosphotyrosine-dependent
protein-protein interactions.
4.1.6.3 SH2 domains are well-defined and have virtually no func-
tions other than phosphotyrosine recognition
There is a large number of SH2 proteins in the human genome. This number
of bona fide SH2 domains and SH2 proteins in the human genome has grown
from 95 SH2 domains in 87 proteins (Venter et al. 2001) to 121 SH2 domains in
111 proteins (Liu et al. 2011a). Pawson et al. (Pawson et al. 2005) talk about 115
human SH2 domains. Jones et al. (Jones et al. 2006) give a slightly lower number
of 108 SH2 domains in 98 proteins. In the same year, Liu et al. (2006) describe
120 SH2 domains in 110 proteins. In the next five years, this set was expanded
only by SH2D7 (Liu et al. 2011a). Because of the intimate link to the regulation
of processes necessary for multicellular organism and phosphotyrosine signaling,
SH2 proteins can be categorized in eleven functional groups (Liu et al. 2006).
Known disease-causing mutations in SH2 genes result mostly in various types
of cancer or immune disease (Liu et al. 2006). Similarly, phenotypes observed
in SH2 gene knock-out mice are mostly related immune functions (Liu et al.
2006). Thus, the group of SH2 domain-containing proteins is highly relevant
for phosphotyrosine signaling, has virtually no other known functions than
phosphotyrosine binding, is well-defined and important for pressing medical
issues.
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4.1.6.4 PTB domains have to be considered in a comprehensive
analysis of phosphotyrosine signaling
The PTB domain-containing genes, on the other hand, are much more loosely
defined than the SH2 domain-containing genes. The PTB domain has a PH fold
(Blomberg et al. 1999), and the boundary between PTB and PH domains
varies between different authors. Some authors consider the PTB domain a
subclass of the PH domain (Rebecchi & Scarlata 1998), others regard it as
separate (Uhlik et al. 2005). Even functionally the PTB domains cannot be
distinguished sharply. There are subtypes, that clearly recognize to phosphory-
lated tyrosine residues in proteins and others for which this has not been shown
(Uhlik et al. 2005). Even within the same subtype, there can be PTB domains
that bind phosphotyrosine residues, and others that do not. For example, the
PID or Dab-/Shc-like subtype contains domains that bind phosphotyrosine
residues, like in Shc proteins, and others that bind to non-phosphorylated
tyrosine residues or even phenylalanine residues, like the ones found in Dab
proteins (Uhlik et al. 2005). An additional problem is that other functions, like
the ability to bind to phosphate groups on non-protein molecules, are often
carried by the same domains. For example, the Shc PTB domain can bind
phosphatidylinositol-4,5-bisphosphate and phosphatidylinositol-4-phosphate
(Ravichandran et al. 1997). Thus, the PTB domain-containing proteins are
also relevant for phosphotyrosine signaling, but have many members that have
different functions and are less well-defined than SH2 proteins.
4.1.6.5 The relevance of non-SH2, non-PTB domains for phospho-
tyrosine signaling seems negligible
In addition to SH2 and PTB domains, some PH domains not usually referred
to as PTB domains have been shown to bind proteins on phosphotyrosine
residues. However, the number of PH domain-containing genes is very high,
totaling more than 600 genes, and the expected fraction of genes showing a
phosphotyrosine binding ability is expected to be very low. There are even
completely unrelated domains, like the C2 domain of PRKCD, that have been
shown to recognize phosphotyrosine sites on proteins (Benes et al. 2005). Still,
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the reports of unrelated domains binding phosphotyrosine residues seem singular
and anecdotal.
4.1.6.6 All genes containing SH2, IRS1-type or PTB-type PTB do-
mains define a comprehensive basis for phosphotyrosine-de-
pendent protein interaction screening
The more clearly defined PTB domains appear to be the most relevant ones
for phosphotyrosine signaling. Therefore, the screen was restricted to the PTB
domain subgroups of the IRS1 and PID subtype. These subtypes are known
to be substantially involved in phosphotyrosine binding. Additionally, all SH2
domain-containing genes were chosen as bait, even the few that were suspected
not to bind phosphotyrosine residues. In practical terms, the InterPro identifiers
IPR000980 (SH2), IPR002404 (PTB_IRS1) and IPR006020 (PTB_PID) were
used to query the UniProt database and the resulting entries were mapped to
Entrez Genes. We then attempted to obtain protein interactions for at least
one clone belonging to each Gene ID, thus generating a comprehensive set of
phosphotyrosine-dependent protein-protein interactions (Table 4).
4.1.6.7 Human non-recptor tyrosine kinases allow detection of phos-
photyrosine-dependent protein-protein interactions in the
yeast two-hybrid system
We wanted to gain insight into the organization of cellular signaling by tyrosine
phosphorylation. Towards this end, we used the yeast two-hybrid technique to
generate a network of phosphotyrosine-dependent protein-protein interactions,
that is as complete and unbiased as possible. A set of bait proteins containing
phosphotyrosine-recognizing domains was screened against a proteome-scale
matrix of prey proteins in the presence of non-receptor tyrosine kinases.
Introducing a non-receptor tyrosine kinase allows yeast two-hybrid screening
for phosphotyrosine-dependent protein-protein interactions. The kinase gene
is encoded on a third plasmid. This makes it compatible to our established
matrix-based yeast two-hybrid system (Stelzl et al. 2005), allowing genome-
scale screening in a very sensitive, stringent, well-proven setup (Venkatesan
et al. 2009). The system was used to screen a comprehensive set of phosphoty-
rosine-recognizing domain-containing genes. Bait strains with phosphotyrosine-
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recognizing domain-containing genes and kinase plasmids were prepared and
tested for autoactivation. Non-autoactive bait strains were then screened against
a genome-scale prey matrix. Finally, phosphotyrosine-dependent interactions
were distinguished in an independent retest experiment. The use of a retest
experiment is an established concept in our lab (Hegele et al. 2012; Worseck
et al. 2012), as well as in others (Goehler et al. 2004; Stelzl et al. 2005; Rual
et al. 2005; Braun et al. 2009; Vinayagam et al. 2011). It makes the results
more stringent because it uses fresh yeast and short growth period with a
limited number of replications. In this study it has an additional purpose.
Interactions were recognized as phosphotyrosine-dependent by comparing the
same combination of bait and prey with different kinases and empty kinase
vector controls. At the same time the retest provides an even higher degree
of stringency than in conventional yeast two-hybrid. In addition to revealing
phosphotyrosine-dependency, the empty kinase vector controls bait and prey
autoactivity, because the kinase did not contribute to autoactivity. More than
that, it did so in a way that is more relevant than in conventional yeast two-
hybrid, because bait and prey are expressed in the same cell. This additional
stringency allowed us to abstain from using the additional reporter gene read-
out. To test this, we assayed 32 phosphotyrosine-dependent interactions that
had already scored positive in the growth assay for β-galactosidase activity.
This provided virtually no additional information.
There is virtually no background tyrosine kinase activity in S. cerevisiae (Gnad
et al. 2009; Manning et al. 2002a), a fact that has been taken advantage of be-
fore, e.g. to investigate the suppression of SRC kinase activity by CSK (Murphy
et al. 1993). Overexpression of the SRC tyrosine kinase has been reported to
exert toxicity in S. cerevisiae (Brugge et al. 1987; Boschelli et al. 1993; Florio
et al. 1994). On the other hand, the successful introduction of a tyrosine kinase
into a yeast two-hybrid system has been reported several times in the past.
Dombrosky-Ferlan & Corey (1997) used a yeast two-hybrid system to show that
the association between the Src family kinase LYN and the regulatory subunit
of the phosphatidylinositol 3-kinase PIK3R1 is mediated by the E3 ubiqui-
tin ligase CBL and that the interaction between PIK3R1 and CBL depends
on the presence of a kinase-active LYN kinase. Rocchi et al. (1998) used a
plasmid expressing both, a human insulin receptor β(INSR) fragment and a
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LexA fusion protein, to show that PIK3R1 and PTPN11 interact with GAB1
in a phosphorylation-dependent manner. Delahaye et al. (2000) used the same
system to screen a human placenta cDNA library and successfully identified
FRS2 as a phosphotyrosine-dependent interaction partner of PTPN11. Yamada
et al. (2001) report a GAL4-based yeast two-hybrid system employing a third
plasmid expressing a rat Ntrk2 gene fused to a glutathione-S-transferase gene
to screen a commercial human brain cDNA library. Additionally, they found
phosphorylation-dependent interactions of PTPN11 with GRB2 and SIRPA.
There is a number of other yeast two-hybrid studies that, with or without intent,
used protein tyrosine kinases to detect phosphotyrosine-dependent protein inter-
actions (Keegan & Cooper 1996; Osborne et al. 1995; Marti et al. 1998; Warner
et al. 2000; Cao et al. 2002; Sayós et al. 2004; Ingley et al. 2006; Sylvester et al.
2010). Nevertheless, all of these are centered on one or a few genes. In this
study, we present a systematic yeast two-hybrid screen for phosphotyrosine-
dependent protein-protein interactions.
4.1.6.8 Yeast two-hybrid provides high-quality, binary protein-pro-
tein interactions
In an attempt to create a systematic and comprehensive set of phosphotyrosine
protein-protein interactions, we used a yeast two-hybrid system for genome-
scale screening. Yeast two-hybrid has several advantages over other methods
for protein-protein interaction detection.
It provides binary, physical interaction data. This means that for every inter-
action, there are only two interacting proteins and that they come into close
proximity to interact directly with each other. It uses full-length proteins and,
last but not least, has an extremely low false positive rate. A low false positive
rate is especially important for screening applications, because of the compar-
atively small fraction of positives. The false discovery rate of an interaction
detection experiment is given by the formula
FDR = FP/(TP + FP ),
with FP and TP defined as the number of false and true positives, respectively.
The two can be calculated by multiplying the respective rate, the number of
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tests and the prior propabilities. Thus,
FP = n ∗ FPR ∗ (1− PRprior),
with n, the number of tests, FPR, the false positive rate and PRprior, the
expected positve rate. Similarly,
TP = n ∗ (1− FNR) ∗ PRprior,
with FNR, the false negative rate. In unbiased proteome-wide screens, PRprior
is extremely low. Therefore, the false discovery rate may become substantial
even for relatively low false positive rates. Braun et al. (2009) benchmarked
five binary interaction detection methods and found that the false positive
rate of yeast two-hybrid is substantially lower than that of all other methods.
Venkatesan et al. (2009) estimated that they found about eight false positives
in every 1,000,000 interactions assayed.
4.1.6.9 Systematic yeast two-hybrid data complements phosphoty-
rosine-dependent protein interaction knowledge
Methods for the identification of protein-protein interactions are generally
limited in sensitivity and are orthogonal (Braun et al. 2009; Venkatesan et al.
2009). This means that each methods identifies a subset of the interaction in
the assayed interaction space only and that the subset of interactions that can
be found with each method appears to be a different and independent draw
from a pool of true interactions. Consequently, the best approximation of a
complete interactome map is obtained by combining the interactions obtained
by different detection methods. To our knowledge, there is a multitude of
studies using tyrosine kinases in low throughput yeast two-hybrid systems
(Keegan & Cooper 1996; Dombrosky-Ferlan & Corey 1997; Osborne et al. 1995;
Rocchi et al. 1998; Marti et al. 1998; Delahaye et al. 2000; Warner et al. 2000;
Yamada et al. 2001; Cao et al. 2002; Sayós et al. 2004; Ingley et al. 2006;
Sylvester et al. 2010) or E. coli -based two-hybrid systems on the one hand
(Shaywitz et al. 2000), and a number of high throughput studies investigating
phosphotyrosine-dependent protein-protein interaction with mass spectrometry-
based (Schulze et al. 2005; Blagoev et al. 2003; Oyama et al. 2009; Schulze
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& Mann 2004) or other methods (Yaoi et al. 2006; Miller et al. 2008; Jones
et al. 2006; Li et al. 2008) on the other hand, but no high throughput yeast
two-hybrid study. This is astonishing given the inherent advantages of this
method, like the full-length protein context, the binary interaction results, the
clear kinase-interaction relationships and the virtually non-existing tyrosine
phosphorylation background. The selection of yeast two-hybrid as the main
method for this study is therefore not only prudent, but it also fills a void in
the current phosphotyrosine-dependent protein-protein interaction knowledge.
4.2 State-of-the-art yeast two-hybrid screens are
the technical basis for a high-quality phos-
photyrosine-dependent interaction data set
of considerable size
4.2.1 Comprehensive sets of bait and kinase genes and
a genome-scale prey matrix facilitate unbiased and
complete results
In an attempt to provide a comprehensive and unbiased network of phos-
photyrosine-dependent protein-protein interactions a set of genes containing
phosphotyrosine-recognizing domains was co-transformed with a representative
set on non-receptor tyrosine kinases and screened against a genome-scale prey
matrix.
For twenty-two, so about fifteen percent, of the target genes, no clone was
obtained.
The list of genes and the number of clones obtained and screened is shown in
Table 4. There are 149 target genes, 110 of which have at least one SH2 domain
and 46 of which carry at least one PTB domain. Seven genes have both.
The bait-kinase combinations were arrayed in pools that fit into microplates.
This allowed relatively easy preparation and propagation of pools for autoacti-
vation testing, screening and retesting. For the autoactivation test, the bait-
kinase pools were mated with an empty prey strain and controlled for growth.
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For screening, the pools were grown directly in deepwell plates, without any re-
arraying, leaving autoactive positions non-inoculated. By virtue of this practice,
the yeast growth periods were kept as short as possible, reducing the incidence
of late autoactivation, thereby raising the quality of the experimental results.
4.2.1.1 Autoactivation test and retesting guarantee high quality in-
teraction data
In our yeast two-hybrid screens, all bait strains were tested for the ability
to induce prey-independent growth on -HAULT medium. Such bait strains
were rigorously excluded from further experiments. Furthermore, every positive
interaction was reproduced in an independent experiment with fresh yeast. This
practice guarantees high quality of the resulting protein-protein interaction
data (Vinayagam et al. 2011)
4.2.1.2 Repeating the screening experiments with independently
produced yeast strains reduces the number of undetected
protein interactions
4.2.1.2.1 Repeat screening raises the chance of detecting weak in-
teractions
Given the yeast two-hybrid systems inherent tendency for showing false-
negative interactions in an apparently transformation-dependent manner, re-
peating the screens with several independently transformed bait strains raises
the coverage of the assayed interaction space drastically (Venkatesan et al.
2009; Worseck et al. 2012). At the same time, it allows filtering of possible
interacting prey constructs before the retest by the number of times a prey
construct is found in repeated experiments. This practice reveals substantially
more interactions with the same effort (Venkatesan et al. 2009; Worseck et al.
2012).
4.2.1.2.2 Repeat screening reduces the number of clones excluded
due to occasional autoactivity
The number of genes with autoactive clones (i.e. clones that needed to be
removed because they produce a signal in the absence of a prey protein) is only
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five, which is about 3% of all target genes. Considering that about 20% of all
clones are expected to be autoactive in an unbiased setup, this number is very
low (Stelzl et al. 2005; Goehler et al. 2004; Nakayama et al. 2002; Walhout &
Vidal 2001). Apparently some clones are always autoactive, some clones are
never autoactive and some clones show autoactive behavior depending on the
yeast transformation.
For clones whose autoactivity depends on the transformation the four replicate
screens and the many different transformations with the different kinases provide
a sufficiently large number of transformations to guarantee that they can be
screened. This reduced the rate of autoactives by a factor of about two, leaving
twenty-five autoactive bait genes.
4.2.1.3 Our two-step screening protocol boosts coverage substan-
tially
4.2.1.3.1 Testing extra clones for autoactive genes raises the number
of genes included in the screening experiments
For clones that appear to be autoactive in every experiment, additional
clones for the same gene were selected and tested in the second part of our two-
step screening approach. This led to an additional reduction by a factor of five,
leaving only five genes without non-autoactive clones.
4.2.1.3.2 Testing extra clones for initially unsuccessful genes raised
the fraction of successful genes
We also included genes in the second screen that were not autoactive in
the first screen, but failed to produce interactions. Therefore, the remaining
genes have a high coverage in terms of clones that produced interactions when
compared to other proteome-scale interaction studies. There are only 42% of
the screened bait genes for which no clone produced any interactions. In the
systematic matrix-based yeast two-hybrid screens reported by Stelzl et al. (2005)
and Rual et al. (2005), this fraction is 76% and 87%, respectively. The reason
for this is partly that the number of clones without interactions is low to begin
with and partly the two-step screening process (i.e. the inclusion of additional
clones for unsuccessful genes in a second screening round). Initially, there were
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68 genes of the 121 screened ones without interactions, which is about 56%. By
screening additional clones for 42 of these genes, this number was reduced by
17 genes (14%).
4.2.1.3.3 Benefits of the two-step screening protocol far outweigh
potential biases
The two-step screening approach raises the fraction of genes with productive
genes and reduces the percentage of genes unamenable for yeast two-hybrid
screening because of autoactivity. Nevertheless, there are some drawbacks to this
approach. The different treatment of genes can be a source of bias potentially
making further analysis difficult:
1. The number of prey genes in the matrix was higher in the second round,
because those prey genes were not available for the first round.
2. The number of kinases was lower, because it had become apparent that
most of the kinases resulted none or very few interactions and the workload
reduction was substantial.
3. Because there was no third round, for all genes that did not have bait
clones producing interactions in the first round, all available clones were
used in the second round, instead of just one, like in the first round.
The first point can lead to a greater number of interactions for genes screened
in the second round and means that certain prey genes can only interact with
bait genes screened in the second round. This could be cured by disregarding all
interactions found with any of the additional prey genes. Since protein-protein
interaction detection assays are plagued by large false negative rates (Braun
et al. 2009), and, thus, can by no means claim absolute completeness anyway,
the loss of interaction information is much graver than the possible bias for
most analyses. The bias introduced by the second point is probably extremely
weak, from what can be estimated from the results of the first assay. It can
theoretically be cured by removing all interactions from the first round that
did not retest positive with any kinase used for the second round. Since bait
genes and kinases were pooled in the primary screen, it is conceivable that some
interactions that retested positive with kinases used in the both rounds was
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initially detected only because of the presence of one of the other kinases, but
this is extremely unlikely. The third point cannot be cured, except by regarding
the two rounds as independent screens, and can be thought of, at least partly,
as an extension of the biases present in the availability of ORF clones. The
bias that arises from screening a single additional clone for genes that had an
autoactive or non-productive clone in the first round is hard to gauge. There
is no obvious connection between non-productive and productive clones for a
gene. In other words, the prior expectation in terms of, for example, degree does
not change based on the existence of non-productive clones for the same genes.
Similarly, there is no obvious rule for non-autoactive clones for genes that have
autoactive clones, although, in this case, the probability that the next clone
is also autoactive is higher, as autoactivity often seems to be associated with
certain domains or amino acid sequences. If there is no connection between a
genes degree and its clones propensity to be autoactive or non-productive, the
practice of screening additional clones until a non-autoactive and productive
one has been found does not create any bias. Even if there is a connection and
a small biases arises from this method, the completeness gained outweighs the
bias by far. A somewhat greater bias arises from situations where there is no
successful clone in the first round but several successful clones in the second
round. This aspect can be cured by randomly choosing one productive clone for
each such gene and discarding all interactions not found with this clone. Again,
the bias is weak, and the additional interaction knowledge outweighs it by far.
To sum up, there may be some biases introduced by the two-step screening
process, but they are probably very small and the benefits are substantial. For
applications with very strict and specific requirements in terms of freedom
from any bias, many can be cured at the cost of losing interactions. For most
applications, this should not be necessary, because methods used to analyze
protein-protein interaction data should be robust against missing interactions.
Many analyses can be controlled internally. For example, the independent
interaction set can be used for comparisons, because any assay-dependent bias
should be similar to the phosphorylation-dependent interaction set.
In total, the two-step screening strategy seems like a good compromise between
comprehensiveness and freedom from bias, making about half of the genes in
the target set successful bait genes.
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4.2.2 The discovered phosphotyrosine-dependent protein-
protein interactions achieve high coverage in terms
of width and depth
4.2.2.1 The number of discovered phosphotyrosine-dependent pro-
tein-protein interactions is considerable
Screen size can be measured in terms of the size of the interaction space and
in terms of depth. The interaction space is given by the number interactions
that could have been detected. In a binary screen, using the yeast two-hybrid
system, this is the product of the number of bait genes and the number of prey
genes. The screens depth is the number of interactions per bait gene or per
interaction in the search space. Both can be described best in contrast to other
matrix-based proteome-scale studies. This study has a much smaller number
of bait genes than prey genes, which makes it different from the Stelzl et al.
(2005) and the Rual et al. (2005) studies, which had roughly similar numbers
of bait and prey genes. Consequently, the number of bait genes is much smaller
than in the other studies while the number of prey genes is somewhat higher.
The number of interactions found in this study is about half the number found
in each of the other two. Because the number of bait genes is so much smaller
than in the other studies, the number of interactions per bait gene is about three-
fold higher than in each of the other studies. This study has 628 interactions
found with 70 bait genes, which comes out to 9 interactions per bait gene. The
Stelzl and Rual data sets have 3269 interactions for 1064 bait genes and 2754
interactions for 926 bait genes, coming out to 3.1 and 3 interactions per bait
gene, respectively. Due to the different number of prey genes, the numbers are
more similar for the number of interactions per possible interaction. Dividing
the 9 interactions per bait by 17007 (the number of prey genes), puts the
positive rate at 0.053%, which is very similar to the rate of 0.055% obtained
by dividing the 3.1 interactions per bait gene for the Stelzl study by 5632, the
number of prey genes in the Stelzl study. The ratio for the Rual study is 3
divided by 7195 prey genes, which comes out to 0.041%, so slightly lower.
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4.2.2.2 Coverage in terms of false-negative rate is typical for protein-
protein interaction screens
The coverage of the screen has been assesses by comparing the interactions found
among bait genes to the interactions reported in literature for the same interac-
tion space. This analysis puts the estimated false-negative rate at almost 90%,
as is typical for protein interaction screens (Braun et al. 2009).
4.2.2.3 Comparison to phosphotyrosine interaction literature indi-
cates that the size of the phosphotyrosine-dependent inter-
actome may have been underestimated
The combined knowledge covers about 30% of all theoretically detectable
interactions in the bait-bait interaction space. The bait-bait interactions found
in this study are reflected substantially better in the literature than the other
interactions. This reflects a general problem with literature data sets. Literature
data sets are sociologically biased (Venkatesan et al. 2009). Additionally, protein-
protein interaction literature databases may contain incorrect entries and
should be attributed no higher confidence than experimental data. Of the 247
interactions curated for this study, only about two thirds (167) proved correct.
This value is similar to previous analyses, like (Venkatesan et al. 2009) and
(Cusick et al. 2009), who report fractions of 62% and 65%, respectively. Likewise,
in contrast to prevalent assumption (Stumpf et al. 2008; Reguly et al. 2006;
von Mering et al. 2002; Batada et al. 2006), high throughput studies have been
shown to produce more reliable results than low throughput studies (Collins
et al. 2007; Venkatesan et al. 2009; Cusick et al. 2009). Nevertheless, if we ignore
these problems and assume that the success rate in our study is constant, we can
estimate the size of the phosphotyrosine-dependent protein-protein interactome.
To extrapolate the false-negative rate estimate from the bait-bait interaction
space to the genome-scale interaction space, we can first calculate the effective
false-negative rate from number of detected interactions (81) and the estimated
total number of interactions (581) in the bait-bait space. Because the interactions
in the bait-bait space have been assayed in bait-prey and prey-bait direction,
the resulting false-negative rate of 89.8% is the square of the false-negative rate
for the bait-non-bait interactions. The estimated size of the phosphotyrosine-
191
4. DISCUSSION
dependent protein-protein interactome can be calculated by dividing the number
of phosphotyrosine-dependent interactions by one minus the false-negative rate.
Following this reasoning, the human phosphotyrosine-dependent protein-protein
interactome contains about 5,500 interactions. On the one hand, this value
seems relatively high compared to the complete interactome, which is estimated
to contain about 74,000-200,000 interactions (Venkatesan et al. 2009). This
means that the phosphotyrosine-dependent interactions make up about 2.5-7%
of the human interactome. On the other hand, it lends credence to the prognosis
that ”[t]he current catalog of characterized tyrosine phosphorylated protein,
however, appears to represent a significant underestimate of the prevalence of
tyrosine phosphorylation.” (Hunter 2009).
4.2.2.4 The phylogenetic tree of SH2 domains is well-covered by the
phosphotyrosine-dependent proteins interactions discovered
Apparently the phoshotyrosine-dependent and independent interaction data
sets are not strongly related in terms of numbers of interactions per gene. The
high coverage of the phylogeny given the fact that only half of the bait genes
produced interactions is owed mainly to the high density of the network. A
minor contributing factor is that the PTB domain-containing genes are slightly
over-represented in the set of genes for which no clones have been screened.
When projecting the interactions onto the phylogenetic tree of SH2 domains
(Figure 10), the interactions appear spread more of less evenly. This is true for
phoshotyrosine-dependent and independent interactions.
The distribution of interactions among the phylogeny agrees very well with
prior expectations even in terms of numbers of interactions. The genes PIK3R3,
CRK, STAT3 and GRB2 are among the genes with the most interactions in
this study and among the genes with the highest number of phosphotyrosine-
dependent interactions in the literature.
There are two clades without interactions, the one of VAV1, VAV2 and VAV3 and
the one of SHC1, SHC2, SHC3 and SHC4. The first one might be explained by
the relatively large size of the proteins, all of which contain more than 800 amino
acid residues. Proteins of this size are known to work badly in protein-protein
detection assays. In fact, Nakayama et al. (2002) even developed a yeast two-
hybrid approach designed specifically to deal with this problem.
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4.2.2.5 Experimental validation in mammalian cell culture affirms
high quality
The quality of the protein-protein interactions found in this study has been
assessed experimentally by transferring about 10% of the interactions to hu-
man cell culture and testing them by co-immunoprecipitation. The obtained
validation rates are indistinguishable from validation rates obtained for positive
reference sets (Braun et al. 2009), supporting a high confidence in our results.
4.3 The phosphotyrosine-dependent interaction
network grants insight on system and gene
level
The graphical representation of the phosphotyrosine-dependent network paints
it as a typical protein-protein interaction network, but one that is very dense
and focused on the set of target genes. This impression is generally supported
by the topological parameters.
4.3.1 Statistical network analysis shows that the tyrosine-
dependent interaction network is scale-free, unusu-
ally dense and build around a central core
4.3.1.1 Selection of appropriate data sets for comparison is impor-
tant for a meaningful statistical network analysis of real-
world networks
The selection of an appropriate frame of reference is of paramount important for
any statistical evaluation. For protein-protein networks, the most meaningful
conclusions are derived from comparison to another network that is as similar
to the network examined, except in the aspect under scrutiny. As a consequence,
the best choice may vary and an optimal choice may be unavailable.
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4.3.1.1.1 The interaction data sets provided by Stelzl et al. (2005)
and Rual et al. (2005) are the largest sets of binary inter-
actions among human proteins
The meaning of the statistical network parameters is understood best in
comparison to suitable reference data sets. The data sets that are used most
often in this context are two matrix-based genome-scale yeast two-hybrid data
sets presented by Stelzl et al. (2005) and Rual et al. (2005). These data sets
are the largest binary human protein-protein interaction data sets available.
4.3.1.1.2 The interaction data sets provided by Lim et al. (2006) and
Wong et al. (2007) are smaller but have an asymmetrical
setup
Both of the usual reference sets used for matrix-type yeast two-hybrid screens,
the Stelzl and Rual datasets, are symmetrical, i.e. they generally used each
tested ORF as bait and as prey. In contrast, this study focused on a set of target
genes, carrying a phosphotyrosine-recognizing domain, and screened this set of
genes against a genome-scale prey matrix. It is conceivable that this fact alone
has an impact on the network structure. For example, the bait genes (the target
genes) might have a higher average number of interactions, simply because they
were tested with many more potential partners than the other proteins. This
is exactly what we observe. The average number of neighbors is about 9.9 for
the bait genes and only about 1.6 for the other genes. Since pairs of non-target
genes are not tested for interaction, the clustering coefficient is expected to
be lower than for non-targeted approaches. Similarly, a targeted approach is
expected to produce data sets with a higher degree of centralization.
Therefore we also compare our results to two data sets resulting from targeted
matrix-based yeast two-hybrid approaches. The first one, presented by Lim
et al. (2006), focuses on genes that either have Ataxia-causing mutations or are
known to interact with such genes. It was generated using a setup similar to the
study of Rual et al. (2005) with 54 bait genes. The data set was validated by
GST-pulldown. Interestingly, there are only twenty-one bait-bait interactions in
the data set, although thirty-one of the target genes were chosen because they
are known interact with the other twenty-three. The other one (Wong et al.
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2007) focuses on genes related to mitotic spindle formation in S. cerevisiae. The
screening setup is very similar to this study. It has 102 bait-bait interactions.
These two targeted studies may be more suitable reference sets than the two
non-targeted ones.
4.3.1.1.3 Domain dependence places phosphotyrosine recognition
between symmetrical and asymmetrical setup logic
On the other hand, if we consider the network of phosphotyrosine-dependent
interactions alone and assume that the number of phosphotyrosine-dependent
interactions that are not phosphotyrosine-recognizing domain-mediated is neg-
ligible, we can argue that the only bias introduced by the targeted approach is
that bait-bait interactions are assayed twice as often as other interactions. In
this case, the Stelzl et al. (2005) and Rual et al. (2005) data sets are appropriate
references and the differences we observe are biologically relevant.
4.3.1.1.4 Intermediate setup symmetry suggests using all four ref-
erence data sets for statistical network analysis
To sum up, we use an asymmetrical screening setup, because we focus on
phosphotyrosine-recognizing domain-containing genes as bait. This means that
the largest reference data sets might be unsuitable. On the other hand, the
best asymmetrical reference data sets are smaller and both of them have a
certain biological focus that might influence our analyses. Additionally, we also
consider the bait-bait interaction space alone, which is symmetrical. Therefore,
there is no single best reference set and we compare our data to four sets total,
two symmetrical and two asymmetrical ones.
4.3.1.2 Statistical network parameters are consistent with an un-
usually dense protein-protein interaction networks
4.3.1.2.1 High clustering coefficient and centralization suggest high
density or modularity
The network of phosphotyrosine-dependent protein-protein interactions dis-
covered in this study has a clustering coefficient of 0.027 and a centralization of
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0.22. These numbers change only marginally when the independent interactions
are also considered.
The clustering coefficient is higher than that of the Wong and even the Stelzl
data set, which is unexpected because of the targeted setup. The extremely high
clustering of the Lim data set is probably a direct consequence of the selection
of target genes that are related by protein interaction. Like the phosphotyrosine-
dependent network, the Wong data set is very coherent and contains many more
bait-bait interactions than expected by chance. This means that it provides
a good frame of reference for biologically coherent protein interaction data
sets generated by targeted yeast two-hybrid approaches, which show higher
than random clustering. The centralization of the phosphotyrosine-dependent
network is much higher than for the Rual and Stelzl and also the Wong data set.
It is comparable to that of the Lim data set. A higher degree of centralization
is expected for targeted approaches, but is expected to be accompanied by low
clustering. The fact that both, the clustering coefficient and the centralization,
are relatively high, suggests that the network displays tendencies of a dense
modular or hierarchical structure.
4.3.1.2.2 The unexpectedly high number of interactions among SH2
genes indicates biological coherence
The bait genes clearly favor other bait genes as interaction partners which
means that the domain-containing genes are themselves highly tyrosine-phos-
phorylated. They are not necessarily phosphorylated to a higher degree than
other proteins, but, if they are not, their tyrosine-phosphorylations are at least
more meaningful for protein-protein interactions. This indicates that phosphoty-
rosine-dependent protein-protein interactions are coherent in terms of biological
function and probably also evolutionary origin and development.
4.3.1.2.3 The arrangement of the phophotyrosine-dependent inter-
actions fits a central computational function
Despite its high density and coherence the phosphotyrosine-dependent in-
teraction network is open to influences from different fields and pathways.
Since the main topic associated with tyrosine phosphorylation is regulation of
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growth and development it needs to have connections to proteins associated
with related functions. The network of phosphotyrosine-dependent interactions
has to be understood as a computational control module integrating all the
relevant signals into a compound cellular decision. A solution using several
distinct modules or other functional modules using tyrosine phosphorylation for
the regulation of different biological processes would also have been imaginable.
4.3.1.2.4 The phosphotyrosine-dependent protein interaction net-
work is scale-free and has an unusual exponent
The phosphotyrosine-dependent interaction network is scale-free (Albert
& Barabási 2002), as are virtually all protein-protein interaction networks
(Barabási & Oltvai 2004). Interestingly, the ratio of high-degree to low-degree
nodes is uncharacteristically high, as is the resulting exponent of −1.41 in the
log-log-fitted degree distribution. This exponent usually lies between −2 and
−3 for protein-protein interaction networks (Yook et al. 2004). The biological
meaning of this finding is not immediately clear. It is possible that is purely
coincidental or a consequence of the depth of the screen or the fact that the bait
genes were not chosen randomly, but, at least implicitly, by biological function.
4.3.1.2.5 The unusual scale-free exponent may be related to addi-
tional controllability due to phosphorylation
It is also possible that the reason lies in the possibility of switching phos-
phorylation-dependent interactions on or off. This means that, at each time, or
for each state, etc. only a subset of the interactions in the network are active,
reducing the networks factual density. In this context, a network-theoretical
study presented by Liu et al. (2011b) might be instructive. The authors argue
that network controllability is highly related to the exponent, and that mediocre,
practically useful controllability can only be achieved between exponents of
−2 and −3, which is precisely what is usually observed for protein-protein
interaction networks. In other words, the phosphorylation aspect might add an
additional layer of regulation that needs to be resolved before the network can
be used for classical, i.e. static, network analysis.
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4.3.1.3 The phosphotyrosine-dependent interaction network has a
central core
4.3.1.3.1 Most core genes discovered are known to be central to
phosphotyrosine signaling
Although the fact that the network is organized around a core of proteins
that keep the network connected is evident, the eight nodes forming the core in
the network may not be the most important ones in the true cellular context,
rather arising only from idiosyncrasies of the yeast two-hybrid screen. On the
other hand, many of the core nodes are excellent candidates for this role. GRB2,
CRK, CBL and SH2D2A are central adapters binding directly or indirectly to
a magnitude of growth factor receptors, linking them to intracellular signaling
networks (Dikic et al. 2003; Acuto et al. 2008; Olayioye et al. 2000; Oda et al.
2005; Normanno et al. 2006). PIK3R3 is an important player in the extracellular
signal-PTEN-AKT1-MTOR axis (LoPiccolo et al. 2008) and SOCS4 and STAT3
are important in JAK/STAT signaling (Naka et al. 1999; Croker et al. 2008;
Kile et al. 2001). Only APPL1 is not immediately recognized as an important
phosphotyrosine-related signaling molecule. On closer inspection, it may still fit
this role very well. It binds to ADIPOQ receptors (Mao et al. 2006), as well as
molecules in both the PTEN-PI3K-AKT1-MTOR (Mitsuuchi et al. 1999) and
the Rab/Gab (Mao et al. 2006; Lee et al. 2011) axes of growth factor action,
regulates phospholipase C (Deepa et al. 2011) and EGFR (Lee et al. 2011) and
has even been found in the nucleus (Miaczynska et al. 2004).
4.3.1.3.2 Network analysis identifies PTK2, OLIG1 and LNX1 as
important phosphotyrosine signaling genes without SH2
or PTK domain
Another interesting question is whether there are any genes belonging to
the set of highly related genes encompassing the bait genes. In other words, if
the target genes had been chosen for network coherence, are there any genes
in the network that should have been target genes and are they connected by
biological function? These genes should be the most prominent genes in the
network that are not bait genes. The non-bait gene of the highest degree is
PTK2 with six interactions, followed by OLIG1 with five and LNX1 with four
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interactions. PTK2 is highly related to tyrosine phosphorylation and cellular
proliferation and migration (Hanks et al. 2003). It is a tyrosine kinase itself and
extremely important in integrin-directed growth. OLIG1 is a transcription factor
whose expression is correlated with cell survival in lung cancer (Brena et al.
2007). LNX1 is an E3 ubiquitin ligase specialized in mediating the proteasomal
degradation primarily of PTB domain-containing proteins like NUMB (Nie
et al. 2002). Its down-regulation leads to cell cycle arrest (Zheng et al. 2011).
4.3.2 The phosphotyrosine-dependent protein-protein in-
teractions confirm and improve upon established
phosphotyrosine signaling knowledge
4.3.2.1 Tyrosine phosphorylation-associated functions are strongly
connected
The network of the phosphotyrosine-dependent interaction is very dense (i.e.
the proteins are very highly connected) and consists of a single module. This
suggests a strong connection between tyrosine phosphorylation and protein
phosphotyrosine binding as a biochemical mechanism and the associated biolog-
ical functions, like regulation of growth and development or immune response.
Furthermore, all of these functions are linked by phosphotyrosine-dependent
protein-protein interactions. This contrasts a notion of several independent,
isolated modules employing tyrosine phosphorylation as a mechanism, one of
several phosphotyrosine modules linked by other mechanisms or even one of
many structurally related proteins functioning in different biological contexts,
like zinc finger proteins (Laity et al. 2001). Therefore, biological functions
regulated by tyrosine phosphorylation are probably overlapping. Since growth
and development are often hard to distinguish clearly, this is comprehensible.
The same is true for immune responses, many of which comprise a develop-
mental process, termed maturation, followed by a strong replication of the
adult immune cells adequate for the respective stimulus (Paul 2008). Thus, the
findings presented here link to the question: How do cells integrate signals?
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4.3.2.2 The phosphotyrosine-dependent protein interactions fulfill
cellular signal integration functions
The question ”How do cells integrate signals?” was first raised more than twenty
years ago, when it was realized that different growth factor signaling path-
ways utilize the same signals and signaling molecules to affect different cellular
responses (reviewed in (Chao 1992)), and still has not been answered to full
satisfaction. (Schlessinger & Ullrich 1992) propose that each cell expresses a
tissue-specific set of SH2 domain-containing proteins that result in different
tissue-specific responses to the same growth factor. (Tan & Kim 1999) discuss
four different hypotheses for tissue-specificity in RAS-MAP signaling. (Bhalla &
Iyengar 1999) argue that signaling pathways overlap to form signaling networks
that have properties that the single components do not have. In most of these
models, there is a need for one or more mechanisms for separating the network
components, either temporally or spatially.
The key to understanding signaling integration lies in protein phosphoryla-
tion as an additional layer of regulation. Signaling proteins can be present in
the inactive, unphosphosphorylated form and become phosphorylated at the
appropriate time and location only. As a consequence, the interaction maps
are more dense than expected for biological networks based on controllability
considerations (Liu et al. 2011b) and genes regulated by phosphorylation, like
cancer genes, have a higher average degree and are more central than average
(Jonsson & Bates 2006).
The additional layer of network control is governed by kinases and phosphatases,
that effect and reverse phosphorylation, respectively. Both, kinases and phos-
phatases, are subject to regulation themselves. As demonstrated by the kinase
plate assay experiments conducted in this study, there is a specificity regard-
ing kinases and interactions that suggests the presence of several potentially
phosphorylated tyrosine residues on most tyrosine-phosphorylated proteins,
allowing for signal adjustment. This agrees well with findings regarding well-
studied examples, like growth factor receptors or IRS1 and IRS2, that have been
shown to have many potential phosphotyrosine residues and often have many-
many relationships between binding partners and potential phosphotyrosine
residues (Schulze et al. 2005; Hanke & Mann 2009). Integration of signals in
vivo could thus be mediated by several kinases acting on a single protein with
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several potentially phosphorylated tyrosine residues. The combined efficacy of
several kinases might be a result of the single kinases binding affinities and
phosphorylation efficacies on a single residue basis. Globally, kinases could act
partially redundant and partially complementary to achieve complex regulatory
logic. Such a configuration can achieve virtually any kind of signal integration
logic, especially in combination with a similarly complex system of partially
overlapping binding specificity in the reader components, i.e. the SH2 proteins.
For instance, CBL is phosphorylated by the kinase domains of FYN, SYK
and Abl in in-vitro assays, and each of these displays preferences for different
tyrosine residues (Grossmann et al. 2004). Further, CBL can bind and ubiqui-
tinate EGFR either directly or by virtue of adapter molecules. Interestingly,
the ubiqitination has different functional consequences depending on the mode
of binding, which has been demonstrated by means of EGFR carrying a point
mutation on tyrosine 1045, the CBL binding site, and double-SH3-mutant GRB2
(Grøvdal et al. 2004). Similar arguments can be made for SH2 binding. For
example, only three point mutations are sufficient to enhance the affinity of
the FYN SH2 domain for the phosphorylated EGFR tyrosine residue 978 by
a factor of 380, suggesting an evolutionary optimization for dynamics rather
than binding strength (Kaneko et al. 2012a). In surface plasmon resonance-vali-
dated fluorescence popularization assays with ErbB peptides and SH2 domains,
(Hause et al. 2012) found many weak high confidence interactions, as well as
interactions with tyrosine residues previously not described as phosphorylated.
In short, the structure of the phosphotyrosine-dependent protein-protein inter-
action network strongly suggests that the process of cellular decision making
regarding growth and development is reflected in the interplay of phosphotyro-
sine-dependent protein-protein interactions with tyrosine phosphorylation and
dephoshorylation.
4.3.2.3 The phosphotyrosine-dependent protein interactions reflect
and connect many signaling pathways
In this study, we present a set of 292 tyrosine phosphorylation-dependent protein-
protein interactions. Most of these are novel and many involve proteins that have
not been studied intensely. Therefore, the data set is well-suited for hypothesis
generation. We demonstrate how the findings provided here apply to the
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Figure 24: Established pathways provide biological context for phos-
photyrosine-dependent interactions. Overview of selected interactions
from the KEGG pathways related to phosphotyrosine signaling and phos-
photyrosine-dependent protein-protein interactions found in this study. KEGG
entities were mapped to Entrez GeneIDs using the KEGG annotations and
reaggregated for greatest clarity. Protein components are shown as elliptical
nodes, pathways are represented as squares. Edge directions were adopted
from KEGG pathways where applicable. Edge were colored according to
source. Edges originating from Cancer/Growth factor signaling KEGG path-
ways (hsa04012, hsa04910, hsa05200, hsa05210, hsa05211, hsa05212, hsa05213,
hsa05214, hsa05218, hsa05219, hsa05220, hsa05222 and hsa05223) are purple,
edges originating from MAPK, Toll-like receptor or Jak-STAT signaling KEGG
pathways (hsa04010, hsa04620, hsa04630) are cyan, edges from immune-related
KEGG pathways (hsa04660, hsa04662, hsa04664, hsa04666) are grey, edges
occurring in more than one of these groups are black and edges that are not
in these KEGG pathways are green. Thick edges represent phosphotyrosine-
dependent protein-protein interaction found in this study. The components
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pathways in the KEGG database, because this database is generally considered a
rather conservative knowledgebase,making it a great point of reference. Figure 24
shows an aggregation of KEGG pathways related to functions associated with
tyrosine phosphorylation, like growth factor receptor and immune signaling
or different kinds of cancer. In addition, selected phosphorylation-dependent
protein-protein interaction detected in this study are shown. Some of the
added interactions are confirmatory, others suggest the existence of previously
unappreciated regulatory loops or cross-pathway signal integration points.
4.3.2.3.1 The high number of KEGG pathway connections in the
phosphotyrosine-dependent interaction network confirms
its relevance
There are seven links in the network of phosphotyrosine protein-protein
interactions that are reflected as direct links in the KEGG pathways database.
These are the interactions between CRK and PTK2 (Akagi et al. 2002), CRK
and PI3K (Akagi et al. 2002), IRS1 and PI3K (Felder et al. 1993; Pons et al.
1995; Mothe et al. 1997), CBL and CRK (Fukazawa et al. 1996), CBL and
CRKL (Andoniou et al. 1996), CBL and PI3K (Fukazawa et al. 1996; Hunter
et al. 1999), as well as between CRK and ABL (Ren et al. 1994). Most of these,
specifically CRK-PI3K, CBL-CRK, CBL-CRKL, CBL-PI3K and CRK-ABL,
are related to chronic myeloid leukemia. The interaction between IRS1 and
PI3K is central to the insulin signaling pathway, as is the interaction between
CBL and CRKL. The interaction between CRK and PTK2 is involved in the
bacterial invasion of epithelial cells pathway.
Since the KEGG pathway interactions reflect information flow through biological
systems, it is to be expected that some of the KEGG interactions, especially for
pathways related to growth and development, immune functions and cancer, are
were arranged in a circular pattern maximizing the number of directed edges
pointing inwards and interactions of similar KEGG pathway source were tried
to place together. Where possible, protein components that are found predom-
inantly in the nucleus were placed within the inner, slightly darker part of
the figure. For greater clarity, some of the extracellular components and their
membrane-bound receptors were split and occur more than once.
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identical to phosphotyrosine-dependent protein interactions, as well as tyrosine
phosphorylation and dephosphorylation events. Therefore, some overlap between
the phosphotyrosine-dependent protein-protein interaction network and the
KEGG pathways is to be expected and confirms the relevance and accuracy of
the phosphotyrosine-dependent interaction network.
4.3.2.3.2 A direct link between PI3K and BTK provides additional
feed-back possibilities in the Fcε receptor pathway
The interaction between PI3K and BTK is included in the Fcε receptor
pathway (KEGG hsa04664) as an indirect interaction. PI3K function is thought
to promote BTK membrane localization by creating PIP3, which is then bound
by the BTK PH domain (Salim et al. 1996; Rameh et al. 1997). Membrane asso-
ciation has been shown to potentiate BTK activation (Li et al. 1997). The direct
phosphotyrosine-dependent interaction strengthens the link between PI3K and
BTK. Furthermore, it is possible that one of the two proteins works as a scaffold,
allowing the other one to interact with its interaction partners. For example,
BTK has been found to bind phosphatidylinositol-4-phosphate-5 kinases and
account for its membrane localization (Carpenter 2004). Phosphatidylinositol-
4-phosphate-5 kinases synthesize phosphatidylinositol-(4,5)-bisphosphate, the
substrate for PI3K. Therefore, BTK can stimulate the output of PI3K by raising
the local concentration of its substrate. Conversely, BTK is a substrate of SYK
(Baba et al. 2001) and ABL (Bäckesjö et al. 2002). PI3K is phosphorylated
by SYK in the Fcγand Fcεreceptor signaling pathways (KEGG hsa04664 &
hsa04666) and was found as a phosphotyrosine-dependent interactor of ABL2.
Thus, PI3K can also act as a scaffold for BTK phosphorylation.
4.3.2.3.3 Phosphotyrosine-dependent protein interactions connect
and modify signaling pathways
More interesting than the overlap between KEGG pathways and the phos-
photyrosine-dependent protein-protein interactions reported in this study in
terms of scientific advancement are interactions that improve upon the current
knowledge. Those interactions typically connect or ”short-circuit” established
pathways, i.e. that connect two or more pathways that result similar responses
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to different inputs or directly connect components of a single pathway not con-
nected in the canonical view, respectively. The latter are especially interesting
where they are phosphotyrosine-dependent, because they are likely to consti-
tute optional or delayed feed-forward or feed-back mechanisms. The former
are important, because they can provide valuable hints for augmenting and
integrating pathway knowledge.
4.3.2.3.3.1 Phosphotyrosine-dependent interactions between com-
ponents of the ErbB signaling pathway might explain the
ability to appropriately react to different growth factors
Different biological signals going through the epidermal growth factor re-
ceptor family result in different biological responses (Graus-Porta et al. 1997;
Hackel et al. 1999; Zwick et al. 1999). The canonical ErbB signaling path-
way (KEGG hsa04012) splits up almost immediately downstream of the ErbB
receptors. The different receptors, constituted by different combinations of
ErbB monomers, affect specific downstream proteins leading to specific cellular
responses. Our data suggest that the different branches of the ErbB signaling
pathway are connected. The PI3 kinase, which signals through AKT1, and
is downstream of the ErbB dimers binding neuregulins (NRG1-4), namely
ErbB2-ErbB3, ErbB2-ErbB4 and ErbB4-ErbB4, has been found to interact
in a phosphotyrosine-dependent manner with the tyrosine kinases SRC and
Abl. These kinases are downstream targets of the EGF, TNFα and AR binding
receptors, specifically ErbB1-ErbB1 and ErbB1-ErbB2. Similarly, ELK1, a tran-
scription factor regulated through the Ras-Raf-ERK axis, has been shown to
interact, in a phosphotyrosine-dependent manner, with CRK and PLCG2, both
of which are downstream targets of the EGF, TNFα and AR binding receptors
only. It is thus possible that they act antagonistically, sharpening the specificity
of the response to different growth factors, or cooperatively, differentiating
responses to BTC, HB-EGF and EREG, which can bind to almost all ErbB
dimers, from the others.
4.3.2.3.3.2 The adaptor GRB2 has membrane-integral, cytoplasmic
and nuclear interaction partners
A particularly interesting pair of links are the interactions of GRB2 with
RB1 and E2F. RB1 and E2F are nuclear regulators of cell cycle progression
(Dyson 1998). In healthy tissue, RB1 binds and inhibits E2F. Release of this
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inhibition is a major hallmark of cancer progression (Hanahan & Weinberg
2000). GRB2 is an adapter molecule that is usually thought of as membrane-
associated, immediately downstream of receptor tyrosine kinases. GRB2 has
been appreciated as a binding partner of nuclear proteins only recently (Hino
et al. 2011; Bisson et al. 2011), although (Verbeek et al. 1997) reported in 1997
already, that the relative amount of GRB2 in the nucleus is increased in breast
cancer tissue. RB1 binds E2F directly (Helin et al. 1993). Therefore, the fact that
GRB2 interacts with both, RB1 and E2F, suggests a more complex function
than e.g. simple scaffolding or sequestering of interaction partners. It also
emphasizes the importance of nuclear GRB2 and provides new leads for further
study. Many of the GRB2 interactors found in this study were also nuclear.
Because protein-protein interactions between proteins localized at different
subcellular localizations are often suspected to be technical or biological false-
positive, we validated several of these interactions by co-immunoprecipitation
from mammalian cells. We further asked, where the interactions take place
in the mammalian cell. We used protein complementation assays to establish
that GRB2 can interacts in different subcellular localizations, depending on its
interaction partners. Comparing the localization patterns of endogenous and
over-expressed proteins to interaction signals, it seems that GRB2 meets its
interaction partners in their respective localizations: the interaction between
GRB2 and RB1 takes place in the nucleus, the interaction with C10orf81 is
cytoplasmic and the interaction between GRB2 and TSPAN2 occurs at the
membrane. Hence, the dynamics of GRB2 interactions seem to be regulated
at several levels. Protein levels are regulated by modulation of expression and
degradation, effective protein concentration depends on localization and tyrosine
phosphorylation is constantly and potentially rapidly adjusted by a multitude
of kinases and phosphatases.
4.3.2.3.3.3 The JAK/STAT signaling pathways is highly integrated
indicating an early evolutionary origin
The JAK/STAT signaling pathway is another pathway for which phospho-
tyrosine binding is important. The pathway is triggered by cytokines, like
interferons or interleukins, binding to transmembrane cytokine receptors. This
activates Janus kinases (JAK1-3), which phosphorylate signal transducer and
activator of transcription (STAT) proteins, as well as other cytoplasmic proteins,
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like PI3K and PTPN11. The STAT proteins are transcription factors that dimer-
ize upon phosphorylation and translocate to the nucleus, where they bind to
DNA and regulate gene expression. The JAK/STAT pathway is down-regulated
by Suppressor of Cytokine Signaling (SOCS) proteins through a negative feed-
back mechanism. Typically, the SOCS proteins are not expressed in resting
cells. They are induced upon cytokine receptor binding. In fact, SOCS protein
induction is usually mediated, at least partially, by STAT proteins (Starr &
Hilton 1998). Once expressed, the SOCS proteins inhibit JAK/STAT signaling
by competing with Janus kinase substrates or by marking Janus kinases for
proteosomal degradation (Alexander & Hilton 2004). In this study, we found
STAT5A interacting with CBL and STAT3 interacting with PIK3R3 and CBL,
both of which are members of the KEGG JAK/STAT signaling pathway, but not
in the same branch as the STATs. This points to the existence of mechanisms
attuning the different branches. Interestingly, CBL overexpression has been
shown to cause ubiquitination and degradation of STAT5 but not STAT3 in
pUC-CAGGS-transfected NIH3T3 cells (Goh et al. 2002). Such a mechanism
might have evolved to integrate JAK/STAT signaling in a larger phosphotyro-
sine signaling context. Most of the components of the JAK/STAT signaling
pathway are members of other pathways as well. There is an especially intimate
connection between JAK/STAT and insulin signaling. This is exemplified most
strikingly by the cytokine Leptin, which acts through both, the JAK/STAT
and the insulin pathway (Carvalheira et al. 2003). Fittingly, there is a cross-talk
between JAK/STAT and IGF1 signaling that is modulated by SOCS proteins
(Himpe & Kooijman 2009). STAT proteins have been found in Dictyostelium
discoideum, a lower eukaryote, making them probably the evolutionarily oldest
SH2 genes (Kawata et al. 1997), especially in light of the actin gene phylogeny
(Drouin et al. 1995). Accordingly, the JAK/STAT signaling pathway might be
the oldest signaling pathway utilizing tyrosine phosphorylation, acting as a
foundation for the evolution of phosphotyrosine signaling. In this context, it
is interesting to note that we found phosphotyrosine-dependent interactions
between SOCS and the insulin pathway components PI3K, GRB2, CRK and
CRKL. PI3K and GRB2 are components of the insulin signaling pathway and
the JAK/STAT signaling pathway; all four are connections between different
branches of the respective pathways, again providing a network structure suit-
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able for the integration of different input signals affecting the same output.
Canonically, the ubiquitination function of SOCS is thought to operate through
TCEB1/2 (Zhang et al. 1999). The interactions of SOCS with CRK and CRKL
provide hints towards alternative regulatory mechanisms for the degradation of
JAK or IRS1/2. CRK and CRKL are often associated with the E3 ubiquitinase
CBL that might contribute to JAK down-regulation. Conversely, TCEB1/2
could be considered as additional ubiquitin ligases for CRK/CRKL targets, as
Rui et al. (2002) suggested for IRS1 and IRS2. IRS1 and IRS2 degradation has
been shown to be mediated by several ubiquitin ligases, like CBL (Nakao et al.
2009) and CUL7 (Xu et al. 2008). In this context, the interaction of STAT4 and
CRK is similar to the interaction of STAT3 and CBL. Both are interactions
between STATs and ubiquitination-related proteins and might reflect synergistic
or antagonistic effects of multiple cytokines.
The interactions of STAT3 with LCK, Abl and SH2D2A seem to be related to
STAT3 function in T cells, where it has been shown to be responsible for IL6-
induced proliferation (Takeda et al. 1998). Here, STAT3 (but not STAT5) is
phosphorylated upon anti-CD3 stimulation (Gerwien et al. 1999), supporting an
immunological context for the interaction with SH2D2A. This phosphorylation
can be blocked by the Src family and Abl-specific inhibitor PP1 (Gerwien et al.
1999). Therefore, the interactions of STAT3 with LCK and Abl probably repre-
sent kinase-substrate relationships. Indeed, the interaction of STAT3 with Abl
has been described as a minor kinase-substrate relationship (Ilaria & Van Etten
1996). The respective major Abl substrate STAT5A has been shown to be
important for the transformation of K562 leukemia cells (de Groot et al. 1999).
Interestingly, STAT3 had by far the most phosphorylation-dependent inter-
actions in our study. STAT3 interacted with 46 other proteins, while STAT1,
STAT2, STAT4 and STAT5A had only 1, 1, 2 and 2 interactions, respectively.
Given yeast two-hybrids tendency to favor specific genes, or even clones, for
non-apparent reasons, this might be a coincidence. On the other hand, there
is considerable evidence pointing toward a special role of STAT3. Genetically,
STAT genes are organized in 3 tandem clusters, STAT1-STAT4, STAT2-STAT6
and STAT3-STAT5 with a relatively recent split of STAT5 into STAT5A and
STAT5B (Copeland et al. 1995). STAT3-STAT5 seems to be the oldest cluster
(Copeland et al. 1995; Miyoshi et al. 2001). Apparently, STAT3 and STAT5 are
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also the only STAT genes that have transforming potential and are activated
by a larger number of cytokines and more pleiotropic in their function than the
other STAT genes (Kisseleva et al. 2002). STAT3 seems to play an important
role in a higher number of different biological processes than other STAT genes
(Hirano et al. 2000; Levy & Lee 2002). Furthermore, STAT3 knockout mice die
at early during embryogenesis (E6.5-E7.5) (Takeda et al. 1997), while the other
STAT gene knockouts have much more moderate phenotypes (O’Shea 1997).
Finally, STAT3 has been proposed to function not only as a transcription factor
but also as an adapter, e.g. linking PI3K and the interferon 1 receptor (Pfeffer
et al. 1997).
On the whole, the KEGG pathway overlay supports the conclusions drawn
from the network statistics. The core nodes STAT3, SOCS4, GRB2, PIK3R3,
CBL and CRK are all important members of the JAK/STAT signaling pathway
and take central positions in the aggregated KEGG pathway network. This
emphasizes the importance of the core nodes and suggest that the JAK/STAT
signaling pathway is the most strongly inter-connected pathway in the context
of phosphotyrosine signaling.
4.3.2.3.3.4 The adaptor SH2D2A appears to be an under-appreci-
ated signaling hub
Another core gene that links several KEGG pathways by phosphotyrosine-
dependent interactions is SH2D2A. The highest expression levels for this gene
have been measured in activated T and NK cells, as well as certain types of
endothelial and epithelial cells (Berge et al. 2012). Accordingly, a nucleotide
polymorphism in the promoter region of the SH2D2A gene has been linked to
reduced protein levels and susceptibility to multiple sclerosis (Dai et al. 2001)
and SH2D2A knock-out mice show severe disturbances in the fine structures of
the basal membrane and intercellular epithelial spaces (Kolltveit et al. 2010).
Lapinski et al. (2009) argue that one would expect a more severe phenotype,
but the fact that SH2D2A, SH2D4A and SH2D4B have overlapping functions,
is masking some knock-out effects. Initially, SH2D2A was described as a binder
of LCK (Choi et al. 1999), ITK and TXK (Rajagopal et al. 1999), important
in the activation of T cells. However, its exact function is still debated, owed
in no small part to its connection to cAMP, which is intimitely entangled in
T cell signaling. The SH2D2A promoter contains a cAMP response element
209
4. DISCUSSION
that is critically important for transcriptional regulation in T cells (Dai et al.
2004), as does the T cell receptor itself (Lee et al. 1992). SH2D2A protein
concentration is regulated on two levels: cAMP-mediated signals are sufficient
to induce transcription of the SH2D2A gene, whereas TCR/CD3-dependent
signals are necessary for the translation of the transcript (Kolltveit et al. 2008).
The SH2D2A protein is widely agreed to regulate LCK kinase activity, but
several models have been submitted explaining the mechanism of action. Marti
et al. (2006) showed that SH2D2A binds the SH2 and the SH3 domain of
LCK, releasing intramolecular inhibition. This was proposed to follow LCK
phosphorylation by activated T cell receptors (Lapinski et al. 2009). Since
SH2D2A and LCK are usually found in a 1:1 ratio, others speculated that
SH2D2A acts as a competitive LCK inhibitor, effectively sequestering it from
other potential targets (Granum et al. 2008). Both models have merit and are
not entirely exclusive. SH2D2A might actually have an inhibiting as well as
an activating effect on LCK. Similarly, PTPRC, the phosphatase responsible
for removing the activating phospho group on LCK tyrosine residue 394, also
removes the inhibitory phospho group on LCK tyrosine residue 505 (D’Oro
& Ashwell 1999). The inhibitory site LCK-Y505 is phosphorylated by CSK,
down-regulating TCR signaling and IL-2 production (Vang et al. 2001). CSK,
in turn, is activated by protein kinase A (PKA) through phosphorylation
of CSK-S364. PKA is regulated by cAMP and colocalizes with the TCR-
CD3 complex in primary peripheral T cells (Skålhegg et al. 1994). It also
effects CREB phosphorylation. In normal peripheral T cells and thymocytes
CREB phosphorylation can be mediated by at least three distinct pathways: a
PKA-dependent pathway, a Ca2+/calmodulin-dependent pathway, and a PKC-
dependent pathway (Muthusamy & Leiden 1998). Thus, the different modes of
cAMP action circle back and converge on the CRE-mediated regulation of gene
expression, contributing to the difficulties in breaking down the exact function
of SH2D2A in T cells.
However, both of models of LCK regulation by SH2D2A fail to satisfactorily
explain the function of the SH2D2A SH2 domain. This domain might bestow
an adapter function upon SH2D2A. In this study, protein kinase A (PKA)
interacted with CRK in a phosphotyrosine-dependent manner. As a consequence,
the phosphotyrosine-dependent interaction of SH2D2A and CRK may provide
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a feedback mechanism and a connection of T cell receptor signaling and MAP
kinase signaling. Furthermore, in PC12 cells, cAMP has been demonstrated to
activate ELK1, another phosphotyrosine-dependent interactor of CRK found in
this study (Vossler et al. 1997). Moreover, binding SH2D2A could allow LCK to
further phosphorylate other phosphotyrosine proteins. This behavior is in good
accordance with the progressive phosphorylation model (Zhao et al. 2013) and
findings reported in context with VEGFR signaling. SH2D2A attaches to the
VEGF receptor and becomes phosphorylated (Matsumoto et al. 2005). It further
binds SRC and other Src family kinases to affect cytoskeletal rearrangements
(Matsumoto et al. 2005). FRS2, one of the main targets of the VEGF receptors,
acts as an adapter for SRC, which binds it through its SH3 domain (Meakin
et al. 1999). Meakin et al. (1999) proposed that competition for VEGF receptor
binding between FRS2 and SHC1 is a key mechanism for the differentiation
of proliferation and differentiation signals. Possibly, SH2D2A fulfills a similar
function, either in VEGF or T cell receptor signaling. In our study, SH2D2A
interacted with several bona fide signaling hubs, each of which plays important
roles in several pathways. Notably, Berg & Ostergaard (1997) showed a direct
association between PTK2 and the SH2 domain of the SH2D2A interacting
kinase LCK. Therefore, if connecting PTK2 and LCK is a biologically relevant
function of SH2D2A, it is probably regulated by different kinases than the direct
interaction. It seems more plausible that SH2D2A connects both PTK2 and
LCK to other proteins. For example, PTK2 becomes phosphorylated upon TCR
activation, even in LCK−/− cells (Berg & Ostergaard 1997). Correspondingly,
in endothelial cells, SH2D2A binds VEGFR2 on phosphotyrosine 951 and
mutating this tyrosine residue to phenylalanine blocks VEGFA-induced actin
stress fibers and migration, but not mitogenesis (Matsumoto et al. 2005). In
contrast, in TCR signaling, the PTK2-related kinase ZAP70 is a substrate
of LCK and signals through p38. In endothelial cells, VEGFR2-pY1214 is
required for Rho/Rac-independent activation of CDC42 and p38 (Lamalice
et al. 2004). In porcine aortic endothelial cells expressing human VEGFR2,
SHB has been shown to bind VEGFR2 phopsphotyrosine 1175 after being
phosphorylated in a manner sensitive to the Src family kinase inhibitor PP2
(Holmqvist et al. 2004). After binding to VEGFR2, SHB activates PTK2 and
PI3K, both of which interacted with SH2D2A in phosphotyrosine-dependent
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manner in this study. Interestingly, the association between SH2D2A and PI3K
has been shown to be independent of VEGF treatment in human endothelial
cells (Wu et al. 2000). The most obvious function of SH2D2A in vivo is
the induction of superantigen-induced T cell death, exemplified by a raised
susceptibility to lupus-like autoimmune diseases (Marti et al. 2005). T cells
have two apoptosis pathways: one operating through FAS-FADD, CASP8-
CASP3 and a ”mitochondrial” one operating through CytC-CASP9-CASP3
(Hildeman et al. 2002b). SH2D2A seems to play a role in the induction of
this intrinsic FAS-independent mechanism for programmed cell death, which is
most probably mediated by BCL2L11 (Hildeman et al. 2002a). SH2D2A exerts
its effects through the transcriptional regulation of interleukin 2 (IL-2) and
other genes, but does not appear to modulate other regulators of apoptosis like
NF-kappaB, NFAT or AP-1 (Marti et al. 2001). The interaction of SH2D2A and
APPL1 seems immediately relevant in this context, since disruption of APPL1
signaling through CASP9/CASP3 is known to contribute to colorectal cancer
(compare KEGG pathway hsa05210). The IL-2 promoter contains many binding
motifs, e.g. for Jun, Fos, AP1, ELK1 and NFAT (Serfling et al. 1995). It has
been speculated that other factors bind the IL-2 promoter indirectly (Serfling
et al. 1995). In our study, SH2D2A interacted with many proven or putative
transcriptional regulators, like ARID5A (Patsialou et al. 2005), LRRFIP1 (Reed
et al. 1998), NAA16 (inferred from structural similarity), RAD54B (Wesoly
et al. 2006), ZHX3 (Yamada et al. 2003) or ZSCAN1 (inferred from electronic
annotation). This casts SH2D2A as a nuclear adapter for transcription factors
and regulators. This role fits the findings of (Drappa et al. 2003) who analyze
differences in mRNA expression upon SH2D2A knock-out in C57BL/6 mice and
find many transcription factors and other genes related DNA damage response
and apoptosis down-regulated.
In short, the SH2D2A gene encodes an adapter protein with important functions
in the cytoplasm and in the nucleus. A similar characterization fits several of
SH2D2As interaction partners: APPL1, PIK3R3, STAT3 and GRB2. The last
interaction was not found in this study, but has been described to be stimulated
by PDGF treatment in human embryonic lung cells (Park et al. 2001) and shown
to be phosphotyrosine-dependent in yeast two-hybrid experiments elsewhere
(Park & Yun 2001). The nuclear import of SH2D2A is dependent on its SH2
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domain and a phosphorylation on the tyrosine residue 805 in the AAA ATPase
VCP, although a direct binding has not been shown (Marti & King 2005). In
this study, VCP interacted with GRB2 in a phosphorylation-dependent manner.
This suggests a connection between the nuclear import mechanisms of SH2D2A
and GRB2. Interestingly, VCP is necessary for ionizing radiation-induced 53BP1
recruitment to DNA double strand breaks (Acs et al. 2011; Meerang et al. 2011).
Thus, it is probable that the connection between SH2D2A and DNA damage
response is connected to TP53 function.
In conclusion, our results suggest that SH2D2A plays a much more important
role as a signaling hub than is currently appreciated.
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4.3.3 Conclusion
In this study, we present a comprehensive screen for phosphotyrosine-depen-
dent interactions among human proteins. Using a yeast two-hybrid system
that employs non-receptor tyrosine kinases to allow tyrosine phosphorylation.
We screened a total of 159 clones, representing 121 genes containing known
phosphotyrosine-recognizing domains, against a proteome-scale prey matrix.
We obtained 292 phosphotyrosine-dependent interactions involving 86 phospho-
tyrosine-recognizing domain-containing genes. The high quality of the collected
interaction data was demonstrated in high throughput co-immunoprecipitation
experiments from mammalian cell culture. The interactions were compared to
the literature and are mostly novel. This emphasizes the strong utility of a yeast
two-hybrid screen complementing the prior knowledge about phosphotyrosine
signaling, which comprised mostly peptide array- and affinity purification-cou-
pled mass spectrometry-based experiments. The network of phosphotyrosine-
dependent interactions is extremely dense and genes associated with known
phosphotyrosine signaling-related processes, pathways and disease are over-
represented among the interaction partners . Consistent with other protein-
protein interactions, the phosphotyrosine-dependent interactions form a scale-
free network, albeit one with an unusually steep degree distribution, possibly
indicating a unique property of post translational modification-dependent pro-
tein interaction networks. The closely connected single-module structure of the
phosphotyrosine-dependent protein interaction network contrast with the possi-
bility of several discrete modules responsible for different biological functions.
This structure suggests that the high number of growth- and development-
related signals relayed by a multitude of growth factor/receptor tyrosine kinase
binding events are integrated by the phosphotyrosine-dependent interaction
network. This picture is in accordance with reports finding highly overlapping
tyrosine kinase substrate pairings or that many SH2 domains usually recognize
more than one binding site on the same protein. In this study, we show that,
even in the artificial yeast environment, there is a specificity of interactions for
the assayed kinases, that is not explained by one of the interacting proteins
alone, lending further credence to this view. The phosphotyrosine-dependent
interaction partners of SH2 domain-containing proteins are enriched for the
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respective reported linear peptide binding motifs, but the motifs are unable
to explain all of the interactions. What is more, we closely examined selected
phosphotyrosine-dependent GRB2 interactions with conflicting subcellular lo-
calizations using protein complentation assays in living mammalian cells and
found that GRB2 displayed a high motility allowing it to meet its interaction
partners at the plasma membrane, in the cytoplasm or in the nucleus. Finally,
we analyzed the phosphotyrosine-dependent interactions in the context of the
conservative KEGG pathway knowledgebase. In this analysis, we find not only
confirmatory overlaps and complementary cross-pathway interactions, we also
identify SH2D2A as an under-appreciated signaling hub. To sum up, we pro-
vide a comprehensive, high-quality set of phosphotyrosine-dependent protein-
protein interaction that lays the foundation for a plethora of medically relevant
analyses.
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Appendix A
Interacting ORFs
For each interacting ORF, i.e. each ORF involved in a successful experiment,
the best matching RefSeqRNA identifier is provided, including the matching
region and the quality of the match.
In a post-hoc analysis, the ORF nucleotide sequences were matched against
the RefSeqRNA sequences (Release 67) using BLAST, as described for Release
31. For better clarity, only one RefSeq identifier is provided for each ORF,
provided matching regions are identical. The criteria applied to choose among
RefSeq identifiers matching equally were, in order of priority, (1) absolute
length of coding sequence (CDS) covered, percentage of CDS covered, known or
predicted (NM_ or XM_), percentage of RefSeq sequence covered, matching
primary human genome assembly. Where all of the criteria failed, the oldest
identifier, i.e. the one with the lowest number, was chosen. ORFs containing
phosphotyrosine-recognizing domains are shown in boldface. St = Start; Len =
Length.
Note that, due to the ongoing annotation efforts, certain RefSeq matches differ
between release 31 and release 67 with regard to Entrez GeneID. The respective
RefSeq identifiers have been marked (†).
ORF RefSeq
ORF RefSeqRNA Identity St End Len St End Len
ABL1 NM_007313.2 99 1 3450 3450 440 3889 5881
ABL2 NM_005158.4 99 1 3504 3504 46 3549 11957
ACAP1 NM_014716.3 100 1 2223 2223 207 2429 2523
ADCK5 XM_006716527.1 100 1 510 510 1297 1806 1974
AHDC1 NM_001029882.3 100 1 1200 1200 4444 5643 6374
AKT1 NM_001014431.1 100 1 1441 1443 341 1781 2794
ANAPC10 NM_014885.4 100 1 558 558 102 659 1457
ANGPT1 NM_001199859.1 100 1 442 444 1231 1672 4335
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ANKRD50 NM_001167882.1 100 1 2232 2232 1822 4053 7519
ANKS1A NM_015245.2 99 1 1381 1383 2165 3545 6355
ANKS1B NM_001204066.1 99 1 1074 1074 135 1208 3063
ANKZF1 NM_001282792.1 100 17 774 881 1392 2149 2193
ANLN NM_001284302.1 100 1 1218 1218 2265 3482 4687
AP1S2 NM_003916.4 100 1 474 474 328 801 2320
APBB3 NM_133173.2 99 1 1460 1461 360 1819 2146
APPL1
ORF #1 NM_012096.2 99 1 2130 2130 148 2277 6061
ORF #2 NM_012096.2 99 1 2129 2130 148 2276 6061
APPL2 NM_018171.3 99 1 1995 1995 219 2213 3289
ARAP3 XM_005268499.1 100 1 225 225 3948 4172 5200
ARFGAP1 NM_001281482.1 100 1 1212 1212 141 1352 3524
ARHGAP10 XM_005263216.2 99 13 656 660 1566 2209 2910
ARID5A XM_005263860.1 100 1 1293 1293 428 1720 2041
ARL6IP4 NM_001002252.2 100 1 648 648 698 1345 1681
ASB3 NM_016115.4 100 1 1557 1557 203 1759 2290
ASB8 NM_024095.3 100 1 867 867 170 1036 2629
ASB9 NM_001031739.2 100 1 885 885 298 1182 1714
ASCL4 NM_203436.2 100 1 519 519 835 1353 2260
ATF3 NM_001030287.3 100 1 546 546 155 700 1935
BAIAP2
ORF #1 NM_001144888.1 100 1 1536 1539 109 1644 3306
ORF #2 XM_005256948.1 99 1 1569 1569 112 1680 3198
BAT2L NM_013318.3 100 1 975 1018 56 1030 11062
BATF3 NM_018664.2 100 1 384 384 224 607 992
BCAR3 NM_003567.3 100 1 2478 2478 253 2730 3203
BECN1 NM_003766.3 100 1 1353 1353 163 1515 2143
BEX5 NM_001012978.2 100 1 336 336 261 596 840
BLK NM_001715.2 99 1 1518 1518 582 2099 2642
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BMX
ORF #1 NM_001721.6 100 1 2026 2028 112 2137 2530
ORF #2 NM_001721.6 100 1 2028 2028 112 2139 2530
ORF #3 NM_001721.6 100 1 2028 2028 112 2139 2530
BRWD1 NM_001007246.2 100 1 363 363 296 658 2653
BTK
ORF #1 NM_000061.2 100 1 1980 1980 194 2173 2611
ORF #2 NM_000061.2 99 1 1978 1980 194 2171 2611
C10orf18 NM_017782.4 99 1 2226 2226 5693 7918 8636
C10orf81 XM_005270162.2 99 1 849 849 1025 1873 2172
C17orf53 XM_006722075.1 99 1 1224 1566 92 1315 1964
C17orf53 XM_006722075.1 100 1223 1566 1566 1539 1882 1964
C17orf82 NM_203425.1 100 1 756 756 226 981 1546
C19orf66 NM_018381.2 100 1 489 492 299 787 2139
C1orf135 NM_024037.2 100 1 1074 1074 102 1175 2178
C1orf62 NM_152763.4 99 1 1245 1248 280 1524 3063
C1QTNF3 NM_030945.3 99 1 381 381 502 882 3624
C21orf77 NM_144659.5 99 1 381 381 1697 2077 2730
C22orf28 NM_014306.4 99 1 1518 1518 132 1649 2081
C22orf29 NM_024627.5 100 1 912 912 695 1606 6693
C22orf39 NM_001166242.1 99 1 243 243 545 787 1558
C3orf10 NM_018462.4 100 1 228 228 54 281 1197
C3orf34 NM_032898.4 100 1 492 492 437 928 2216
C4orf17 NM_032149.2 99 1 1184 1184 363 1546 1652
C5orf35 NM_153706.3 99 1 900 900 387 1286 1722
C6orf125 NM_032340.3 100 1 381 381 66 446 1355
C6orf141 NM_001145652.1 100 1 714 714 415 1128 1696
C6orf146 NM_173563.2 99 1 1527 1527 407 1933 2270
C8orf33 NM_023080.2 100 1 690 690 55 744 2617
C9orf43 NM_001278629.1 100 1 1386 1386 408 1793 2091
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CA8 NM_004056.4 99 1 417 462 249 665 2278
CAMK1 NM_003656.4 100 1 1113 1113 186 1298 1500
CAPN10 NM_023083.3 99 1 2019 2019 197 2215 2662
CBL NM_005188.3 100 1 2721 2721 143 2863 11241
CBLB
ORF #1 NM_170662.3 99 1 2949 2949 323 3271 3976
ORF #2 NM_170662.3 99 1 2949 2949 323 3271 3976
CBLC NM_012116.3 99 1 1423 1425 64 1486 1591
CCDC14 XM_005247714.2 99 1 2262 2262 345 2606 3665
CCDC33 NM_182791.3 99 1 1026 1026 50 1077 2141
CCDC74A NM_001258306.1 100 1 939 939 138 1076 1357
CCDC87 NM_018219.2 99 1 2550 2550 69 2618 2915
CCM2 NM_031443.3 100 1 1335 1335 147 1481 1904
CDCA4 NM_145701.2 99 1 726 726 97 822 1927
CENPB NM_001810.5 97 29 860 899 1604 2434 2856
CHN2 NM_004067.3 99 1 1406 1407 438 1843 3461
CHTF18 NM_022092.2 99 1 2928 2928 64 2991 3096
CKM NM_001824.4 99 1 1146 1146 176 1321 1666
CNDP2 NM_018235.2 100 1 1428 1428 260 1687 5089
COQ9 NM_020312.3 100 1 957 957 82 1038 1699
CORO6 XM_005258056.2 100 1 714 714 301 1014 1764
COX6B2 NM_144613.4 100 1 267 267 184 450 1679
CRBN NM_001173482.1 99 1 1326 1326 31 1356 2593
CRK
ORF #1 NM_016823.3 99 1 915 915 151 1065 3225
ORF #2 NM_005206.4 100 1 615 615 151 765 3055
ORF #3 NM_016823.3 99 1 913 915 151 1063 3225
ORF #4 NM_016823.3 99 1 915 915 151 1065 3225
CRKL
ORF #1 NM_005207.3 100 1 910 912 510 1419 5336
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ORF #2 NM_005207.3 100 1 910 912 510 1419 5336
CRLF3 NM_015986.3 100 1 1329 1329 110 1438 2954
CRP NM_000567.2 100 1 141 141 639 779 2024
CRYBA2 NM_057094.1 100 1 594 594 36 629 709
CSAD NM_001244706.1 99 16 943 943 587 1513 1757
CSK NM_001127190.1 100 1 1350 1350 184 1533 2236
CSRP3 NM_003476.4 99 1 585 585 240 824 1464
CTNNBL1 NM_001281495.1 100 1 936 936 1026 1961 2089
CYB561D2 NM_001291284.1 100 1 669 669 316 984 1348
CYP2C8 NM_000770.3 99 1 1473 1473 96 1568 1924
CYP46A1 NM_006668.1 100 1 1503 1503 1 1503 2138
DAPP1
ORF #1 NM_014395.2 100 1 843 843 91 933 2953
ORF #2 NM_014395.2 100 1 799 799 76 874 2953
DBN1 NM_004395.3 99 1 1950 1950 173 2122 2942
DDIT4L NM_145244.3 100 1 582 582 246 827 2649
DDX5 NM_004396.3 100 17 608 608 186 777 3769
DOK1 NM_001381.3 100 1 1446 1446 371 1816 2269
DOK2
ORF #1 NM_003974.2 99 1 1239 1239 94 1332 1870
ORF #2 NM_003974.2 99 1 1239 1239 94 1332 1870
DOK3
ORF #1 NM_001144875.1 99 1 993 993 203 1195 2354
ORF #2 NM_001144875.1 99 1 993 993 203 1195 2354
DOK4 NM_018110.3 100 1 981 981 351 1331 2750
DOK5 NM_177959.2 100 1 597 597 446 1042 1734
DOK7 NM_173660.4 99 1 1515 1515 71 1585 2583
DTNA NM_001128175.1 100 1 1116 1116 348 1463 1728
DUSP18 NM_152511.3 100 1 165 354 502 666 2453
DUSP18 NM_152511.3 100 164 354 354 775 965 2453
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E2F2 NM_004091.3 100 1 252 252 4109 4360 5201
E2F6 NM_198256.3 100 1 846 846 299 1144 3246
EFHC1 NM_018100.3 99 1 1923 1923 216 2138 5596
ELK1 NM_005229.4 100 1 1287 1287 217 1503 2828
EPB41L4A XM_005272043.2 100 1 555 558 452 1006 4797
EPS8 NM_004447.5 99 1 2469 2469 438 2906 4088
EPS8L2 NM_022772.3 99 1 2148 2148 248 2395 3156
EPYC
ORF #1 NM_004950.4 99 1 969 969 94 1062 1553
ORF #2 NM_004950.4 99 1 969 969 94 1062 1553
ESD NM_001984.1 99 1 849 849 184 1032 1208
EVI1 XM_006713537.1 100 1 375 510 397 771 2994
EYA3 NM_001990.3 100 1 1083 1089 183 1265 6040
EZH2 NM_004456.4 100 1 2256 2256 194 2449 2723
FABP7 NM_001446.3 100 1 399 399 295 693 1005
FAM114A1 NM_138389.2 99 1 1692 1692 260 1951 4138
FAM117B NM_173511.3 100 1 1038 1038 743 1780 5795
FAM127C NM_001078173.1 100 1 342 342 78 419 2038
FAM46A NM_017633.2 99 1 136 1344 319 454 5617
FAM46A NM_017633.2 100 85 1344 1344 388 1647 5617
FAM46B NM_052943.3 100 1 1275 1275 176 1450 2391
FAM59A NM_001242409.1 100 1 2631 2631 57 2687 7051
FANCG NM_004629.1 100 1 1869 1869 493 2361 2649
FER NM_005246.2 100 35 2501 2530 385 2851 2950
FES NM_002005.3 99 1 2469 2469 97 2565 2783
FGF12 NM_004113.5 99 1 546 546 247 792 5408
FGF13 NM_004114.3 100 1 738 738 663 1400 2705
FGF21 NM_019113.2 99 1 630 630 151 780 940
FGR NM_001042729.1 99 1 1589 1590 213 1801 2442
FOXO1 NM_007062.1† 99 1 1504 1506 88 1591 1853
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FRK NM_002031.2 100 1 1518 1518 448 1965 2864
FRS2 NM_001278357.1 99 1 1536 1539 304 1839 6676
FRS3
ORF #1 NM_006653.4 100 1 1479 1479 258 1736 2198
ORF #2 NM_006653.4 100 1 1475 1479 258 1732 2198
FSTL1 NM_007085.4 100 1 927 927 176 1102 3840
FYB NM_199335.3 100 1 891 891 1625 2515 4720
FYN
ORF #1 NM_002037.5 100 1 1613 1614 608 2220 3628
ORF #2 NM_153048.3 100 1 1449 1449 104 1552 2959
SH2 NM_002037.5 100 34 379 397 1031 1376 3628
GABPB2
ORF #1 NM_144618.2 100 1 1347 1347 332 1678 1953
ORF #2 NM_144618.2 100 1 1347 1347 332 1678 1953
GALNT3 XM_006712402.1 100 1 362 426 532 893 1680
GATA1 NM_002049.3 100 1 869 1008 92 960 1501
GBA3 NM_001128432.2 100 1 489 489 103 591 1268
GBL XM_005255480.2 99 1 981 981 328 1308 1990
GLIS3 NM_152629.3 99 1 2328 2328 195 2522 6672
GRAP2
ORF #1 NM_004810.3 100 1 993 993 264 1256 3514
ORF #2 NM_004810.3 100 1 993 993 264 1256 3514
GRB2
ORF #1 NM_002086.4 100 1 654 654 358 1011 3303
ORF #2 NM_002086.4 99 1 651 651 358 1008 3303
SH2 NM_002086.4 100 1 309 309 529 837 3303
GRB7 NM_001030002.2 100 1 1599 1599 121 1719 2130
GRB10 NM_001001550.2 99 1 1609 1611 286 1894 4793
GRB14 NM_004490.2 99 1 1623 1623 542 2164 2402
GSTCD NM_001031720.3 99 1 1899 1899 73 1974 4122
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HABP4 XM_005251812.1 96 16 826 849 160 963 2210
HCK NM_001172129.1 100 1 1518 1518 301 1818 2168
HESX1 NM_003865.2 100 1 558 558 335 892 1182
HLA-C NM_002117.5 96 1 1101 1101 66 1166 1586
HSH2D
ORF #1 NM_032855.3 100 1 1059 1059 532 1590 2403
ORF #2 NM_032855.3 100 1 1059 1059 532 1590 2403
HSPA1A
ORF #1 NM_153201.3† 99 17 594 595 309 886 2014
ORF #2 NM_005346.4† 99 1 1926 1926 217 2142 2551
HSPD1
ORF #1 NM_199440.1 98 17 852 922 142 982 2319
ORF #1 NM_199440.1 96 886 912 922 1021 1048 2319
ORF #2 NM_199440.1 100 1 1722 1722 118 1839 2319
HUWE1 XM_005261972.2 99 18 945 965 11826 12753 13271
ID1 NM_002165.3 100 1 468 468 106 573 1000
ID2 NM_002166.4 100 1 405 405 184 588 1402
IFT140 NM_014714.3 99 16 959 960 2528 3471 5277
ING4 NM_001127582.1 100 1 750 750 42 791 1461
INO80E NM_173618.1 100 1 735 735 102 836 1185
IQUB XM_005250162.2 100 1 1119 1122 150 1268 2487
IRS1 NM_005544.2 100 1 3729 3729 53 3781 8743
ISL1 NM_002202.2 99 1 1050 1050 549 1598 2729
ITGB1BP1
ORF #1 NM_004763.3 99 1 603 603 178 780 1930
ORF #2 NM_004763.3 99 1 599 603 178 776 1930
ITK NM_005546.3 100 1 1863 1863 83 1945 4366
JAK2 NM_004972.3 99 1 3397 3399 495 3891 5285
JAK3 NM_000215.3 99 1 1787 1860 101 1887 5449
KCTD13 NM_178863.4 99 1 990 990 200 1189 1745
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KCTD17 NM_001282684.1 99 1 945 945 26 970 1779
KCTD4 NM_198404.2 99 1 780 780 405 1184 2133
KIAA0317 NM_001039479.1 99 1 2369 2370 506 2874 5445
KLF15 NM_014079.3 100 1 1251 1251 183 1433 2539
KLHL20 NM_014458.3 100 1 599 693 180 778 3505
KLRAQ1 NM_001193475.1 100 1 1088 1092 186 1273 3055
KRIT1 NM_194454.1 99 1 2209 2211 546 2754 4523
KRTAP10-7 NM_198689.2 100 1 1113 1113 26 1138 1606
KRTAP23-1 NM_181624.1 100 1 198 198 1 198 208
KRTAP3-1 NM_031958.1 100 1 297 297 41 337 614
KRTCAP2 NM_173852.3 100 1 489 489 27 515 577
LASP1 NM_006148.3 99 1 599 972 332 930 4135
LCK
ORF #1 NM_001042771.2 100 1 964 1620 122 1085 2102
ORF #1 NM_001042771.2 100 1054 1620 1620 1085 1651 2102
ORF #2 NM_001042771.2 100 1 964 1530 122 1085 2102
ORF #2 NM_001042771.2 100 1054 1530 1530 1085 1561 2102
LCP2 NM_005565.3 100 1 1602 1602 208 1809 2472
LDHAL6B NM_033195.2 99 1 1146 1146 126 1271 1773
LECT1 NM_001011705.1 100 1 1002 1002 112 1113 1535
LEFTY2 NM_003240.3 100 1 1101 1101 244 1344 2187
LETMD1 NM_015416.4 100 1 1083 1083 59 1141 2151
LGALS9C NM_001042685.1† 99 1 1071 1071 66 1133 1243
LHX8 NM_001001933.1 99 1 1071 1071 665 1735 2393
LIX1 NM_153234.4 99 1 849 849 241 1089 3979
LMX1A XM_006711319.1 99 1 303 303 700 1002 1013
LNX1 NM_001126328.2 100 1 2187 2187 286 2472 3199
LNX2 NM_153371.3 100 1 2073 2073 310 2382 4804
LOC285398 NM_052859.3 100 1 375 375 3210 3584 5112
LOC492311 NM_001007189.1 100 1 144 144 2560 2703 2900
291
APPENDIX A
ORF RefSeq
ORF RefSeqRNA Identity St End Len St End Len
LRRFIP1 NM_001137551.1 100 1 318 318 1160 1477 3599
LSM8 NM_016200.4 100 1 289 291 193 481 12520
LYN
ORF #1 NM_002350.3 99 1 1539 1539 283 1821 4158
ORF #2 NM_002350.3 99 1 1539 1539 283 1821 4158
MAGEC3 NM_177456.2 100 1 1041 1041 528 1568 1707
MAPK8IP2 NM_012324.4 99 1 2475 2475 135 2609 3395
MAPKAPK2 NM_032960.3 99 17 917 917 1078 1979 2997
MAPRE3 NM_012326.2 100 1 846 846 154 999 1880
MATK
ORF #1 NM_139355.2 100 1 1524 1524 401 1924 2163
ORF #2 NM_139355.2 100 1 1522 1524 401 1922 2163
MIST NM_052964.2 100 1 1286 1287 138 1423 1710
MLL3 NM_170606.2 99 17 976 976 326 1288 16872
MLL4 XM_006723515.1 97 15 683 936 2453 3120 3907
MNDA NM_002432.1 100 1 1224 1224 201 1424 1670
MPEG1 NM_001039396.1 99 1 2151 2151 157 2307 4527
MPG NM_001015052.2 100 1 882 882 141 1022 1096
MPP5 NM_022474.3 99 1 2026 2028 476 2501 5608
MPZL1 NM_003953.5 100 1 444 444 3334 3777 5026
MRE11A NM_005590.3 100 1 618 621 297 914 5164
MRPS22 NM_020191.2 99 1 1083 1083 9 1091 1155
MSRB3 NM_001193461.1 100 1 558 558 137 694 4296
MST4 NM_001042452.1 100 1 339 414 11 349 2875
MST4 NM_001042452.1 100 335 414 414 796 875 2875
MT2A NM_005953.3 100 1 186 186 91 276 466
MTF2 NM_001164392.1 100 1 1611 1611 293 1903 3973
MYBPHL NM_001010985.2 99 1 1065 1065 51 1115 1372
MYH7B NM_020884.4 100 1 524 528 513 1036 6602
MYLIP NM_013262.3 100 1 1338 1338 238 1575 3086
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MYOZ1 NM_021245.3 100 1 900 900 366 1265 1583
MYOZ2 NM_016599.4 99 1 795 795 214 1008 2604
MZF1 NM_001267033.1 99 1 873 873 562 1434 2694
NACAD NM_001146334.1 99 29 826 827 3255 4052 4778
NARG1L NM_001110798.1 99 1 1290 1290 325 1614 1833
NCK1
ORF #1 NM_006153.5 100 1 1134 1134 131 1264 4421
ORF #2 NM_006153.5 100 1 1134 1134 131 1264 4421
NCK2 NM_001004720.2 100 1 1141 1143 167 1307 2417
NGEF NM_019850.2 99 1 2133 2133 249 2381 3184
NHLRC2 NM_198514.3 100 1 1104 1104 1319 2422 6409
NHP2 NM_017838.3 100 1 462 462 144 605 867
NKAP
ORF #1 NM_024528.3 99 1 1248 1248 168 1415 1600
ORF #2 NM_024528.3 100 1 1248 1248 168 1415 1600
NME4 NM_005009.2 100 1 564 564 32 595 1059
NMU NM_006681.3 99 1 525 525 107 631 834
NOS1AP NM_014697.2 99 1 1521 1521 388 1908 4464
NT5C XM_006721851.1 99 1 276 354 83 358 1136
NT5C XM_006721851.1 100 276 354 354 382 460 1136
NUFIP2 NM_020772.2 100 1 2088 2088 90 2177 10897
NUMB
ORF #1 NM_001005745.1 100 1 622 738 321 942 3470
ORF #2 XM_006720296.1 100 1 408 408 1031 1438 2811
NXT2 NM_018698.4 99 1 594 594 103 696 2713
OBSL1 NM_001173408.1 98 1 186 186 2884 3069 3578
OFCC1 XM_003118558.3 100 1 343 696 387 729 1595
OLIG1 NM_138983.2 100 1 768 768 152 919 2293
OSAP NM_032623.3 100 1 723 723 181 903 1339
OSBPL6 XM_005246268.1 99 1 1527 1527 541 2067 2232
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OTUD7B NM_020205.3 99 1 1283 1284 357 1639 6415
P4HA2 NM_001017974.1 100 1 1515 1515 180 1694 2110
PACRGL NM_145048.3 100 1 666 666 392 1057 2090
PACSIN3 NM_001184974.1 100 1 1275 1275 211 1485 1913
PAFAH1B2 NM_002572.3 100 1 690 690 143 832 4200
PAQR7 NM_178422.5 99 1 1041 1041 668 1708 3023
PARD6A NM_001037281.1 100 1 1038 1038 92 1129 1270
PCDHB5 NM_015669.3 99 1 2388 2388 230 2617 2926
PDPK1
ORF #1 NM_031268.5 99 1 628 638 812 1439 6862
ORF #2 NM_031268.5 99 1 449 457 989 1437 6862
PELI1 NM_020651.3 99 1 1257 1257 461 1717 3780
PELI3 NM_145065.2 99 1 842 996 165 1006 2763
PELO NM_015946.4 99 1 1158 1158 986 2143 2941
PER1 XM_005256690.1 100 1 855 885 239 1093 4529
PGRMC1
ORF #1 NM_006667.4 98 17 610 610 92 683 1931
ORF #2 NM_006667.4 100 1 588 588 120 707 1931
PHC2 NM_004427.3 99 1 972 972 353 1324 2566
PIK3CA NM_006218.2 99 1 3205 3207 158 3362 3724
PIK3CB NM_006219.2 100 1 3212 3213 17 3228 5931
PIK3R1 NM_181504.3 99 1 1365 1365 91 1455 5691
PIK3R2 NM_005027.3 99 1 762 762 1966 2727 3981
PIK3R3
ORF #1 NM_001114172.1 99 1 1386 1386 258 1643 5194
ORF #2 NM_001114172.1 99 1 1385 1386 258 1642 5194
ORF #3 NM_001114172.1 99 1 1385 1386 258 1642 5194
ORF #4 NM_001114172.1 99 1 1386 1386 258 1643 5194
ORF #5 NM_001114172.1 99 1 1386 1386 258 1643 5194
PINK1 NM_032409.2 99 1 1746 1746 95 1840 2680
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PLAGL2 NM_002657.3 100 1 1491 1491 218 1708 5656
PLB1 NM_153021.4 100 1 1385 1467 981 2365 5148
PLCG2 NM_002661.4 99 1 3798 3798 215 4012 8707
PLEKHB1 NM_001130035.1 100 1 570 570 230 799 2027
PNP NM_000270.3 100 1 867 867 147 1013 2438
POLR3F NM_006466.3 99 1 951 951 119 1069 2159
PPAPDC2 NM_203453.3 97 17 453 883 10 444 2981
PPARA XM_006724271.1 100 1 777 777 398 1174 1751
PPARD NM_177435.2 99 1 1086 1086 310 1395 2028
PPP1R12B NM_001167858.1 100 1 1161 1161 151 1311 1751
PPP1R7 NM_001282410.1 100 1 843 843 839 1681 1803
PRKACA NM_002730.3 100 1 1056 1056 201 1256 2689
PRKCA NM_002737.2 100 1 1032 1032 1032 2063 8787
PRRG2 NM_000951.2 99 15 540 540 249 774 1411
PSG11 NM_001113410.1 99 1 660 660 90 749 1175
PSMC1 NM_002802.2 99 1 1323 1323 49 1371 1586
PSMD3 NM_002809.3 99 1 1605 1605 204 1808 2187
PSMD9 NM_002813.6 100 1 672 672 127 798 2368
PTK2
ORF #1 NM_153831.3 99 59 2043 2043 1485 3469 4561
ORF #2 NM_153831.3 100 1 2230 3021 311 2540 4561
ORF #2 NM_153831.3 100 2228 3019 3021 2676 3467 4561
PTK2B NM_173176.2 99 1 3030 3030 241 3270 4180
PTK6 NM_005975.3 100 1 1356 1356 57 1412 2535
PTK7 NM_152880.3 96 41 813 924 1881 2661 4153
PTPN11 NM_080601.1 100 1 1383 1383 381 1763 2069
PTPN6 NM_080548.4 100 1 1794 1794 150 1943 2234
PTTG1 NM_004219.3 99 1 609 609 97 705 786
RAB2B NM_001163380.1 100 1 36 456 180 215 2883
RAB2B NM_001163380.1 100 35 456 456 258 679 2883
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RABGAP1 NM_012197.3 100 1 2992 2994 351 3342 4999
RABGAP1L
ORF #1 XM_005245681.1 99 1 1599 1818 278 1876 8629
ORF #2 NM_001243763.1 100 1 219 219 225 443 740
ORF #3 NM_005684.4† 100 1 1086 1086 39 1124 1472
RAD54B NM_001256141.1† 100 1 477 477 508 984 5418
RAI2 NM_021785.4 99 1 1593 1593 265 1857 2229
RALBP1 NM_006788.3 100 1 1968 1968 216 2183 4368
RANBP3 NM_007320.2 100 1 1050 1194 228 1277 3211
RASA1 NM_022650.2 100 1 2613 2613 125 2737 3796
RASSF1 NM_170713.2 100 1 811 813 146 956 1770
RB1 NM_000321.2 100 1 2787 2787 167 2953 4772
RBM4 NM_002896.3 100 1 1095 1095 149 1243 1714
RBP7 NM_052960.2 100 1 405 405 63 467 704
RCAN3 NM_001251979.1 99 1 726 726 173 898 2646
RIN1 NM_004292.2 99 1 2352 2352 128 2479 2698
RIN3
ORF #1 NM_024832.3 100 1 502 522 153 654 3869
ORF #2 NM_024832.3 100 1 743 885 153 895 3869
ORF #2 NM_024832.3 100 735 772 885 3073 3110 3869
ORF #3 NM_024832.3 99 1 2955 2958 153 3110 3869
RP13-36C9.6 NM_001291529.1† 99 1 570 570 91 660 1166
RPAIN NM_001160246.1 100 1 321 321 571 891 1362
RPS6 NM_001010.2 100 1 750 750 43 792 829
RTDR1 NM_014433.2 99 1 1047 1047 159 1205 1286
RYBP
ORF #1 NM_012234.6 99 1 687 687 184 870 4678
ORF #2 NM_012234.6 99 1 687 687 184 870 4678
SCAPER NM_001145923.1 100 1 879 879 3527 4405 4874
SCLT1 NM_001300897.1 100 1 240 240 505 744 1793
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SCOC NM_001153635.1 100 1 366 366 46 411 1873
SDCCAG8 XM_005273023.2 100 1 1083 1083 149 1231 1702
SEMA4D NM_006378.3 99 1 2589 2589 573 3161 4642
SEPT6
ORF #1 NM_015129.5 100 1 1305 1305 266 1570 3387
ORF #2 NM_015129.5 99 1 1305 1305 266 1570 3387
SERPINA5 NM_000624.5 99 1 1221 1221 236 1456 2352
SFMBT1 NM_016329.3 99 1 2601 2601 389 2989 4558
SH2B1 NM_001145796.1 99 1 1281 1281 1008 2288 3046
SH2B3 NM_001291424.1 100 1 156 156 2809 2964 4500
SH2D1A NM_002351.4 100 1 387 387 362 748 2523
SH2D1B
ORF #1 NM_053282.4 100 1 199 234 123 321 2553
ORF #1 NM_053282.4 100 198 234 234 485 521 2553
ORF #2 NM_053282.4 100 1 397 399 123 519 2553
ORF #3 NM_053282.4 100 1 397 399 123 519 2553
SH2D2A NM_001161444.1 99 1 1170 1170 141 1310 1445
SH2D3A NM_005490.2 100 1 1731 1731 195 1925 2376
SH2D4A NM_001174160.1 99 1 819 819 620 1438 3031
SH3BP2
ORF #1 NM_001122681.1 99 1 1684 1686 121 1804 9068
ORF #2 XM_006713911.1 99 17 817 818 947 1748 2348
SHD NM_020209.3 100 1 1023 1023 1464 2486 2598
SHE NM_001010846.2 99 1 1488 1488 25 1512 6186
SLC39A13
ORF #1 NM_001128225.2 99 1 1116 1116 177 1292 2429
ORF #2 NM_152264.4 99 1 1095 1095 198 1292 2429
SLPI NM_003064.3 100 1 399 399 22 420 625
SMARCD1 NM_003076.4 100 1 1548 1548 171 1718 3431
SOCS1 NM_003745.1 100 35 668 697 155 788 1216
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SOCS3 NM_003955.4 100 1 678 678 419 1096 2737
SOCS4 NM_080867.2 100 1 1323 1323 437 1759 6900
SOCS6 NM_004232.3 100 1 1608 1608 317 1924 5846
SPATA12 NM_181727.1 100 1 573 573 676 1248 2430
SPINK2 NM_021114.3 100 1 255 255 208 462 763
SPRY2 NM_005842.2 99 1 1062 1062 382 1444 2126
SPRY4 NM_001127496.1 100 1 900 900 260 1159 4941
SPSB2 NM_001146316.1 100 1 792 792 157 948 1220
SPSB3 NM_080861.3 97 16 678 849 843 1503 1553
SPTB NM_001024858.2 97 17 546 805 5984 6513 10074
SRC
ORF #1 NM_198291.2 100 1 1611 1611 375 1985 4056
ORF #2 NM_198291.2 100 1 1611 1611 375 1985 4056
SRMS NM_080823.3 99 35 1508 1528 42 1515 2402
SRP19 NM_003135.2 99 1 435 435 190 624 1502
STAT1 NM_139266.2 100 1 2138 2139 389 2526 2798
STAT2 NM_005419.3 100 1 2556 2556 204 2759 4576
STAT3
ORF #1 NM_003150.3 100 1 2310 2310 219 2528 4953
ORF #2 NM_139276.2 100 1 2313 2313 241 2553 4978
STAT4 NM_001243835.1 100 1 2247 2247 265 2511 2789
STAT5A NM_003152.3 99 1 2385 2385 643 3027 4314
STK36 NM_015690.4 99 1 3948 3948 280 4227 4946
STRN4 NM_013403.2 100 1 2262 2262 34 2295 3221
SUV39H1 NM_003173.3 100 1 1239 1239 53 1291 2752
SYK
ORF #1 NM_001174167.2 99 1 1908 1908 202 2109 5075
ORF #2 NM_001174168.2 100 1 1839 1839 121 1959 4925
SYMPK NM_004819.2 100 1 1599 1602 246 1844 4188
TARBP2 NM_134323.1 100 1 1101 1101 489 1589 1888
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TCAP NM_003673.3 99 1 504 504 15 518 963
TDG NM_003211.4 99 1 1233 1233 224 1456 3251
TEC NM_003215.2 100 1 1896 1896 92 1987 3620
TENC1 NM_198316.1 100 1 3858 3858 336 4193 4690
TERF2 XM_005256123.1 100 1 714 756 141 854 2977
TGM1 NM_000359.2 100 1 2454 2454 125 2578 2777
TM4SF19 NM_138461.3 99 1 630 630 159 788 1077
TMEM128 NM_032927.3 100 1 426 426 618 1043 1785
TMEM168 NM_022484.5 100 1 1281 1281 1206 2486 7317
TNFAIP1 NM_021137.4 100 1 951 951 450 1400 3822
TNK1 NM_003985.4 99 1 1986 1986 233 2218 2912
TNK2 XM_006713468.1 99 1 1452 1587 796 2247 2511
TNK2 XM_006713468.1 100 1478 1587 1587 2247 2356 2511
TNNC2 NM_003279.2 99 1 483 483 67 549 698
TNS1 NM_022648.4 99 40 1148 1251 345 1453 10276
TNS4 NM_032865.5 99 1 1442 1443 870 2311 4090
TP53 NM_001126112.2 99 1 1180 1182 200 1379 2588
TP53RK NM_033550.3 100 1 762 762 224 985 3384
TRDN NM_001256022.1 99 1 504 504 319 822 1413
TRIT1 XM_006710706.1 99 1 975 975 512 1492 2185
TSC1
ORF #1 NM_001162426.1 100 1 1030 1101 235 1264 8623
ORF #2 XM_006717272.1 100 1 1030 1101 235 1264 2286
TSPAN2 NM_005725.4 99 1 666 666 69 734 3213
TSSK3 NM_052841.3 100 1 807 807 442 1248 1330
TUBA1C NM_032704.3 99 1 1350 1350 101 1450 1581
TWIST1 NM_000474.3 100 1 609 609 352 960 1669
TWIST2 NM_057179.2 100 1 483 483 185 667 1186
TWSG1 NM_020648.5 100 1 672 672 192 863 3779
TXK NM_003328.2 100 1 1582 1584 87 1668 2914
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TYK2 NM_003331.4 99 1 3562 3564 379 3940 4262
UBD NM_006398.3 99 1 498 498 225 722 1006
USP2 NM_001243759.1 99 1 1089 1089 210 1298 2933
USP46 NM_022832.3 100 1 1101 1101 186 1286 7981
VAC14 NM_018052.3 100 1 2349 2349 259 2607 3107
VASP
ORF #1 XM_005259199.1 100 1 321 321 331 651 2282
ORF #2 NM_003370.3 100 1 1143 1143 343 1485 2298
VCP
ORF #1 NM_007126.3 100 1 2420 2421 390 2809 3859
ORF #2 NM_007126.3 100 1 2420 2421 390 2809 3859
VPS39 NM_015289.3 100 1 2154 2154 648 2801 4873
VSTM2L NM_080607.2 99 1 615 615 255 869 2018
WBSCR27 NM_152559.2 99 1 738 738 41 778 958
WDFY3 NM_014991.4 99 1 846 846 10144 10989 14329
WDR20 NM_144574.3 99 1 1710 1710 73 1782 2446
WDR23 NM_181357.2 100 17 637 662 1099 1719 3663
WDR40B NM_178470.4 99 1 1392 1392 252 1643 3403
WDR42A
ORF #1 NM_015726.3 100 1 724 822 213 936 3901
ORF #2 NM_015726.3 99 1 724 822 213 936 3901
WDR83 NM_032332.3 100 1 948 948 89 1036 1219
WIZ XM_005260007.2 99 15 894 894 1911 2790 6763
WRNIP1 NM_130395.2 99 1 1923 1923 192 2114 2592
WWOX NM_016373.3 100 1 518 705 367 884 2505
WWOX NM_016373.3 100 516 704 705 1422 1610 2505
XAGE2XX NM_130777.2† 99 1 336 336 214 549 651
YES1 NM_005433.3 100 1 1632 1632 222 1853 4685
YPEL3 NM_031477.4 99 1 606 606 586 1192 1588
YWHAQ NM_006826.3 100 1 737 738 198 934 2272
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ORF RefSeq
ORF RefSeqRNA Identity St End Len St End Len
ZAP70
ORF #1 NM_001079.3 99 1 1860 1860 208 2067 2450
ORF #2 NM_001079.3 100 23 1480 1482 608 2065 2450
ZBTB24 NM_014797.2 100 1 2094 2094 169 2262 5597
ZHX3 XM_005260341.2 99 1 2910 2910 403 3312 9788
ZMAT1 NM_001011657.3 99 1 1710 1710 351 2061 3489
ZNF167 NM_001288591.1 100 1 831 831 426 1256 1742
ZNF281 NM_012482.4 99 1 2688 2688 128 2815 4904
ZNF451 XM_005248994.1 100 1 2753 2799 245 2997 5079
ZNF557 NM_001044387.1 100 1 1126 1126 474 1599 5990
ZNF586 NM_017652.3 97 1 162 300 192 353 2235
ZNF639 NM_016331.1 99 1 1458 1458 446 1903 3013
ZNF655 NM_001009960.1 99 1 1476 1476 221 1696 4585
ZNF670 NM_033213.4 100 1 1170 1170 218 1387 4198
ZNF71 NM_021216.4 99 1 1470 1470 239 1708 3144
ZNF767 XM_005249956.1† 97 7 356 357 308 657 3872
ZNF829 NM_001037232.3 100 1 1299 1299 366 1664 5056
ZNHIT1 NM_006349.2 100 1 465 465 493 957 1208
ZNRD1 NM_001278785.1 99 1 381 381 161 541 760
ZSCAN1 NM_182572.3 99 1 370 537 248 617 2054
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Appendix B
List of Protein-Protein
Interactions
For each protein-protein interaction detected in this study phosphotyrosine-
dependency (pYd) and the collected evidence are indicated. For greater clarity,
each (non-self-)interaction is listed twice. Y2H = Yeast two-hybrid; bp = bait-
prey; pb = prey-bait; mm = multimer; PCA = protein complementation assay;
CoIP = co-immunoprecipitation from mammalian cell culture; pos = positive;
neg = negative.
Interaction pYd Evidence
ABL2 (KD) CRK (ORF #1) Yes Y2H(pb)
ABL2 (WT) PIK3R3 (ORF #2) Yes Y2H(bp)
ABL2 (KD) STAT3 (ORF #1) Yes Y2H(pb)
ACAP1 GRB2 (ORF #2) Yes Y2H(pb)
ACAP1 RABGAP1L (ORF #1) Yes Y2H(pb)
ADCK5 TENC1 No Y2H(pb)
AHDC1 DOK5 No Y2H(pb)
AKT1 APPL1 (ORF #1) No Y2H(pb)
ANAPC10 MAPK8IP2 No Y2H(pb)
ANGPT1 MAPK8IP2 Yes Y2H(pb), CoIP(pos)
ANKRD50 MIST No Y2H(pb)
ANKS1A ARHGAP10 No Y2H(bp)
ANKS1A DOK3 (ORF #1) No Y2H(bp)
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Interaction pYd Evidence
ANKS1A KLF15 No Y2H(bp)
ANKS1A NHLRC2 No Y2H(bp)
ANKS1A PIK3R3 (ORF #5) Yes Y2H(bp)
ANKS1A RANBP3 No Y2H(bp)
ANKS1A RB1 No Y2H(bp)
ANKS1A SMARCD1 No Y2H(bp)
ANKS1A TRIT1 No Y2H(bp)
ANKS1B RIN1 No Y2H(pb)
ANKZF1 CRK (ORF #3) No Y2H(pb)
ANLN CRK (ORF #3) No Y2H(pb)
AP1S2 TENC1 No Y2H(pb)
APBB3 DAPP1 (ORF #1) No Y2H(pb), CoIP(pos)
APBB3 PDPK1 (ORF #1) Yes Y2H(bp), CoIP(neg)
APPL1 (ORF #1) AKT1 No Y2H(bp)
APPL1 (ORF #2) BATF3 Yes Y2H(bp)
APPL1 (ORF #2) BRWD1 Yes Y2H(bp)
APPL1 (ORF #1) C22orf28 Yes Y2H(bp), CoIP(pos)
APPL1 (ORF #2) CBL Yes Y2H(bp)
APPL1 (ORF #2) CBLB (ORF #2) Yes Y2H(bp)
APPL1 (ORF #2) DOK2 (ORF #2) Yes Y2H(bp)
APPL1 (ORF #2) DOK3 (ORF #2) Yes Y2H(bp)
APPL1 (ORF #2) DOK7 Yes Y2H(bp)
APPL1 (ORF #2) ID1 Yes Y2H(bp)
APPL1 (ORF #2) INO80E Yes Y2H(bp)
APPL1 (ORF #2) KLF15 Yes Y2H(bp)
APPL1 (ORF #2) MAGEC3 Yes Y2H(bp)
APPL1 (ORF #2) PIK3R1 Yes Y2H(bp)
APPL1 (ORF #1) PIK3R2 No Y2H(bp), CoIP(neg)
APPL1 (ORF #1) SCAPER No Y2H(bp)
APPL1 SH2D2A Yes
ORF #1 SH2D2A CoIP(neg)
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Interaction pYd Evidence
ORF #2 SH2D2A Y2H(bp)
APPL1 (ORF #2) SOCS6 Yes Y2H(bp)
APPL1 (ORF #1) TP53 No Y2H(bp)
APPL1 (ORF #2) ZNF829 Yes Y2H(bp)
APPL2 ATF3 No Y2H(bp)
APPL2 C17orf82 No Y2H(bp)
APPL2 CRBN No Y2H(bp)
APPL2 CRLF3 No Y2H(bp)
APPL2 DOK3 (ORF #1) No Y2H(bp)
APPL2 GBL Yes Y2H(bp)
APPL2 LDHAL6B No Y2H(bp)
APPL2 LECT1 No Y2H(bp)
APPL2 LGALS9C Yes Y2H(bp), CoIP(neg)
APPL2 LIX1 Yes Y2H(bp), CoIP(neg)
APPL2 MAPRE3 Yes Y2H(bp), CoIP(pos)
APPL2 MLL3 Yes Y2H(bp)
APPL2 PINK1 No Y2H(bp)
APPL2 RAI2 No Y2H(bp)
APPL2 RBP7 No Y2H(bp)
APPL2 TSC1 (ORF #1) No Y2H(bp)
ARAP3 MIST Yes Y2H(pb)
ARFGAP1 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(neg)
ARHGAP10 ANKS1A No Y2H(pb)
ARHGAP10 SH3BP2 (ORF #1) Yes Y2H(pb)
ARID5A SH2D2A No Y2H(pb)
ARL6IP4 GRB2 (ORF #2) No
Y2H(pb), PCA(pos),
CoIP(pos)
ARL6IP4 PIK3R3 Yes
ARL6IP4 ORF #1 PCA(pos)
ARL6IP4 ORF #2 Y2H(pb), CoIP(pos)
ASB3 RIN3 No
ASB3 ORF #1 Y2H(pb)
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ASB3 ORF #2 Y2H(pb)
ASB3 SH2D2A Yes Y2H(pb), CoIP(pos)
ASB3 TENC1 No Y2H(pb)
ASB8 RIN3 (ORF #1) No Y2H(pb)
ASB9 CRK (ORF #3) No Y2H(pb), CoIP(pos)
ASB9 PLCG2 No Y2H(pb), CoIP(neg)
ASCL4 CRK (ORF #2) No Y2H(pb)
ATF3 APPL2 No Y2H(pb)
ATF3 CRK (ORF #2) No Y2H(pb)
ATF3 DOK5 No Y2H(pb)
ATF3 SH2D1A Yes Y2H(pb)
ATF3 STAT3 (ORF #2) No Y2H(pb)
BAIAP2 EPS8 No
ORF #1 EPS8 Y2H(pb)
ORF #2 EPS8 Y2H(pb)
BAIAP2 (ORF #2) GRB10 Yes Y2H(pb)
BAT2L CRK (ORF #3) No Y2H(pb)
BATF3 APPL1 (ORF #2) Yes Y2H(pb)
BATF3 CRK No
BATF3 ORF #1 Y2H(pb)
BATF3 ORF #2 Y2H(pb)
BATF3 STAT3 (ORF #2) No Y2H(pb)
BCAR3 IRS1 Yes Y2H(pb), CoIP(pos)
BECN1 BTK (ORF #2) No Y2H(pb)
BECN1 FRS2 No Y2H(pb)
BECN1 SHD No Y2H(pb)
BECN1 YES1 Yes Y2H(pb), CoIP(neg)
BEX5 CRK (ORF #2) Yes Y2H(pb)
BMX MIST No
ORF #2 MIST Y2H(pb)
ORF #3 MIST Y2H(pb)
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Interaction pYd Evidence
BMX (ORF #2) STAT3 (ORF #2) No Y2H(pb)
BRWD1 APPL1 (ORF #2) Yes Y2H(pb)
BRWD1 STAT3 (ORF #1) Yes Y2H(pb)
BTK (ORF #2) BECN1 No Y2H(bp)
BTK (ORF #2) MRPS22 No Y2H(bp)
BTK (ORF #2) PIK3R3 (ORF #2) Yes Y2H(pb)
C10orf18 STAT3 Yes
C10orf18 ORF #1 Y2H(pb)
C10orf18 ORF #2 Y2H(pb)
C10orf81 GRB2 (ORF #2) Yes
Y2H(pb), PCA(pos),
CoIP(pos)
C10orf81 PIK3R3 Yes
C10orf81 ORF #1 PCA(pos)
C10orf81 ORF #2 Y2H(pb), CoIP(pos)
C17orf53 PIK3R3 (ORF #2) No Y2H(pb)
C17orf82 APPL2 No Y2H(pb)
C17orf82 SH2D2A No Y2H(pb)
C19orf66 TENC1 No Y2H(pb)
C1orf135 GRB2 (ORF #2) Yes Y2H(pb)
C1orf135 PIK3R3 No
C1orf135 ORF #1 Y2H(pb)
C1orf135 ORF #2 CoIP(neg)
C1orf62 NOS1AP No Y2H(pb)
C1QTNF3 MAPK8IP2 No Y2H(pb)
C21orf77 TENC1 No Y2H(pb)
C22orf28 APPL1 (ORF #1) Yes Y2H(pb), CoIP(pos)
C22orf28 CRK (ORF #3) Yes Y2H(pb), CoIP(neg)
C22orf29 PLCG2 No Y2H(pb)
C22orf39 MAPK8IP2 Yes Y2H(pb), CoIP(neg)
C3orf10 PIK3R3 (ORF #2) No Y2H(pb)
C3orf34 PIK3R3 (ORF #2) No Y2H(pb)
C4orf17 CRK (ORF #2) No Y2H(pb)
307
APPENDIX B
Interaction pYd Evidence
C5orf35 CRK (ORF #3) No Y2H(pb)
C5orf35 PLCG2 No Y2H(pb)
C6orf125 GRB2 (ORF #2) Yes Y2H(pb)
C6orf125 RABGAP1L (ORF #1) Yes Y2H(pb)
C6orf141 CRK (ORF #2) No Y2H(pb)
C6orf141 EPS8 No Y2H(pb)
C6orf146 MIST Yes Y2H(pb)
C8orf33 MAPK8IP2 Yes Y2H(pb), CoIP(neg)
C9orf43 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(pos)
CA8 STAT3 (ORF #2) Yes Y2H(pb)
CAMK1 PIK3R3 (ORF #2) No Y2H(pb)
CAPN10 SHD Yes Y2H(pb)
CBL APPL1 (ORF #2) Yes Y2H(pb)
CBL CBL No Y2H(mm)
CBL CRK Yes
CBL ORF #1 Y2H(pb)
CBL ORF #2 Y2H(pb)
CBL CRKL (ORF #2) No Y2H(bp)
CBL EPS8 Yes Y2H(pb)
CBL FYN (ORF #2) No Y2H(bp)
CBL GRAP2 (ORF #1) No Y2H(pb)
CBL GRB2 (ORF #2) No Y2H(pb), CoIP(pos)
CBL MZF1 No Y2H(bp)
CBL PIK3R1 Yes Y2H(bp)
CBL PIK3R2 Yes Y2H(pb), CoIP(neg)
CBL PIK3R3 Yes
CBL ORF #1 Y2H(bp)
CBL ORF #2
Y2H(bp & pb),
CoIP(pos)
CBL PRKCA No Y2H(bp)
CBL SERPINA5 No Y2H(bp)
CBL STAT3 (ORF #2) Yes Y2H(pb)
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Interaction pYd Evidence
CBL STAT5A Yes Y2H(pb), CoIP(neg)
CBLB (ORF #2) APPL1 (ORF #2) Yes Y2H(pb)
CBLB CRK Yes
ORF #1 ORF #1 Y2H(bp)
ORF #1 ORF #3 CoIP(neg)
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
CBLB (ORF #1) CRKL (ORF #2) Yes Y2H(bp)
CBLB (ORF #1) FYN (ORF #2) No Y2H(pb), CoIP(neg)
CBLB (ORF #2) GRAP2 (ORF #1) No Y2H(pb)
CBLC CRK (ORF #2) Yes Y2H(pb)
CCDC14 PIK3R3 (ORF #2) Yes Y2H(pb)
CCDC33 PIK3R3 (ORF #2) No Y2H(pb)
CCDC74A SH2D1A No Y2H(pb)
CCDC87 STAT3 (ORF #2) Yes Y2H(pb)
CCM2 DOK4 Yes Y2H(pb), CoIP(pos)
CCM2 KRIT1 No Y2H(bp)
CCM2 TWIST2 Yes Y2H(bp), CoIP(pos)
CCM2 VSTM2L Yes Y2H(bp), CoIP(pos)
CDCA4 DOK5 No Y2H(pb)
CENPB SH2D3A No Y2H(pb)
CHN2 RANBP3 No Y2H(bp)
CHN2 RB1 No Y2H(bp)
CHN2 SMARCD1 No Y2H(bp)
CHN2 TP53RK No Y2H(bp)
CHTF18 CRK (ORF #2) Yes Y2H(pb)
CHTF18 STAT3 No
CHTF18 ORF #1 Y2H(pb)
CHTF18 ORF #2 Y2H(pb)
CKM NOS1AP No Y2H(pb)
CNDP2 CRK (ORF #2) Yes Y2H(pb)
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CNDP2 DAPP1 (ORF #2) No Y2H(pb)
CNDP2 STAT3 No
CNDP2 ORF #1 Y2H(pb)
CNDP2 ORF #2 Y2H(pb)
COQ9 MIST Yes Y2H(pb)
CORO6 CRK (ORF #3) No Y2H(pb)
COX6B2 TENC1 No Y2H(pb)
CRBN APPL2 No Y2H(pb)
CRBN GRB2 (ORF #2) Yes Y2H(pb)
CRBN PIK3R3 (ORF #2) No Y2H(pb)
CRK (ORF #1) ABL2 (KD) Yes Y2H(bp)
CRK (ORF #3) ANKZF1 No Y2H(bp)
CRK (ORF #3) ANLN No Y2H(bp)
CRK (ORF #3) ASB9 No Y2H(bp), CoIP(pos)
CRK (ORF #2) ASCL4 No Y2H(bp)
CRK (ORF #2) ATF3 No Y2H(bp)
CRK (ORF #3) BAT2L No Y2H(bp)
CRK BATF3 No
ORF #1 BATF3 Y2H(bp)
ORF #2 BATF3 Y2H(bp)
CRK (ORF #2) BEX5 Yes Y2H(bp)
CRK (ORF #3) C22orf28 Yes Y2H(bp), CoIP(neg)
CRK (ORF #2) C4orf17 No Y2H(bp)
CRK (ORF #3) C5orf35 No Y2H(bp)
CRK (ORF #2) C6orf141 No Y2H(bp)
CRK CBL Yes
ORF #1 CBL Y2H(bp)
ORF #2 CBL Y2H(bp)
CRK CBLB Yes
ORF #1 ORF #1 Y2H(pb)
ORF #1 ORF #2 Y2H(bp)
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Interaction pYd Evidence
ORF #2 ORF #2 Y2H(bp)
ORF #3 ORF #1 CoIP(neg)
CRK (ORF #2) CBLC Yes Y2H(bp)
CRK (ORF #2) CHTF18 Yes Y2H(bp)
CRK (ORF #2) CNDP2 Yes Y2H(bp)
CRK (ORF #3) CORO6 No Y2H(bp)
CRK DOK2 Yes
ORF #1 ORF #2 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
CRK DOK3 Yes
ORF #1 ORF #2 Y2H(bp)
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
CRK (ORF #2) DOK7 Yes Y2H(bp)
CRK (ORF #3) ELK1 Yes Y2H(bp), CoIP(neg)
CRK (ORF #3) EPYC (ORF #2) Yes Y2H(bp)
CRK (ORF #3) ESD No Y2H(bp)
CRK (ORF #2) EYA3 Yes Y2H(bp)
CRK FAM59A Yes
ORF #1 FAM59A Y2H(bp)
ORF #2 FAM59A Y2H(bp)
CRK (ORF #1) FER No Y2H(pb)
CRK (ORF #3) FSTL1 Yes Y2H(bp)
CRK (ORF #2) GABPB2 (ORF #2) Yes Y2H(bp)
CRK (ORF #3) HABP4 No Y2H(bp)
CRK (ORF #2) HSH2D (ORF #1) Yes Y2H(bp)
CRK (ORF #3) IFT140 No Y2H(bp)
CRK (ORF #2) INO80E No Y2H(bp)
CRK (ORF #3) ISL1 No Y2H(bp)
CRK KCTD13 Yes
ORF #1 KCTD13 Y2H(bp)
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ORF #2 KCTD13 Y2H(bp)
CRK (ORF #3) KCTD17 No Y2H(bp)
CRK (ORF #2) KLF15 No Y2H(bp)
CRK (ORF #2) KLHL20 Yes Y2H(bp)
CRK LASP1 Yes
ORF #1 LASP1 Y2H(bp)
ORF #2 LASP1 Y2H(bp)
ORF #3 LASP1 CoIP(neg)
CRK (ORF #3) LHX8 No Y2H(bp)
CRK (ORF #2) MAGEC3 Yes Y2H(bp)
CRK (ORF #1) MIST No Y2H(pb)
CRK MNDA No
ORF #1 MNDA Y2H(bp)
ORF #2 MNDA Y2H(bp)
CRK (ORF #3) MPG Yes Y2H(bp)
CRK (ORF #2) MYLIP Yes Y2H(bp)
CRK (ORF #2) MYOZ2 Yes Y2H(bp)
CRK (ORF #2) NUFIP2 Yes Y2H(bp)
CRK (ORF #2) OFCC1 Yes Y2H(bp)
CRK (ORF #2) PAFAH1B2 Yes Y2H(bp)
CRK (ORF #2) PHC2 Yes Y2H(bp)
CRK PIK3R1 Yes
ORF #1 PIK3R1 Y2H(bp)
ORF #2 PIK3R1 Y2H(bp)
ORF #3 PIK3R1 CoIP(neg)
CRK PIK3R2 Yes
ORF #2 PIK3R2 Y2H(bp)
ORF #3 PIK3R2 CoIP(neg)
CRK PIK3R3 Yes
ORF #1 ORF #3 Y2H(bp)
ORF #1 ORF #5 Y2H(bp)
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Interaction pYd Evidence
ORF #2 ORF #3 Y2H(bp)
ORF #2 ORF #4 Y2H(bp)
ORF #2 ORF #5 Y2H(bp)
CRK (ORF #2) PRKACA Yes Y2H(bp)
CRK (ORF #3) PRRG2 Yes Y2H(bp)
CRK (ORF #2) PSMC1 No Y2H(bp)
CRK (ORF #1) PTK2 (ORF #1 KD) Yes Y2H(bp)
CRK (ORF #3) PTTG1 No Y2H(bp)
CRK (ORF #2) RAB2B Yes Y2H(bp)
CRK (ORF #4) RIN3 (ORF #3) No Y2H(pb)
CRK RYBP No
ORF #1 ORF #2 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
CRK (ORF #3) SEMA4D Yes Y2H(bp), CoIP(neg)
CRK SEPT6 No
ORF #1 ORF #1 Y2H(bp)
ORF #1 ORF #2 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
CRK SH2D2A Yes
ORF #1 SH2D2A Y2H(bp)
ORF #2 SH2D2A Y2H(bp)
ORF #3 SH2D2A CoIP(neg)
CRK (ORF #2) SOCS1 Yes Y2H(bp)
CRK (ORF #2) SOCS6 Yes Y2H(bp)
CRK (ORF #3) STAT4 Yes Y2H(bp), CoIP(neg)
CRK (ORF #3) STRN4 No Y2H(bp)
CRK (ORF #2) TCAP Yes Y2H(bp)
CRK (ORF #2) TDG No Y2H(bp)
CRK (ORF #2) TM4SF19 Yes Y2H(bp)
CRK (ORF #3) TP53 No Y2H(bp)
CRK (ORF #3) TUBA1C No Y2H(bp)
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CRK (ORF #3) TWIST2 No Y2H(bp), CoIP(neg)
CRK (ORF #1) VAC14 Yes Y2H(bp)
CRK WDR83 No
ORF #1 WDR83 Y2H(bp)
ORF #2 WDR83 Y2H(bp)
CRK (ORF #3) ZNF167 No Y2H(bp)
CRK (ORF #2) ZNF557 No Y2H(bp)
CRKL (ORF #2) CBL No Y2H(pb)
CRKL (ORF #2) CBLB (ORF #1) Yes Y2H(pb)
CRKL (ORF #1) DOK1 Yes Y2H(pb)
CRKL (ORF #1) DOK2 (ORF #1) Yes Y2H(pb)
CRKL (ORF #1) KIAA0317 Yes Y2H(bp)
CRKL (ORF #1) RIN3 (ORF #3) No Y2H(pb)
CRKL (ORF #1) SOCS1 Yes Y2H(bp)
CRKL (ORF #1) TENC1 No Y2H(pb)
CRKL (ORF #1) TMEM168 Yes Y2H(bp)
CRLF3 APPL2 No Y2H(pb)
CRP MAPK8IP2 No Y2H(pb)
CRYBA2 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
CSAD SH2B1 Yes Y2H(pb)
CSK PDPK1 (ORF #2) Yes Y2H(bp), CoIP(neg)
CSRP3 RIN3 No
CSRP3 ORF #1 Y2H(pb)
CSRP3 ORF #2 Y2H(pb)
CTNNBL1 MAPK8IP2 No Y2H(pb)
CYB561D2 MIST Yes Y2H(pb)
CYP2C8 RIN3 (ORF #1) No Y2H(pb)
CYP46A1 RIN3 (ORF #1) No Y2H(pb)
DAPP1 (ORF #1) APBB3 No Y2H(bp), CoIP(pos)
DAPP1 (ORF #2) CNDP2 No Y2H(bp)
DAPP1 (ORF #2) GSTCD Yes Y2H(bp)
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DAPP1 (ORF #2) MYLIP Yes Y2H(bp)
DAPP1 (ORF #2) OSAP No Y2H(bp)
DAPP1 (ORF #1) PLAGL2 No Y2H(bp), CoIP(neg)
DAPP1 (ORF #1) RBP7 No Y2H(bp)
DAPP1 (ORF #2) TM4SF19 No Y2H(bp)
DAPP1 (ORF #2) TNFAIP1 Yes Y2H(bp)
DAPP1 (ORF #1) WDR20 Yes Y2H(bp), CoIP(pos)
DAPP1 (ORF #1) ZNHIT1 Yes Y2H(bp)
DBN1 GRB2 (ORF #2) Yes Y2H(pb), CoIP(pos)
DBN1 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(neg)
DDIT4L TENC1 No Y2H(pb)
DDX5 FRS3 (ORF #2) No Y2H(pb)
DOK1 CRKL (ORF #1) Yes Y2H(bp)
DOK1 DOK3 (ORF #1) Yes Y2H(bp)
DOK2 (ORF #2) APPL1 (ORF #2) Yes Y2H(pb)
DOK2 CRK Yes
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
DOK2 (ORF #1) CRKL (ORF #1) Yes Y2H(bp)
DOK2 (ORF #1) DOK3 (ORF #1) Yes Y2H(bp)
DOK2 (ORF #1) LCK (ORF #2) Yes Y2H(bp)
DOK2 (ORF #2) STAT3 (ORF #1) Yes Y2H(pb)
DOK3 (ORF #1) ANKS1A No Y2H(pb)
DOK3 (ORF #2) APPL1 (ORF #2) Yes Y2H(pb)
DOK3 (ORF #1) APPL2 No Y2H(pb)
DOK3 CRK Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
DOK3 (ORF #1) DOK1 Yes Y2H(pb)
DOK3 (ORF #1) DOK2 (ORF #1) Yes Y2H(pb)
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DOK3 (ORF #1) DOK4 Yes Y2H(pb), CoIP(pos)
DOK3 (ORF #1) DOK5 Yes Y2H(pb)
DOK3 (ORF #1) RIN3 (ORF #2) No Y2H(pb)
DOK3 (ORF #1) SHE Yes Y2H(pb)
DOK3 STAT3 Yes
ORF #1 ORF #1 Y2H(pb)
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
DOK3 (ORF #1) TENC1 No Y2H(pb)
DOK4 CCM2 Yes Y2H(bp), CoIP(pos)
DOK4 DOK3 (ORF #1) Yes Y2H(bp), CoIP(pos)
DOK4 LIX1 No Y2H(bp)
DOK4 MAPRE3 No Y2H(bp)
DOK4 OLIG1 No Y2H(bp), CoIP(neg)
DOK4 PTK2 (ORF #1 WT) Yes Y2H(bp), CoIP(neg)
DOK4 RBP7 No Y2H(bp)
DOK4 STAT2 Yes Y2H(bp), CoIP(neg)
DOK5 AHDC1 No Y2H(bp)
DOK5 ATF3 No Y2H(bp)
DOK5 CDCA4 No Y2H(bp)
DOK5 DOK3 (ORF #1) Yes Y2H(bp)
DOK5 FANCG No Y2H(bp)
DOK5 OLIG1 No Y2H(bp)
DOK5 RAI2 No Y2H(bp)
DOK5 SCOC Yes Y2H(bp), CoIP(neg)
DOK5 TSC1 (ORF #1) No Y2H(bp)
DOK5 WIZ No Y2H(bp)
DOK7 APPL1 (ORF #2) Yes Y2H(pb)
DOK7 CRK (ORF #2) Yes Y2H(pb)
DOK7 EFHC1 No Y2H(bp)
DOK7 MPZL1 Yes Y2H(bp)
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DOK7 YPEL3 No Y2H(bp)
DTNA STAT3 Yes
DTNA ORF #1 Y2H(pb)
DTNA ORF #2 Y2H(pb)
DUSP18 MAPK8IP2 No Y2H(pb)
E2F2 GRB2 (ORF #2) Yes Y2H(pb)
E2F6 PIK3R3 (ORF #2) Yes Y2H(pb)
EFHC1 DOK7 No Y2H(pb)
ELK1 CRK (ORF #3) Yes Y2H(pb), CoIP(neg)
ELK1 PLCG2 Yes Y2H(pb), CoIP(neg)
EPB41L4A TENC1 No Y2H(pb)
EPS8 BAIAP2 No
EPS8 ORF #1 Y2H(bp)
EPS8 ORF #2 Y2H(bp)
EPS8 C6orf141 No Y2H(bp)
EPS8 CBL Yes Y2H(bp)
EPS8 RCAN3 No Y2H(bp), CoIP(neg)
EPS8 RTDR1 No Y2H(bp)
EPS8 SERPINA5 No Y2H(bp)
EPS8 XAGE2XX Yes Y2H(bp)
EPS8L2 RIN3 No
EPS8L2 ORF #1 Y2H(pb)
EPS8L2 ORF #2 Y2H(pb)
EPS8L2 TENC1 No Y2H(pb)
EPYC (ORF #2) CRK (ORF #3) Yes Y2H(pb)
EPYC (ORF #1) PLCG2 Yes Y2H(pb)
ESD CRK (ORF #3) No Y2H(pb)
ESD PLCG2 No Y2H(pb)
EVI1 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(neg)
EVI1 RABGAP1L Yes
EVI1 ORF #1 Y2H(pb)
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EVI1 ORF #3 CoIP(pos)
EYA3 CRK (ORF #2) Yes Y2H(pb)
EZH2 RIN3 (ORF #2) No Y2H(pb)
FABP7 TENC1 No Y2H(pb)
FAM114A1 TENC1 No Y2H(pb)
FAM117B STAT3 (ORF #2) Yes Y2H(pb)
FAM127C RIN3 (ORF #1) No Y2H(pb)
FAM46A RIN3 No
FAM46A ORF #1 Y2H(pb)
FAM46A ORF #2 Y2H(pb)
FAM46A SH2D2A Yes Y2H(pb), CoIP(pos)
FAM46A SYK (ORF #1 WT) Yes Y2H(pb), CoIP(pos)
FAM46A TENC1 No Y2H(pb)
FAM46B SH2D2A Yes Y2H(pb), CoIP(pos)
FAM59A CRK Yes
FAM59A ORF #1 Y2H(pb)
FAM59A ORF #2 Y2H(pb)
FAM59A GRAP2 (ORF #1) No Y2H(pb)
FANCG DOK5 No Y2H(pb)
FER CRK (ORF #1) No Y2H(bp)
FER KCTD4 Yes Y2H(bp)
FER PIK3R1 No Y2H(bp)
FER PIK3R3 (ORF #5) No Y2H(bp)
FER PPP1R7 No Y2H(bp)
FGF12 MAPK8IP2 No Y2H(pb)
FGF13 MAPK8IP2 No Y2H(pb)
FGF21 TENC1 No Y2H(pb)
FOXO1 PIK3R3 (ORF #2) No Y2H(pb)
FOXO1 TENC1 No Y2H(pb)
FRS2 BECN1 No Y2H(bp)
FRS2 RPS6 No Y2H(bp)
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FRS3 (ORF #2) DDX5 No Y2H(bp)
FRS3 FRS3 No
ORF #1 ORF #2 Y2H(mm)
ORF #2 ORF #2 CoIP(pos)
FRS3 (ORF #2) GRB14 No Y2H(bp)
FRS3 HCK No
ORF #1 HCK Y2H(pb)
ORF #2 HCK CoIP(pos)
FRS3 (ORF #2) MATK (ORF #2) Yes Y2H(bp), CoIP(neg)
FRS3 (ORF #2) NUMB (ORF #2) Yes Y2H(bp), CoIP(neg)
FRS3 (ORF #2) PIK3R3 (ORF #2) Yes Y2H(bp), CoIP(pos)
FRS3 (ORF #2) SH2B1 No Y2H(bp)
FRS3 (ORF #2) SOCS4 No Y2H(bp), CoIP(pos)
FRS3 (ORF #2) SOCS6 No Y2H(bp)
FRS3 (ORF #2) TNS1 No Y2H(bp)
FRS3 VASP Yes
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 CoIP(neg)
FSTL1 CRK (ORF #3) Yes Y2H(pb)
FYB FYN Yes
FYB ORF #2 Y2H(bp)
FYB SH2 Y2H(bp)
FYB LCP2 Yes Y2H(bp)
FYB NCK2 Yes Y2H(bp)
FYN (ORF #2) CBL No Y2H(pb)
FYN (ORF #2) CBLB (ORF #1) No Y2H(bp), CoIP(neg)
FYN FYB Yes
ORF #2 FYB Y2H(pb)
SH2 FYB Y2H(pb)
FYN (SH2) NOS1AP No Y2H(pb)
FYN (ORF #1 WT) PIK3R3 (ORF #2) No Y2H(pb)
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GABPB2 (ORF #2) CRK (ORF #2) Yes Y2H(pb)
GABPB2 (ORF #1) PLCG2 No Y2H(pb)
GALNT3 MAPK8IP2 No Y2H(pb)
GATA1 RIN3 (ORF #2) No Y2H(pb)
GATA1 TENC1 No Y2H(pb)
GBA3 TENC1 No Y2H(pb)
GBL APPL2 Yes Y2H(pb)
GLIS3 MIST Yes Y2H(pb)
GRAP2 (ORF #1) CBL No Y2H(bp)
GRAP2 (ORF #1) CBLB (ORF #2) No Y2H(bp)
GRAP2 (ORF #1) FAM59A No Y2H(bp)
GRAP2 (ORF #2) RIN3 (ORF #3) No Y2H(pb)
GRB2 (ORF #2) ACAP1 Yes Y2H(bp)
GRB2 (ORF #2) ARL6IP4 No
Y2H(bp), PCA(pos),
CoIP(pos)
GRB2 (ORF #2) C10orf81 Yes
Y2H(bp), PCA(pos),
CoIP(pos)
GRB2 (ORF #2) C1orf135 Yes Y2H(bp)
GRB2 (ORF #2) C6orf125 Yes Y2H(bp)
GRB2 (ORF #2) CBL No Y2H(bp), CoIP(pos)
GRB2 (ORF #2) CRBN Yes Y2H(bp)
GRB2 (ORF #2) DBN1 Yes Y2H(bp), CoIP(pos)
GRB2 (ORF #2) E2F2 Yes Y2H(bp)
GRB2 (ORF #2) LMX1A Yes Y2H(bp), CoIP(pos)
GRB2 (ORF #1) MIST No Y2H(pb)
GRB2 (ORF #2) MYOZ1 Yes Y2H(bp), CoIP(neg)
GRB2 (ORF #2) OLIG1 No
Y2H(bp), PCA(neg),
CoIP(neg)
GRB2 (ORF #2) PACRGL Yes Y2H(bp), CoIP(neg)
GRB2 (ORF #2) PARD6A Yes
Y2H(bp), PCA(pos),
CoIP(pos)
GRB2 (ORF #2) PCDHB5 Yes Y2H(bp)
GRB2 (ORF #2) PPARA Yes Y2H(bp), CoIP(pos)
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GRB2 (ORF #2) RB1 Yes
Y2H(bp), PCA(pos),
CoIP(pos)
GRB2 (ORF #2) SOCS4 Yes
Y2H(bp), PCA(neg),
CoIP(pos)
GRB2 (ORF #2) TMEM128 Yes
Y2H(bp), PCA(neg),
CoIP(pos)
GRB2 (ORF #2) TSPAN2 Yes
Y2H(bp), PCA(pos),
CoIP(pos)
GRB2 VCP Yes
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 CoIP(pos)
GRB2 (ORF #2) WBSCR27 No
Y2H(bp), PCA(neg),
CoIP(neg)
GRB2 (ORF #2) WDFY3 Yes Y2H(bp), CoIP(neg)
GRB2 (ORF #2) ZMAT1 No Y2H(bp)
GRB7 OLIG1 Yes Y2H(bp), CoIP(pos)
GRB7 PTK2 (ORF #1 WT) Yes Y2H(bp), CoIP(pos)
GRB7 ZNHIT1 Yes Y2H(bp)
GRB10 BAIAP2 (ORF #2) Yes Y2H(bp)
GRB10 RCAN3 Yes Y2H(bp), CoIP(pos)
GRB14 FRS3 (ORF #2) No Y2H(pb)
GRB14 HCK No Y2H(pb)
GRB14 MST4 Yes Y2H(bp)
GSTCD DAPP1 (ORF #2) Yes Y2H(pb)
GSTCD MIST No Y2H(pb)
GSTCD STAT3 Yes
GSTCD ORF #1 Y2H(pb)
GSTCD ORF #2 Y2H(pb)
GSTCD TNS4 Yes Y2H(pb)
HABP4 CRK (ORF #3) No Y2H(pb)
HCK FRS3 No
HCK ORF #1 Y2H(bp)
HCK ORF #2 CoIP(pos)
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HCK GRB14 No Y2H(bp)
HCK LETMD1 No Y2H(bp)
HCK NGEF Yes Y2H(bp)
HCK OLIG1 No Y2H(bp), CoIP(pos)
HCK PIK3R3 Yes
HCK ORF #1 Y2H(bp)
HCK ORF #2 Y2H(bp), CoIP(pos)
HCK ORF #3 Y2H(bp)
HCK PTK2 (ORF #1 WT) No Y2H(bp), CoIP(pos)
HESX1 STAT3 Yes
HESX1 ORF #1 Y2H(pb)
HESX1 ORF #2 Y2H(pb)
HLA-C MAPK8IP2 No Y2H(pb)
HSH2D (ORF #1) CRK (ORF #2) Yes Y2H(pb)
HSH2D (ORF #2) LDHAL6B Yes Y2H(bp)
HSH2D (ORF #2) LECT1 Yes Y2H(bp)
HSH2D (ORF #2) OLIG1 No Y2H(bp)
HSH2D PIK3R3 Yes
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 Y2H(bp), CoIP(neg)
ORF #2 ORF #3 Y2H(bp)
HSH2D (ORF #2) PINK1 Yes Y2H(bp)
HSH2D (ORF #2) PPAPDC2 Yes Y2H(bp)
HSH2D (ORF #2) RBP7 Yes Y2H(bp)
HSH2D (ORF #2) TNK2 No Y2H(bp)
HSH2D (ORF #2) TSC1 (ORF #1) Yes Y2H(bp)
HSPA1A MAPK8IP2 No
ORF #1 MAPK8IP2 Y2H(pb)
ORF #2 MAPK8IP2 CoIP(pos)
HSPA1A SH2D1B Yes
ORF #1 ORF #3 Y2H(pb)
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ORF #2 ORF #3 CoIP(pos)
HSPD1 (ORF #1) NOS1AP No Y2H(pb)
HSPD1 (ORF #2) PLCG2 Yes Y2H(pb)
HUWE1 TENC1 No Y2H(pb)
ID1 APPL1 (ORF #2) Yes Y2H(pb)
ID2 RIN3 No
ID2 ORF #1 Y2H(pb)
ID2 ORF #2 Y2H(pb)
ID2 TENC1 No Y2H(pb)
IFT140 CRK (ORF #3) No Y2H(pb)
ING4 MAPK8IP2 No Y2H(pb)
INO80E APPL1 (ORF #2) Yes Y2H(pb)
INO80E CRK (ORF #2) No Y2H(pb)
IQUB PIK3R3 (ORF #2) Yes Y2H(pb)
IRS1 BCAR3 Yes Y2H(bp), CoIP(pos)
IRS1 NUMB (ORF #2) Yes Y2H(bp), CoIP(neg)
IRS1 PELI1 No Y2H(bp)
IRS1 PIK3R1 Yes Y2H(bp), CoIP(pos)
IRS1 PIK3R3 Yes
IRS1 ORF #1 Y2H(bp)
IRS1 ORF #2 Y2H(bp), CoIP(pos)
IRS1 ORF #3 Y2H(bp)
ISL1 CRK (ORF #3) No Y2H(pb)
ISL1 PLCG2 No Y2H(pb)
ITGB1BP1 (ORF #1) KRIT1 No Y2H(bp)
ITGB1BP1 PGRMC1 Yes
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 CoIP(pos)
JAK3 LNX1 Yes Y2H(bp), CoIP(neg)
KCTD13 CRK Yes
KCTD13 ORF #1 Y2H(pb)
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KCTD13 ORF #2 Y2H(pb)
KCTD17 CRK (ORF #3) No Y2H(pb)
KCTD17 PLCG2 No Y2H(pb)
KCTD17 RIN3 (ORF #1) No Y2H(pb)
KCTD4 FER Yes Y2H(pb)
KCTD4 TNS4 No Y2H(pb)
KIAA0317 CRKL (ORF #1) Yes Y2H(pb)
KLF15 ANKS1A No Y2H(pb)
KLF15 APPL1 (ORF #2) Yes Y2H(pb)
KLF15 CRK (ORF #2) No Y2H(pb)
KLF15 PIK3R3 (ORF #2) No Y2H(pb)
KLF15 STAT3 No
KLF15 ORF #1 Y2H(pb)
KLF15 ORF #2 Y2H(pb)
KLHL20 CRK (ORF #2) Yes Y2H(pb)
KLRAQ1 SH2D2A Yes Y2H(pb), CoIP(neg)
KRIT1 CCM2 No Y2H(pb)
KRIT1 ITGB1BP1 (ORF #1) No Y2H(pb)
KRTAP10-7 STAT3 (ORF #2) Yes Y2H(pb)
KRTAP23-1 TENC1 No Y2H(pb)
KRTAP3-1 TENC1 No Y2H(pb)
KRTCAP2 SHD No Y2H(pb)
LASP1 CRK Yes
LASP1 ORF #1 Y2H(pb)
LASP1 ORF #2 Y2H(pb)
LASP1 ORF #3 CoIP(neg)
LASP1 SH2D2A No Y2H(pb), CoIP(pos)
LASP1 STAT3 (ORF #2) Yes Y2H(pb)
LCK (ORF #2) DOK2 (ORF #1) Yes Y2H(pb)
LCK (ORF #2) RIN3 (ORF #2) No Y2H(pb)
LCK (ORF #2) STAT3 (ORF #1) Yes Y2H(pb)
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LCP2 FYB Yes Y2H(pb)
LDHAL6B APPL2 No Y2H(pb)
LDHAL6B HSH2D (ORF #2) Yes Y2H(pb)
LDHAL6B SOCS4 Yes Y2H(pb), CoIP(neg)
LECT1 APPL2 No Y2H(pb)
LECT1 HSH2D (ORF #2) Yes Y2H(pb)
LECT1 SOCS4 Yes Y2H(pb)
LEFTY2 MAPK8IP2 No Y2H(pb)
LETMD1 HCK No Y2H(pb)
LETMD1 SH2D1A No Y2H(pb)
LGALS9C APPL2 Yes Y2H(pb), CoIP(neg)
LHX8 CRK (ORF #3) No Y2H(pb)
LHX8 PLCG2 Yes Y2H(pb)
LIX1 APPL2 Yes Y2H(pb), CoIP(neg)
LIX1 DOK4 No Y2H(pb)
LMX1A GRB2 (ORF #2) Yes Y2H(pb), CoIP(pos)
LNX1 JAK3 Yes Y2H(pb), CoIP(neg)
LNX1 PTPN11 Yes Y2H(pb)
LNX1 SH2D2A Yes Y2H(pb), CoIP(neg)
LNX1 SOCS6 Yes Y2H(pb)
LNX2 NUMB (ORF #1) No Y2H(pb)
LOC285398 TENC1 No Y2H(pb)
LOC492311 MAPK8IP2 Yes Y2H(pb), CoIP(neg)
LRRFIP1 SH2D2A Yes Y2H(pb), CoIP(neg)
LSM8 MAPK8IP2 No Y2H(pb)
LYN (ORF #2) PTK2 (ORF #1 WT) No Y2H(bp)
MAGEC3 APPL1 (ORF #2) Yes Y2H(pb)
MAGEC3 CRK (ORF #2) Yes Y2H(pb)
MAPK8IP2 ANAPC10 No Y2H(bp)
MAPK8IP2 ANGPT1 Yes Y2H(bp), CoIP(pos)
MAPK8IP2 C1QTNF3 No Y2H(bp)
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MAPK8IP2 C22orf39 Yes Y2H(bp), CoIP(neg)
MAPK8IP2 C8orf33 Yes Y2H(bp), CoIP(neg)
MAPK8IP2 CRP No Y2H(bp)
MAPK8IP2 CTNNBL1 No Y2H(bp)
MAPK8IP2 DUSP18 No Y2H(bp)
MAPK8IP2 FGF12 No Y2H(bp)
MAPK8IP2 FGF13 No Y2H(bp)
MAPK8IP2 GALNT3 No Y2H(bp)
MAPK8IP2 HLA-C No Y2H(bp)
MAPK8IP2 HSPA1A No
MAPK8IP2 ORF #1 Y2H(bp)
MAPK8IP2 ORF #2 CoIP(pos)
MAPK8IP2 ING4 No Y2H(bp)
MAPK8IP2 LEFTY2 No Y2H(bp)
MAPK8IP2 LOC492311 Yes Y2H(bp), CoIP(neg)
MAPK8IP2 LSM8 No Y2H(bp)
MAPK8IP2 MNDA No Y2H(bp)
MAPK8IP2 MRE11A No Y2H(bp)
MAPK8IP2 MSRB3 No Y2H(bp)
MAPK8IP2 NUMB (ORF #1) No Y2H(bp)
MAPK8IP2 RABGAP1L No
MAPK8IP2 ORF #1 Y2H(bp)
MAPK8IP2 ORF #2 CoIP(pos)
MAPK8IP2 RBM4 No Y2H(bp)
MAPK8IP2 RYBP No
MAPK8IP2 ORF #1 Y2H(bp)
MAPK8IP2 ORF #2 Y2H(bp)
MAPK8IP2 SCLT1 No Y2H(bp)
MAPK8IP2 SH2D1B No
MAPK8IP2 ORF #1 Y2H(bp)
MAPK8IP2 ORF #3 CoIP(neg)
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MAPK8IP2 SLC39A13 No
MAPK8IP2 ORF #1 Y2H(bp)
MAPK8IP2 ORF #2 Y2H(bp)
MAPK8IP2 SLPI No Y2H(bp)
MAPK8IP2 SPINK2 No Y2H(bp)
MAPK8IP2 SPSB3 No Y2H(bp)
MAPK8IP2 SRP19 No Y2H(bp)
MAPK8IP2 TARBP2 No Y2H(bp)
MAPK8IP2 TMEM128 Yes Y2H(bp), CoIP(neg)
MAPK8IP2 UBD Yes Y2H(bp), CoIP(pos)
MAPK8IP2 USP46 No Y2H(bp)
MAPK8IP2 ZNF670 No Y2H(bp)
MAPK8IP2 ZNRD1 No Y2H(bp)
MAPKAPK2 STAT3 (ORF #2) Yes Y2H(pb)
MAPRE3 APPL2 Yes Y2H(pb), CoIP(pos)
MAPRE3 DOK4 No Y2H(pb)
MATK (ORF #2) FRS3 (ORF #2) Yes Y2H(pb), CoIP(neg)
MIST ANKRD50 No Y2H(bp)
MIST ARAP3 Yes Y2H(bp)
MIST BMX No
MIST ORF #2 Y2H(bp)
MIST ORF #3 Y2H(bp)
MIST C6orf146 Yes Y2H(bp)
MIST COQ9 Yes Y2H(bp)
MIST CRK (ORF #1) No Y2H(bp)
MIST CYB561D2 Yes Y2H(bp)
MIST GLIS3 Yes Y2H(bp)
MIST GRB2 (ORF #1) No Y2H(bp)
MIST GSTCD No Y2H(bp)
MIST NME4 Yes Y2H(bp)
MIST P4HA2 No Y2H(bp)
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MIST PACSIN3 No Y2H(bp)
MIST PIK3R1 Yes Y2H(bp)
MIST PIK3R3 Yes
MIST ORF #3 Y2H(bp)
MIST ORF #5 Y2H(bp)
MIST PPP1R7 Yes Y2H(bp)
MIST PTK7 Yes Y2H(bp)
MIST RASSF1 No Y2H(bp)
MIST RB1 No Y2H(bp)
MIST RPAIN Yes Y2H(bp)
MIST SFMBT1 Yes Y2H(bp)
MIST SMARCD1 No Y2H(bp)
MIST SOCS6 Yes Y2H(bp)
MIST STK36 No Y2H(bp)
MIST TXK No Y2H(bp)
MIST WWOX No Y2H(bp)
MLL3 APPL2 Yes Y2H(pb)
MLL4 PIK3R3 (ORF #2) No Y2H(pb)
MNDA CRK No
MNDA ORF #1 Y2H(pb)
MNDA ORF #2 Y2H(pb)
MNDA MAPK8IP2 No Y2H(pb)
MNDA STAT3 No
MNDA ORF #1 Y2H(pb)
MNDA ORF #2 Y2H(pb)
MPEG1 RIN3 (ORF #2) No Y2H(pb)
MPEG1 TENC1 No Y2H(pb)
MPG CRK (ORF #3) Yes Y2H(pb)
MPP5 SOCS4 Yes Y2H(pb), CoIP(neg)
MPZL1 DOK7 Yes Y2H(pb)
MPZL1 STAT3 (ORF #2) Yes Y2H(pb)
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MRE11A MAPK8IP2 No Y2H(pb)
MRPS22 BTK (ORF #2) No Y2H(pb)
MRPS22 SHD No Y2H(pb)
MSRB3 MAPK8IP2 No Y2H(pb)
MST4 GRB14 Yes Y2H(pb)
MT2A RIN3 No
MT2A ORF #1 Y2H(pb)
MT2A ORF #2 Y2H(pb)
MT2A TENC1 No Y2H(pb)
MTF2 PIK3R3 (ORF #2) No Y2H(pb)
MYBPHL TENC1 No Y2H(pb)
MYH7B TENC1 No Y2H(pb)
MYLIP CRK (ORF #2) Yes Y2H(pb)
MYLIP DAPP1 (ORF #2) Yes Y2H(pb)
MYOZ1 GRB2 (ORF #2) Yes Y2H(pb), CoIP(neg)
MYOZ2 CRK (ORF #2) Yes Y2H(pb)
MZF1 CBL No Y2H(pb)
NACAD STAT3 (ORF #2) No Y2H(pb)
NARG1L SH2D2A No Y2H(pb)
NCK1 (ORF #2) OLIG1 Yes Y2H(bp)
NCK1 (ORF #1) PIK3R3 (ORF #2) Yes Y2H(bp)
NCK1 (ORF #1) SH2D1A Yes Y2H(bp)
NCK2 FYB Yes Y2H(pb)
NGEF HCK Yes Y2H(pb)
NGEF SH2D1A No Y2H(pb)
NHLRC2 ANKS1A No Y2H(pb)
NHP2 NOS1AP No Y2H(pb)
NKAP NOS1AP No
ORF #1 NOS1AP Y2H(pb)
ORF #2 NOS1AP Y2H(pb)
NME4 MIST Yes Y2H(pb)
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NME4 TNS4 Yes Y2H(pb)
NMU TENC1 No Y2H(pb)
NOS1AP C1orf62 No Y2H(bp)
NOS1AP CKM No Y2H(bp)
NOS1AP FYN (SH2) No Y2H(bp)
NOS1AP HSPD1 (ORF #1) No Y2H(bp)
NOS1AP NHP2 No Y2H(bp)
NOS1AP NKAP No
NOS1AP ORF #1 Y2H(bp)
NOS1AP ORF #2 Y2H(bp)
NOS1AP PLAGL2 No Y2H(bp)
NOS1AP PNP No Y2H(bp)
NOS1AP RP13-36C9.6 No Y2H(bp)
NOS1AP RYBP No
NOS1AP ORF #1 Y2H(bp)
NOS1AP ORF #2 Y2H(bp)
NT5C TENC1 No Y2H(pb)
NUFIP2 CRK (ORF #2) Yes Y2H(pb)
NUFIP2 STAT3 (ORF #1) Yes Y2H(pb)
NUMB (ORF #2) FRS3 (ORF #2) Yes Y2H(pb), CoIP(neg)
NUMB (ORF #2) IRS1 Yes Y2H(pb), CoIP(neg)
NUMB (ORF #1) LNX2 No Y2H(bp)
NUMB (ORF #1) MAPK8IP2 No Y2H(pb)
NUMB OLIG1 Yes
ORF #1 OLIG1 Y2H(bp)
ORF #2 OLIG1 CoIP(neg)
NUMB (ORF #1) TERF2 No Y2H(bp)
NXT2 STAT3 (ORF #2) No Y2H(pb)
OBSL1 TENC1 No Y2H(pb)
OFCC1 CRK (ORF #2) Yes Y2H(pb)
OFCC1 STAT3 (ORF #2) No Y2H(pb)
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OLIG1 DOK4 No Y2H(pb), CoIP(neg)
OLIG1 DOK5 No Y2H(pb)
OLIG1 GRB2 (ORF #2) No
Y2H(pb), PCA(neg),
CoIP(neg)
OLIG1 GRB7 Yes Y2H(pb), CoIP(pos)
OLIG1 HCK No Y2H(pb), CoIP(pos)
OLIG1 HSH2D (ORF #2) No Y2H(pb)
OLIG1 NCK1 (ORF #2) Yes Y2H(pb)
OLIG1 NUMB Yes
OLIG1 ORF #1 Y2H(pb)
OLIG1 ORF #2 CoIP(neg)
OLIG1 PIK3R3 (ORF #2) No Y2H(pb), CoIP(pos)
OLIG1 PTPN6 Yes Y2H(pb), CoIP(neg)
OLIG1 RASA1 Yes Y2H(pb)
OLIG1 SH2D1A No Y2H(pb)
OLIG1 SH2D1B No
OLIG1 ORF #2 Y2H(pb)
OLIG1 ORF #3 CoIP(pos)
OLIG1 SH2D4A No Y2H(pb)
OLIG1 SHD No Y2H(pb)
OLIG1 STAT5A Yes Y2H(pb), CoIP(neg)
OLIG1 YES1 Yes Y2H(pb), CoIP(pos)
OSAP DAPP1 (ORF #2) No Y2H(pb)
OSBPL6 SHD No Y2H(pb)
OTUD7B PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
P4HA2 MIST No Y2H(pb)
P4HA2 TNS4 Yes Y2H(pb)
PACRGL GRB2 (ORF #2) Yes Y2H(pb), CoIP(neg)
PACRGL PIK3R3 No
PACRGL ORF #1 CoIP(neg)
PACRGL ORF #2 Y2H(pb)
PACSIN3 MIST No Y2H(pb)
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PAFAH1B2 CRK (ORF #2) Yes Y2H(pb)
PAFAH1B2 STAT3 (ORF #2) No Y2H(pb)
PAQR7 STAT3 (ORF #2) Yes Y2H(pb)
PARD6A GRB2 (ORF #2) Yes
Y2H(pb), PCA(pos),
CoIP(pos)
PARD6A PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
PCDHB5 GRB2 (ORF #2) Yes Y2H(pb)
PCDHB5 PIK3R3 (ORF #2) Yes Y2H(pb)
PDPK1 (ORF #1) APBB3 Yes Y2H(pb), CoIP(neg)
PDPK1 (ORF #2) CSK Yes Y2H(pb), CoIP(neg)
PELI1 IRS1 No Y2H(pb)
PELI3 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
PELO PIK3R3 (ORF #2) Yes Y2H(pb)
PER1 TENC1 No Y2H(pb)
PGRMC1 ITGB1BP1 Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 CoIP(pos)
PHC2 CRK (ORF #2) Yes Y2H(pb)
PIK3CA PIK3R3 (ORF #2) No Y2H(pb)
PIK3CB PIK3R3 (ORF #2) No Y2H(pb)
PIK3R1 APPL1 (ORF #2) Yes Y2H(pb)
PIK3R1 CBL Yes Y2H(pb)
PIK3R1 CRK Yes
PIK3R1 ORF #1 Y2H(pb)
PIK3R1 ORF #2 Y2H(pb)
PIK3R1 ORF #3 CoIP(neg)
PIK3R1 FER No Y2H(pb)
PIK3R1 IRS1 Yes Y2H(pb), CoIP(pos)
PIK3R1 MIST Yes Y2H(pb)
PIK3R1 SH2D2A Yes
Y2H(pb), PCA(neg),
CoIP(pos)
PIK3R1 SOCS1 Yes Y2H(pb)
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PIK3R1 STAT3 (ORF #2) Yes Y2H(pb)
PIK3R1 TNS4 Yes Y2H(pb)
PIK3R2 APPL1 (ORF #1) No Y2H(pb), CoIP(neg)
PIK3R2 CBL Yes Y2H(bp), CoIP(neg)
PIK3R2 CRK Yes
PIK3R2 ORF #2 Y2H(pb)
PIK3R2 ORF #3 CoIP(neg)
PIK3R2 STAT3 (ORF #1) Yes Y2H(pb)
PIK3R3 (ORF #2) ABL2 (WT) Yes Y2H(pb)
PIK3R3 (ORF #5) ANKS1A Yes Y2H(pb)
PIK3R3 ARL6IP4 Yes
ORF #1 ARL6IP4 PCA(pos)
ORF #2 ARL6IP4 Y2H(bp)
ORF #2 ARL6IP4 CoIP(pos)
PIK3R3 (ORF #2) BTK (ORF #2) Yes Y2H(bp)
PIK3R3 C10orf81 Yes
ORF #1 C10orf81 PCA(pos)
ORF #2 C10orf81 Y2H(bp)
ORF #2 C10orf81 CoIP(pos)
PIK3R3 (ORF #2) C17orf53 No Y2H(bp)
PIK3R3 C1orf135 No
ORF #1 C1orf135 CoIP(neg)
ORF #2 C1orf135 Y2H(bp)
PIK3R3 (ORF #2) C3orf10 No Y2H(bp)
PIK3R3 (ORF #2) C3orf34 No Y2H(bp)
PIK3R3 (ORF #2) CAMK1 No Y2H(bp)
PIK3R3 CBL Yes
ORF #1 CBL Y2H(pb)
ORF #2 CBL
Y2H(bp), Y2H(pb),
CoIP(pos)
PIK3R3 (ORF #2) CCDC14 Yes Y2H(bp)
PIK3R3 (ORF #2) CCDC33 No Y2H(bp)
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PIK3R3 (ORF #2) CRBN No Y2H(bp)
PIK3R3 CRK Yes
ORF #3 ORF #2 Y2H(pb)
ORF #4 ORF #2 Y2H(pb)
ORF #5 ORF #2 Y2H(pb)
ORF #3 ORF #1 Y2H(pb)
ORF #5 ORF #1 Y2H(pb)
PIK3R3 (ORF #2) CRYBA2 Yes Y2H(bp), CoIP(pos)
PIK3R3 (ORF #2) E2F6 Yes Y2H(bp)
PIK3R3 (ORF #2) EVI1 Yes Y2H(bp), CoIP(neg)
PIK3R3 (ORF #5) FER No Y2H(pb)
PIK3R3 (ORF #2) FOXO1 No Y2H(bp)
PIK3R3 (ORF #2) FRS3 (ORF #2) Yes Y2H(pb), CoIP(pos)
PIK3R3 (ORF #2) FYN (ORF #1 WT) No Y2H(bp)
PIK3R3 HCK Yes
ORF #1 HCK Y2H(pb)
ORF #2 HCK Y2H(pb), CoIP(pos)
ORF #3 HCK Y2H(pb)
PIK3R3 HSH2D Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 Y2H(pb), CoIP(neg)
ORF #3 ORF #2 Y2H(pb)
PIK3R3 (ORF #2) IQUB Yes Y2H(bp)
PIK3R3 IRS1 Yes
ORF #1 IRS1 Y2H(pb)
ORF #2 IRS1 Y2H(pb), CoIP(pos)
ORF #3 IRS1 Y2H(pb)
PIK3R3 (ORF #2) KLF15 No Y2H(bp)
PIK3R3 MIST Yes
ORF #3 MIST Y2H(pb)
ORF #5 MIST Y2H(pb)
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PIK3R3 (ORF #2) MLL4 No Y2H(bp)
PIK3R3 (ORF #2) MTF2 No Y2H(bp)
PIK3R3 (ORF #2) NCK1 (ORF #1) Yes Y2H(pb)
PIK3R3 (ORF #2) OLIG1 No Y2H(bp), CoIP(pos)
PIK3R3 (ORF #2) OTUD7B Yes Y2H(bp), CoIP(pos)
PIK3R3 PACRGL No
ORF #1 PACRGL CoIP(neg)
ORF #2 PACRGL Y2H(bp)
PIK3R3 (ORF #2) PARD6A Yes Y2H(bp), CoIP(pos)
PIK3R3 (ORF #2) PCDHB5 Yes Y2H(bp)
PIK3R3 (ORF #2) PELI3 Yes Y2H(bp), CoIP(pos)
PIK3R3 (ORF #2) PELO Yes Y2H(bp)
PIK3R3 (ORF #2) PIK3CA No Y2H(bp)
PIK3R3 (ORF #2) PIK3CB No Y2H(bp)
PIK3R3 (ORF #2) PLB1 Yes Y2H(bp)
PIK3R3 (ORF #2) PPARA Yes Y2H(bp), CoIP(neg)
PIK3R3 (ORF #2) PPP1R12B No Y2H(bp), CoIP(pos)
PIK3R3 (ORF #2) PTK2 (ORF #1 WT) No Y2H(bp), CoIP(pos)
PIK3R3 RBP7 Yes
ORF #2 RBP7 Y2H(bp), CoIP(pos)
ORF #4 RBP7 PCA(pos)
PIK3R3 SH2D2A Yes
ORF #1 SH2D2A PCA(neg)
ORF #2 SH2D2A Y2H(pb), CoIP(pos)
PIK3R3 SOCS4 Yes
ORF #2 SOCS4 Y2H(bp), CoIP(pos)
ORF #4 SOCS4 PCA(pos)
PIK3R3 (ORF #2) SOCS6 No Y2H(bp)
PIK3R3 (ORF #2) SPSB2 Yes Y2H(bp), CoIP(pos)
PIK3R3 SRC Yes
ORF #1 ORF #1 Y2H(pb)
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ORF #2 ORF #1 CoIP(neg)
ORF #3 ORF #1 Y2H(pb)
PIK3R3 STAT3 Yes
ORF #3 ORF #2 Y2H(pb)
ORF #5 ORF #1 Y2H(pb)
PIK3R3 (ORF #2) TERF2 No Y2H(bp)
PIK3R3 (ORF #2) TNNC2 No Y2H(bp)
PIK3R3 (ORF #2) USP2 Yes Y2H(bp)
PIK3R3 VCP Yes
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 CoIP(neg)
PIK3R3 (ORF #2) WBSCR27 Yes Y2H(bp), CoIP(pos)
PIK3R3 WDFY3 No
ORF #1 WDFY3 CoIP(pos)
ORF #2 WDFY3 Y2H(bp)
PIK3R3 WDR42A No
ORF #2 ORF #1 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
PIK3R3 (ORF #2) WRNIP1 No Y2H(bp)
PIK3R3 (ORF #2) ZMAT1 No Y2H(bp)
PIK3R3 (ORF #2) ZNF281 Yes Y2H(bp), CoIP(neg)
PIK3R3 (ORF #2) ZNF451 No Y2H(bp)
PIK3R3 (ORF #2) ZNF767 Yes Y2H(bp), CoIP(pos)
PINK1 APPL2 No Y2H(pb)
PINK1 HSH2D (ORF #2) Yes Y2H(pb)
PINK1 SOCS4 Yes Y2H(pb), CoIP(pos)
PINK1 STAT3 No
PINK1 ORF #1 Y2H(pb)
PINK1 ORF #2 Y2H(pb)
PLAGL2 DAPP1 (ORF #1) No Y2H(pb), CoIP(neg)
PLAGL2 NOS1AP No Y2H(pb)
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PLB1 PIK3R3 (ORF #2) Yes Y2H(pb)
PLB1 RIN3 No
PLB1 ORF #1 Y2H(pb)
PLB1 ORF #2 Y2H(pb)
PLB1 TENC1 No Y2H(pb)
PLCG2 ASB9 No Y2H(bp), CoIP(neg)
PLCG2 C22orf29 No Y2H(bp)
PLCG2 C5orf35 No Y2H(bp)
PLCG2 ELK1 Yes Y2H(bp), CoIP(neg)
PLCG2 EPYC (ORF #1) Yes Y2H(bp)
PLCG2 ESD No Y2H(bp)
PLCG2 GABPB2 (ORF #1) No Y2H(bp)
PLCG2 HSPD1 (ORF #2) Yes Y2H(bp)
PLCG2 ISL1 No Y2H(bp)
PLCG2 KCTD17 No Y2H(bp)
PLCG2 LHX8 Yes Y2H(bp)
PLCG2 PSMD3 No Y2H(bp), CoIP(pos)
PLCG2 PTTG1 Yes Y2H(bp)
PLCG2 RAD54B No Y2H(bp), CoIP(pos)
PLCG2 RALBP1 No Y2H(bp), CoIP(neg)
PLCG2 TP53 Yes Y2H(bp)
PLCG2 TWIST2 No Y2H(bp), CoIP(neg)
PLCG2 ZNF167 No Y2H(bp)
PLEKHB1 SH2D2A Yes Y2H(pb), CoIP(pos)
PNP NOS1AP No Y2H(pb)
POLR3F RIN3 No
POLR3F ORF #1 Y2H(pb)
POLR3F ORF #2 Y2H(pb)
POLR3F TENC1 No Y2H(pb)
PPAPDC2 HSH2D (ORF #2) Yes Y2H(pb)
PPAPDC2 SOCS4 Yes Y2H(pb)
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PPARA GRB2 (ORF #2) Yes Y2H(pb), CoIP(pos)
PPARA PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(neg)
PPARD STAT3 (ORF #2) Yes Y2H(pb)
PPP1R12B PIK3R3 (ORF #2) No Y2H(pb), CoIP(pos)
PPP1R7 FER No Y2H(pb)
PPP1R7 MIST Yes Y2H(pb)
PRKACA CRK (ORF #2) Yes Y2H(pb)
PRKCA CBL No Y2H(pb)
PRRG2 CRK (ORF #3) Yes Y2H(pb)
PSG11 SHD Yes Y2H(pb)
PSMC1 CRK (ORF #2) No Y2H(pb)
PSMD3 PLCG2 No Y2H(pb), CoIP(pos)
PSMD9 RIN3 (ORF #2) No Y2H(pb)
PTK2 (ORF #1 KD) CRK (ORF #1) Yes Y2H(pb)
PTK2 (ORF #1 WT) DOK4 Yes Y2H(pb), CoIP(neg)
PTK2 (ORF #1 WT) GRB7 Yes Y2H(pb), CoIP(pos)
PTK2 (ORF #1 WT) HCK No Y2H(pb), CoIP(pos)
PTK2 (ORF #1 WT) LYN (ORF #2) No Y2H(pb)
PTK2 (ORF #1 WT) PIK3R3 (ORF #2) No Y2H(pb), CoIP(pos)
PTK2 (ORF #1 WT) PTPN6 Yes Y2H(pb), CoIP(pos)
PTK2 (ORF #1 WT) SH2D1A Yes Y2H(pb)
PTK2 SH2D1B No
ORF #1 WT ORF #2 Y2H(pb)
ORF #1 WT ORF #3 CoIP(neg)
PTK2 SH2D2A Yes
ORF #1 WT SH2D2A
Y2H(pb), PCA(neg),
CoIP(pos)
ORF #2 SH2D2A Y2H(pb)
PTK2 SRC No
ORF #1 WT ORF #1 Y2H(pb), CoIP(neg)
ORF #1 WT ORF #2 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
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PTK7 MIST Yes Y2H(pb)
PTPN11 LNX1 Yes Y2H(bp)
PTPN6 OLIG1 Yes Y2H(bp), CoIP(neg)
PTPN6 PTK2 (ORF #1 WT) Yes Y2H(bp), CoIP(pos)
PTTG1 CRK (ORF #3) No Y2H(pb)
PTTG1 PLCG2 Yes Y2H(pb)
RAB2B CRK (ORF #2) Yes Y2H(pb)
RABGAP1 STAT3 (ORF #2) Yes Y2H(pb)
RABGAP1L (ORF #1) ACAP1 Yes Y2H(bp)
RABGAP1L (ORF #1) ARFGAP1 Yes Y2H(bp), CoIP(neg)
RABGAP1L (ORF #1) C6orf125 Yes Y2H(bp)
RABGAP1L (ORF #1) C9orf43 Yes Y2H(bp), CoIP(pos)
RABGAP1L (ORF #1) DBN1 Yes Y2H(bp), CoIP(neg)
RABGAP1L EVI1 Yes
ORF #1 EVI1 Y2H(bp)
ORF #3 EVI1 CoIP(pos)
RABGAP1L MAPK8IP2 No
ORF #1 MAPK8IP2 CoIP(pos)
ORF #2 MAPK8IP2 Y2H(pb)
RABGAP1L (ORF #1) RB1 Yes Y2H(bp), CoIP(neg)
RABGAP1L (ORF #1) TSPAN2 Yes Y2H(bp), CoIP(neg)
RABGAP1L (ORF #1) WDFY3 Yes Y2H(bp), CoIP(neg)
RAD54B PLCG2 No Y2H(pb), CoIP(pos)
RAD54B SH2D2A Yes Y2H(pb), CoIP(pos)
RAI2 APPL2 No Y2H(pb)
RAI2 DOK5 No Y2H(pb)
RALBP1 PLCG2 No Y2H(pb), CoIP(neg)
RANBP3 ANKS1A No Y2H(pb)
RANBP3 CHN2 No Y2H(pb)
RASA1 OLIG1 Yes Y2H(bp)
RASSF1 MIST No Y2H(pb)
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RB1 ANKS1A No Y2H(pb)
RB1 CHN2 No Y2H(pb)
RB1 GRB2 (ORF #2) Yes
Y2H(pb), PCA(pos),
CoIP(pos)
RB1 MIST No Y2H(pb)
RB1 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(neg)
RBM4 MAPK8IP2 No Y2H(pb)
RBP7 APPL2 No Y2H(pb)
RBP7 DAPP1 (ORF #1) No Y2H(pb)
RBP7 DOK4 No Y2H(pb)
RBP7 HSH2D (ORF #2) Yes Y2H(pb)
RBP7 PIK3R3 Yes
RBP7 ORF #2 Y2H(pb), CoIP(pos)
RBP7 ORF #4 PCA(pos)
RBP7 SOCS4 Yes
Y2H(pb), PCA(pos),
CoIP(pos)
RCAN3 EPS8 No Y2H(pb), CoIP(neg)
RCAN3 GRB10 Yes Y2H(pb), CoIP(pos)
RIN1 ANKS1B No Y2H(bp)
RIN3 ASB3 No
ORF #1 ASB3 Y2H(bp)
ORF #2 ASB3 Y2H(bp)
RIN3 (ORF #1) ASB8 No Y2H(bp)
RIN3 (ORF #3) CRK (ORF #4) No Y2H(bp)
RIN3 (ORF #3) CRKL (ORF #1) No Y2H(bp)
RIN3 CSRP3 No
ORF #1 CSRP3 Y2H(bp)
ORF #2 CSRP3 Y2H(bp)
RIN3 (ORF #1) CYP2C8 No Y2H(bp)
RIN3 (ORF #1) CYP46A1 No Y2H(bp)
RIN3 (ORF #2) DOK3 (ORF #1) No Y2H(bp)
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RIN3 EPS8L2 No
ORF #1 EPS8L2 Y2H(bp)
ORF #2 EPS8L2 Y2H(bp)
RIN3 (ORF #2) EZH2 No Y2H(bp)
RIN3 (ORF #1) FAM127C No Y2H(bp)
RIN3 FAM46A No
ORF #1 FAM46A Y2H(bp)
ORF #2 FAM46A Y2H(bp)
RIN3 (ORF #2) GATA1 No Y2H(bp)
RIN3 (ORF #3) GRAP2 (ORF #2) No Y2H(bp)
RIN3 ID2 No
ORF #1 ID2 Y2H(bp)
ORF #2 ID2 Y2H(bp)
RIN3 (ORF #1) KCTD17 No Y2H(bp)
RIN3 (ORF #2) LCK (ORF #2) No Y2H(bp)
RIN3 (ORF #2) MPEG1 No Y2H(bp)
RIN3 MT2A No
ORF #1 MT2A Y2H(bp)
ORF #2 MT2A Y2H(bp)
RIN3 PLB1 No
ORF #1 PLB1 Y2H(bp)
ORF #2 PLB1 Y2H(bp)
RIN3 POLR3F No
ORF #1 POLR3F Y2H(bp)
ORF #2 POLR3F Y2H(bp)
RIN3 (ORF #2) PSMD9 No Y2H(bp)
RIN3 (ORF #2) SPATA12 No Y2H(bp)
RIN3 SPRY4 No
ORF #1 SPRY4 Y2H(bp)
ORF #2 SPRY4 Y2H(bp)
RIN3 (ORF #2) SUV39H1 No Y2H(bp)
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RIN3 (ORF #1) SYMPK No Y2H(bp)
RIN3 (ORF #1) TGM1 No Y2H(bp)
RIN3 TM4SF19 No
ORF #1 TM4SF19 Y2H(bp)
ORF #2 TM4SF19 Y2H(bp)
RIN3 (ORF #2) TSC1 (ORF #2) No Y2H(bp)
RIN3 (ORF #1) TSSK3 No Y2H(bp)
RIN3 (ORF #1) ZBTB24 No Y2H(bp)
RIN3 ZNF639 No
ORF #1 ZNF639 Y2H(bp)
ORF #2 ZNF639 Y2H(bp)
RIN3 ZNF655 No
ORF #1 ZNF655 Y2H(bp)
ORF #2 ZNF655 Y2H(bp)
RIN3 (ORF #1) ZNF71 No Y2H(bp)
RP13-36C9.6 NOS1AP No Y2H(pb)
RPAIN MIST Yes Y2H(pb)
RPAIN TNS4 Yes Y2H(pb)
RPS6 FRS2 No Y2H(pb)
RTDR1 EPS8 No Y2H(pb)
RYBP CRK No
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
RYBP MAPK8IP2 No
ORF #1 MAPK8IP2 Y2H(pb)
ORF #2 MAPK8IP2 Y2H(pb)
RYBP NOS1AP No
ORF #1 NOS1AP Y2H(pb)
ORF #2 NOS1AP Y2H(pb)
SCAPER APPL1 (ORF #1) No Y2H(pb)
SCLT1 MAPK8IP2 No Y2H(pb)
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SCOC DOK5 Yes Y2H(pb), CoIP(neg)
SDCCAG8 TENC1 No Y2H(pb)
SEMA4D CRK (ORF #3) Yes Y2H(pb), CoIP(neg)
SEPT6 CRK No
ORF #1 ORF #1 Y2H(pb)
ORF #2 ORF #1 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
SERPINA5 CBL No Y2H(pb)
SERPINA5 EPS8 No Y2H(pb)
SFMBT1 MIST Yes Y2H(pb)
SH2B1 CSAD Yes Y2H(bp)
SH2B1 FRS3 (ORF #2) No Y2H(pb)
SH2B3 TENC1 No Y2H(pb)
SH2D1A ATF3 Yes Y2H(bp)
SH2D1A CCDC74A No Y2H(bp)
SH2D1A LETMD1 No Y2H(bp)
SH2D1A NCK1 (ORF #1) Yes Y2H(pb)
SH2D1A NGEF No Y2H(bp)
SH2D1A OLIG1 No Y2H(bp)
SH2D1A PTK2 (ORF #1 WT) Yes Y2H(bp)
SH2D1A ZNHIT1 Yes Y2H(bp)
SH2D1B HSPA1A Yes
ORF #3 ORF #1 Y2H(bp)
ORF #3 ORF #2 CoIP(pos)
SH2D1B MAPK8IP2 No
ORF #1 MAPK8IP2 Y2H(pb)
ORF #3 MAPK8IP2 CoIP(neg)
SH2D1B OLIG1 No
ORF #2 OLIG1 Y2H(bp)
ORF #3 OLIG1 CoIP(pos)
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SH2D1B PTK2 No
ORF #2 ORF #1 WT Y2H(bp)
ORF #3 ORF #1 WT CoIP(neg)
SH2D1B (ORF #3) STAT4 Yes Y2H(bp), CoIP(neg)
SH2D2A APPL1 Yes
SH2D2A ORF #1 CoIP(neg)
SH2D2A ORF #2 Y2H(pb)
SH2D2A ARID5A No Y2H(bp)
SH2D2A ASB3 Yes Y2H(bp), CoIP(pos)
SH2D2A C17orf82 No Y2H(bp)
SH2D2A CRK Yes
SH2D2A ORF #1 Y2H(pb)
SH2D2A ORF #2 Y2H(pb)
SH2D2A ORF #3 CoIP(neg)
SH2D2A FAM46A Yes Y2H(bp), CoIP(pos)
SH2D2A FAM46B Yes Y2H(bp), CoIP(pos)
SH2D2A KLRAQ1 Yes Y2H(bp), CoIP(neg)
SH2D2A LASP1 No Y2H(bp), CoIP(pos)
SH2D2A LNX1 Yes Y2H(bp), CoIP(neg)
SH2D2A LRRFIP1 Yes Y2H(bp), CoIP(neg)
SH2D2A NARG1L No Y2H(bp)
SH2D2A PIK3R1 Yes
Y2H(bp), PCA(neg),
CoIP(pos)
SH2D2A PIK3R3 Yes
SH2D2A ORF #1 PCA(neg)
SH2D2A ORF #2 Y2H(bp), CoIP(pos)
SH2D2A PLEKHB1 Yes Y2H(bp), CoIP(pos)
SH2D2A PTK2 Yes
SH2D2A ORF #1 WT
Y2H(bp), PCA(neg),
CoIP(pos)
SH2D2A ORF #2 Y2H(bp)
SH2D2A RAD54B Yes Y2H(bp), CoIP(pos)
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SH2D2A SOCS3 Yes Y2H(pb)
SH2D2A SPTB Yes Y2H(bp)
SH2D2A STAT3 Yes
SH2D2A ORF #1 Y2H(pb)
SH2D2A ORF #2 Y2H(pb)
SH2D2A TSC1 Yes
SH2D2A ORF #1 Y2H(bp)
SH2D2A ORF #2 Y2H(bp), CoIP(neg)
SH2D2A WDR40B Yes Y2H(bp), CoIP(pos)
SH2D2A ZHX3 Yes Y2H(bp), CoIP(neg)
SH2D2A ZSCAN1 Yes Y2H(bp)
SH2D3A CENPB No Y2H(bp)
SH2D4A OLIG1 No Y2H(bp)
SH3BP2 (ORF #1) ARHGAP10 Yes Y2H(bp)
SH3BP2 (ORF #2) STAT3 (ORF #2) Yes Y2H(pb)
SHD BECN1 No Y2H(bp)
SHD CAPN10 Yes Y2H(bp)
SHD KRTCAP2 No Y2H(bp)
SHD MRPS22 No Y2H(bp)
SHD OLIG1 No Y2H(bp)
SHD OSBPL6 No Y2H(bp)
SHD PSG11 Yes Y2H(bp)
SHE DOK3 (ORF #1) Yes Y2H(bp)
SHE TRIT1 Yes Y2H(bp)
SLC39A13 MAPK8IP2 No
ORF #1 MAPK8IP2 Y2H(pb)
ORF #2 MAPK8IP2 Y2H(pb)
SLPI MAPK8IP2 No Y2H(pb)
SMARCD1 ANKS1A No Y2H(pb)
SMARCD1 CHN2 No Y2H(pb)
SMARCD1 MIST No Y2H(pb)
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SOCS1 CRK (ORF #2) Yes Y2H(pb)
SOCS1 CRKL (ORF #1) Yes Y2H(pb)
SOCS1 PIK3R1 Yes Y2H(bp)
SOCS3 SH2D2A Yes Y2H(bp)
SOCS3 TRDN Yes Y2H(bp)
SOCS3 YWHAQ No Y2H(bp)
SOCS4 FRS3 (ORF #2) No Y2H(pb), CoIP(pos)
SOCS4 GRB2 (ORF #2) Yes
Y2H(pb), PCA(neg),
CoIP(pos)
SOCS4 LDHAL6B Yes Y2H(bp), CoIP(neg)
SOCS4 LECT1 Yes Y2H(bp)
SOCS4 MPP5 Yes Y2H(bp), CoIP(neg)
SOCS4 PIK3R3 Yes
SOCS4 ORF #2 Y2H(pb), CoIP(pos)
SOCS4 ORF #4 PCA(pos)
SOCS4 PINK1 Yes Y2H(bp), CoIP(pos)
SOCS4 PPAPDC2 Yes Y2H(bp)
SOCS4 RBP7 Yes
Y2H(bp), PCA(pos),
CoIP(pos)
SOCS4 TNK2 Yes Y2H(bp)
SOCS6 APPL1 (ORF #2) Yes Y2H(pb)
SOCS6 CRK (ORF #2) Yes Y2H(pb)
SOCS6 FRS3 (ORF #2) No Y2H(pb)
SOCS6 LNX1 Yes Y2H(bp)
SOCS6 MIST Yes Y2H(pb)
SOCS6 PIK3R3 (ORF #2) No Y2H(pb)
SPATA12 RIN3 (ORF #2) No Y2H(pb)
SPATA12 TENC1 No Y2H(pb)
SPINK2 MAPK8IP2 No Y2H(pb)
SPRY2 TENC1 No Y2H(pb)
SPRY4 RIN3 No
SPRY4 ORF #1 Y2H(pb)
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SPRY4 ORF #2 Y2H(pb)
SPRY4 TENC1 No Y2H(pb)
SPSB2 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
SPSB3 MAPK8IP2 No Y2H(pb)
SPTB SH2D2A Yes Y2H(pb)
SPTB STAT1 Yes Y2H(pb)
SRC PIK3R3 Yes
ORF #1 ORF #1 Y2H(bp)
ORF #1 ORF #2 CoIP(neg)
ORF #1 ORF #3 Y2H(bp)
SRC PTK2 No
ORF #1 ORF #1 WT Y2H(bp), CoIP(neg)
ORF #2 ORF #1 WT Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
SRP19 MAPK8IP2 No Y2H(pb)
STAT1 SPTB Yes Y2H(bp)
STAT2 DOK4 Yes Y2H(pb), CoIP(neg)
STAT3 (ORF #1) ABL2 (KD) Yes Y2H(bp)
STAT3 (ORF #2) ATF3 No Y2H(bp)
STAT3 (ORF #2) BATF3 No Y2H(bp)
STAT3 (ORF #2) BMX (ORF #2) No Y2H(bp)
STAT3 (ORF #1) BRWD1 Yes Y2H(bp)
STAT3 C10orf18 Yes
ORF #1 C10orf18 Y2H(bp)
ORF #2 C10orf18 Y2H(bp)
STAT3 (ORF #2) CA8 Yes Y2H(bp)
STAT3 (ORF #2) CBL Yes Y2H(bp)
STAT3 (ORF #2) CCDC87 Yes Y2H(bp)
STAT3 CHTF18 No
ORF #1 CHTF18 Y2H(bp)
ORF #2 CHTF18 Y2H(bp)
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STAT3 CNDP2 No
ORF #1 CNDP2 Y2H(bp)
ORF #2 CNDP2 Y2H(bp)
STAT3 (ORF #1) DOK2 (ORF #2) Yes Y2H(bp)
STAT3 DOK3 Yes
ORF #1 ORF #1 Y2H(bp)
ORF #1 ORF #2 Y2H(bp)
ORF #2 ORF #2 Y2H(bp)
STAT3 DTNA Yes
ORF #1 DTNA Y2H(bp)
ORF #2 DTNA Y2H(bp)
STAT3 (ORF #2) FAM117B Yes Y2H(bp)
STAT3 GSTCD Yes
ORF #1 GSTCD Y2H(bp)
ORF #2 GSTCD Y2H(bp)
STAT3 HESX1 Yes
ORF #1 HESX1 Y2H(bp)
ORF #2 HESX1 Y2H(bp)
STAT3 KLF15 No
ORF #1 KLF15 Y2H(bp)
ORF #2 KLF15 Y2H(bp)
STAT3 (ORF #2) KRTAP10-7 Yes Y2H(bp)
STAT3 (ORF #2) LASP1 Yes Y2H(bp)
STAT3 (ORF #1) LCK (ORF #2) Yes Y2H(bp)
STAT3 (ORF #2) MAPKAPK2 Yes Y2H(bp)
STAT3 MNDA No
ORF #1 MNDA Y2H(bp)
ORF #2 MNDA Y2H(bp)
STAT3 (ORF #2) MPZL1 Yes Y2H(bp)
STAT3 (ORF #2) NACAD No Y2H(bp)
STAT3 (ORF #1) NUFIP2 Yes Y2H(bp)
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STAT3 (ORF #2) NXT2 No Y2H(bp)
STAT3 (ORF #2) OFCC1 No Y2H(bp)
STAT3 (ORF #2) PAFAH1B2 No Y2H(bp)
STAT3 (ORF #2) PAQR7 Yes Y2H(bp)
STAT3 (ORF #2) PIK3R1 Yes Y2H(bp)
STAT3 (ORF #1) PIK3R2 Yes Y2H(bp)
STAT3 PIK3R3 Yes
ORF #1 ORF #5 Y2H(bp)
ORF #2 ORF #3 Y2H(bp)
STAT3 PINK1 No
ORF #1 PINK1 Y2H(bp)
ORF #2 PINK1 Y2H(bp)
STAT3 (ORF #2) PPARD Yes Y2H(bp)
STAT3 (ORF #2) RABGAP1 Yes Y2H(bp)
STAT3 SH2D2A Yes
ORF #1 SH2D2A Y2H(bp)
ORF #2 SH2D2A Y2H(bp)
STAT3 (ORF #2) SH3BP2 (ORF #2) Yes Y2H(bp)
STAT3 (ORF #2) TDG No Y2H(bp)
STAT3 TM4SF19 Yes
ORF #1 TM4SF19 Y2H(bp)
ORF #2 TM4SF19 Y2H(bp)
STAT3 (ORF #2) TWIST1 Yes Y2H(bp)
STAT3 (ORF #1) VPS39 Yes Y2H(bp)
STAT3 (ORF #2) WDFY3 Yes Y2H(bp)
STAT3 (ORF #2) ZNF281 Yes Y2H(bp)
STAT3 (ORF #2) ZNF557 No Y2H(bp)
STAT3 (ORF #2) ZNF829 Yes Y2H(bp)
STAT4 CRK (ORF #3) Yes Y2H(pb), CoIP(neg)
STAT4 SH2D1B (ORF #3) Yes Y2H(pb), CoIP(neg)
STAT5A CBL Yes Y2H(bp), CoIP(neg)
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STAT5A OLIG1 Yes Y2H(bp), CoIP(neg)
STK36 MIST No Y2H(pb)
STRN4 CRK (ORF #3) No Y2H(pb)
SUV39H1 RIN3 (ORF #2) No Y2H(pb)
SUV39H1 TENC1 No Y2H(pb)
SYK (ORF #1 WT) FAM46A Yes Y2H(bp), CoIP(pos)
SYMPK RIN3 (ORF #1) No Y2H(pb)
TARBP2 MAPK8IP2 No Y2H(pb)
TCAP CRK (ORF #2) Yes Y2H(pb)
TDG CRK (ORF #2) No Y2H(pb)
TDG STAT3 (ORF #2) No Y2H(pb)
TENC1 ADCK5 No Y2H(bp)
TENC1 AP1S2 No Y2H(bp)
TENC1 ASB3 No Y2H(bp)
TENC1 C19orf66 No Y2H(bp)
TENC1 C21orf77 No Y2H(bp)
TENC1 COX6B2 No Y2H(bp)
TENC1 CRKL (ORF #1) No Y2H(bp)
TENC1 DDIT4L No Y2H(bp)
TENC1 DOK3 (ORF #1) No Y2H(bp)
TENC1 EPB41L4A No Y2H(bp)
TENC1 EPS8L2 No Y2H(bp)
TENC1 FABP7 No Y2H(bp)
TENC1 FAM114A1 No Y2H(bp)
TENC1 FAM46A No Y2H(bp)
TENC1 FGF21 No Y2H(bp)
TENC1 FOXO1 No Y2H(bp)
TENC1 GATA1 No Y2H(bp)
TENC1 GBA3 No Y2H(bp)
TENC1 HUWE1 No Y2H(bp)
TENC1 ID2 No Y2H(bp)
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TENC1 KRTAP23-1 No Y2H(bp)
TENC1 KRTAP3-1 No Y2H(bp)
TENC1 LOC285398 No Y2H(bp)
TENC1 MPEG1 No Y2H(bp)
TENC1 MT2A No Y2H(bp)
TENC1 MYBPHL No Y2H(bp)
TENC1 MYH7B No Y2H(bp)
TENC1 NMU No Y2H(bp)
TENC1 NT5C No Y2H(bp)
TENC1 OBSL1 No Y2H(bp)
TENC1 PER1 No Y2H(bp)
TENC1 PLB1 No Y2H(bp)
TENC1 POLR3F No Y2H(bp)
TENC1 SDCCAG8 No Y2H(bp)
TENC1 SH2B3 No Y2H(bp)
TENC1 SPATA12 No Y2H(bp)
TENC1 SPRY2 No Y2H(bp)
TENC1 SPRY4 No Y2H(bp)
TENC1 SUV39H1 No Y2H(bp)
TENC1 TM4SF19 No Y2H(bp)
TENC1 TSC1 (ORF #2) No Y2H(bp)
TENC1 TWSG1 No Y2H(bp)
TENC1 WDFY3 No Y2H(bp)
TENC1 WDR23 No Y2H(bp)
TENC1 WDR42A (ORF #2) No Y2H(bp)
TENC1 ZNF586 No Y2H(bp)
TENC1 ZNF655 No Y2H(bp)
TENC1 ZNRD1 No Y2H(bp)
TERF2 NUMB (ORF #1) No Y2H(pb)
TERF2 PIK3R3 (ORF #2) No Y2H(pb)
TGM1 RIN3 (ORF #1) No Y2H(pb)
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TM4SF19 CRK (ORF #2) Yes Y2H(pb)
TM4SF19 DAPP1 (ORF #2) No Y2H(pb)
TM4SF19 RIN3 No
TM4SF19 ORF #1 Y2H(pb)
TM4SF19 ORF #2 Y2H(pb)
TM4SF19 STAT3 Yes
TM4SF19 ORF #1 Y2H(pb)
TM4SF19 ORF #2 Y2H(pb)
TM4SF19 TENC1 No Y2H(pb)
TMEM128 GRB2 (ORF #2) Yes
Y2H(pb), PCA(neg),
CoIP(pos)
TMEM128 MAPK8IP2 Yes Y2H(pb), CoIP(neg)
TMEM168 CRKL (ORF #1) Yes Y2H(pb)
TNFAIP1 DAPP1 (ORF #2) Yes Y2H(pb)
TNK2 HSH2D (ORF #2) No Y2H(pb)
TNK2 SOCS4 Yes Y2H(pb)
TNNC2 PIK3R3 (ORF #2) No Y2H(pb)
TNS1 FRS3 (ORF #2) No Y2H(pb)
TNS4 GSTCD Yes Y2H(bp)
TNS4 KCTD4 No Y2H(bp)
TNS4 NME4 Yes Y2H(bp)
TNS4 P4HA2 Yes Y2H(bp)
TNS4 PIK3R1 Yes Y2H(bp)
TNS4 RPAIN Yes Y2H(bp)
TP53 APPL1 (ORF #1) No Y2H(pb)
TP53 CRK (ORF #3) No Y2H(pb)
TP53 PLCG2 Yes Y2H(pb)
TP53RK CHN2 No Y2H(pb)
TRDN SOCS3 Yes Y2H(pb)
TRIT1 ANKS1A No Y2H(pb)
TRIT1 SHE Yes Y2H(pb)
TSC1 (ORF #1) APPL2 No Y2H(pb)
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TSC1 (ORF #1) DOK5 No Y2H(pb)
TSC1 (ORF #1) HSH2D (ORF #2) Yes Y2H(pb)
TSC1 (ORF #2) RIN3 (ORF #2) No Y2H(pb)
TSC1 SH2D2A Yes
ORF #1 SH2D2A Y2H(pb)
ORF #2 SH2D2A Y2H(pb), CoIP(neg)
TSC1 (ORF #2) TENC1 No Y2H(pb)
TSPAN2 GRB2 (ORF #2) Yes
Y2H(pb), PCA(pos),
CoIP(pos)
TSPAN2 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(neg)
TSSK3 RIN3 (ORF #1) No Y2H(pb)
TUBA1C CRK (ORF #3) No Y2H(pb)
TWIST1 STAT3 (ORF #2) Yes Y2H(pb)
TWIST2 CCM2 Yes Y2H(pb), CoIP(pos)
TWIST2 CRK (ORF #3) No Y2H(pb), CoIP(neg)
TWIST2 PLCG2 No Y2H(pb), CoIP(neg)
TWSG1 TENC1 No Y2H(pb)
TXK MIST No Y2H(pb)
UBD MAPK8IP2 Yes Y2H(pb), CoIP(pos)
USP2 PIK3R3 (ORF #2) Yes Y2H(pb)
USP46 MAPK8IP2 No Y2H(pb)
VAC14 CRK (ORF #1) Yes Y2H(pb)
VASP FRS3 Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 CoIP(neg)
VCP GRB2 Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 CoIP(pos)
VCP PIK3R3 Yes
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 CoIP(neg)
VPS39 STAT3 (ORF #1) Yes Y2H(pb)
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VSTM2L CCM2 Yes Y2H(pb), CoIP(pos)
WBSCR27 GRB2 (ORF #2) No
Y2H(pb), PCA(neg),
CoIP(neg)
WBSCR27 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
WDFY3 GRB2 (ORF #2) Yes Y2H(pb), CoIP(neg)
WDFY3 PIK3R3 No
WDFY3 ORF #2 Y2H(pb)
WDFY3 ORF #1 CoIP(pos)
WDFY3 RABGAP1L (ORF #1) Yes Y2H(pb), CoIP(neg)
WDFY3 STAT3 (ORF #2) Yes Y2H(pb)
WDFY3 TENC1 No Y2H(pb)
WDR20 DAPP1 (ORF #1) Yes Y2H(pb), CoIP(pos)
WDR23 TENC1 No Y2H(pb)
WDR40B SH2D2A Yes Y2H(pb), CoIP(pos)
WDR42A PIK3R3 No
ORF #1 ORF #2 Y2H(pb)
ORF #2 ORF #2 Y2H(pb)
WDR42A (ORF #2) TENC1 No Y2H(pb)
WDR83 CRK No
WDR83 ORF #1 Y2H(pb)
WDR83 ORF #2 Y2H(pb)
WIZ DOK5 No Y2H(pb)
WRNIP1 PIK3R3 (ORF #2) No Y2H(pb)
WWOX MIST No Y2H(pb)
XAGE2XX EPS8 Yes Y2H(pb)
YES1 BECN1 Yes Y2H(bp), CoIP(neg)
YES1 OLIG1 Yes Y2H(bp), CoIP(pos)
YPEL3 DOK7 No Y2H(pb)
YWHAQ SOCS3 No Y2H(pb)
ZBTB24 RIN3 (ORF #1) No Y2H(pb)
ZHX3 SH2D2A Yes Y2H(pb), CoIP(neg)
ZMAT1 GRB2 (ORF #2) No Y2H(pb)
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ZMAT1 PIK3R3 (ORF #2) No Y2H(pb)
ZNF167 CRK (ORF #3) No Y2H(pb)
ZNF167 PLCG2 No Y2H(pb)
ZNF281 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(neg)
ZNF281 STAT3 (ORF #2) Yes Y2H(pb)
ZNF451 PIK3R3 (ORF #2) No Y2H(pb)
ZNF557 CRK (ORF #2) No Y2H(pb)
ZNF557 STAT3 (ORF #2) No Y2H(pb)
ZNF586 TENC1 No Y2H(pb)
ZNF639 RIN3 No
ZNF639 ORF #1 Y2H(pb)
ZNF639 ORF #2 Y2H(pb)
ZNF655 RIN3 No
ZNF655 ORF #1 Y2H(pb)
ZNF655 ORF #2 Y2H(pb)
ZNF655 TENC1 No Y2H(pb)
ZNF670 MAPK8IP2 No Y2H(pb)
ZNF71 RIN3 (ORF #1) No Y2H(pb)
ZNF767 PIK3R3 (ORF #2) Yes Y2H(pb), CoIP(pos)
ZNF829 APPL1 (ORF #2) Yes Y2H(pb)
ZNF829 STAT3 (ORF #2) Yes Y2H(pb)
ZNHIT1 DAPP1 (ORF #1) Yes Y2H(pb)
ZNHIT1 GRB7 Yes Y2H(pb)
ZNHIT1 SH2D1A Yes Y2H(pb)
ZNRD1 MAPK8IP2 No Y2H(pb)
ZNRD1 TENC1 No Y2H(pb)
ZSCAN1 SH2D2A Yes Y2H(pb)
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Appendix C
Screened ORF-kinase
combinations
For each ORF screened in Round One and Round Two, the exact number of
bait strains with each kinase construct resulting from each parent strain is
provided. The numbers of prey genes represented in the matrix were 13,807
and 17,007, respectively. Unsuccessful ORFs, i.e. ORFs without interactions,
are marked in italics. NLS = nuclear localization signal; U2 = L40ccU2
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Round One
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
ABL2 (WT) 2 2 1 2 2 1 1 0 2 2 2 1 1 1 1 2 2 1 2 2 1 0 1 1 1 2 2 2 0 1 1 0 0 1 0 1
ANKS1B
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
APBB2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
APBB3
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
APPL2 1 1 1 0 1 1 0 1 2 1 1 1 1 2 1 1 1 1 1 0 1 1 1 0 0 1 1 2 1 0 2 2 1 2 2 1
BCAR3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2
BLK 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
BMX
(ORF #1 WT)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2
BTK
(ORF #2)
2 2 2 2 2 2 2 1 2 2 2 0 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2
CBL 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CBLB
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
CBLC
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
CCM2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2
CHN1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CISH 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CRK
(ORF #3)
0 0 1 2 0 0 1 1 0 0 1 0 0 0 2 2 0 0 1 1 0 0 0 2 0 0 1 1 0 0 1 1 0 0 0 1
CSK 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
DOK3
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
DOK4 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2
DOK5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
DOK6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
EPS8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
FAM43A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
FES (WT) 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
FRK (WT) 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
FRS2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
FRS3
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
FYN (ORF #1
WT)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GRB2
(ORF #2)
2 0 0 0 1 2 0 0 0 1 1 1 2 2 1 2 1 0 0 0 2 2 1 0 2 1 1 0 0 2 1 1 2 2 1 1
GRB7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GRB10 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
GRB14 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
HCK 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
HSH2D
(ORF #2)
2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
IRS1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
ITGB1BP1
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
JAK3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
LCP2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2
LDLRAP1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
LYN
(ORF #2)
0 0 2 1 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2 0 0 2 2
MAPK8IP2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2
MATK
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
NCK1
(ORF #2)
2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 0 2 2 1 2 2 2 2 1 2 1
NOS1AP 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
NUMB
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PID1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2361
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
PIK3R2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PIK3R3
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PLCG2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 1
PTPN11 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
PTPN6 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RABGAP1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RABGAP1L
(ORF #1)
2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2
RASA1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
RIN1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SH2B1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
SH2B3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2
SH2D1A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SH2D1B
(ORF #2)
2 0 2 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
SH2D2A 2 0 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
SH2D3A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SH2D3C 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SH2D4A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SHC4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SHD 0 0 0 1 0 0 1 1 0 0 0 0 0 0 1 0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 1 1 0 0 2 0
SOCS2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SOCS4 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
SOCS5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SOCS6 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2
SRC
(ORF #2)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2
STAP1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
STAT1 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
STAT2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
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Round One (continued)
Kinase: ABL2 BMX FES FRK FYN JAK2 PTK2 SYK TNK1
Parent strain: U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - + - +
ORF:
STAT5A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2
STAT6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
SYK (ORF #1
WT)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
TNS1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2
TNS3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
TYK2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
VAV1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
VAV3 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
YES1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
ZAP70
(ORF #1)
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
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Round Two
Kinase: ABL2 FYN TNK1
Parent strain: U2 L40c U2 L40c U2 L40c
NLS: – + – + – + – + – + – +
ORF:
ANKS1A 4 4 4 4 4 4 4 4 4 4 4 4
APBA2 4 4 4 4 4 4 4 4 4 4 4 4
APBB1 4 4 4 4 4 4 4 4 4 4 4 4
APPL1 (ORF #2) 4 4 4 4 4 4 4 4 4 4 4 4
BLNK 4 3 4 4 4 4 4 4 4 4 4 4
CHN2 4 4 4 4 4 4 4 4 4 4 4 4
CRK (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
CRK (ORF #2) 4 4 4 4 4 4 4 4 4 4 4 4
DAB2 4 4 4 4 4 4 4 4 4 4 4 4
DOK1 4 4 4 4 4 4 4 4 4 4 4 4
DOK2 (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
DOK7 4 4 4 4 4 4 4 4 4 4 4 4
EPS8L2 4 4 4 4 4 4 4 4 4 4 4 4
FAM43B 4 4 4 4 4 4 4 4 4 4 4 4
FER 4 4 4 4 4 4 4 4 4 4 4 4
GRAP 4 4 4 4 4 4 4 4 4 4 4 4
INPP5D (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
INPP5D (ORF #2) 4 4 4 4 4 4 4 4 4 4 4 4
ITK 4 4 4 4 4 4 4 4 4 4 4 4
LYN (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
LYN (ORF #3) 4 4 4 4 4 4 4 4 4 4 4 4
MAPK8IP1 4 4 4 4 4 4 4 4 4 4 4 4
MIST 4 4 4 3 4 4 4 4 4 4 4 4
PIK3R1 4 4 4 4 4 3 4 4 4 4 4 4
PLCG1 4 4 4 4 4 4 4 4 4 4 4 4
PTK6 4 4 4 4 4 4 4 4 4 4 4 4
RIN2 4 4 4 4 4 4 4 4 4 4 4 4
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Round Two (continued)
Kinase: ABL2 FYN TNK1
Parent strain: U2 L40c U2 L40c U2 L40c
NLS: - + - + - + - + - + - +
ORF:
RIN3 (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
RIN3 (ORF #2) 4 4 4 4 4 4 4 4 4 4 4 4
RIN3 (ORF #3) 4 4 4 4 4 4 4 4 4 4 4 4
SH2D5 4 4 4 4 4 4 4 4 4 4 4 4
SH3BP2 (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 4
SHC3 4 4 4 4 4 4 4 4 4 4 4 4
SHE 4 4 4 4 4 4 4 4 4 4 4 4
SLA 4 4 4 4 4 4 4 4 4 4 4 4
SOCS1 4 4 4 4 4 4 4 4 4 4 4 4
SOCS3 4 4 4 4 4 4 4 4 4 4 4 4
SRMS 4 4 4 4 4 4 4 4 4 4 4 4
STAP2 4 4 4 4 4 4 4 4 4 4 4 4
STAT3 (ORF #1) 4 4 4 4 4 4 4 4 4 4 4 2
STAT3 (ORF #2) 4 4 4 3 4 4 4 4 4 2 4 2
TBC1D4 4 4 4 4 4 4 4 4 4 4 4 4
TENC1 4 4 4 4 4 4 4 4 4 4 4 4
TNS4 4 4 4 4 4 4 4 3 4 4 4 4
VAV2 4 4 4 4 4 4 4 4 4 4 4 4
VAV3 4 4 4 4 4 4 4 4 4 4 4 4
366
Appendix D
Yeast two-hybrid
kinase-interaction specificity
For each phosphotyrosine-dependent protein-protein interaction detected in
this study the kinases that enabled growth in the yeast two-hybrid system are
provided. The interactions are sorted alphabetically by the phosphotyrosine-rec-
ognizing domain-containing partner. Interactions among two phosphotyrosine-
recognizing domain-containing partners are listed twice. Boldface font indicates
phosphotyrosine-recognizing domain-containing genes.
Interaction Kinases
ABL2 CRK ABL2, FYN, TNK1
ABL2 PIK3R3 BMX, FES, FRK, FYN, JAK2, PTK2, SYK, TNK1
ABL2 STAT3 ABL2, TNK1
ANKS1A PIK3R3 ABL2
APBB3 PDPK1 FYN
APPL1 BATF3 ABL2
APPL1 BRWD1 ABL2, TNK1
APPL1 C22orf28 ABL2
APPL1 CBL ABL2, FYN
APPL1 CBLB ABL2
APPL1 DOK2 ABL2
APPL1 DOK3 ABL2
APPL1 DOK7 ABL2
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Interaction Kinases
APPL1 ID1 ABL2
APPL1 INO80E ABL2
APPL1 KLF15 ABL2, TNK1
APPL1 LOC401296 ABL2
APPL1 MAGEC3 ABL2, TNK1
APPL1 PIK3R1 ABL2
APPL1 SH2D2A ABL2
APPL1 SOCS6 ABL2
APPL1 ZNF829 ABL2
APPL2 GBL ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
APPL2 LGALS9C FES, TNK1
APPL2 LIX1 FES, FRK, FYN, JAK2, PTK2, SYK, TNK1
APPL2 MAPRE3 FRK, JAK2, TNK1
APPL2 MLL3 FYN
BCAR3 IRS1 ABL2, BLK, FER, FGR, FRK, FYN, HCK, LYN,
PTK2, SRC, TNK1, YES1
BTK PIK3R3 FYN
CBL APPL1 ABL2, FYN
CBL CRK ABL2, FYN, TNK1
CBL EPS8 ABL2
CBL PIK3R1 ABL2, FRK, FYN
CBL PIK3R2 ABL2, FYN
CBL PIK3R3 ABL2, BLK, FER, FGR, FRK, FYN, HCK, SRC,
SYK, YES1
CBL STAT3 ABL2, TNK1
CBL STAT5A BMX
CBLB APPL1 ABL2
CBLB CRK ABL2, FYN, TNK1
CBLB CRKL ABL2, FYN, TNK1
CBLC CRK ABL2
CCM2 DOK4 FYN
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Interaction Kinases
CCM2 TWIST2 BMX, FRK, FYN
CCM2 VSTM2L TNK1
CRK ABL2 ABL2, FYN, TNK1
CRK BEX5 ABL2
CRK C14orf65 ABL2
CRK C22orf28 ABL2
CRK C3orf36 ABL2, TNK1
CRK CBL ABL2, FYN, TNK1
CRK CBLB ABL2, FYN, TNK1
CRK CBLC ABL2
CRK CHTF18 ABL2, FYN, TNK1
CRK CNDP2 ABL2, TNK1
CRK DOK2 ABL2, FYN
CRK DOK3 ABL2, FYN, TNK1
CRK DOK7 ABL2, FYN, TNK1
CRK ELK1 ABL2
CRK EPYC ABL2
CRK EYA3 ABL2, FYN
CRK FAM59A ABL2, FYN, TNK1
CRK FSTL1 ABL2, BMX, FRK, JAK2, PTK2, SYK, TNK1
CRK GABPB2 ABL2, FYN, TNK1
CRK HSH2D ABL2, FYN
CRK KCTD13 ABL2, FYN, TNK1
CRK KLHL20 ABL2, FYN
CRK LASP1 ABL2, FYN, TNK1
CRK LOC401296 ABL2, FYN, TNK1
CRK MAGEC3 ABL2, FYN, TNK1
CRK MPG BMX, FES, FRK, FYN, JAK2, PTK2, TNK1
CRK MYLIP ABL2
CRK MYOZ2 ABL2, FYN
CRK NUFIP2 ABL2
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Interaction Kinases
CRK OFCC1 ABL2, FYN, TNK1
CRK PAFAH1B2 ABL2
CRK PHC2 ABL2, FYN, TNK1
CRK PIK3R1 ABL2, FYN, TNK1
CRK PIK3R2 ABL2, TNK1
CRK PIK3R3 ABL2, FYN, TNK1
CRK PRKACA ABL2
CRK PRRG2 ABL2, FES, JAK2
CRK PTK2 FYN
CRK RAB2B ABL2, TNK1
CRK SEMA4D ABL2
CRK SH2D2A ABL2, FYN, TNK1
CRK SOCS1 ABL2
CRK SOCS6 ABL2
CRK STAT4 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
CRK TCAP ABL2, FYN, TNK1
CRK TM4SF19 ABL2, TNK1
CRK TUG1 ABL2, FYN, TNK1
CRK VAC14 FYN
CRK XAGE1XX ABL2, TNK1
CRKL CBLB ABL2, FYN, TNK1
CRKL DOK1 FYN
CRKL DOK2 ABL2, FYN
CRKL KIAA0317 ABL2, FYN, TNK1
CRKL SOCS1 ABL2, FYN, TNK1
CRKL TMEM168 ABL2
CSK PDPK1 FYN
DAPP1 GSTCD ABL2, TNK1
DAPP1 MYLIP ABL2, TNK1
DAPP1 TNFAIP1 ABL2, FYN
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Interaction Kinases
DAPP1 WDR20 ABL2, BLK, FER, FGR, FRK, FYN, HCK, LYN,
SRC, SYK, YES1
DAPP1 ZNHIT1 TNK1
DOK1 CRKL FYN
DOK1 DOK3 ABL2, FYN
DOK2 APPL1 ABL2
DOK2 CRK ABL2, FYN
DOK2 CRKL ABL2, FYN
DOK2 DOK3 ABL2
DOK2 LCK ABL2, FYN
DOK2 STAT3 ABL2, TNK1
DOK3 APPL1 ABL2
DOK3 CRK ABL2, FYN, TNK1
DOK3 DOK1 ABL2, FYN
DOK3 DOK2 ABL2
DOK3 DOK4 ABL2, BLK, FER, FGR, FYN, HCK, SYK, YES1
DOK3 DOK5 FYN
DOK3 SHE ABL2
DOK3 STAT3 ABL2, FYN, TNK1
DOK4 CCM2 FYN
DOK4 DOK3 ABL2, BLK, FER, FGR, FYN, HCK, SYK, YES1
DOK4 PTK2 BLK, FGR, FYN, HCK, SRC, YES1
DOK4 STAT2 FYN
DOK5 DOK3 FYN
DOK5 SCOC ABL2, FES, PTK2
DOK7 APPL1 ABL2
DOK7 CRK ABL2, FYN, TNK1
DOK7 MPZL1 ABL2, FYN, TNK1
EPS8 CBL ABL2
EPS8 XAGE2XX FYN
FER KCTD4 ABL2
FRS3 MATK FYN
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Interaction Kinases
FRS3 NUMB FYN
FRS3 PIK3R3 FYN
FRS3 VASP FYN
FYN FYB FYN
GRB10 BAIAP2 ABL2, BMX, FES, FRK, PTK2, SYK, TNK1
GRB10 RCAN3 ABL2
GRB14 MST4 ABL2
GRB2 ACAP1 ABL2, FYN, SYK
GRB2 C10orf81 ABL2, BLK, FER, FGR, FYN, HCK, SRC, SYK,
TNK1, YES1
GRB2 C1orf135 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
GRB2 C6orf125 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
GRB2 CRBN ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
GRB2 DBN1 ABL2
GRB2 E2F2 ABL2, FYN
GRB2 LMX1A ABL2, FER, FGR, FYN, YES1
GRB2 MYOZ1 ABL2
GRB2 PACRGL ABL2, BMX, FES, FRK, FYN, JAK2, TNK1
GRB2 PARD6A ABL2, FER, FGR, FYN, HCK, SYK, YES1
GRB2 PCDHB1 ABL2, BLK, FER, FGR, FYN, HCK, SYK, YES1
GRB2 PCDHB5 ABL2, BMX, FES, FRK, FYN, JAK2
GRB2 PPARA FER, FGR, FRK, FYN
GRB2 RB1 ABL2, FER, FGR, FYN, HCK, YES1
GRB2 SOCS4 FYN
GRB2 TMEM128 ABL2, BMX, FYN, SYK
GRB2 TSPAN2 ABL2, BLK, FER, FGR, FYN, HCK, PTK2, TNK1,
YES1
GRB2 VCP ABL2, BLK, BMX, FER, FES, FGR, FRK, FYN,
HCK, JAK2, PTK2, SRC, SYK, TNK1, YES1
GRB2 WDFY3 ABL2, BMX, FES, FYN, JAK2, PTK2, SYK,
TNK1
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Interaction Kinases
GRB2 XAGE1XX ABL2, FES, FRK, FYN, JAK2, PTK2, SYK
GRB7 OLIG1 ABL2, FER, FES
GRB7 PTK2 ABL2, PTK2
GRB7 ZNHIT1 FRK, SYK
HCK NGEF ABL2, FRK, FYN, JAK2, PTK2, SYK, TNK1
HCK PIK3R3 FYN
HSH2D CRK ABL2, FYN
HSH2D LDHAL6B ABL2, FYN
HSH2D LECT1 ABL2
HSH2D PIK3R3 BLK, FER, FGR, FYN, YES1
HSH2D PINK1 ABL2
HSH2D PPAPDC2 ABL2
HSH2D RBP7 ABL2
HSH2D TSC1 ABL2
IRS1 BCAR3 ABL2, BLK, FER, FGR, FRK, FYN, HCK, LYN,
PTK2, SRC, TNK1, YES1
IRS1 NUMB ABL2, BLK, FER, FGR, FRK, FYN, HCK, PTK2,
SRC, TNK1, YES1
IRS1 PIK3R1 ABL2, FRK, FYN, PTK2, TNK1
IRS1 PIK3R3 ABL2, BLK, FER, FGR, FRK, FYN, HCK, PTK2,
SRC, TNK1, YES1
ITGB1BP1 PGRMC1 FER, FGR, FYN
JAK3 LNX1 ABL2, SYK
LCK DOK2 ABL2, FYN
LCK STAT3 ABL2
LCP2 FYB BLK, FER, FGR, FYN, HCK, LCK, LYN, SRC,
SYK, YES1
MAPK8IP2 ANGPT1 FRK, FYN, TNK1
MAPK8IP2 C22orf39 FRK, PTK2
MAPK8IP2 C8orf33 FRK
MAPK8IP2 FLJ21463 ABL2, BMX, FES, FRK, PTK2, SYK, TNK1
MAPK8IP2 LOC492311 PTK2
MAPK8IP2 MIA3 FES, FRK, FYN, PTK2
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MAPK8IP2 TMEM128 ABL2
MAPK8IP2 UBD ABL2, JAK2, PTK2, TNK1
MATK FRS3 FYN
MIST ARAP3 ABL2
MIST C6orf146 ABL2, TNK1
MIST COQ9 ABL2
MIST CYB561D2 ABL2
MIST GLIS3 ABL2, FYN, TNK1
MIST NME4 ABL2, FYN, TNK1
MIST PIK3R1 ABL2, FYN, TNK1
MIST PIK3R3 ABL2, FYN, TNK1
MIST PPP1R7 ABL2
MIST PTK7 ABL2
MIST RPAIN ABL2
MIST SFMBT1 ABL2, FYN, TNK1
MIST SOCS6 ABL2, FYN, TNK1
NCK1 OLIG1 ABL2, FER
NCK1 PIK3R3 ABL2, BLK, FYN, SYK
NCK1 SH2D1A BLK, FER, FGR, FYN, HCK, LYN, SRC
NCK2 FYB FYN, YES1
NUMB FRS3 FYN
NUMB IRS1 ABL2, BLK, FER, FGR, FRK, FYN, HCK, PTK2,
SRC, TNK1, YES1
NUMB OLIG1 ABL2
PIK3R1 APPL1 ABL2
PIK3R1 CBL ABL2, FRK, FYN
PIK3R1 CRK ABL2, FYN, TNK1
PIK3R1 IRS1 ABL2, FRK, FYN, PTK2, TNK1
PIK3R1 MIST ABL2, FYN, TNK1
PIK3R1 SH2D2A ABL2, FYN
PIK3R1 SOCS1 ABL2, FYN, TNK1
PIK3R1 STAT3 ABL2
374
YEAST TWO-HYBRID KINASE-INTERACTION SPECIFICITY
Interaction Kinases
PIK3R1 TNS4 ABL2, FYN
PIK3R2 CBL ABL2, FYN
PIK3R2 CRK ABL2, TNK1
PIK3R2 STAT3 ABL2
PIK3R3 ABL2 BMX, FES, FRK, FYN, JAK2, PTK2, SYK, TNK1
PIK3R3 ANKS1A ABL2
PIK3R3 ARL6IP4 ABL2, FER, FGR, FYN, HCK, LYN, YES1
PIK3R3 BTK FYN
PIK3R3 C10orf81 ABL2, BLK, BMX, FER, FES, FGR, FRK, FYN,
HCK, SRC, SYK, TNK1, YES1
PIK3R3 CBL ABL2, BLK, FER, FGR, FRK, FYN, HCK, SRC,
SYK, YES1
PIK3R3 CCDC14 ABL2, BLK, FER, FES, FGR, FYN, HCK, SYK,
YES1
PIK3R3 CRK ABL2, FYN, TNK1
PIK3R3 CRYBA2 ABL2
PIK3R3 E2F6 ABL2, FYN
PIK3R3 EVI1 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
PIK3R3 FRS3 FYN
PIK3R3 HCK FYN
PIK3R3 HSH2D BLK, FER, FGR, FYN, YES1
PIK3R3 IQUB ABL2, BMX, FES, FRK, FYN, JAK2, PTK2,
TNK1
PIK3R3 IRS1 ABL2, BLK, FER, FGR, FRK, FYN, HCK, PTK2,
SRC, TNK1, YES1
PIK3R3 MIST ABL2, FYN, TNK1
PIK3R3 NCK1 ABL2, BLK, FYN, SYK
PIK3R3 OTUD7B ABL2, FYN
PIK3R3 PARD6A ABL2, FYN
PIK3R3 PCDHB5 ABL2, BMX, FES, FYN, JAK2, SYK, TNK1
PIK3R3 PELI3 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
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PIK3R3 PELO ABL2, BLK, BMX, FES, FGR, FRK, FYN, HCK,
PTK2, TNK1, YES1
PIK3R3 PLB1 ABL2, BMX, FES, FYN, JAK2, SYK, TNK1
PIK3R3 PPARA ABL2, FYN
PIK3R3 RBP7 ABL2, BMX, FYN
PIK3R3 SH2D2A ABL2, FYN
PIK3R3 SOCS4 ABL2
PIK3R3 SPSB2 FES
PIK3R3 SRC FYN
PIK3R3 STAT3 ABL2, TNK1
PIK3R3 USP2 ABL2, FES, FYN, JAK2, SYK, TNK1
PIK3R3 VCP ABL2, FYN
PIK3R3 WBSCR27 ABL2
PIK3R3 ZNF281 ABL2, FYN, TNK1
PIK3R3 ZNF767 ABL2
PLCG2 ELK1 BMX
PLCG2 EPYC FRK, FYN, PTK2, SYK, TNK1
PLCG2 HSPD1 BMX
PLCG2 LHX8 BMX, FRK, JAK2, PTK2, SYK, TNK1
PLCG2 PTTG1 FES, PTK2
PLCG2 TP53 FRK, FYN, SYK
PTPN11 LNX1 ABL2, FES, FRK, PTK2
PTPN6 OLIG1 ABL2
PTPN6 PTK2 ABL2, FES
RABGAP1 STAT3 ABL2, FYN, TNK1
RABGAP1L ACAP1 ABL2
RABGAP1L ARFGAP1 BMX
RABGAP1L C6orf125 ABL2, FRK, JAK2
RABGAP1L C9orf43 ABL2, FES
RABGAP1L DBN1 ABL2
RABGAP1L EVI1 ABL2, BMX, FES, FRK, SYK
RABGAP1L RB1 ABL2, FER, FGR, FRK, FYN
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Interaction Kinases
RABGAP1L TSPAN2 ABL2, FES
RABGAP1L WDFY3 ABL2, BMX
RASA1 OLIG1 FER, TNK1
SH2B1 CSAD FRK, TNK1
SH2D1A ATF3 ABL2, BMX, JAK2, PTK2, SYK, TNK1
SH2D1A NCK1 BLK, FER, FGR, FYN, HCK, LYN, SRC
SH2D1A PTK2 ABL2, FYN, TNK1
SH2D1A ZNHIT1 ABL2, BLK, FER, FGR, FYN, HCK
SH2D1B HSPA1A ABL2, BLK, BMX, FGR, FYN, HCK, SRC, TNK1,
YES1
SH2D1B STAT4 ABL2, BLK, FYN
SH2D2A APPL1 ABL2
SH2D2A ASB3 ABL2
SH2D2A CRK ABL2, FYN, TNK1
SH2D2A FAM46A ABL2
SH2D2A FAM46B ABL2, FES, FRK, FYN, JAK2, TNK1
SH2D2A KLRAQ1 ABL2
SH2D2A LNX1 ABL2
SH2D2A LRRFIP1 ABL2, CSK, FER, FGR, FYN, JAK3, TNK1
SH2D2A PIK3R1 ABL2, FYN
SH2D2A PIK3R3 ABL2, FYN
SH2D2A PLEKHB1 ABL2, FRK, FYN, JAK2, SYK
SH2D2A PTK2 BLK, FGR, FYN, HCK, SRC, SYK, YES1
SH2D2A RAD54B ABL2, TNK1
SH2D2A SOCS3 ABL2, FYN
SH2D2A SPTB ABL2, BLK, FER, FGR, TNK1, YES1
SH2D2A STAT3 ABL2, FYN
SH2D2A TMEM148 ABL2
SH2D2A TSC1 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
SH2D2A WDR40B ABL2
SH2D2A ZHX3 ABL2
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SH2D2A ZSCAN1 ABL2, FYN
SH3BP2 ARHGAP10 FYN
SH3BP2 STAT3 ABL2, TNK1
SHD CAPN10 ABL2, BMX, FES, FRK, JAK2, PTK2, SYK,
TNK1
SHD PSG11 ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
SHE DOK3 ABL2
SHE TRIT1 ABL2
SOCS1 CRK ABL2
SOCS1 CRKL ABL2, FYN, TNK1
SOCS1 PIK3R1 ABL2, FYN, TNK1
SOCS3 SH2D2A ABL2, FYN
SOCS3 TRDN FYN
SOCS4 GRB2 FYN
SOCS4 LDHAL6B ABL2, PTK2
SOCS4 LECT1 ABL2
SOCS4 MPP5 ABL2, FES, TNK1
SOCS4 PIK3R3 ABL2
SOCS4 PINK1 ABL2, PTK2
SOCS4 PPAPDC2 ABL2, PTK2
SOCS4 RBP7 ABL2, PTK2
SOCS4 TNK2 BMX, FRK, PTK2, TNK1
SOCS6 APPL1 ABL2
SOCS6 CRK ABL2
SOCS6 LNX1 BMX, FES, FRK, FYN, PTK2, TNK1
SOCS6 MIST ABL2, FYN, TNK1
SRC PIK3R3 FYN
STAT1 SPTB ABL2, BMX, FES, FYN, JAK2
STAT2 DOK4 FYN
STAT3 ABL2 ABL2, TNK1
STAT3 BRWD1 ABL2, FYN
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Interaction Kinases
STAT3 C10orf18 ABL2, FYN, TNK1
STAT3 CA8 ABL2
STAT3 CBL ABL2, TNK1
STAT3 CCDC87 ABL2, TNK1
STAT3 DOK2 ABL2, TNK1
STAT3 DOK3 ABL2, FYN, TNK1
STAT3 DTNA ABL2, FYN, TNK1
STAT3 FAM117B ABL2, FYN, TNK1
STAT3 GSTCD ABL2, FYN, TNK1
STAT3 HESX1 ABL2, FYN, TNK1
STAT3 KRTAP10-7 ABL2, FYN, TNK1
STAT3 LASP1 ABL2, FYN, TNK1
STAT3 LCK ABL2
STAT3 LOC401296 ABL2, FYN, TNK1
STAT3 MAPKAPK2 ABL2
STAT3 MPZL1 ABL2, FYN, TNK1
STAT3 NUFIP2 ABL2, FYN
STAT3 PAQR7 ABL2, TNK1
STAT3 PIK3R1 ABL2
STAT3 PIK3R2 ABL2
STAT3 PIK3R3 ABL2, TNK1
STAT3 PPARD ABL2, TNK1
STAT3 RABGAP1 ABL2, FYN, TNK1
STAT3 SH2D2A ABL2, FYN
STAT3 SH3BP2 ABL2, TNK1
STAT3 TM4SF19 ABL2, FYN, TNK1
STAT3 TWIST1 ABL2, FYN
STAT3 VPS39 ABL2, TNK1
STAT3 WDFY3 ABL2, FYN, TNK1
STAT3 ZNF281 ABL2, FYN, TNK1
STAT3 ZNF829 ABL2
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Interaction Kinases
STAT4 CRK ABL2, BMX, FES, FRK, FYN, JAK2, PTK2, SYK,
TNK1
STAT4 SH2D1B ABL2, BLK, FYN
STAT5A CBL BMX
STAT5A OLIG1 ABL2, BMX, JAK2, PTK2, SYK, TNK1
SYK FAM46A FES
TNS4 GSTCD ABL2, FYN, TNK1
TNS4 NME4 ABL2, FYN
TNS4 P4HA2 ABL2, FYN, TNK1
TNS4 PIK3R1 ABL2, FYN
TNS4 RPAIN ABL2
YES1 BECN1 ABL2, BMX, FER, FES, FGR, HCK, JAK2, PTK2,
SYK, TNK1, YES1
YES1 OLIG1 ABL2, BLK, FER, FES, FGR, HCK, PTK2, YES1
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Mutant SH2 CoIP results
Co-immunoprecipitation assays employing binding-deficient SH2 domains
demonstrate phosphotyrosine-dependency regardless of high background tyro-
sine kinase activity. Thirty interactions validated in co-immunoprecipitation
assays were selected and repeated with constructs containing mutated SH2
domains. Interaction phosphotyrosine-dependency was considered validated if
the luciferase signal was reduced by a factor of at least two and by at least
two standard deviations compared to wildtype signal, assuming a multiplica-
tive error model. The position of each ORF (”Protein A” or ”Luciferase” for
pPAReni-DM or pFireV5-DM, respectively), the binding signal strength (”Fold
Binding”) and its statistical reliability in terms of standard deviations (”Z-
Score”) are provided for each pair of ORFs.
Protein A – Luciferase Fold Binding Z-Score
PIK3R3
(ORF #2 R90LR383L) – IRS1 0.03
×
÷1.16 −23.6
PIK3R1 (R88KR379K) – IRS1 0.07×÷1.22 −13.6
GRB2 (ORF #2 R86K) – RB1 0.09×÷1.14 −18.3
PIK3R3
(ORF #2 R90LR383L) – WDFY3 0.12
×
÷1.88 −3.4
PIK3R3
(ORF #2 R90LR383L) – CRYBA2 0.15
×
÷1.21 −9.8
PIK3R3
(ORF #2 R90LR383L) – PELI3 0.18
×
÷1.04 −39.3
PIK3R3
(ORF #2 R90LR383L) – PARD6A 0.22
×
÷1.16 −10.5
FRS3 (ORF #2) – SOCS4 (R311L) 0.23×÷1.15 −10.3
PIK3R3
(ORF #2 R90LR383L) – SH2D2A 0.24
×
÷1.25 −6.4
PIK3R3
(ORF #2 R90LR383L) – SPSB2 0.27
×
÷1.17 −8.6
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Protein A – Luciferase Fold Binding Z-Score
GRB2 (ORF #2 R86K) – TSPAN2 0.27×÷1.35 −4.4
C10orf81 – PIK3R3(ORF #2 R90LR383L) 0.29
×
÷1.27 −5.1
GRB2 (ORF #2 R86K) – VCP (ORF #1) 0.32×÷1.17 −7.1
PIK3R3
(ORF #2 R90LR383L) – HCK 0.35
×
÷1.48 −2.7
GRB2 (ORF #2 R86K) – TMEM128 0.35×÷1.19 −5.9
PIK3R3
(ORF #2 R90LR383L) – WBSCR27 0.35
×
÷1.34 −3.6
BCAR3 (R177L) – IRS1 0.44×÷1.33 −2.8
PIK3R3
(ORF #2 R90LR383L) – OTUD7B 0.46
×
÷1.39 −2.4
PIK3R1 (R88KR379K) – SH2D2A 0.48×÷1.23 −3.5
PIK3R3
(ORF #2 R90LR383L) – ARL6IP4 0.48
×
÷1.38 −2.3
ZHX3 – SH2D2A (R120K) 0.59×÷1.19 −3
PIK3R3 (ORF #2
R90LR383L) – PPARA 0.6
×
÷1.56 −1.1
CRK (ORF #3) – SH2D2A (R120K) 0.65×÷1.17 −2.6
GRB2 (ORF #2 R86K) – SOCS4 0.66×÷1.42 −1.2
PINK1 – SOCS4 (R311K) 0.88×÷1.16 −0.9
SH2D2A (R120K) – FAM46A 0.89×÷1.22 −0.6
GRB2 (ORF #2 R86K) – DBN1 0.89×÷1.41 −0.3
GRB2 (ORF #2 R86K) – PPARA 0.93×÷1.4 −0.2
SH2D2A (R120K) – FAM46B 0.94×÷1.25 −0.3
SH2D2A (R120K) – ASB3 0.95×÷1.29 −0.2
PLEKHB1 – SH2D2A (R120K) 0.95×÷1.17 −0.3
RBP7 – SOCS4 (R311K) 0.96×÷1.06 −0.6
GRB2 (ORF #2 R86K) – LMX1A 0.96×÷1.52 −0.1
SH2D2A (R120K) – PTK2 (ORF #1 WT) 1.04×÷1.19 0.2
GRB2 (ORF #2 R86K) – C10orf81 1.1×÷1.11 0.9
RAD54B – SH2D2A (R120K) 1.15×÷1.28 0.6
LRRFIP1 – SH2D2A (R120K) 1.19×÷1.25 0.8
SH2D2A (R120K) – WDR40B 1.19×÷1.22 0.9
TSC1 (ORF #2) – SH2D2A (R120K) 1.22×÷2.49 0.2
PIK3R3
(ORF #2 R90LR383L) – SOCS4 1.47
×
÷1.12 3.4
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Protein Complementation assay
results
Results of the protein complementation assay experiment including observed
subcellular localization and exact configuration of ORFs and fragment fusions.
For each combination of ORF and fragment fusion plasmid not involved in an
experiment with negative outcome, a control experiment is provided. pos =
positive; neg = negative; ctrl = control; C = carboxy-terminal fusion; N =
amino-terminal fusion.
Result Localization F1 fusion F2 fusion
pos nucleus GRB2 (ORF #2) C ARL6IP4 N
pos cytoplasm GRB2 (ORF #2) C C10orf81 C
pos cytoplasm GRB2 (ORF #2) C PARD6A C
pos nucleus GRB2 (ORF #2) C RB1 N
pos nucleus GRB2 (ORF #2) C RB1 C
pos membrane GRB2 (ORF #2) C TSPAN2 C
pos nucleus PIK3R3 (ORF #1) C ARL6IP4 C
pos cytoplasm PIK3R3 (ORF #1) C C10orf81 C
pos cytoplasm PIK3R3 (ORF #1) C C10orf81 C
pos cytoplasm PIK3R3 (ORF #1) C TSPAN2 C
pos nucleus PIK3R3 (ORF #4) C RB1 N
pos nucleus PIK3R3 (ORF #4) C SOCS4 C
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Result Localization F1 fusion F2 fusion
pos cytoplasm RBP7 N PIK3R3 (ORF #4) C
pos nucleus+cytoplasm SOCS4 N RBP7 N
neg perinuclear cloud GRB2 (ORF #2) C OLIG1 N
neg perinuclear cloud GRB2 (ORF #2) C OLIG1 C
neg no signal GRB2 (ORF #2) C SOCS4 C
neg perinuclear cloud GRB2 (ORF #2) C TMEM128 N
neg perinuclear cloud GRB2 (ORF #2) C TMEM128 C
neg perinuclear cloud GRB2 (ORF #2) C WBSCR27 N
neg perinuclear cloud GRB2 (ORF #2) C WBSCR27 C
neg no signal PIK3R1 N SH2D2A N
neg no signal PIK3R3 (ORF #1) C SH2D2A N
neg no signal
PTK2 (ORF #1
WT)
C SH2D2A N
ctrl no signal – - PARD6A C
ctrl no signal – - TSPAN2 C
ctrl no signal ARL6IP4 N PIK3R3 (ORF #4) C
ctrl no signal GRB2 (ORF #2) C ARL6IP4 C
ctrl no signal GRB2 (SH2) N ARL6IP4 N
ctrl no signal GRB2 (SH2) N C10orf81 C
ctrl no signal GRB2 (SH2) N RB1 N
ctrl no signal PIK3R3 (ORF #4) C RB1 C
ctrl no signal PIK3R3 (ORF #4) C RB1 C
ctrl no signal RBP7 N
PIK3R3
(ORF #1
R90LR383L)
C
ctrl no signal SOCS4 N RBP7 C
ctrl no signal SOCS4 C RBP7 N
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Known interactions recovered
For each interaction detected in this study that has been described before, the
phosphotyrosine-dependency in this study (pY-dependent this study) and, where
available, in the previous description (pY-dependent literature) are indicated.
For greater clarity, each (non-self-)interaction is listed twice.
pY-dependent
Interaction this study literature
ABL2 – CRK yes no
AKT1 – APPL1 no –
APPL1 – AKT1 no –
BAIAP2 – EPS8 no no
BMX – STAT3 no yes
CBL – CRK yes yes
CBL – CRKL no both
CBL – FYN no no
CBL – GRB2 no no
CBL – PIK3R1 yes yes
CBL – PIK3R2 yes –
CBLB – CRK yes –
CBLB – CRKL yes yes
CBLB – FYN no –
CBLC – CRK yes no
CCM2 – KRIT1 no –
CRK – ABL2 yes no
CRK – CBL yes yes
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pY-dependent
Interaction this study literature
CRK – CBLB yes –
CRK – CBLC yes no
CRK – PIK3R1 yes –
CRK – PIK3R2 yes –
CRK – PIK3R3 yes –
CRK – PTK2 yes yes
CRK – RIN3 no no
CRK – SOCS1 yes no
CRKL – CBL no both
CRKL – CBLB yes yes
CRKL – DOK1 yes yes
DOK1 – CRKL yes yes
DOK2 – LCK yes –
EPS8 – BAIAP2 no no
FGF12 – MAPK8IP2 no –
FGF13 – MAPK8IP2 no –
FYN – CBL no no
FYN – CBLB no –
GRB2 – CBL no no
GRB7 – PTK2 yes yes
HSH2D – TNK2 no –
IRS1 – PIK3R1 yes yes
IRS1 – PIK3R3 yes –
ITGB1BP1 – KRIT1 no –
KRIT1 – CCM2 no –
KRIT1 – ITGB1BP1 no –
LCK – DOK2 yes –
LNX2 – NUMB no yes
LYN – PTK2 no –
MAPK8IP2 – FGF12 no –
MAPK8IP2 – FGF13 no –
386
KNOWN INTERACTIONS RECOVERED
pY-dependent
Interaction this study literature
NUMB – LNX2 no yes
PIK3CA – PIK3R3 no no
PIK3R1 – CBL yes yes
PIK3R1 – CRK yes –
PIK3R1 – IRS1 yes yes
PIK3R1 – SOCS1 yes no
PIK3R2 – CBL yes –
PIK3R2 – CRK yes –
PIK3R3 – CRK yes –
PIK3R3 – IRS1 yes –
PIK3R3 – PIK3CA no no
PTK2 – CRK yes yes
PTK2 – GRB7 yes yes
PTK2 – LYN no –
PTK2 – SRC no yes
RIN3 – CRK no no
SOCS1 – CRK yes no
SOCS1 – PIK3R1 yes no
SRC – PTK2 no yes
STAT3 – BMX no yes
TNK2 – HSH2D no –
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Appendix H
Literature interactions among
successful bait genes
For each interaction among successful bait genes recovered from the Consen-
susPathDB meta-database, the PubMed identifiers (PMIDs) of the examined
publications and the conclusion reached (validated) are listed.
Note that, due to the points of interests in this study, for a validated interaction,
further publications were examined only if relevant for another interaction.
Interaction validated PMID(s)
ABL2 – CBL no 19380743
ABL2 – CBLB no 19380743
ABL2 – CRK yes 8194526, 17474147
ABL2 – FYN yes 17474147
ABL2 – GRB2 yes 17474147
ABL2 – HCK yes 12748290
ABL2 – PIK3R2 no 19380743
ABL2 – PIK3R3 no 19380743
ABL2 – RIN1 yes 9144171
ABL2 – SRC yes 17474147
APBB3 – APPL2 yes 9461550
APPL1 – APPL2 yes 16189514
APPL2 – APBB3 yes 9461550
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Interaction validated PMID(s)
APPL2 – APPL1 yes 16189514
BTK – CBL yes 7629518
BTK – CBLB yes 12093870
BTK – DAPP1 yes 11524430
BTK – FYN yes 8058772
BTK – GRB2 yes 19380743, 20936779
BTK – HCK yes 8058772
BTK – LYN yes 8058772
BTK – PIK3R2 no 19380743
BTK – PLCG2 yes 10981967, 12093870
BTK – PTPN11 no 19380743
BTK – STAT3 yes 17367410
BTK – STAT5A yes 11413148
BTK – SYK no 8629002, 8630736, 11226282, 11598012,12522270
CBL – ABL2 no 19380743
CBL – BTK yes 7629518
CBL – CBLB no 15657067, 19380743, 21706016
CBL – CRK yes 8524328, 8621483, 8626543, 9178909,9461587, 19380743
CBL – CRKL yes
8621483, 8626543, 8662998, 9092574,
9178909, 9344843, 9461587, 11133830,
15556646
CBL – CSK yes 19380743
CBL – FRS2 yes 11997436
CBL – FYN yes 7642581, 8621719, 9525940, 9535867,9890970, 15190072, 15556646
CBL – GRB2 yes
7642581, 8621719, 8662998, 9178909,
9461587, 11133830, 11964172, 11997436,
19380743, 20936779
CBL – HCK yes 9890970, 10092522, 10799548, 11896602
CBL – IRS1 no 21706016
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Interaction validated PMID(s)
CBL – LYN yes 9160881, 9890970, 15190072
CBL – PIK3R2 yes 11133830
CBL – PIK3R3 no 19380743, 21706016
CBL – PTPN11 yes 11157475
CBL – PTPN6 yes 12176909
CBL – SH3BP2 yes 9846481
CBL – SRC yes 9525940, 11994282
CBL – STAT3 no 15657067
CBL – STAT5A no 12193575
CBL – SYK yes 8621719, 9535867, 15556646
CBL – YES1 yes 9525940
CBLB – ABL2 no 19380743
CBLB – BTK yes 12093870
CBLB – CBL no 15657067, 19380743, 21706016
CBLB – CRK yes 19380743
CBLB – CRKL yes 10022120, 12697763
CBLB – CSK no 21706016
CBLB – FRS2 no 21706016
CBLB – FYN yes 16503409
CBLB – GRB2 yes 10022120, 12577067, 20936779
CBLB – HCK no 12029088
CBLB – IRS1 yes 16734387
CBLB – PIK3R2 no 19380743, 21706016
CBLB – PIK3R3 no 19380743, 21706016
CBLB – PLCG2 yes 12093870
CBLB – PTPN11 no 12577067, 21706016
CBLB – SH3BP2 no 17306257
CBLB – STAT3 no 15657067
CBLB – SYK yes 10022120
CBLB – YES1 no 15657067
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Interaction validated PMID(s)
CRK – ABL2 yes 8194526, 17474147
CRK – CBL yes 8524328, 8621483, 8626543, 9178909,9461587, 19380743
CRK – CBLB yes 19380743
CRK – CRKL no 16713569
CRK – CSK no 19380743
CRK – DOK4 yes 12730241
CRK – FRS2 yes 10092678
CRK – FYN no 9480911, 9642287, 11956190, 12198159
CRK – GRB2 yes 19380743
CRK – IRS1 yes 8621590
CRK – PIK3R2 yes 19380743
CRK – PIK3R3 yes 19380743
CRK – PTPN11 yes 19380743
CRK – RIN3 yes 17474147
CRK – SOCS1 yes 10022833
CRK – SRC yes 12615911
CRK – STAT5A yes 11097834
CRKL – CBL yes
8621483, 8626543, 8662998, 9092574,
9178909, 9344843, 9461587, 11133830,
15556646
CRKL – CBLB yes 10022120, 12697763
CRKL – CRK no 16713569
CRKL – DOK1 yes 11071635
CRKL – FYN no 15556646
CRKL – GRB2 yes 10477741
CRKL – LYN yes 11443118
CRKL – PIK3R2 yes 9092574
CRKL – PTPN11 yes 9344843
CRKL – STAT5A yes 9837784
CRKL – SYK yes 11313252
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Interaction validated PMID(s)
CSK – CBL yes 19380743
CSK – CBLB no 21706016
CSK – CRK no 19380743
CSK – DOK1 no 9221755, 10799545, 10852966, 11551902,12522270, 15144186, 15592455, 16094384
CSK – FRS2 no 21706016
CSK – FYN yes 7524477
CSK – GRB2 no 19380743
CSK – HCK no 10934191, 11976726
CSK – IRS1 no 21706016
CSK – LYN yes 1722201
CSK – PIK3R2 yes 19380743
CSK – PIK3R3 no 21706016
CSK – PTPN11 no 14665621, 21706016
CSK – SRC yes 12387813
CSK – YES1 no 16094384
DAPP1 – BTK yes 11524430
DAPP1 – LYN yes 10880360, 11524430
DAPP1 – PLCG2 yes 10770799
DAPP1 – SRC yes 10880360, 11524430
DOK1 – CRKL yes 11071635
DOK1 – CSK no 9221755, 10799545, 10852966, 11551902,12522270, 15144186, 15592455, 16094384
DOK1 – DOK2 no 10822173
DOK1 – DOK7 no 20562859
DOK1 – FYN yes 15345598
DOK1 – GRB10 no 11551902
DOK1 – HCK yes 11071635
DOK1 – LYN yes 11071635
DOK1 – PTPN11 yes 15546884
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Interaction validated PMID(s)
DOK1 – PTPN6 yes 10585470
DOK1 – SH2D1A yes 10852966
DOK1 – SRC yes 11071635
DOK1 – YES1 yes 11071635
DOK2 – DOK1 no 10822173
DOK2 – HCK no 10428862
DOK2 – LYN no 10428862
DOK2 – SRC no 10428862
DOK4 – CRK yes 12730241
DOK4 – FYN yes 12730241
DOK4 – SRC yes 12730241
DOK7 – DOK1 no 20562859
EPS8 – SRC yes 10395945
FER – IRS1 yes 11006284
FER – STAT3 yes 10878010
FRS2 – CBL yes 11997436
FRS2 – CBLB no 21706016
FRS2 – CRK yes 10092678
FRS2 – CSK no 21706016
FRS2 – GRB2 yes 9182757, 10092678, 11997436
FRS2 – IRS1 no 21706016
FRS2 – PIK3R2 no 21706016
FRS2 – PIK3R3 no 21706016
FRS2 – PTPN11 yes 10650943
FRS2 – SRC yes 10092678
FRS3 – GRB2 no 11432792
FRS3 – PTPN11 yes 11432792
FYN – ABL2 yes 17474147
FYN – BTK yes 8058772
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Interaction validated PMID(s)
FYN – CBL yes 7642581, 8621719, 9525940, 9535867,9890970, 15190072, 15556646
FYN – CBLB yes 16503409
FYN – CRK no 9480911, 9642287, 11956190, 12198159
FYN – CRKL no 15556646
FYN – CSK yes 7524477
FYN – DOK1 yes 15345598
FYN – DOK4 yes 12730241
FYN – GRB10 yes 10871840
FYN – GRB2 yes 9344857
FYN – IRS1 yes 8631859
FYN – LYN no 1544885, 1722201, 7545683, 8530369,8612628, 15190072
FYN – PIK3R2 yes 1334406
FYN – PLCG2 yes 7682059, 8395016
FYN – PTPN11 yes 10212213
FYN – RIN3 yes 17474147
FYN – SH2D1A yes 12545174
FYN – SH3BP2 yes 9846481
FYN – SOCS1 yes 10022833
FYN – SRC no 9169421, 16966330
FYN – STAT1 yes 9804857
FYN – SYK no 9535867, 12522270, 16713569
FYN – YES1 yes 12640114
GRAP2 – GRB2 no 11997510, 12176364, 12640133
GRB2 – ABL2 yes 17474147
GRB2 – BTK yes 19380743, 20936779
GRB2 – CBL yes
7642581, 8621719, 8662998, 9178909,
9461587, 11133830, 11964172, 11997436,
19380743, 20936779
GRB2 – CBLB yes 10022120, 12577067, 20936779
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Interaction validated PMID(s)
GRB2 – CRK yes 19380743
GRB2 – CRKL yes 10477741
GRB2 – CSK no 19380743
GRB2 – FRS2 yes 9182757, 10092678, 11997436
GRB2 – FRS3 no 11432792
GRB2 – FYN yes 9344857
GRB2 – GRAP2 no 11997510, 12176364, 12640133
GRB2 – GRB10 no 8798570, 17474147
GRB2 – GRB7 no 16189514
GRB2 – IRS1 yes 7862167
GRB2 – LYN no 10469124, 16799092
GRB2 – PIK3R2 yes 8662998, 19380743, 20936779
GRB2 – PIK3R3 no 19380743
GRB2 – PLCG2 yes 17474147
GRB2 – PTPN11 yes 10212213, 10747947, 19380743
GRB2 – PTPN6 yes 8632004, 10747947, 11964172
GRB2 – RIN3 yes 17474147
GRB2 – SH2B1 yes 9742218, 20936779
GRB2 – SH2D1A yes 9856458
GRB2 – SH2D4A yes 20936779
GRB2 – SH3BP2 yes 9846481
GRB2 – SOCS1 yes 10022833
GRB2 – SRC yes 11964172
GRB2 – STAT3 no 15657067
GRB2 – SYK yes 10747947, 11964172
GRB2 – YES1 no 15657067
GRB7 – GRB2 no 16189514
GRB10 – DOK1 no 11551902
GRB10 – FYN yes 10871840
GRB10 – GRB2 no 8798570, 17474147
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Interaction validated PMID(s)
GRB10 – IRS1 no 8621530
GRB10 – SRC yes 10871840
GRB14 – IRS1 no 9748281
HCK – ABL2 yes 12748290
HCK – BTK yes 8058772
HCK – CBL yes 9890970, 10092522, 10799548, 11896602
HCK – CBLB no 12029088
HCK – CSK no 10934191, 11976726
HCK – DOK1 yes 11071635
HCK – DOK2 no 10428862
HCK – PIK3R2 yes 12029088
HCK – PLCG2 yes 7682059
HCK – SRC yes 11896602
HCK – STAT3 yes 12244095
IRS1 – CBL no 21706016
IRS1 – CBLB yes 16734387
IRS1 – CRK yes 8621590
IRS1 – CSK no 21706016
IRS1 – FER yes 11006284
IRS1 – FRS2 no 21706016
IRS1 – FYN yes 8631859
IRS1 – GRB10 no 8621530
IRS1 – GRB14 no 9748281
IRS1 – GRB2 yes 7862167
IRS1 – JAK3 yes 7499365
IRS1 – PIK3R2 yes 11120660
IRS1 – PIK3R3 yes 9415396
IRS1 – PTPN11 yes 8505282
IRS1 – PTPN6 no 18729074
IRS1 – SOCS1 yes 12228220
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Interaction validated PMID(s)
IRS1 – SOCS3 no 12228220
JAK3 – IRS1 yes 7499365
JAK3 – PTPN6 no 8114715, 8692915, 9520455, 10574931
JAK3 – SOCS1 yes 11133764
JAK3 – SOCS3 yes 10373548
JAK3 – STAT3 no
8272872, 8626374, 9083098, 9305919,
9343414, 9566874, 9582023, 9872331,
10037026, 10446219, 10521505, 10918587,
11294897, 11335711, 11350938, 11429593,
11850821, 11940572, 12244095, 12576423,
12626508, 12763138, 14551213, 15465816,
15592455, 16189514
JAK3 – STAT5A yes 9047382
LYN – BTK yes 8058772
LYN – CBL yes 9160881, 9890970, 15190072
LYN – CRKL yes 11443118
LYN – CSK yes 1722201
LYN – DAPP1 yes 10880360, 11524430
LYN – DOK1 yes 11071635
LYN – DOK2 no 10428862
LYN – FYN no 1544885, 1722201, 7545683, 8530369,8612628, 15190072
LYN – GRB2 no 10469124, 16799092
LYN – PLCG2 yes 7682059, 8395016, 10981967
LYN – PTPN6 yes 10574931
LYN – SRC no 9169421
LYN – SYK yes 7831290
LYN – YES1 no 1544885
PIK3R2 – ABL2 no 19380743
PIK3R2 – BTK no 19380743
PIK3R2 – CBL yes 11133830
PIK3R2 – CBLB no 19380743, 21706016
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Interaction validated PMID(s)
PIK3R2 – CRK yes 19380743
PIK3R2 – CRKL yes 9092574
PIK3R2 – CSK yes 19380743
PIK3R2 – FRS2 no 21706016
PIK3R2 – FYN yes 1334406
PIK3R2 – GRB2 yes 8662998, 19380743, 20936779
PIK3R2 – HCK yes 12029088
PIK3R2 – IRS1 yes 11120660
PIK3R2 – PIK3R3 no 16456542, 19380743, 21706016
PIK3R2 – PTPN11 yes 19380743
PIK3R2 – SOCS1 yes 10022833
PIK3R2 – SOCS6 yes 12052866
PIK3R2 – SYK yes 15536084
PIK3R2 – YES1 no 17620599
PIK3R3 – ABL2 no 19380743
PIK3R3 – CBL no 19380743, 21706016
PIK3R3 – CBLB no 19380743, 21706016
PIK3R3 – CRK yes 19380743
PIK3R3 – CSK no 21706016
PIK3R3 – FRS2 no 21706016
PIK3R3 – GRB2 no 19380743
PIK3R3 – IRS1 yes 9415396
PIK3R3 – PIK3R2 no 16456542, 19380743, 21706016
PIK3R3 – PTPN11 no 21706016
PLCG2 – BTK yes 10981967, 12093870
PLCG2 – CBLB yes 12093870
PLCG2 – DAPP1 yes 10770799
PLCG2 – FYN yes 7682059, 8395016
PLCG2 – GRB2 yes 17474147
PLCG2 – HCK yes 7682059
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Interaction validated PMID(s)
PLCG2 – LYN yes 7682059, 8395016, 10981967
PLCG2 – PTPN11 yes 12135708
PLCG2 – SH3BP2 yes 11390470
PLCG2 – SYK yes 10469124, 10981967
PTPN11 – BTK no 19380743
PTPN11 – CBL yes 11157475
PTPN11 – CBLB no 12577067, 21706016
PTPN11 – CRK yes 19380743
PTPN11 – CRKL yes 9344843
PTPN11 – CSK no 14665621, 21706016
PTPN11 – DOK1 yes 15546884
PTPN11 – FRS2 yes 10650943
PTPN11 – FRS3 yes 11432792
PTPN11 – FYN yes 10212213
PTPN11 – GRB2 yes 10212213, 10747947, 19380743
PTPN11 – IRS1 yes 8505282
PTPN11 – PIK3R2 yes 19380743
PTPN11 – PIK3R3 no 21706016
PTPN11 – PLCG2 yes 12135708
PTPN11 – PTPN6 no 8541543
PTPN11 – SH2D1A no 11806999
PTPN11 – SOCS3 yes 10777583
PTPN11 – SRC yes 14687660
PTPN11 – STAT1 yes 12270932
PTPN11 – STAT3 yes 11594781
PTPN11 – STAT5A yes 10617656
PTPN6 – CBL yes 12176909
PTPN6 – DOK1 yes 10585470
PTPN6 – GRB2 yes 8632004, 10747947, 11964172
PTPN6 – IRS1 no 18729074
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Interaction validated PMID(s)
PTPN6 – JAK3 no 8114715, 8692915, 9520455, 10574931
PTPN6 – LYN yes 10574931
PTPN6 – PTPN11 no 8541543
PTPN6 – SH3BP2 yes 16649996
PTPN6 – SRC yes 9261115
PTPN6 – STAT3 no 15870198
PTPN6 – SYK yes 10747947
RIN1 – ABL2 yes 9144171
RIN3 – CRK yes 17474147
RIN3 – FYN yes 17474147
RIN3 – GRB2 yes 17474147
RIN3 – SRC yes 17474147
SH2B1 – GRB2 yes 9742218, 20936779
SH2D1A – DOK1 yes 10852966
SH2D1A – FYN yes 12545174
SH2D1A – GRB2 yes 9856458
SH2D1A – PTPN11 no 11806999
SH2D1A – SH2D1B no 11689425
SH2D1B – SH2D1A no 11689425
SH2D2A – SRC yes 15962004
SH2D4A – GRB2 yes 20936779
SH3BP2 – CBL yes 9846481
SH3BP2 – CBLB no 17306257
SH3BP2 – FYN yes 9846481
SH3BP2 – GRB2 yes 9846481
SH3BP2 – PLCG2 yes 11390470
SH3BP2 – PTPN6 yes 16649996
SH3BP2 – SYK yes 9846481
SOCS1 – CRK yes 10022833
SOCS1 – FYN yes 10022833
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Interaction validated PMID(s)
SOCS1 – GRB2 yes 10022833
SOCS1 – IRS1 yes 12228220
SOCS1 – JAK3 yes 11133764
SOCS1 – PIK3R2 yes 10022833
SOCS3 – IRS1 no 12228220
SOCS3 – JAK3 yes 10373548
SOCS3 – PTPN11 yes 10777583
SOCS6 – PIK3R2 yes 12052866
SRC – ABL2 yes 17474147
SRC – CBL yes 9525940, 11994282
SRC – CRK yes 12615911
SRC – CSK yes 12387813
SRC – DAPP1 yes 10880360, 11524430
SRC – DOK1 yes 11071635
SRC – DOK2 no 10428862
SRC – DOK4 yes 12730241
SRC – EPS8 yes 10395945
SRC – FRS2 yes 10092678
SRC – FYN no 9169421, 16966330
SRC – GRB10 yes 10871840
SRC – GRB2 yes 11964172
SRC – HCK yes 11896602
SRC – LYN no 9169421
SRC – PTPN11 yes 14687660
SRC – PTPN6 yes 9261115
SRC – RIN3 yes 17474147
SRC – SH2D2A yes 15962004
SRC – STAT1 yes 10358079
SRC – STAT3 yes 8657134, 12244095
SRC – STAT5A no 7925280, 10358079, 11413148, 16189514
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Interaction validated PMID(s)
SRC – SYK no 7513017, 12522270, 16189514
SRC – YES1 yes 11039464
STAT1 – FYN yes 9804857
STAT1 – PTPN11 yes 12270932
STAT1 – SRC yes 10358079
STAT1 – STAT3 yes 11594781
STAT1 – STAT5A yes 10358045
STAT1 – SYK no 10918587, 11294897
STAT3 – BTK yes 17367410
STAT3 – CBL no 15657067
STAT3 – CBLB no 15657067
STAT3 – FER yes 10878010
STAT3 – GRB2 no 15657067
STAT3 – HCK yes 12244095
STAT3 – JAK3 no
8272872, 8626374, 9083098, 9305919,
9343414, 9566874, 9582023, 9872331,
10037026, 10446219, 10521505, 10918587,
11294897, 11335711, 11350938, 11429593,
11850821, 11940572, 12244095, 12576423,
12626508, 12763138, 14551213, 15465816,
15592455, 16189514
STAT3 – PTPN11 yes 11594781
STAT3 – PTPN6 no 15870198
STAT3 – SRC yes 8657134, 12244095
STAT3 – STAT1 yes 11594781
STAT3 – STAT5A yes 9398404
STAT3 – SYK no
8272872, 8626374, 9083098, 9305919,
9343414, 9566874, 9582023, 9872331,
10446219, 10521505, 10918587, 11294897,
11335711, 11350938, 11429593, 11850821,
11940572, 12244095, 12576423, 12626508,
12763138, 14551213, 15465816, 15592455,
16189514
STAT3 – YES1 no 15657067
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Interaction validated PMID(s)
STAT5A – BTK yes 11413148
STAT5A – CBL no 12193575
STAT5A – CRK yes 11097834
STAT5A – CRKL yes 9837784
STAT5A – JAK3 yes 9047382
STAT5A – PTPN11 yes 10617656
STAT5A – SRC no 7925280, 10358079, 11413148, 16189514
STAT5A – STAT1 yes 10358045
STAT5A – STAT3 yes 9398404
STAT5A – SYK no 7925280, 11413148, 16189514
SYK – BTK no 8629002, 8630736, 11226282, 11598012,12522270
SYK – CBL yes 8621719, 9535867, 15556646
SYK – CBLB yes 10022120
SYK – CRKL yes 11313252
SYK – FYN no 9535867, 12522270, 16713569
SYK – GRB2 yes 10747947, 11964172
SYK – LYN yes 7831290
SYK – PIK3R2 yes 15536084
SYK – PLCG2 yes 10469124, 10981967
SYK – PTPN6 yes 10747947
SYK – SH3BP2 yes 9846481
SYK – SRC no 7513017, 12522270, 16189514
SYK – STAT1 no 10918587, 11294897
SYK – STAT3 no
8272872, 8626374, 9083098, 9305919,
9343414, 9566874, 9582023, 9872331,
10446219, 10521505, 10918587, 11294897,
11335711, 11350938, 11429593, 11850821,
11940572, 12244095, 12576423, 12626508,
12763138, 14551213, 15465816, 15592455,
16189514
SYK – STAT5A no 7925280, 11413148, 16189514
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Interaction validated PMID(s)
YES1 – CBL yes 9525940
YES1 – CBLB no 15657067
YES1 – CSK no 16094384
YES1 – DOK1 yes 11071635
YES1 – FYN yes 12640114
YES1 – GRB2 no 15657067
YES1 – LYN no 1544885
YES1 – PIK3R2 no 17620599
YES1 – SRC yes 11039464
YES1 – STAT3 no 15657067
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Appendix I
Selbstständigkeitserklärung
Hiermit erkläre ich, diese Dissertation selbstständig und nur unter Verwendung
der angegebenen Hilfen und Hilfsmittel angefertigt zu haben. Sämtliche prakti-
schen Hilfen, die über die im Laborbetrieb üblichen hinausgehen, sind spezifisch
benannt. Alle wörtlichen und sinngemäßen Übernahmen aus anderen Werken
sind als solche kenntlich gemacht.
Ort, Datum Arndt Großmann
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